{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c8cdb172-efb2-415f-9450-e253a2b0f332",
   "metadata": {},
   "outputs": [],
   "source": [
    "FORMATTING DRUG DATA ON MARKETTED ONCOLOGY DRUGS (TYPE B&C)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "ed0cc1e7-7a3d-43df-897d-5ccf993a72cd",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Raw response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"PF-07104091\",\n",
      "    \"Drug_Brand_Name\": \"NA\",\n",
      "    \"Drug_CAS_Registry_Number\": \"NA\",\n",
      "    \"DrugBank_ID\": \"NA\",\n",
      "    \"SMILES\": \"C[C@H](Oc1ccccc1)c2ccccc2\",\n",
      "    \"InChI\": \"InChI=1S/C14H14O/c1-14(10-6-3-7-11-14)15-13-9-5-2-4-8-12-13/h2-12,15H,1H3\",\n",
      "    \"Drug_Category\": \"Oncology\",\n",
      "    \"ATC_Code\": \"NA\",\n",
      "    \"Route_of_Administration\": \"Oral\",\n",
      "    \"Target_Gene_IDs\": \"EGFR, ERBB2\",\n",
      "    \"Target_Protein_Names\": \"Epidermal Growth Factor Receptor, Human Epidermal growth factor receptor 2\",\n",
      "    \"Pathway_KEGG_IDs\": \"hsa05200\",\n",
      "    \"Pathway_Name\": \"Pathways in cancer\",\n",
      "    \"Mechanism_of_Action\": \"Inhibits EGFR and ERBB2 tyrosine kinase activity, blocking downstream signaling pathways involved in cell proliferation and survival.\",\n",
      "    \"Interacting_Drug_Bank_IDs\": \"DB00006\",\n",
      "    \"Interaction_Effect\": \"Increased risk of cardiotoxicity when combined with digoxin.\",\n",
      "    \"Number_of_Clinical_Trials\": \"2\",\n",
      "    \"Clinical_Trial_IDs\": \"NCT98765432, NCT87654321\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"PF-07248144\",\n",
      "    \"Drug_Brand_Name\": \"NA\",\n",
      "    \"Drug_CAS_Registry_Number\": \"NA\",\n",
      "    \"DrugBank_ID\": \"NA\",\n",
      "    \"SMILES\": \"CC(=O)Oc1ccccc1C(=O)O\",\n",
      "    \"InChI\": \"InChI=1S/C9H8O4/c1-6(10)12-8-5-3-2-4-7(8)9(11)13/h2-5H,1H3,(H,11,13)\",\n",
      "    \"Drug_Category\": \"Oncology\",\n",
      "    \"ATC_Code\": \"NA\",\n",
      "    \"Route_of_Administration\": \"Intravenous\",\n",
      "    \"Target_Gene_IDs\": \"VEGFA\",\n",
      "    \"Target_Protein_Names\": \"Vascular Endothelial Growth Factor A\",\n",
      "    \"Pathway_KEGG_IDs\": \"hsa04370\",\n",
      "    \"Pathway_Name\": \"VEGF signaling pathway\",\n",
      "    \"Mechanism_of_Action\": \"Binds to VEGFA, preventing its interaction with VEGFR and inhibiting angiogenesis.\",\n",
      "    \"Interacting_Drug_Bank_IDs\": \"DB00007\",\n",
      "    \"Interaction_Effect\": \"Increased risk of bleeding when combined with warfarin.\",\n",
      "    \"Number_of_Clinical_Trials\": \"1\",\n",
      "    \"Clinical_Trial_IDs\": \"NCT76543210\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"PF-07284892\",\n",
      "    \"Drug_Brand_Name\": \"NA\",\n",
      "    \"Drug_CAS_Registry_Number\": \"NA\",\n",
      "    \"DrugBank_ID\": \"NA\",\n",
      "    \"SMILES\": \"c1ccccc1N2C(=O)C(=O)N(c3ccccc3)C2=O\",\n",
      "    \"InChI\": \"InChI=1S/C16H10N2O3/c19-15-16(20)18(13-9-5-6-10-14(13)17)11-12(15)18/h5-11H\",\n",
      "    \"Drug_Category\": \"Oncology\",\n",
      "    \"ATC_Code\": \"NA\",\n",
      "    \"Route_of_Administration\": \"Oral\",\n",
      "    \"Target_Gene_IDs\": \"CDK4, CDK6\",\n",
      "    \"Target_Protein_Names\": \"Cyclin-dependent kinase 4, Cyclin-dependent kinase 6\",\n",
      "    \"Pathway_KEGG_IDs\": \"hsa04110\",\n",
      "    \"Pathway_Name\": \"Cell cycle\",\n",
      "    \"Mechanism_of_Action\": \"Inhibits CDK4 and CDK6, preventing cell cycle progression from G1 to S phase.\",\n",
      "    \"Interacting_Drug_Bank_IDs\": \"DB00014\",\n",
      "    \"Interaction_Effect\": \"Increased risk of neutropenia when combined with methotrexate.\",\n",
      "    \"Number_of_Clinical_Trials\": \"3\",\n",
      "    \"Clinical_Trial_IDs\": \"NCT65432109, NCT54321098, NCT43210987\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"PF-07220060\",\n",
      "    \"Drug_Brand_Name\": \"NA\",\n",
      "    \"Drug_CAS_Registry_Number\": \"NA\",\n",
      "    \"DrugBank_ID\": \"NA\",\n",
      "    \"SMILES\": \"O=C(Nc1ccccc1)c2ccccc2\",\n",
      "    \"InChI\": \"InChI=1S/C13H11NO/c14-13(10-6-3-7-11-13)12-9-5-2-4-8-12/h2-11H\",\n",
      "    \"Drug_Category\": \"Oncology\",\n",
      "    \"ATC_Code\": \"NA\",\n",
      "    \"Route_of_Administration\": \"Intravenous\",\n",
      "    \"Target_Gene_IDs\": \"PD-1\",\n",
      "    \"Target_Protein_Names\": \"Programmed cell death protein 1\",\n",
      "    \"Pathway_KEGG_IDs\": \"hsa04060\",\n",
      "    \"Pathway_Name\": \"Cytokine-cytokine receptor interaction\",\n",
      "    \"Mechanism_of_Action\": \"Blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby reversing T-cell suppression and enhancing anti-tumor immunity.\",\n",
      "    \"Interacting_Drug_Bank_IDs\": \"DB00018\",\n",
      "    \"Interaction_Effect\": \"Increased risk of immune-related adverse events when combined with cyclosporine.\",\n",
      "    \"Number_of_Clinical_Trials\": \"2\",\n",
      "    \"Clinical_Trial_IDs\": \"NCT32109876, NCT21098765\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"PF-07799933\",\n",
      "    \"Drug_Brand_Name\": \"NA\",\n",
      "    \"Drug_CAS_Registry_Number\": \"NA\",\n",
      "    \"DrugBank_ID\": \"NA\",\n",
      "    \"SMILES\": \"C1=CC=C(C=C1)C(=O)NC2=CC=CC=C2\",\n",
      "    \"InChI\": \"InChI=1S/C13H11NO/c14-13(10-6-3-7-11-13)12-9-5-2-4-8-12/h2-11H\",\n",
      "    \"Drug_Category\": \"Oncology\",\n",
      "    \"ATC_Code\": \"NA\",\n",
      "    \"Route_of_Administration\": \"Oral\",\n",
      "    \"Target_Gene_IDs\": \"PIK3CA\",\n",
      "    \"Target_Protein_Names\": \"Phosphatidylinositol 3-kinase catalytic subunit alpha\",\n",
      "    \"Pathway_KEGG_IDs\": \"hsa04151\",\n",
      "    \"Pathway_Name\": \"PI3K-Akt signaling pathway\",\n",
      "    \"Mechanism_of_Action\": \"Inhibits PI3KCA, blocking downstream signaling pathways involved in cell proliferation and survival.\",\n",
      "    \"Interacting_Drug_Bank_IDs\": \"NA\",\n",
      "    \"Interaction_Effect\": \"NA\",\n",
      "    \"Number_of_Clinical_Trials\": \"1\",\n",
      "    \"Clinical_Trial_IDs\": \"NCT10987654\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"PF-07799544\",\n",
      "    \"Drug_Brand_Name\": \"NA\",\n",
      "    \"Drug_CAS_Registry_Number\": \"NA\",\n",
      "    \"DrugBank_ID\": \"NA\",\n",
      "    \"SMILES\": \"C1=CC=C(C=C1)C(=O)NC2=CC=CC=C2\",\n",
      "    \"InChI\": \"InChI=1S/C13H11NO/c14-13(10-6-3-7-11-13)12-9-5-2-4-8-12/h2-11H\",\n",
      "    \"Drug_Category\": \"Oncology\",\n",
      "    \"ATC_Code\": \"NA\",\n",
      "    \"Route_of_Administration\": \"Intravenous\",\n",
      "    \"Target_Gene_IDs\": \"BCL2\",\n",
      "    \"Target_Protein_Names\": \"B-cell lymphoma 2 protein\",\n",
      "    \"Pathway_KEGG_IDs\": \"hsa04110\",\n",
      "    \"Pathway_Name\": \"Apoptosis\",\n",
      "    \"Mechanism_of_Action\": \"Inhibits BCL2, promoting apoptosis in cancer cells.\",\n",
      "    \"Interacting_Drug_Bank_IDs\": \"NA\",\n",
      "    \"Interaction_Effect\": \"NA\",\n",
      "    \"Number_of_Clinical_Trials\": \"2\",\n",
      "    \"Clinical_Trial_IDs\": \"NCT90123456, NCT80123456\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Tucatinib\",\n",
      "    \"Drug_Brand_Name\": \"NA\",\n",
      "    \"Drug_CAS_Registry_Number\": \"NA\",\n",
      "    \"DrugBank_ID\": \"NA\",\n",
      "    \"SMILES\": \"CC(=O)Nc1ccc(Nc2nccc(-c3ccc(C(=O)N4CCOCC4)cc3)n2)cc1\",\n",
      "    \"InChI\": \"InChI=1S/C26H26N6O3/c1-18(28)27-15-12-19(13-16-27)30-24-22(31-26-32-24)17-20-6-8-21(9-7-20)25(33)30-14-4-5-29-14/h6-9,12-13,15-16H,4-5,14,17H2,1H3,(H,28,30)\",\n",
      "    \"Drug_Category\": \"Oncology\",\n",
      "    \"ATC_Code\": \"NA\",\n",
      "    \"Route_of_Administration\": \"Oral\",\n",
      "    \"Target_Gene_IDs\": \"ERBB2\",\n",
      "    \"Target_Protein_Names\": \"Receptor tyrosine-protein kinase erbB-2\",\n",
      "    \"Pathway_KEGG_IDs\": \"hsa05200\",\n",
      "    \"Pathway_Name\": \"Pathways in cancer\",\n",
      "    \"Mechanism_of_Action\": \"A highly selective tyrosine kinase inhibitor of HER2. It binds to the ATP-binding pocket of the HER2 kinase domain, preventing phosphorylation and activation of downstream signaling pathways.\",\n",
      "    \"Interacting_Drug_Bank_IDs\": \"DB00002\",\n",
      "    \"Interaction_Effect\": \"Increased risk of QT prolongation when combined with doxorubicin.\",\n",
      "    \"Number_of_Clinical_Trials\": \"3\",\n",
      "    \"Clinical_Trial_IDs\": \"NCT70234567, NCT60234567, NCT50234567\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Enfortumab vedotin\",\n",
      "    \"Drug_Brand_Name\": \"NA\",\n",
      "    \"Drug_CAS_Registry_Number\": \"NA\",\n",
      "    \"DrugBank_ID\": \"NA\",\n",
      "    \"SMILES\": \"CC1(C(C(=O)N(C(C(=O)O1)C)C(C)C)OC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CC9=CC=CC=C9)C(=O)N[C@@H](CC%10=CC=CC=C%10)C(=O)N[C@@H](CC%11=CC=CC=C%11)C(=O)N[C@@H](CC%12=CC=CC=C%12)C(=O)N[C@@H](CC%13=CC=CC=C%13)C(=O)N[C@@H](CC%14=CC=CC=C%14)C(=O)N[C@@H](CC%15=CC=CC=C%15)C(=O)N[C@@H](CC%16=CC=CC=C%16)C(=O)N[C@@H](CC%17=CC=CC=C%17)C(=O)N[C@@H](CC%18=CC=CC=C%18)C(=O)N[C@@H](CC%19=CC=CC=C%19)C(=O)N[C@@H](CC%20=CC=CC=C%20)C(=O)N[C@@H](CC%21=CC=CC=C%21)C(=O)N[C@@H](CC%22=CC=CC=C%22)C(=O)N[C@@H](CC%23=CC=CC=C%23)C(=O)N[C@@H](CC%24=CC=CC=C%24)C(=O)N[C@@H](CC%25=CC=CC=C%25)C(=O)N[C@@H](CC%26=CC=CC=C%26)C(=O)N[C@@H](CC%27=CC=CC=C%27)C(=O)N[C@@H](CC%28=CC=CC=C%28)C(=O)N[C@@H](CC%29=CC=CC=C%29)C(=O)N[C@@H](CC%30=CC=CC=C%30)C(=O)N[C@@H](CC%31=CC=CC=C%31)C(=O)N[C@@H](CC%32=CC=CC=C%32)C(=O)N[C@@H](CC%33=CC=CC=C%33)C(=O)N[C@@H](CC%34=CC=CC=C%34)C(=O)N[C@@H](CC%35=CC=CC=C%35)C(=O)N[C@@H](CC%36=CC=CC=C%36)C(=O)N[C@@H](CC%37=CC=CC=C%37)C(=O)N[C@@H](CC%38=CC=CC=C%38)C(=O)N[C@@H](CC%39=CC=CC=C%39)C(=O)N[C@@H](CC%40=CC=CC=C%40)C(=O)N[C@@H](CC%41=CC=CC=C%41)C(=O)N[C@@H](CC%42=CC=CC=C%42)C(=O)N[C@@H](CC%43=CC=CC=C%43)C(=O)N[C@@H](CC%44=CC=CC=C%44)C(=O)N[C@@H](CC%45=CC=CC=C%45)C(=O)N[C@@H](CC%46=CC=CC=C%46)C(=O)N[C@@H](CC%47=CC=CC=C%47)C(=O)N[C@@H](CC%48=CC=CC=C%48)C(=O)N[C@@H](CC%49=CC=CC=C%49)C(=O)N[C@@H](CC%50=CC=CC=C%50)C(=O)N[C@@H](CC%51=CC=CC=C%51)C(=O)N[C@@H](CC%52=CC=CC=C%52)C(=O)N[C@@H](CC%53=CC=CC=C%53)C(=O)N[C@@H](CC%54=CC=CC=C%54)C(=O)N[C@@H](CC%55=CC=CC=C%55)C(=O)N[C@@H](CC%56=CC=CC=C%56)C(=O)N[C@@H](CC%57=CC=CC=C%57)C(=O)N[C@@H](CC%58=CC=CC=C%58)C(=O)N[C@@H](CC%59=CC=CC=C%59)C(=O)N[C@@H](CC%60=CC=CC=C%60)C(=O)N[C@@H](CC%61=CC=CC=C%61)C(=O)N[C@@H](CC%62=CC=CC=C%62)C(=O)N[C@@H](CC%63=CC=CC=C%63)C(=O)N[C@@H](CC%64=CC=CC=C%64)C(=O)N[C@@H](CC%65=CC=CC=C%65)C(=O)N[C@@H](CC%66=CC=CC=C%66)C(=O)N[C@@H](CC%67=CC=CC=C%67)C(=O)N[C@@H](CC%68=CC=CC=C%68)C(=O)N[C@@H](CC%69=CC=CC=C%69)C(=O)N[C@@H](CC%70=CC=CC=C%70)C(=O)N[C@@H](CC%71=CC=CC=C%71)C(=O)N[C@@H](CC%72=CC=CC=C%72)C(=O)N[C@@H](CC%73=CC=CC=C%73)C(=O)N[C@@H](CC%74=CC=CC=C%74)C(=O)N[C@@H](CC%75=CC=CC=C%75)C(=O)N[C@@H](CC%76=CC=CC=C%76)C(=O)N[C@@H](CC%77=CC=CC=C%77)C(=O)N[C@@H](CC%78=CC=CC=C%78)C(=O)N[C@@H](CC%79=CC=CC=C%79)C(=O)N[C@@H](CC%80=CC=CC=C%80)C(=O)N[C@@H](CC%81=CC=CC=C%81)C(=O)N[C@@H](CC%82=CC=CC=C%82)C(=O)N[C@@H](CC%83=CC=CC=C%83)C(=O)N[C@@H](CC%84=CC=CC=C%84)C(=O)N[C@@H](CC%85=CC=CC=C%85)C(=O)N[C@@H](CC%86=CC=CC=C%86)C(=O)N[C@@H](CC%87=CC=CC=C%87)C(=O)N[C@@H](CC%88=CC=CC=C%88)C(=O)N[C@@H](CC%89=CC=CC=C%89)C(=O)N[C@@H](CC%90=CC=CC=C%90)C(=O)N[C@@H](CC%91=CC=CC=C%91)C(=O)N[C@@H](CC%92=CC=CC=C%92)C(=O)N[C@@H](CC%93=CC=CC=C%93)C(=O)N[C@@H](CC%94=CC=CC=C%94)C(=O)N[C@@H](CC%95=CC=CC=C%95)C(=O)N[C@@H](CC%96=CC=CC=C%96)C(=O)N[C@@H](CC%97=CC=CC=C%97)C(=O)N[C@@H](CC%98=CC=CC=C%98)C(=O)N[C@@H](CC%99=CC=CC=C%99)C(=O)N[C@@H](CC%100=CC=CC=C%100)C(=O)N[C@@H](CC%101=CC=CC=C%101)C(=O)N[C@@H](CC%102=CC=CC=C%102)C(=O)N[C@@H](CC%103=CC=CC=C%103)C(=O)N[C@@H](CC%104=CC=CC=C%104)C(=O)N[C@@H](CC%105=CC=CC=C%105)C(=O)N[C@@H](CC%106=CC=CC=C%106)C(=O)N[C@@H](CC%107=CC=CC=C%107)C(=O)N[C@@H](CC%108=CC=CC=C%108)C(=O)N[C@@H](CC%109=CC=CC=C%109)C(=O)N[C@@H](CC%110=CC=CC=C%110)C(=O)N[C@@H](CC%111=CC=CC=C%111)C(=O)N[C@@H](CC%112=CC=CC=C%112)C(=O)N[C@@H](CC%113=CC=CC=C%113)C(=O)N[C@@H](CC%114=CC=CC=C%114)C(=O)N[C@@H](CC%115=CC=CC=C%115)C(=O)N[C@@H](CC%116=CC=CC=C%116)C(=O)N[C@@H](CC%117=CC=CC=C%117)C(=O)N[C@@H](CC%118=CC=CC=C%118)C(=O)N[C@@H](CC%119=CC=CC=C%119)C(=O)N[C@@H](CC%120=CC=CC=C%120)C(=O)N[C@@H](CC%121=CC=CC=C%121)C(=O)N[C@@H](CC%122=CC=CC=C%122)C(=O)N[C@@H](CC%123=CC=CC=C%123)C(=O)N[C@@H](CC%124=CC=CC=C%124)C(=O)N[C@@H](CC%125=CC=CC=C%125)C(=O)N[C@@H](CC%126=CC=CC=C%126)C(=O)N[C@@H](CC%127=CC=CC=C%127)C(=O)N[C@@H](CC%128=CC=CC=C%128)C(=O)N[C@@H](CC%129=CC=CC=C%129)C(=O)N[C@@H](CC%130=CC=CC=C%130)C(=O)N[C@@H](CC%131=CC=CC=C%131)C(=O)N[C@@H](CC%132=CC=CC=C%132)C(=O)N[C@@H](CC%133=CC=CC=C%133)C(=O)N[C@@H](CC%134=CC=CC=C%134)C(=O)N[C@@H](CC%135=CC=CC=C%135)C(=O)N[C@@H](CC%136=CC=CC=C%136)C(=O)N[C@@H](CC%137=CC=CC=C%137)C(=O)N[C@@H](CC%138=CC=CC=C%138)C(=O)N[C@@H](CC%139=CC=CC=C%139)C(=O)N[C@@H](CC%140=CC=CC=C%140)C(=O)N[C@@H](CC%141=CC=CC=C%141)C(=O)N[C@@H](CC%142=CC=CC=C%142)C(=O)N[C@@H](CC%143=CC=CC=C%143)C(=O)N[C@@H](CC%144=CC=CC=C%144)C(=O)N[C@@H](CC%145=CC=CC=C%145)C(=O)N[C@@H](CC%146=CC=CC=C%146)C(=O)N[C@@H](CC%147=CC=CC=C%147)C(=O)N[C@@H](CC%148=CC=CC=C%148)C(=O)N[C@@H](CC%149=CC=CC=C%149)C(=O)N[C@@H](CC%150=CC=CC=C%150)C(=O)N[C@@H](CC%151=CC=CC=C%151)C(=O)N[C@@H](CC%152=CC=CC=C%152)C(=O)N[C@@H](CC%153=CC=CC=C%153)C(=O)N[C@@H](CC%154=CC=CC=C%154)C(=O)N[C@@H](CC%155=CC=CC=C%155)C(=O)N[C@@H](CC%156=CC=CC=C%156)C(=O)N[C@@H](CC%157=CC=CC=C%157)C(=O)N[C@@H](CC%158=CC=CC=C%158)C(=O)N[C@@H](CC%159=CC=CC=C%159)C(=O)N[C@@H](CC%160=CC=CC=C%160)C(=O)N[C@@H](CC%161=CC=CC=C%161)C(=O)N[C@@H](CC%162=CC=CC=C%162)C(=O)N[C@@H](CC%163=CC=CC=C%163)C(=O)N[C@@H](CC%164=CC=CC=C%164)C(=O)N[C@@H](CC%165=CC=CC=C%165)C(=O)N[C@@H](CC%166=CC=CC=C%166)C(=O)N[C@@H](CC%167=CC=CC=C%167)C(=O)N[C@@H](CC%168=CC=CC=C%168)C(=O)N[C@@H](CC%169=CC=CC=C%169)C(=O)N[C@@H](CC%170=CC=CC=C%170)C(=O)N[C@@H](CC%171=CC=CC=C%171)C(=O)N[C@@H](CC%172=CC=CC=C%172)C(=O)N[C@@H](CC%173=CC=CC=C%173)C(=O)N[C@@H](CC%174=CC=CC=C%174)C(=O)N[C@@H](CC%175=CC=CC=C%175)C(=O)N[C@@H](CC%176=CC=CC=C%176)C(=O)N[C@@H](CC%177=CC=CC=C%177)C(=O)N[C@@H](CC%178=CC=CC=C%178)C(=O)N[C@@H](CC%179=CC=CC=C%179)C(=O)N[C@@H](CC%180=CC=CC=C%180)C(=O)N[C@@H](CC%181=CC=CC=C%181)C(=O)N[C@@H](CC%182=CC=CC=C%182)C(=O)N[C@@H](CC%183=CC=CC=C%183)C(=O)N[C@@H](CC%184=CC=CC=C%184)C(=O)N[C@@H](CC%185=CC=CC=C%185)C(=O)N[C@@H](CC%186=CC=CC=C%186)C(=O)N[C@@H](CC%187=CC=CC=C%187)C(=O)N[C@@H](CC%188=CC=CC=C%188)C(=O)N[C@@H](CC%189=CC=CC=C%189)C(=O)N[C@@H](CC%190=CC=CC=C%190)C(=O)N[C@@H](CC%191=CC=CC=C%191)C(=O)N[C@@H](CC%192=CC=CC=C%192)C(=O)N[C@@H](CC%193=CC=CC=C%193)C(=O)N[C@@H](CC%194=CC=CC=C%194)C(=O)N[C@@H](CC%195=CC=CC=C%195)C(=O)N[C@@H](CC%196=CC=CC=C%196)C(=O)N[C@@H](CC%197=CC=CC=C%197)C(=O)N[C@@H](CC%198=CC=CC=C%198)C(=O)N[C@@H](CC%199=CC=CC=C%199)C(=O)N[C@@H](CC%200=CC=CC=C%200)C(=O)N[C@@H](CC%201=CC=CC=C%201)C(=O)N[C@@H](CC%202=CC=CC=C%202)C(=O)N[C@@H](CC%203=CC=CC=C%203)C(=O)N[C@@H](CC%204=CC=CC=C%204)C(=O)N[C@@H](CC%205=CC=CC=C%205)C(=O)N[C@@H](CC%206=CC=CC=C%206)C(=O)N[C@@H](CC%207=CC=CC=C%207)C(=O)N[C@@H](CC%208=CC=CC=C%208)C(=O)N[C@@H](CC%209=CC=CC=C%209)C(=O)N[C@@H](CC%210=CC=CC=C%210)C(=O)N[C@@H](CC%211=CC=CC=C%211)C(=O)N[C@@H](CC%212=CC=CC=C%212)C(=O)N[C@@H](CC%213=CC=CC=C%213)C(=O)N[C@@H](CC%214=CC=CC=C%214)C(=O)N[C@@H](CC%215=CC=CC=C%215)C(=O)N[C@@H](CC%216=CC=CC=\n",
      "Error parsing JSON: Unterminated string starting at: line 147 column 15 (char 6569). Response text may be incomplete.\n",
      "Recovered partial data: [{'Drug_Name': 'PF-07104091', 'Drug_Brand_Name': 'NA', 'Drug_CAS_Registry_Number': 'NA', 'DrugBank_ID': 'NA', 'SMILES': 'C[C@H](Oc1ccccc1)c2ccccc2', 'InChI': 'InChI=1S/C14H14O/c1-14(10-6-3-7-11-14)15-13-9-5-2-4-8-12-13/h2-12,15H,1H3', 'Drug_Category': 'Oncology', 'ATC_Code': 'NA', 'Route_of_Administration': 'Oral', 'Target_Gene_IDs': 'EGFR, ERBB2', 'Target_Protein_Names': 'Epidermal Growth Factor Receptor, Human Epidermal growth factor receptor 2', 'Pathway_KEGG_IDs': 'hsa05200', 'Pathway_Name': 'Pathways in cancer', 'Mechanism_of_Action': 'Inhibits EGFR and ERBB2 tyrosine kinase activity, blocking downstream signaling pathways involved in cell proliferation and survival.', 'Interacting_Drug_Bank_IDs': 'DB00006', 'Interaction_Effect': 'Increased risk of cardiotoxicity when combined with digoxin.', 'Number_of_Clinical_Trials': '2', 'Clinical_Trial_IDs': 'NCT98765432, NCT87654321'}, {'Drug_Name': 'PF-07248144', 'Drug_Brand_Name': 'NA', 'Drug_CAS_Registry_Number': 'NA', 'DrugBank_ID': 'NA', 'SMILES': 'CC(=O)Oc1ccccc1C(=O)O', 'InChI': 'InChI=1S/C9H8O4/c1-6(10)12-8-5-3-2-4-7(8)9(11)13/h2-5H,1H3,(H,11,13)', 'Drug_Category': 'Oncology', 'ATC_Code': 'NA', 'Route_of_Administration': 'Intravenous', 'Target_Gene_IDs': 'VEGFA', 'Target_Protein_Names': 'Vascular Endothelial Growth Factor A', 'Pathway_KEGG_IDs': 'hsa04370', 'Pathway_Name': 'VEGF signaling pathway', 'Mechanism_of_Action': 'Binds to VEGFA, preventing its interaction with VEGFR and inhibiting angiogenesis.', 'Interacting_Drug_Bank_IDs': 'DB00007', 'Interaction_Effect': 'Increased risk of bleeding when combined with warfarin.', 'Number_of_Clinical_Trials': '1', 'Clinical_Trial_IDs': 'NCT76543210'}, {'Drug_Name': 'PF-07284892', 'Drug_Brand_Name': 'NA', 'Drug_CAS_Registry_Number': 'NA', 'DrugBank_ID': 'NA', 'SMILES': 'c1ccccc1N2C(=O)C(=O)N(c3ccccc3)C2=O', 'InChI': 'InChI=1S/C16H10N2O3/c19-15-16(20)18(13-9-5-6-10-14(13)17)11-12(15)18/h5-11H', 'Drug_Category': 'Oncology', 'ATC_Code': 'NA', 'Route_of_Administration': 'Oral', 'Target_Gene_IDs': 'CDK4, CDK6', 'Target_Protein_Names': 'Cyclin-dependent kinase 4, Cyclin-dependent kinase 6', 'Pathway_KEGG_IDs': 'hsa04110', 'Pathway_Name': 'Cell cycle', 'Mechanism_of_Action': 'Inhibits CDK4 and CDK6, preventing cell cycle progression from G1 to S phase.', 'Interacting_Drug_Bank_IDs': 'DB00014', 'Interaction_Effect': 'Increased risk of neutropenia when combined with methotrexate.', 'Number_of_Clinical_Trials': '3', 'Clinical_Trial_IDs': 'NCT65432109, NCT54321098, NCT43210987'}, {'Drug_Name': 'PF-07220060', 'Drug_Brand_Name': 'NA', 'Drug_CAS_Registry_Number': 'NA', 'DrugBank_ID': 'NA', 'SMILES': 'O=C(Nc1ccccc1)c2ccccc2', 'InChI': 'InChI=1S/C13H11NO/c14-13(10-6-3-7-11-13)12-9-5-2-4-8-12/h2-11H', 'Drug_Category': 'Oncology', 'ATC_Code': 'NA', 'Route_of_Administration': 'Intravenous', 'Target_Gene_IDs': 'PD-1', 'Target_Protein_Names': 'Programmed cell death protein 1', 'Pathway_KEGG_IDs': 'hsa04060', 'Pathway_Name': 'Cytokine-cytokine receptor interaction', 'Mechanism_of_Action': 'Blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby reversing T-cell suppression and enhancing anti-tumor immunity.', 'Interacting_Drug_Bank_IDs': 'DB00018', 'Interaction_Effect': 'Increased risk of immune-related adverse events when combined with cyclosporine.', 'Number_of_Clinical_Trials': '2', 'Clinical_Trial_IDs': 'NCT32109876, NCT21098765'}, {'Drug_Name': 'PF-07799933', 'Drug_Brand_Name': 'NA', 'Drug_CAS_Registry_Number': 'NA', 'DrugBank_ID': 'NA', 'SMILES': 'C1=CC=C(C=C1)C(=O)NC2=CC=CC=C2', 'InChI': 'InChI=1S/C13H11NO/c14-13(10-6-3-7-11-13)12-9-5-2-4-8-12/h2-11H', 'Drug_Category': 'Oncology', 'ATC_Code': 'NA', 'Route_of_Administration': 'Oral', 'Target_Gene_IDs': 'PIK3CA', 'Target_Protein_Names': 'Phosphatidylinositol 3-kinase catalytic subunit alpha', 'Pathway_KEGG_IDs': 'hsa04151', 'Pathway_Name': 'PI3K-Akt signaling pathway', 'Mechanism_of_Action': 'Inhibits PI3KCA, blocking downstream signaling pathways involved in cell proliferation and survival.', 'Interacting_Drug_Bank_IDs': 'NA', 'Interaction_Effect': 'NA', 'Number_of_Clinical_Trials': '1', 'Clinical_Trial_IDs': 'NCT10987654'}, {'Drug_Name': 'PF-07799544', 'Drug_Brand_Name': 'NA', 'Drug_CAS_Registry_Number': 'NA', 'DrugBank_ID': 'NA', 'SMILES': 'C1=CC=C(C=C1)C(=O)NC2=CC=CC=C2', 'InChI': 'InChI=1S/C13H11NO/c14-13(10-6-3-7-11-13)12-9-5-2-4-8-12/h2-11H', 'Drug_Category': 'Oncology', 'ATC_Code': 'NA', 'Route_of_Administration': 'Intravenous', 'Target_Gene_IDs': 'BCL2', 'Target_Protein_Names': 'B-cell lymphoma 2 protein', 'Pathway_KEGG_IDs': 'hsa04110', 'Pathway_Name': 'Apoptosis', 'Mechanism_of_Action': 'Inhibits BCL2, promoting apoptosis in cancer cells.', 'Interacting_Drug_Bank_IDs': 'NA', 'Interaction_Effect': 'NA', 'Number_of_Clinical_Trials': '2', 'Clinical_Trial_IDs': 'NCT90123456, NCT80123456'}, {'Drug_Name': 'Tucatinib', 'Drug_Brand_Name': 'NA', 'Drug_CAS_Registry_Number': 'NA', 'DrugBank_ID': 'NA', 'SMILES': 'CC(=O)Nc1ccc(Nc2nccc(-c3ccc(C(=O)N4CCOCC4)cc3)n2)cc1', 'InChI': 'InChI=1S/C26H26N6O3/c1-18(28)27-15-12-19(13-16-27)30-24-22(31-26-32-24)17-20-6-8-21(9-7-20)25(33)30-14-4-5-29-14/h6-9,12-13,15-16H,4-5,14,17H2,1H3,(H,28,30)', 'Drug_Category': 'Oncology', 'ATC_Code': 'NA', 'Route_of_Administration': 'Oral', 'Target_Gene_IDs': 'ERBB2', 'Target_Protein_Names': 'Receptor tyrosine-protein kinase erbB-2', 'Pathway_KEGG_IDs': 'hsa05200', 'Pathway_Name': 'Pathways in cancer', 'Mechanism_of_Action': 'A highly selective tyrosine kinase inhibitor of HER2. It binds to the ATP-binding pocket of the HER2 kinase domain, preventing phosphorylation and activation of downstream signaling pathways.', 'Interacting_Drug_Bank_IDs': 'DB00002', 'Interaction_Effect': 'Increased risk of QT prolongation when combined with doxorubicin.', 'Number_of_Clinical_Trials': '3', 'Clinical_Trial_IDs': 'NCT70234567, NCT60234567, NCT50234567'}]\n",
      "File created: drug_data_report.csv\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import csv\n",
    "import json\n",
    "import google.generativeai as genai\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "api_key = \"AIzaSyBSpjhnYk97Un4eTDcxs9I2oDosw7YNr6g\"\n",
    "genai.configure(api_key=api_key)\n",
    "\n",
    "generation_config = {\n",
    "    \"temperature\": 0,\n",
    "    \"top_p\": 0.95,\n",
    "    \"top_k\": 40,\n",
    "    \"max_output_tokens\": 8192,\n",
    "    \"response_mime_type\": \"application/json\",\n",
    "}\n",
    "\n",
    "model = genai.GenerativeModel(\n",
    "    model_name=\"gemini-2.0-flash\",\n",
    "    generation_config=generation_config,\n",
    ")\n",
    "\n",
    "def save_csv(filename, data):\n",
    "    csv_file = f\"{filename}.csv\"\n",
    "    headers = [\n",
    "        \"Drug_Name\",\n",
    "        \"Drug_Brand_Name\",\n",
    "        \"Drug_CAS_Registry_Number\",\n",
    "        \"DrugBank_ID\",\n",
    "        \"SMILES\",\n",
    "        \"InChI\",\n",
    "        \"Drug_Category\",\n",
    "        \"ATC_Code\",\n",
    "        \"Route_of_Administration\",\n",
    "        \"Target_Gene_IDs\",\n",
    "        \"Target_Protein_Names\",\n",
    "        \"Pathway_KEGG_IDs\",\n",
    "        \"Pathway_Name\",\n",
    "        \"Mechanism_of_Action\",\n",
    "        \"Interacting_Drug_Bank_IDs\",\n",
    "        \"Interaction_Effect\",\n",
    "        \"Number_of_Clinical_Trials\",\n",
    "        \"Clinical_Trial_IDs\"\n",
    "    ]\n",
    "    with open(csv_file, mode='w', newline='', encoding='utf-8') as file:\n",
    "        writer = csv.DictWriter(file, fieldnames=headers)\n",
    "        writer.writeheader()\n",
    "        for row in data:\n",
    "            writer.writerow(row)\n",
    "    print(\"File created:\", csv_file)\n",
    "\n",
    "def prompt_drug_data_extraction(drug_batch):\n",
    "    drug_list = ', '.join(f'\"{drug}\"' for drug in drug_batch)\n",
    "    PROMPT = f'''\n",
    "    You are an expert in oncology drug development. Your task is to generate realistic, but entirely fictitious (dummy) data for the following list of oncology drugs that are currently in Phase 1 clinical trials: {drug_list}. The data should be formatted to be easily compared with an existing ocology drug data store which consists of drugs that are already marketed and have available FAERS data.\n",
    "\n",
    "    For EACH drug, provide the following information, labeling any unavailable or truly unknown information as \"NA\":\n",
    "\n",
    "    - Drug_Name: Common or generic name.\n",
    "    - Drug_Brand_Name: Brand name (if one exists, otherwise NA).\n",
    "    - Drug_CAS_Registry_Number: CAS registry number (if known, otherwise NA).\n",
    "    - DrugBank_ID: DrugBank identifier (if available, otherwise NA).\n",
    "    - SMILES: SMILES string (if known, otherwise NA). Prioritize plausible, though incorrect, SMILES if a real one is unavailable.\n",
    "    - InChI: InChI identifier (if known, otherwise NA).\n",
    "    - Drug_Category: Therapeutic category (e.g., \"Oncology\").\n",
    "    - ATC_Code: ATC code (if known, otherwise NA).\n",
    "    - Route_of_Administration: Route(s) of administration (e.g., \"Oral\", \"Intravenous\").\n",
    "    - Target_Gene_IDs: Comma-separated list of 1-3 target gene IDs. For some drugs in the list, make these genes similar (but NOT identical) to targets of drugs already in our data store (drugs in a list of drug data store), suggesting some therapeutic similarities; for others, make these completely novel. If unknown, label as NA.\n",
    "    - Target_Protein_Names: Comma-separated list of target protein names, corresponding to the Target_Gene_IDs. If unknown, label as NA.\n",
    "    - Pathway_KEGG_IDs: Comma-separated list of 1-2 KEGG pathway IDs that the drug is thought to affect. If unknown, label as NA.\n",
    "    - Pathway_Name: Comma-separated list of pathway names corresponding to the KEGG IDs. If unknown, label as NA.\n",
    "    - Mechanism_of_Action: A brief, plausible description of how the drug is thought to work at a molecular level.\n",
    "    - Interacting_Drug_Bank_IDs: Comma-separated list of DrugBank IDs of a few drugs that MIGHT interact with this drug. Suggest plausible interactions, perhaps drawing from common oncology drugs. If unknown, label as NA.\n",
    "    - Interaction_Effect: A brief description of the potential effect of the interaction. If Interacting_Drug_Bank_IDs is NA, this should also be NA.\n",
    "    - Number_of_Clinical_Trials: A small number (1-3) of clinical trials in Phase 1. Use realistic numbers.\n",
    "    - Clinical_Trial_IDs: Comma-separated list of ClinicalTrials.gov identifiers (NCT numbers) for the clinical trials. Generate plausible but fake NCT numbers (e.g., NCT98765432).\n",
    "\n",
    "    Specifically:\n",
    "    *   Focus on creating plausible (but fictitious) data that is relevant for oncology drugs still in Phase 1 trials.\n",
    "    *   The data should be suitable for comparing with and finding similarities to existing oncology drugs.\n",
    "    *   Emphasize plausible target information, even if the SMILES string or CAS registry number is approximate.\n",
    "\n",
    "    Here's an example set of DrugBank IDs of the drugs in our data store you can derive drug data based on: DB00002, DB00006, DB00007, DB00014, DB00018. For some of the drugs in {drug_list}, make the Target_Gene_IDs and Target_Protein_Names similar to these drugs.\n",
    "    Return the data in JSON format with the specified keys. Each drug should be represented as a separate JSON object within a JSON array.\n",
    "    '''\n",
    "    return PROMPT\n",
    "\n",
    "def get_extracted_drug_data(drug_batches):\n",
    "    all_data = []\n",
    "    for drug_batch in drug_batches:\n",
    "        chat_session = model.start_chat(\n",
    "            history=[\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"parts\": [prompt_drug_data_extraction(drug_batch)],\n",
    "                },\n",
    "            ],\n",
    "        )\n",
    "        response = chat_session.send_message(prompt_drug_data_extraction(drug_batch))\n",
    "\n",
    "        # Print the raw response text for debugging\n",
    "        print(\"Raw response text:\", response.text)\n",
    "\n",
    "        try:\n",
    "            # Attempt to load the JSON response\n",
    "            extracted_data = json.loads(response.text)\n",
    "            # Check if the extracted data is a list and not empty\n",
    "            if isinstance(extracted_data, list) and extracted_data:\n",
    "                print(\"Extracted drug data:\", extracted_data)\n",
    "                all_data.extend(extracted_data)\n",
    "            else:\n",
    "                print(\"Extracted data is not in the expected format or is empty.\")\n",
    "        except json.JSONDecodeError as e:\n",
    "            # Handle JSON parsing error\n",
    "            print(f\"Error parsing JSON: {e}. Response text may be incomplete.\")\n",
    "            # Attempt to recover partial data if possible\n",
    "            try:\n",
    "                # Use a more forgiving JSON parser if available, or manually fix the response\n",
    "                # For example, you could try to close the JSON array manually if you know the structure\n",
    "                partial_data = response.text.rsplit('}', 1)[0] + '}]'\n",
    "                extracted_data = json.loads(partial_data)\n",
    "                print(\"Recovered partial data:\", extracted_data)\n",
    "                all_data.extend(extracted_data)\n",
    "            except Exception as recovery_exception:\n",
    "                print(f\"Failed to recover partial data: {recovery_exception}\")\n",
    "\n",
    "    return all_data\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    drugs = [\n",
    "        \"PF-07104091\",\n",
    "        \"PF-07248144\",\n",
    "        \"PF-07284892\",\n",
    "        \"PF-07220060\",\n",
    "        \"PF-07799933\",\n",
    "        \"PF-07799544\",\n",
    "        \"Tucatinib\",\n",
    "        \"Enfortumab vedotin\",\n",
    "        \"Tisotumab vedotin\"\n",
    "    ]\n",
    "\n",
    "    # Define the batch size\n",
    "    batch_size = 10\n",
    "\n",
    "    # Create batches of drugs\n",
    "    drug_batches = [drugs[i:i + batch_size] for i in range(0, len(drugs), batch_size)]\n",
    "\n",
    "    data = get_extracted_drug_data(drug_batches)\n",
    "    if data:\n",
    "        save_csv(filename=report_name, data=data)\n",
    "    else:\n",
    "        print(\"No data to save.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2018d2fb-8f51-426b-847b-b95cfcb51a10",
   "metadata": {},
   "outputs": [],
   "source": [
    "FORMATTING DRUG DATA ON UNDER TRIAL ONCOLOGY DRUGS (TYPE A)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "e5b241c4-722d-462b-ab37-a4f1db497564",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generating batch 1 of size 10\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"4\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Febrile neutropenia\",\n",
      "    \"AEDECOD\": \"Febrile neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"Yes\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"18\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J15\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study789', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '25', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient006', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '60', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '12', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '68', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '4', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '55', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient009', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25', 'Age': '72', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Febrile neutropenia', 'AEDECOD': 'Febrile neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'Yes', 'AESMIE': 'Yes', 'AESTDY': '18', 'AEENDY': '28', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J15', 'Age': '63', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}]\n",
      "Generating batch 2 of size 10\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"20\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"9\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"73\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25.10\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Febrile neutropenia\",\n",
      "    \"AEDECOD\": \"Febrile neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"Yes\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"82\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study789', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '71', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '9', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '12', 'AEENDY': '20', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient006', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '69', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '9', 'AEENDY': '12', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '55', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '8', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '73', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient009', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25.10', 'Age': '60', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Febrile neutropenia', 'AEDECOD': 'Febrile neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'Yes', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '25', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '82', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}]\n",
      "Generating batch 3 of size 10\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"20\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"9\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"73\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25.10\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Febrile neutropenia\",\n",
      "    \"AEDECOD\": \"Febrile neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"Yes\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"82\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study789', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '71', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '9', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '12', 'AEENDY': '20', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient006', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '69', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '9', 'AEENDY': '12', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '55', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '8', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '73', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient009', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25.10', 'Age': '60', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Febrile neutropenia', 'AEDECOD': 'Febrile neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'Yes', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '25', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '82', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}]\n",
      "Generating batch 4 of size 10\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study001\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study001\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study001\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study001\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study001\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study001\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study001\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"20\",\n",
      "    \"AEENDY\": \"30\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study001\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study001\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25.1\",\n",
      "    \"Age\": \"81\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study001\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Febrile neutropenia\",\n",
      "    \"AEDECOD\": \"Febrile neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"Yes\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"18\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J15\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study001', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study001', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study001', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study001', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '9', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study001', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '25', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study001', 'USUBJID': 'Patient006', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '69', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study001', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '20', 'AEENDY': '30', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '72', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study001', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '55', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study001', 'USUBJID': 'Patient009', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25.1', 'Age': '81', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '150 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study001', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Febrile neutropenia', 'AEDECOD': 'Febrile neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'Yes', 'AESMIE': 'Yes', 'AESTDY': '18', 'AEENDY': '28', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J15', 'Age': '60', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}]\n",
      "Generating batch 5 of size 10\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"4\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Febrile neutropenia\",\n",
      "    \"AEDECOD\": \"Febrile neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"Yes\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"18\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J15\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study789', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '25', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient006', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '60', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '12', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '68', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '4', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '55', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient009', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25', 'Age': '72', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Febrile neutropenia', 'AEDECOD': 'Febrile neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'Yes', 'AESMIE': 'Yes', 'AESTDY': '18', 'AEENDY': '28', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J15', 'Age': '63', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}]\n",
      "File created: PF-07104091_patient_data.csv\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import csv\n",
    "import json\n",
    "import google.generativeai as genai\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "api_key = \"AIzaSyBSpjhnYk97Un4eTDcxs9I2oDosw7YNr6g\"  # Replace with your actual API key\n",
    "genai.configure(api_key=api_key)\n",
    "\n",
    "generation_config = {\n",
    "    \"temperature\": 0,\n",
    "    \"top_p\": 0.95,\n",
    "    \"top_k\": 40,\n",
    "    \"max_output_tokens\": 16384,\n",
    "    \"response_mime_type\": \"application/json\",\n",
    "}\n",
    "\n",
    "model = genai.GenerativeModel(\n",
    "    model_name=\"gemini-2.0-flash\",\n",
    "    generation_config=generation_config,\n",
    ")\n",
    "\n",
    "def save_patient_csv(filename, data):\n",
    "    csv_file = f\"{filename}.csv\"\n",
    "    headers = [\n",
    "        \"STUDYID\",\n",
    "        \"USUBJID\",\n",
    "        \"AESEQ\",\n",
    "        \"AETERM\",\n",
    "        \"AEDECOD\",\n",
    "        \"AESER\",\n",
    "        \"AEOUT\",\n",
    "        \"AESTDY\",\n",
    "        \"AEENDY\",\n",
    "        \"AESDISAB\",\n",
    "        \"AESDTH\",\n",
    "        \"AESHOSP\",\n",
    "        \"AESLIFE\",\n",
    "        \"AESMIE\",\n",
    "        \"MHCAT\",\n",
    "        \"MHSCAT\",\n",
    "        \"MHTERM\",\n",
    "        \"Age\",\n",
    "        \"Sex\",\n",
    "        \"Race\",\n",
    "        \"Smoking_Status\",\n",
    "        \"Alcohol_Consumption\",\n",
    "        \"Dosage\",\n",
    "        \"Treatment_Duration\"\n",
    "    ]\n",
    "    with open(csv_file, mode='w', newline='', encoding='utf-8') as file:\n",
    "        writer = csv.DictWriter(file, fieldnames=headers)\n",
    "        writer.writeheader()\n",
    "        for row in data:\n",
    "            writer.writerow(row)\n",
    "    print(\"File created:\", csv_file)\n",
    "\n",
    "def prompt_patient_data_generation(drug_name, num_patients):\n",
    "    PROMPT = f'''\n",
    "    You are an expert in clinical trial data generation. Your task is to generate realistic, but entirely fictitious (dummy) data for patients participating in a Phase 1 clinical trial for the oncology drug \"{drug_name}\".\n",
    "\n",
    "    Generate data for {num_patients} patients. For EACH patient, provide the following information:\n",
    "\n",
    "    - STUDYID: A unique study identifier (e.g., \"Study123\").\n",
    "    - USUBJID: A unique subject (patient) identifier (e.g., \"Patient001\", \"Patient002\").\n",
    "    - AESEQ: An adverse event sequence number, start at 1, and increment for each adverse event the patient experiences (or NA if no adverse event).\n",
    "    - AETERM: The verbatim adverse event term reported by the investigator. Use MedDRA Preferred Terms (PTs) where possible. Examples include: Nausea, Fatigue, Vomiting, Diarrhea, Neutropenia, Anemia, or NA if there are no adverse events.\n",
    "    - AEDECOD: The standardized MedDRA Preferred Term for the adverse event (or NA if there are no adverse events). Make sure it relates to the corresponding AETERM.\n",
    "    - AESER: Whether the adverse event was serious (\"Yes\" or \"No\", or NA if there are no adverse events). If any of the AETERMs are serious, return yes.\n",
    "    - AEOUT: The outcome of the adverse event (e.g., \"Resolved\", \"Recovering\", \"Fatal\", or NA if there are no adverse events). Choose a plausible outcome given the term and whether the AESER is Yes or No\n",
    "\n",
    "    - AESDISAB: Whether the adverse event resulted in a disability (\"Yes\" or \"No\", or NA if there are no adverse events).\n",
    "    - AESDTH: Whether the adverse event resulted in death (\"Yes\" or \"No\", or NA if there are no adverse events).  Be very sparing in returning \"Yes\" for this, especially if AESER is also \"No\"\n",
    "    - AESHOSP: Whether the patient was hospitalized due to the adverse event (\"Yes\" or \"No\", or NA if there are no adverse events).\n",
    "    - AESLIFE: Whether the adverse event was life-threatening (\"Yes\" or \"No\", or NA if there are no adverse events). Be very sparing in returning \"Yes\" for this, especially if AESER is also \"No\"\n",
    "    - AESMIE: Whether the adverse event was medically important (\"Yes\" or \"No\", or NA if there are no adverse events). Use yes or no for medically important events.\n",
    "\n",
    "\n",
    "    - AESTDY: The adverse event start day (relative to treatment start) as a number (or NA if there are no adverse events).\n",
    "    - AEENDY: The adverse event end day (relative to treatment start) as a number (or NA if there are no adverse events).\n",
    "\n",
    "    - MHCAT: A medical history category (e.g., \"Cardiac\", \"Respiratory\", \"Endocrine\"). Use plausible and medically accurate descriptions.\n",
    "    - MHSCAT: A medical history subcategory for the medical conditions related to MHCAT (e.g., \"Hypertension\" for Cardiac, \"Asthma\" for Respiratory, \"Diabetes Mellitus\" for Endocrine).\n",
    "\n",
    "    - MHTERM: Verbatim term for medical conditions for the patient, use snowmed codes where possible, or NA if there are no conditions.\n",
    "    - Age: A realistic age for oncology patients (e.g., between 30 and 85).\n",
    "    - Sex: Either \"Male\" or \"Female\".\n",
    "    - Race: A common race/ethnicity (e.g., \"White\", \"Black\", \"Asian\", \"Hispanic\").\n",
    "    - Smoking_Status: One of \"Never Smoker\", \"Former Smoker\", or \"Current Smoker\".\n",
    "    - Alcohol_Consumption: One of \"None\", \"Light\", \"Moderate\", or \"Heavy\".\n",
    "    - Dosage: A plausible dosage for a Phase 1 oncology trial (e.g., \"50 mg\", \"100 mg\", \"150 mg\").\n",
    "    - Treatment_Duration: A plausible treatment duration (e.g., \"21 days\", \"28 days\", \"42 days\").\n",
    "\n",
    "    Specifically:\n",
    "    *   Focus on generating data that is realistic for a Phase 1 clinical trial for an oncology drug.\n",
    "    *   When a patient does not experience an adverse event, use NA for adverse event related parameters.\n",
    "    *   Be very sparing in returning \"Yes\" for AESDTH and AESLIFE, especially if AESER is also \"No\"\n",
    "    *   The generated data should contain essential information on the patient, their medical history, and any adverse events experienced.\n",
    "    *   Adhere to the specified data types and value ranges.\n",
    "    *   Ensure logical consistency: if an AETERM and AEDECOD values are defined as NA, ALL other AE columns must also be NA\n",
    "\n",
    "    Return the data in JSON format with the specified keys. Each patient should be represented as a separate JSON object within a JSON array.\n",
    "    '''\n",
    "    return PROMPT\n",
    "\n",
    "def get_extracted_patient_data(drug_name, num_patients):\n",
    "    chat_session = model.start_chat(\n",
    "        history=[\n",
    "            {\n",
    "                \"role\": \"user\",\n",
    "                \"parts\": [prompt_patient_data_generation(drug_name, num_patients)],\n",
    "            },\n",
    "        ],\n",
    "    )\n",
    "    response = chat_session.send_message(prompt_patient_data_generation(drug_name, num_patients))\n",
    "\n",
    "    # Print the raw response text for debugging\n",
    "    print(\"Raw patient data response text:\", response.text)\n",
    "\n",
    "    try:\n",
    "        extracted_data = json.loads(response.text)\n",
    "        if isinstance(extracted_data, list) and extracted_data:\n",
    "            print(\"Extracted patient data:\", extracted_data)\n",
    "            return extracted_data\n",
    "        else:\n",
    "            print(\"Extracted data is not in the expected format or is empty.\")\n",
    "            return None\n",
    "    except json.JSONDecodeError as e:\n",
    "        print(f\"Error parsing JSON: {e}. Response text may be incomplete.\")\n",
    "        try:\n",
    "            # Attempt to fix common JSON errors (e.g., missing closing bracket)\n",
    "            if not response.text.strip().endswith(']'):\n",
    "                repaired_text = response.text.strip() + ']'\n",
    "            else:\n",
    "                repaired_text = response.text.strip()\n",
    "\n",
    "            extracted_data = json.loads(repaired_text) # Attempt to parse fixed JSON\n",
    "            print(\"Successfully parsed recovered JSON\")\n",
    "            return extracted_data\n",
    "\n",
    "        except json.JSONDecodeError as recovery_exception:\n",
    "            print(f\"Failed to recover JSON: {recovery_exception}\")\n",
    "        return None\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    drug_name = \"PF-07104091\"  # Replace with your Drug A name\n",
    "    total_patients = 50  # Adjust the number of patients\n",
    "    batch_size = 10\n",
    "    report_name = f\"{drug_name}_patient_data\"\n",
    "\n",
    "    all_patient_data = []  # Accumulate data from all batches\n",
    "\n",
    "    for i in range(0, total_patients, batch_size):\n",
    "        num_patients = min(batch_size, total_patients - i)  # Handle the last batch\n",
    "        print(f\"Generating batch {i//batch_size + 1} of size {num_patients}\")\n",
    "        patient_data = get_extracted_patient_data(drug_name, num_patients)\n",
    "        if patient_data:\n",
    "            all_patient_data.extend(patient_data)\n",
    "        else:\n",
    "            print(f\"Failed to generate batch {i//batch_size + 1}\")\n",
    "\n",
    "    if all_patient_data:\n",
    "        save_patient_csv(filename=report_name, data=all_patient_data)\n",
    "    else:\n",
    "        print(\"No patient data to save.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4ffde812-ace2-45a9-9783-d35f039fd271",
   "metadata": {},
   "outputs": [],
   "source": [
    "FORMATTING CLINICAL TRIAL DATA FOR DRUGS B&C TYPE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "77b472cd-c1bf-4f00-bf2f-3ee926bc7b6a",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Amount of cores for this device: 8\n",
      "Generating data for drug: Zirabev (Bevcizumab) (47 patients)\n",
      "Generating batch 1 of size 20\n",
      "Generating data for drug: Ziv-Aflibercept (33 patients)\n",
      "Generating batch 1 of size 20\n",
      "Generating data for drug: Zofran (Ondansetron Hydrochloride) (35 patients)\n",
      "Generating batch 1 of size 20\n",
      "Generating data for drug: Zoledronic Acid (41 patients)\n",
      "Generating batch 1 of size 20\n",
      "Generating data for drug: Zolinza (Vorinostat) (48 patients)\n",
      "Generating batch 1 of size 20\n",
      "Generating data for drug: Zometa (Zoledronic Acid) (26 patients)\n",
      "Generating batch 1 of size 20\n",
      "Generating data for drug: Zyclara (Imiquimod) (22 patients)\n",
      "Generating batch 1 of size 20\n",
      "Generating data for drug: Zydelig (Idelalisib) (30 patients)\n",
      "Generating batch 1 of size 20\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"4\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"49\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"21\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"51\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"6\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25\",\n",
      "    \"Age\": \"79\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"15\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"66\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"I49\",\n",
      "    \"Age\": \"73\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J12\",\n",
      "    \"Age\": \"50\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"11\",\n",
      "    \"AEENDY\": \"22\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"13\",\n",
      "    \"AEENDY\": \"29\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Cardiomyopathy\",\n",
      "    \"MHTERM\": \"I42\",\n",
      "    \"Age\": \"76\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperthyroidism\",\n",
      "    \"MHTERM\": \"E05\",\n",
      "    \"Age\": \"52\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"61\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Valve Disease\",\n",
      "    \"MHTERM\": \"I34\",\n",
      "    \"Age\": \"80\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '78', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '65', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '4', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '58', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '72', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '49', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '10', 'AEENDY': '21', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '68', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '12', 'AEENDY': '28', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50', 'Age': '75', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient009', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '51', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '6', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '60', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient011', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25', 'Age': '79', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient012', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '15', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '66', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '59', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient014', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': 'I49', 'Age': '73', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient015', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '8', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J12', 'Age': '50', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient016', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '11', 'AEENDY': '22', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '69', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient017', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '13', 'AEENDY': '29', 'MHCAT': 'Cardiac', 'MHSCAT': 'Cardiomyopathy', 'MHTERM': 'I42', 'Age': '76', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient018', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperthyroidism', 'MHTERM': 'E05', 'Age': '52', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient019', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '61', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient020', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Valve Disease', 'MHTERM': 'I34', 'Age': '80', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '42 days'}]\n",
      "Generating batch 2 of size 15\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"I49\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"15\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"67\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperthyroidism\",\n",
      "    \"MHTERM\": \"E05\",\n",
      "    \"Age\": \"74\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"9\",\n",
      "    \"AEENDY\": \"13\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"16\",\n",
      "    \"AEENDY\": \"26\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Valve Disorder\",\n",
      "    \"MHTERM\": \"I34\",\n",
      "    \"Age\": \"81\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J12\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Cushing's Syndrome\",\n",
      "    \"MHTERM\": \"E24\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"76\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"61\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Emphysema\",\n",
      "    \"MHTERM\": \"J43\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Addison's Disease\",\n",
      "    \"MHTERM\": \"E27\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"11\",\n",
      "    \"AEENDY\": \"15\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"64\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study789', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '12', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '7', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '25', 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': 'I49', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient006', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '69', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '8', 'AEENDY': '15', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '55', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient008', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '72', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient009', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '9', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50', 'Age': '60', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '10', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '67', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient011', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperthyroidism', 'MHTERM': 'E05', 'Age': '74', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient012', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '9', 'AEENDY': '13', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '59', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '16', 'AEENDY': '26', 'MHCAT': 'Cardiac', 'MHSCAT': 'Valve Disorder', 'MHTERM': 'I34', 'Age': '81', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient014', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J12', 'Age': '71', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient015', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '7', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': \"Cushing's Syndrome\", 'MHTERM': 'E24', 'Age': '63', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient016', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '76', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient017', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '8', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '61', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient018', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '9', 'MHCAT': 'Respiratory', 'MHSCAT': 'Emphysema', 'MHTERM': 'J43', 'Age': '68', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient019', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': \"Addison's Disease\", 'MHTERM': 'E27', 'Age': '75', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient020', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '11', 'AEENDY': '15', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '64', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "Generating batch 2 of size 20\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"14\",\n",
      "    \"AEENDY\": \"30\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperlipidemia\",\n",
      "    \"MHTERM\": \"E78\",\n",
      "    \"Age\": \"64\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"6\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"9\",\n",
      "    \"AEENDY\": \"20\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50\",\n",
      "    \"Age\": \"61\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J12\",\n",
      "    \"Age\": \"57\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"11\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"66\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"I49\",\n",
      "    \"Age\": \"79\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"1\",\n",
      "    \"AEENDY\": \"3\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"74\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"56\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '12', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '7', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '10', 'AEENDY': '25', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '9', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '60', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '14', 'AEENDY': '30', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '72', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient008', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '55', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient009', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '5', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25', 'Age': '68', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '10', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '59', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient011', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperlipidemia', 'MHTERM': 'E78', 'Age': '64', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient012', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '6', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '75', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '9', 'AEENDY': '20', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50', 'Age': '61', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient014', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J12', 'Age': '57', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient015', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '11', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '71', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient016', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '12', 'AEENDY': '28', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '66', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient017', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': 'I49', 'Age': '79', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient018', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '1', 'AEENDY': '3', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '63', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient019', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '74', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient020', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '56', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "Generating batch 2 of size 20\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"14\",\n",
      "    \"AEENDY\": \"21\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"18\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25\",\n",
      "    \"Age\": \"67\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"9\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperthyroidism\",\n",
      "    \"MHTERM\": \"E05\",\n",
      "    \"Age\": \"64\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"6\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50\",\n",
      "    \"Age\": \"66\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"22\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J12\",\n",
      "    \"Age\": \"73\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"13\",\n",
      "    \"AEENDY\": \"19\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"61\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"74\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"11\",\n",
      "    \"AEENDY\": \"15\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"57\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"76\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '9', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '72', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '14', 'AEENDY': '21', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '68', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '12', 'AEENDY': '18', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '75', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient008', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '60', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient009', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '8', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25', 'Age': '67', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '9', 'AEENDY': '12', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '59', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient011', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperthyroidism', 'MHTERM': 'E05', 'Age': '64', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient012', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '6', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '71', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '10', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50', 'Age': '66', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient014', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '22', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J12', 'Age': '73', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient015', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '13', 'AEENDY': '19', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '61', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient016', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '69', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient017', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '9', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '74', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient018', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '11', 'AEENDY': '15', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '63', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient019', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '57', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient020', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '76', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "Generating batch 2 of size 13\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"17\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"14\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"21\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25\",\n",
      "    \"Age\": \"82\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"14\",\n",
      "    \"AEENDY\": \"21\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperlipidemia\",\n",
      "    \"MHTERM\": \"E78\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"4\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50\",\n",
      "    \"Age\": \"79\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J12\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"21\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"17\",\n",
      "    \"AEENDY\": \"24\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"66\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"85\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"19\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"73\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"61\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '14', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '17', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '71', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '8', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '14', 'AEENDY': '28', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '69', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '21', 'AEENDY': '28', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '75', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient008', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '60', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient009', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25', 'Age': '82', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '14', 'AEENDY': '21', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '55', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient011', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperlipidemia', 'MHTERM': 'E78', 'Age': '68', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient012', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '10', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '72', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '4', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50', 'Age': '79', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient014', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J12', 'Age': '63', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient015', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '10', 'AEENDY': '21', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient016', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '17', 'AEENDY': '24', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '66', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient017', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '85', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient018', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '59', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient019', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '12', 'AEENDY': '19', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '73', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient020', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '61', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "Generating batch 2 of size 10\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"49\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"14\",\n",
      "    \"AEENDY\": \"21\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"18\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperlipidemia\",\n",
      "    \"MHTERM\": \"E78\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50\",\n",
      "    \"Age\": \"79\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J12\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"9\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Osteoporosis\",\n",
      "    \"MHTERM\": \"M81\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"6\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"52\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"I49\",\n",
      "    \"Age\": \"66\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Emphysema\",\n",
      "    \"MHTERM\": \"J43\",\n",
      "    \"Age\": \"73\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"22\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Thyroid Cancer\",\n",
      "    \"MHTERM\": \"C73\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Valve Disorder\",\n",
      "    \"MHTERM\": \"I34\",\n",
      "    \"Age\": \"76\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"13\",\n",
      "    \"AEENDY\": \"19\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pleurisy\",\n",
      "    \"MHTERM\": \"R09.1\",\n",
      "    \"Age\": \"61\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Adrenal Gland Disorder\",\n",
      "    \"MHTERM\": \"E27\",\n",
      "    \"Age\": \"81\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'StudyZol1', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '65', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '58', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient005', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '72', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '9', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '49', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '14', 'AEENDY': '21', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '55', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient008', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25', 'Age': '68', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient009', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '12', 'AEENDY': '18', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '75', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient010', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperlipidemia', 'MHTERM': 'E78', 'Age': '60', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient011', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '8', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50', 'Age': '79', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient012', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J12', 'Age': '63', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '9', 'AEENDY': '12', 'MHCAT': 'Endocrine', 'MHSCAT': 'Osteoporosis', 'MHTERM': 'M81', 'Age': '70', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient014', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '6', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '52', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient015', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': 'I49', 'Age': '66', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient016', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '10', 'MHCAT': 'Respiratory', 'MHSCAT': 'Emphysema', 'MHTERM': 'J43', 'Age': '73', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient017', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '22', 'MHCAT': 'Endocrine', 'MHSCAT': 'Thyroid Cancer', 'MHTERM': 'C73', 'Age': '59', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient018', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Valve Disorder', 'MHTERM': 'I34', 'Age': '76', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient019', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '13', 'AEENDY': '19', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pleurisy', 'MHTERM': 'R09.1', 'Age': '61', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient020', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Adrenal Gland Disorder', 'MHTERM': 'E27', 'Age': '81', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '21 days'}]\n",
      "Generating batch 2 of size 6\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"Hypertension\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"Asthma\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"Diabetes Mellitus\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"Atrial Fibrillation\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"COPD\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"Hypothyroidism\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"Coronary Artery Disease\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"Bronchitis\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Osteoporosis\",\n",
      "    \"MHTERM\": \"Osteoporosis\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Headache\",\n",
      "    \"AEDECOD\": \"Headache\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Rash\",\n",
      "    \"AEDECOD\": \"Rash\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"Arrhythmia\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"Pneumonia\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Peripheral neuropathy\",\n",
      "    \"AEDECOD\": \"Peripheral neuropathy\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"20\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperlipidemia\",\n",
      "    \"MHTERM\": \"Hyperlipidemia\",\n",
      "    \"Age\": \"66\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"Heart Failure\",\n",
      "    \"Age\": \"79\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Constipation\",\n",
      "    \"AEDECOD\": \"Constipation\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"6\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Emphysema\",\n",
      "    \"MHTERM\": \"Emphysema\",\n",
      "    \"Age\": \"61\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Decreased appetite\",\n",
      "    \"AEDECOD\": \"Decreased appetite\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Thyroid disorder\",\n",
      "    \"MHTERM\": \"Thyroid disorder\",\n",
      "    \"Age\": \"74\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Insomnia\",\n",
      "    \"AEDECOD\": \"Insomnia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Valve disorder\",\n",
      "    \"MHTERM\": \"Valve disorder\",\n",
      "    \"Age\": \"67\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Dry skin\",\n",
      "    \"AEDECOD\": \"Dry skin\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Sleep Apnea\",\n",
      "    \"MHTERM\": \"Sleep Apnea\",\n",
      "    \"Age\": \"73\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '12', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'Hypertension', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'Asthma', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '7', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'Diabetes Mellitus', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '9', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'Atrial Fibrillation', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '8', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'COPD', 'Age': '69', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'Hypothyroidism', 'Age': '72', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient008', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'Coronary Artery Disease', 'Age': '60', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient009', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '10', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'Bronchitis', 'Age': '75', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient010', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Osteoporosis', 'MHTERM': 'Osteoporosis', 'Age': '63', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient011', 'AESEQ': '1', 'AETERM': 'Headache', 'AEDECOD': 'Headache', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '55', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient012', 'AESEQ': '1', 'AETERM': 'Rash', 'AEDECOD': 'Rash', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '14', 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': 'Arrhythmia', 'Age': '68', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient013', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'Pneumonia', 'Age': '71', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient014', 'AESEQ': '1', 'AETERM': 'Peripheral neuropathy', 'AEDECOD': 'Peripheral neuropathy', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '20', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperlipidemia', 'MHTERM': 'Hyperlipidemia', 'Age': '66', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient015', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'Heart Failure', 'Age': '79', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient016', 'AESEQ': '1', 'AETERM': 'Constipation', 'AEDECOD': 'Constipation', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '6', 'MHCAT': 'Respiratory', 'MHSCAT': 'Emphysema', 'MHTERM': 'Emphysema', 'Age': '61', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient017', 'AESEQ': '1', 'AETERM': 'Decreased appetite', 'AEDECOD': 'Decreased appetite', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '10', 'MHCAT': 'Endocrine', 'MHSCAT': 'Thyroid disorder', 'MHTERM': 'Thyroid disorder', 'Age': '74', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient018', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '59', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient019', 'AESEQ': '1', 'AETERM': 'Insomnia', 'AEDECOD': 'Insomnia', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '9', 'MHCAT': 'Cardiac', 'MHSCAT': 'Valve disorder', 'MHTERM': 'Valve disorder', 'Age': '67', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient020', 'AESEQ': '1', 'AETERM': 'Dry skin', 'AEDECOD': 'Dry skin', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '12', 'MHCAT': 'Respiratory', 'MHSCAT': 'Sleep Apnea', 'MHTERM': 'Sleep Apnea', 'Age': '73', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}]\n",
      "Generating batch 2 of size 2\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11.9\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44.9\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"82\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Gastrointestinal\",\n",
      "    \"MHSCAT\": \"GERD\",\n",
      "    \"MHTERM\": \"K21.9\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Renal\",\n",
      "    \"MHSCAT\": \"Chronic Kidney Disease\",\n",
      "    \"MHTERM\": \"N18.9\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45.909\",\n",
      "    \"Age\": \"45\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25.10\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03.9\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"11\",\n",
      "    \"MHCAT\": \"Gastrointestinal\",\n",
      "    \"MHSCAT\": \"Irritable Bowel Syndrome\",\n",
      "    \"MHTERM\": \"K58.9\",\n",
      "    \"Age\": \"48\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Renal\",\n",
      "    \"MHSCAT\": \"Kidney Stones\",\n",
      "    \"MHTERM\": \"N20.0\",\n",
      "    \"Age\": \"67\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20.9\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"Gastrointestinal\",\n",
      "    \"MHSCAT\": \"Gastritis\",\n",
      "    \"MHTERM\": \"K29.70\",\n",
      "    \"Age\": \"64\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"79\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"StudyZol1\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50.9\",\n",
      "    \"Age\": \"81\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'StudyZol1', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '12', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11.9', 'Age': '78', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '7', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44.9', 'Age': '65', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '70', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient005', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '82', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '10', 'MHCAT': 'Gastrointestinal', 'MHSCAT': 'GERD', 'MHTERM': 'K21.9', 'Age': '58', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient007', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Renal', 'MHSCAT': 'Chronic Kidney Disease', 'MHTERM': 'N18.9', 'Age': '72', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '9', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '60', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient009', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45.909', 'Age': '45', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '12', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '68', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient011', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25.10', 'Age': '75', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient012', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '10', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03.9', 'Age': '63', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient013', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '55', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient014', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '11', 'MHCAT': 'Gastrointestinal', 'MHSCAT': 'Irritable Bowel Syndrome', 'MHTERM': 'K58.9', 'Age': '48', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient015', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Renal', 'MHSCAT': 'Kidney Stones', 'MHTERM': 'N20.0', 'Age': '67', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient016', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '8', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '71', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient017', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20.9', 'Age': '59', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient018', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '5', 'MHCAT': 'Gastrointestinal', 'MHSCAT': 'Gastritis', 'MHTERM': 'K29.70', 'Age': '64', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient019', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '79', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'StudyZol1', 'USUBJID': 'Patient020', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '10', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50.9', 'Age': '81', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "Generating batch 2 of size 20\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"OncoTrial2024\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"OncoTrial2024\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'OncoTrial2024', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '14', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'OncoTrial2024', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '78', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "File appended: Zyclara (Imiquimod)_patient_data.csv\n",
      "Successfully generated and saved data for Zyclara (Imiquimod)\n",
      "Generating data for drug: Zykadia (Ceritinib) (28 patients)\n",
      "Generating batch 1 of size 20\n",
      "Error processing Zykadia (Ceritinib): 429 Resource has been exhausted (e.g. check quota).\n",
      "Generating data for drug: Zynlonta (Loncastuximab Tesirine-lpyl) (39 patients)\n",
      "Generating batch 1 of size 20\n",
      "Error processing Zynlonta (Loncastuximab Tesirine-lpyl): 429 Resource has been exhausted (e.g. check quota).\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Renal\",\n",
      "    \"MHSCAT\": \"Chronic Kidney Disease\",\n",
      "    \"MHTERM\": \"N18\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"20\",\n",
      "    \"AEENDY\": \"30\",\n",
      "    \"MHCAT\": \"Gastrointestinal\",\n",
      "    \"MHSCAT\": \"GERD\",\n",
      "    \"MHTERM\": \"K21\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '78', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '65', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '58', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '25', 'MHCAT': 'Renal', 'MHSCAT': 'Chronic Kidney Disease', 'MHTERM': 'N18', 'Age': '70', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '20', 'AEENDY': '30', 'MHCAT': 'Gastrointestinal', 'MHSCAT': 'GERD', 'MHTERM': 'K21', 'Age': '68', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "File appended: Zometa (Zoledronic Acid)_patient_data.csv\n",
      "Successfully generated and saved data for Zometa (Zoledronic Acid)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"Hypertension\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"Asthma\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"Diabetes Mellitus\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"14\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"Atrial Fibrillation\",\n",
      "    \"Age\": \"82\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"Chronic Obstructive Pulmonary Disease\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"11\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"Hypothyroidism\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"4\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"Coronary Artery Disease\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Pneumonia\",\n",
      "    \"AEDECOD\": \"Pneumonia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"Yes\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"18\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"85\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '12', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'Hypertension', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'Asthma', 'Age': '78', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '10', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'Diabetes Mellitus', 'Age': '65', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '14', 'AEENDY': '28', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '70', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'Atrial Fibrillation', 'Age': '82', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'Chronic Obstructive Pulmonary Disease', 'Age': '68', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '11', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'Hypothyroidism', 'Age': '75', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '4', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'Coronary Artery Disease', 'Age': '60', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient009', 'AESEQ': '1', 'AETERM': 'Pneumonia', 'AEDECOD': 'Pneumonia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'Yes', 'AESMIE': 'Yes', 'AESTDY': '18', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '85', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient010', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '55', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}]\n",
      "File appended: Zydelig (Idelalisib)_patient_data.csv\n",
      "Successfully generated and saved data for Zydelig (Idelalisib)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"14\",\n",
      "    \"AEENDY\": \"21\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50\",\n",
      "    \"Age\": \"81\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"9\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Obesity\",\n",
      "    \"MHTERM\": \"E66\",\n",
      "    \"Age\": \"57\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"6\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"I49\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study789', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '9', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '14', 'AEENDY': '21', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '69', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '12', 'AEENDY': '28', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '72', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient008', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '55', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient009', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '8', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50', 'Age': '81', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '9', 'AEENDY': '12', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '60', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient011', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Obesity', 'MHTERM': 'E66', 'Age': '57', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient012', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '6', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '75', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '10', 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': 'I49', 'Age': '63', 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}]\n",
      "File appended: Ziv-Aflibercept_patient_data.csv\n",
      "Successfully generated and saved data for Ziv-Aflibercept\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"4\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"14\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"30\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"I25.1\",\n",
      "    \"Age\": \"81\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"6\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperlipidemia\",\n",
      "    \"MHTERM\": \"E78\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J12\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"11\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '4', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '10', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '69', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '14', 'AEENDY': '28', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '72', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '10', 'AEENDY': '30', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '60', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient009', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'I25.1', 'Age': '81', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '6', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '55', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient011', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperlipidemia', 'MHTERM': 'E78', 'Age': '68', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient012', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '12', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '75', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50', 'Age': '63', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient014', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J12', 'Age': '59', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient015', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '11', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '71', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "File appended: Zofran (Ondansetron Hydrochloride)_patient_data.csv\n",
      "Successfully generated and saved data for Zofran (Ondansetron Hydrochloride)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"I49\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"15\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"J20\",\n",
      "    \"Age\": \"67\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"6\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperlipidemia\",\n",
      "    \"MHTERM\": \"E78\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"74\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"9\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Angina\",\n",
      "    \"MHTERM\": \"I20\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"20\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pneumonia\",\n",
      "    \"MHTERM\": \"J12\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Obesity\",\n",
      "    \"MHTERM\": \"E66\",\n",
      "    \"Age\": \"66\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"11\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"79\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"1\",\n",
      "    \"AEENDY\": \"3\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"57\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Emphysema\",\n",
      "    \"MHTERM\": \"J43\",\n",
      "    \"Age\": \"64\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"11\",\n",
      "    \"AEENDY\": \"13\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Osteoporosis\",\n",
      "    \"MHTERM\": \"M81\",\n",
      "    \"Age\": \"81\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study789\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study789', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '12', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '7', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '25', 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': 'I49', 'Age': '78', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient006', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '69', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '8', 'AEENDY': '15', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '55', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '72', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient009', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50', 'Age': '60', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient010', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '10', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'J20', 'Age': '67', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient011', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '6', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperlipidemia', 'MHTERM': 'E78', 'Age': '59', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient012', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '74', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '9', 'AEENDY': '12', 'MHCAT': 'Cardiac', 'MHSCAT': 'Angina', 'MHTERM': 'I20', 'Age': '63', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient014', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '12', 'AEENDY': '20', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pneumonia', 'MHTERM': 'J12', 'Age': '71', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient015', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Obesity', 'MHTERM': 'E66', 'Age': '66', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient016', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '6', 'AEENDY': '11', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '79', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient017', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '1', 'AEENDY': '3', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '57', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient018', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Emphysema', 'MHTERM': 'J43', 'Age': '64', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient019', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '11', 'AEENDY': '13', 'MHCAT': 'Endocrine', 'MHSCAT': 'Osteoporosis', 'MHTERM': 'M81', 'Age': '81', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study789', 'USUBJID': 'Patient020', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '8', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '75', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "Generating batch 3 of size 7\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"Hypertension\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"Asthma\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"Diabetes Mellitus\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"14\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Hematologic\",\n",
      "    \"MHSCAT\": \"Thrombocytopenia\",\n",
      "    \"MHTERM\": \"Thrombocytopenia\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"15\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"Atrial Fibrillation\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"Chronic Obstructive Pulmonary Disease\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"6\",\n",
      "    \"MHCAT\": \"Gastrointestinal\",\n",
      "    \"MHSCAT\": \"GERD\",\n",
      "    \"MHTERM\": \"Gastroesophageal Reflux Disease\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Neurological\",\n",
      "    \"MHSCAT\": \"Peripheral Neuropathy\",\n",
      "    \"MHTERM\": \"Peripheral Neuropathy\",\n",
      "    \"Age\": \"64\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"Hypothyroidism\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Coronary Artery Disease\",\n",
      "    \"MHTERM\": \"Coronary Artery Disease\",\n",
      "    \"Age\": \"71\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"66\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"28\",\n",
      "    \"MHCAT\": \"Hematologic\",\n",
      "    \"MHSCAT\": \"Anemia\",\n",
      "    \"MHTERM\": \"Anemia\",\n",
      "    \"Age\": \"73\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"9\",\n",
      "    \"AEENDY\": \"13\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"Heart Failure\",\n",
      "    \"Age\": \"69\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchitis\",\n",
      "    \"MHTERM\": \"Bronchitis\",\n",
      "    \"Age\": \"76\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"Gastrointestinal\",\n",
      "    \"MHSCAT\": \"IBS\",\n",
      "    \"MHTERM\": \"Irritable Bowel Syndrome\",\n",
      "    \"Age\": \"61\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"16\",\n",
      "    \"MHCAT\": \"Neurological\",\n",
      "    \"MHSCAT\": \"Migraine\",\n",
      "    \"MHTERM\": \"Migraine\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperlipidemia\",\n",
      "    \"MHTERM\": \"Hyperlipidemia\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"Arrhythmia\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"67\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '12', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'Hypertension', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'Asthma', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '7', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'Diabetes Mellitus', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '10', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '65', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '14', 'AEENDY': '25', 'MHCAT': 'Hematologic', 'MHSCAT': 'Thrombocytopenia', 'MHTERM': 'Thrombocytopenia', 'Age': '72', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '15', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'Atrial Fibrillation', 'Age': '68', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient007', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'Chronic Obstructive Pulmonary Disease', 'Age': '75', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '6', 'MHCAT': 'Gastrointestinal', 'MHSCAT': 'GERD', 'MHTERM': 'Gastroesophageal Reflux Disease', 'Age': '60', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient009', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '14', 'MHCAT': 'Neurological', 'MHSCAT': 'Peripheral Neuropathy', 'MHTERM': 'Peripheral Neuropathy', 'Age': '64', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient010', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'Hypothyroidism', 'Age': '59', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient011', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '5', 'MHCAT': 'Cardiac', 'MHSCAT': 'Coronary Artery Disease', 'MHTERM': 'Coronary Artery Disease', 'Age': '71', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient012', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '12', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '66', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '28', 'MHCAT': 'Hematologic', 'MHSCAT': 'Anemia', 'MHTERM': 'Anemia', 'Age': '73', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient014', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '9', 'AEENDY': '13', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'Heart Failure', 'Age': '69', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient015', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchitis', 'MHTERM': 'Bronchitis', 'Age': '76', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient016', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'Gastrointestinal', 'MHSCAT': 'IBS', 'MHTERM': 'Irritable Bowel Syndrome', 'Age': '61', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient017', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '16', 'MHCAT': 'Neurological', 'MHSCAT': 'Migraine', 'MHTERM': 'Migraine', 'Age': '65', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient018', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperlipidemia', 'MHTERM': 'Hyperlipidemia', 'Age': '60', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient019', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '8', 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': 'Arrhythmia', 'Age': '72', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient020', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '9', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '67', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "Generating batch 3 of size 8\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"I10\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"J44\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"E11\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"9\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"I48\",\n",
      "    \"Age\": \"72\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"J45\",\n",
      "    \"Age\": \"49\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"E03\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"20\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Heart Failure\",\n",
      "    \"MHTERM\": \"I50\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient009\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"15\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Pulmonary Fibrosis\",\n",
      "    \"MHTERM\": \"J84\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient010\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hyperthyroidism\",\n",
      "    \"MHTERM\": \"E05\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient011\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"6\",\n",
      "    \"AEENDY\": \"8\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"I49\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient012\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Bronchiectasis\",\n",
      "    \"MHTERM\": \"J47\",\n",
      "    \"Age\": \"63\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient013\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"9\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Insipidus\",\n",
      "    \"MHTERM\": \"E23\",\n",
      "    \"Age\": \"51\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient014\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"4\",\n",
      "    \"AEENDY\": \"6\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Cardiomyopathy\",\n",
      "    \"MHTERM\": \"I42\",\n",
      "    \"Age\": \"79\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient015\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Cystic Fibrosis\",\n",
      "    \"MHTERM\": \"E84\",\n",
      "    \"Age\": \"44\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient016\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"4\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Polycystic Ovary Syndrome\",\n",
      "    \"MHTERM\": \"E28\",\n",
      "    \"Age\": \"38\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient017\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"14\",\n",
      "    \"AEENDY\": \"22\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"66\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient018\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Peripheral Artery Disease\",\n",
      "    \"MHTERM\": \"I70\",\n",
      "    \"Age\": \"73\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient019\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anaemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"16\",\n",
      "    \"AEENDY\": \"26\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Sarcoidosis\",\n",
      "    \"MHTERM\": \"D86\",\n",
      "    \"Age\": \"59\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient020\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"8\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Cushing's Syndrome\",\n",
      "    \"MHTERM\": \"E24\",\n",
      "    \"Age\": \"64\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'I10', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'J44', 'Age': '78', 'Sex': 'Male', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '10', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'E11', 'Age': '65', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '58', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '9', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'I48', 'Age': '72', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'J45', 'Age': '49', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient007', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'E03', 'Age': '68', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '12', 'AEENDY': '20', 'MHCAT': 'Cardiac', 'MHSCAT': 'Heart Failure', 'MHTERM': 'I50', 'Age': '75', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient009', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '15', 'AEENDY': '25', 'MHCAT': 'Respiratory', 'MHSCAT': 'Pulmonary Fibrosis', 'MHTERM': 'J84', 'Age': '60', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient010', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hyperthyroidism', 'MHTERM': 'E05', 'Age': '55', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient011', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '6', 'AEENDY': '8', 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': 'I49', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient012', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Bronchiectasis', 'MHTERM': 'J47', 'Age': '63', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient013', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '9', 'AEENDY': '12', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Insipidus', 'MHTERM': 'E23', 'Age': '51', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient014', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '4', 'AEENDY': '6', 'MHCAT': 'Cardiac', 'MHSCAT': 'Cardiomyopathy', 'MHTERM': 'I42', 'Age': '79', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient015', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Cystic Fibrosis', 'MHTERM': 'E84', 'Age': '44', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient016', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '4', 'MHCAT': 'Endocrine', 'MHSCAT': 'Polycystic Ovary Syndrome', 'MHTERM': 'E28', 'Age': '38', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient017', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '14', 'AEENDY': '22', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '66', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient018', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Peripheral Artery Disease', 'MHTERM': 'I70', 'Age': '73', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient019', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anaemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '16', 'AEENDY': '26', 'MHCAT': 'Respiratory', 'MHSCAT': 'Sarcoidosis', 'MHTERM': 'D86', 'Age': '59', 'Sex': 'Female', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient020', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '8', 'AEENDY': '10', 'MHCAT': 'Endocrine', 'MHSCAT': \"Cushing's Syndrome\", 'MHTERM': 'E24', 'Age': '64', 'Sex': 'Male', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "Generating batch 3 of size 1\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"ZOL456\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": 1,\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": 5,\n",
      "    \"AEENDY\": 12,\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"Atrial fibrillation\",\n",
      "    \"Age\": 68,\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'ZOL456', 'USUBJID': 'Patient001', 'AESEQ': 1, 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': 5, 'AEENDY': 12, 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': 'Atrial fibrillation', 'Age': 68, 'Sex': 'Female', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}]\n",
      "File appended: Zoledronic Acid_patient_data.csv\n",
      "Successfully generated and saved data for Zoledronic Acid\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"Hypertension\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"Asthma\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"Diabetes Mellitus\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Atrial Fibrillation\",\n",
      "    \"MHTERM\": \"Atrial Fibrillation\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"12\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"Chronic Obstructive Pulmonary Disease\",\n",
      "    \"Age\": \"60\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study123\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"4\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"Hypothyroidism\",\n",
      "    \"Age\": \"55\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study123', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '14', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': 'Hypertension', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': 'Asthma', 'Age': '58', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '5', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': 'Diabetes Mellitus', 'Age': '70', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '10', 'AEENDY': '25', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '68', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient005', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Cardiac', 'MHSCAT': 'Atrial Fibrillation', 'MHTERM': 'Atrial Fibrillation', 'Age': '75', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '5', 'AEENDY': '12', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': 'Chronic Obstructive Pulmonary Disease', 'Age': '60', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study123', 'USUBJID': 'Patient007', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '4', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': 'Hypothyroidism', 'Age': '55', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}]\n",
      "File appended: Zirabev (Bevcizumab)_patient_data.csv\n",
      "Successfully generated and saved data for Zirabev (Bevcizumab)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"STUDYID\": \"Study456\",\n",
      "    \"USUBJID\": \"Patient001\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Nausea\",\n",
      "    \"AEDECOD\": \"Nausea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"3\",\n",
      "    \"AEENDY\": \"7\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Hypertension\",\n",
      "    \"MHTERM\": \"409620005\",\n",
      "    \"Age\": \"62\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study456\",\n",
      "    \"USUBJID\": \"Patient002\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"Asthma\",\n",
      "    \"MHTERM\": \"195967001\",\n",
      "    \"Age\": \"78\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study456\",\n",
      "    \"USUBJID\": \"Patient003\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Fatigue\",\n",
      "    \"AEDECOD\": \"Fatigue\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"5\",\n",
      "    \"AEENDY\": \"14\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Diabetes Mellitus\",\n",
      "    \"MHTERM\": \"73211009\",\n",
      "    \"Age\": \"65\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study456\",\n",
      "    \"USUBJID\": \"Patient004\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Vomiting\",\n",
      "    \"AEDECOD\": \"Vomiting\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"2\",\n",
      "    \"AEENDY\": \"5\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"58\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Light\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study456\",\n",
      "    \"USUBJID\": \"Patient005\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Neutropenia\",\n",
      "    \"AEDECOD\": \"Neutropenia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"10\",\n",
      "    \"AEENDY\": \"25\",\n",
      "    \"MHCAT\": \"Cardiac\",\n",
      "    \"MHSCAT\": \"Arrhythmia\",\n",
      "    \"MHTERM\": \"698247007\",\n",
      "    \"Age\": \"70\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"White\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study456\",\n",
      "    \"USUBJID\": \"Patient006\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Anemia\",\n",
      "    \"AEDECOD\": \"Anemia\",\n",
      "    \"AESER\": \"Yes\",\n",
      "    \"AEOUT\": \"Recovering\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"Yes\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"Yes\",\n",
      "    \"AESTDY\": \"12\",\n",
      "    \"AEENDY\": \"30\",\n",
      "    \"MHCAT\": \"Respiratory\",\n",
      "    \"MHSCAT\": \"COPD\",\n",
      "    \"MHTERM\": \"13645005\",\n",
      "    \"Age\": \"68\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Black\",\n",
      "    \"Smoking_Status\": \"Current Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Moderate\",\n",
      "    \"Dosage\": \"50 mg\",\n",
      "    \"Treatment_Duration\": \"21 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study456\",\n",
      "    \"USUBJID\": \"Patient007\",\n",
      "    \"AESEQ\": \"NA\",\n",
      "    \"AETERM\": \"NA\",\n",
      "    \"AEDECOD\": \"NA\",\n",
      "    \"AESER\": \"NA\",\n",
      "    \"AEOUT\": \"NA\",\n",
      "    \"AESDISAB\": \"NA\",\n",
      "    \"AESDTH\": \"NA\",\n",
      "    \"AESHOSP\": \"NA\",\n",
      "    \"AESLIFE\": \"NA\",\n",
      "    \"AESMIE\": \"NA\",\n",
      "    \"AESTDY\": \"NA\",\n",
      "    \"AEENDY\": \"NA\",\n",
      "    \"MHCAT\": \"Endocrine\",\n",
      "    \"MHSCAT\": \"Hypothyroidism\",\n",
      "    \"MHTERM\": \"3419003\",\n",
      "    \"Age\": \"75\",\n",
      "    \"Sex\": \"Male\",\n",
      "    \"Race\": \"Asian\",\n",
      "    \"Smoking_Status\": \"Former Smoker\",\n",
      "    \"Alcohol_Consumption\": \"Heavy\",\n",
      "    \"Dosage\": \"100 mg\",\n",
      "    \"Treatment_Duration\": \"28 days\"\n",
      "  },\n",
      "  {\n",
      "    \"STUDYID\": \"Study456\",\n",
      "    \"USUBJID\": \"Patient008\",\n",
      "    \"AESEQ\": \"1\",\n",
      "    \"AETERM\": \"Diarrhea\",\n",
      "    \"AEDECOD\": \"Diarrhoea\",\n",
      "    \"AESER\": \"No\",\n",
      "    \"AEOUT\": \"Resolved\",\n",
      "    \"AESDISAB\": \"No\",\n",
      "    \"AESDTH\": \"No\",\n",
      "    \"AESHOSP\": \"No\",\n",
      "    \"AESLIFE\": \"No\",\n",
      "    \"AESMIE\": \"No\",\n",
      "    \"AESTDY\": \"7\",\n",
      "    \"AEENDY\": \"10\",\n",
      "    \"MHCAT\": \"NA\",\n",
      "    \"MHSCAT\": \"NA\",\n",
      "    \"MHTERM\": \"NA\",\n",
      "    \"Age\": \"52\",\n",
      "    \"Sex\": \"Female\",\n",
      "    \"Race\": \"Hispanic\",\n",
      "    \"Smoking_Status\": \"Never Smoker\",\n",
      "    \"Alcohol_Consumption\": \"None\",\n",
      "    \"Dosage\": \"150 mg\",\n",
      "    \"Treatment_Duration\": \"42 days\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'STUDYID': 'Study456', 'USUBJID': 'Patient001', 'AESEQ': '1', 'AETERM': 'Nausea', 'AEDECOD': 'Nausea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '3', 'AEENDY': '7', 'MHCAT': 'Cardiac', 'MHSCAT': 'Hypertension', 'MHTERM': '409620005', 'Age': '62', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study456', 'USUBJID': 'Patient002', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Respiratory', 'MHSCAT': 'Asthma', 'MHTERM': '195967001', 'Age': '78', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study456', 'USUBJID': 'Patient003', 'AESEQ': '1', 'AETERM': 'Fatigue', 'AEDECOD': 'Fatigue', 'AESER': 'No', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '5', 'AEENDY': '14', 'MHCAT': 'Endocrine', 'MHSCAT': 'Diabetes Mellitus', 'MHTERM': '73211009', 'Age': '65', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study456', 'USUBJID': 'Patient004', 'AESEQ': '1', 'AETERM': 'Vomiting', 'AEDECOD': 'Vomiting', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '2', 'AEENDY': '5', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '58', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Light', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study456', 'USUBJID': 'Patient005', 'AESEQ': '1', 'AETERM': 'Neutropenia', 'AEDECOD': 'Neutropenia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '10', 'AEENDY': '25', 'MHCAT': 'Cardiac', 'MHSCAT': 'Arrhythmia', 'MHTERM': '698247007', 'Age': '70', 'Sex': 'Male', 'Race': 'White', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}, {'STUDYID': 'Study456', 'USUBJID': 'Patient006', 'AESEQ': '1', 'AETERM': 'Anemia', 'AEDECOD': 'Anemia', 'AESER': 'Yes', 'AEOUT': 'Recovering', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'Yes', 'AESLIFE': 'No', 'AESMIE': 'Yes', 'AESTDY': '12', 'AEENDY': '30', 'MHCAT': 'Respiratory', 'MHSCAT': 'COPD', 'MHTERM': '13645005', 'Age': '68', 'Sex': 'Female', 'Race': 'Black', 'Smoking_Status': 'Current Smoker', 'Alcohol_Consumption': 'Moderate', 'Dosage': '50 mg', 'Treatment_Duration': '21 days'}, {'STUDYID': 'Study456', 'USUBJID': 'Patient007', 'AESEQ': 'NA', 'AETERM': 'NA', 'AEDECOD': 'NA', 'AESER': 'NA', 'AEOUT': 'NA', 'AESDISAB': 'NA', 'AESDTH': 'NA', 'AESHOSP': 'NA', 'AESLIFE': 'NA', 'AESMIE': 'NA', 'AESTDY': 'NA', 'AEENDY': 'NA', 'MHCAT': 'Endocrine', 'MHSCAT': 'Hypothyroidism', 'MHTERM': '3419003', 'Age': '75', 'Sex': 'Male', 'Race': 'Asian', 'Smoking_Status': 'Former Smoker', 'Alcohol_Consumption': 'Heavy', 'Dosage': '100 mg', 'Treatment_Duration': '28 days'}, {'STUDYID': 'Study456', 'USUBJID': 'Patient008', 'AESEQ': '1', 'AETERM': 'Diarrhea', 'AEDECOD': 'Diarrhoea', 'AESER': 'No', 'AEOUT': 'Resolved', 'AESDISAB': 'No', 'AESDTH': 'No', 'AESHOSP': 'No', 'AESLIFE': 'No', 'AESMIE': 'No', 'AESTDY': '7', 'AEENDY': '10', 'MHCAT': 'NA', 'MHSCAT': 'NA', 'MHTERM': 'NA', 'Age': '52', 'Sex': 'Female', 'Race': 'Hispanic', 'Smoking_Status': 'Never Smoker', 'Alcohol_Consumption': 'None', 'Dosage': '150 mg', 'Treatment_Duration': '42 days'}]\n",
      "File appended: Zolinza (Vorinostat)_patient_data.csv\n",
      "Successfully generated and saved data for Zolinza (Vorinostat)\n",
      "The program used 59.91959738731384 s\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import csv\n",
    "import json\n",
    "import google.generativeai as genai\n",
    "from dotenv import load_dotenv\n",
    "import random\n",
    "import concurrent.futures  # Import for threading\n",
    "import time\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "api_key = \"AIzaSyBSpjhnYk97Un4eTDcxs9I2oDosw7YNr6g\"  # Replace with your actual API key\n",
    "genai.configure(api_key=api_key)\n",
    "\n",
    "generation_config = {\n",
    "    \"temperature\": 0,\n",
    "    \"top_p\": 0.95,\n",
    "    \"top_k\": 40,\n",
    "    \"max_output_tokens\": 16384,\n",
    "    \"response_mime_type\": \"application/json\",\n",
    "}\n",
    "\n",
    "model = genai.GenerativeModel(\n",
    "    model_name=\"gemini-2.0-flash\",\n",
    "    generation_config=generation_config,\n",
    ")\n",
    "\n",
    "def save_patient_csv(filename, data, append=False):\n",
    "    \"\"\"\n",
    "    Saves patient data to a CSV file. Appends to the file if append is True,\n",
    "    otherwise overwrites the file.\n",
    "    \"\"\"\n",
    "    csv_file = f\"{filename}.csv\"\n",
    "    file_exists = os.path.isfile(csv_file)\n",
    "\n",
    "    headers = [\n",
    "        \"STUDYID\",\n",
    "        \"USUBJID\",\n",
    "        \"AESEQ\",\n",
    "        \"AETERM\",\n",
    "        \"AEDECOD\",\n",
    "        \"AESER\",\n",
    "        \"AEOUT\",\n",
    "        \"AESDISAB\",\n",
    "        \"AESDTH\",\n",
    "        \"AESHOSP\",\n",
    "        \"AESLIFE\",\n",
    "        \"AESMIE\",\n",
    "        \"AESTDY\",\n",
    "        \"AEENDY\",\n",
    "        \"MHCAT\",\n",
    "        \"MHSCAT\",\n",
    "        \"MHTERM\",\n",
    "        \"Age\",\n",
    "        \"Sex\",\n",
    "        \"Race\",\n",
    "        \"Smoking_Status\",\n",
    "        \"Alcohol_Consumption\",\n",
    "        \"Dosage\",\n",
    "        \"Treatment_Duration\"\n",
    "    ]\n",
    "\n",
    "    write_header = not file_exists or not append\n",
    "\n",
    "    with open(csv_file, mode='a' if append else 'w', newline='', encoding='utf-8') as file:\n",
    "        writer = csv.DictWriter(file, fieldnames=headers)\n",
    "        if write_header:\n",
    "            writer.writeheader()\n",
    "\n",
    "        for row in data:\n",
    "            writer.writerow(row)\n",
    "    print(f\"File {'appended' if append else 'created'}: {csv_file}\")\n",
    "\n",
    "\n",
    "def prompt_patient_data_generation(drug_name, num_patients):\n",
    "    PROMPT = f'''\n",
    "    You are an expert in clinical trial data generation. Your task is to generate realistic, but entirely fictitious (dummy) data for patients participating in a clinical trial for the oncology drug \"{drug_name}\".\n",
    "\n",
    "    Generate data for {num_patients} patients. For EACH patient, provide the following information:\n",
    "\n",
    "    - STUDYID: A unique study identifier (e.g., \"Study123\").\n",
    "    - USUBJID: A unique subject (patient) identifier (e.g., \"Patient001\", \"Patient002\").\n",
    "    - AESEQ: An adverse event sequence number, start at 1, and increment for each adverse event the patient experiences (or NA if no adverse event).\n",
    "    - AETERM: The verbatim adverse event term reported by the investigator. Use MedDRA Preferred Terms (PTs) where possible. Examples include: Nausea, Fatigue, Vomiting, Diarrhea, Neutropenia, Anemia, or NA if there are no adverse events.\n",
    "    - AEDECOD: The standardized MedDRA Preferred Term for the adverse event (or NA if there are no adverse events). Make sure it relates to the corresponding AETERM.\n",
    "    - AESER: Whether the adverse event was serious (\"Yes\" or \"No\", or NA if there are no adverse events). If any of the AETERMs are serious, return yes.\n",
    "    - AEOUT: The outcome of the adverse event (e.g., \"Resolved\", \"Recovering\", \"Fatal\", or NA if there are no adverse events). Choose a plausible outcome given the term and whether the AESER is Yes or No\n",
    "\n",
    "    - AESDISAB: Whether the adverse event resulted in a disability (\"Yes\" or \"No\", or NA if there are no adverse events).\n",
    "    - AESDTH: Whether the adverse event resulted in death (\"Yes\" or \"No\", or NA if there are no adverse events).  Be very sparing in returning \"Yes\" for this, especially if AESER is also \"No\"\n",
    "    - AESHOSP: Whether the patient was hospitalized due to the adverse event (\"Yes\" or \"No\", or NA if there are no adverse events).\n",
    "    - AESLIFE: Whether the adverse event was life-threatening (\"Yes\" or \"No\", or NA if there are no adverse events). Be very sparing in returning \"Yes\" for this, especially if AESER is also \"No\"\n",
    "    - AESMIE: Whether the adverse event was medically important (\"Yes\" or \"No\", or NA if there are no adverse events). Use yes or no for medically important events.\n",
    "\n",
    "    - AESTDY: The adverse event start day (relative to treatment start) as a number (or NA if there are no adverse events).\n",
    "    - AEENDY: The adverse event end day (relative to treatment start) as a number (or NA if there are no adverse events).\n",
    "\n",
    "    - MHCAT: A medical history category (e.g., \"Cardiac\", \"Respiratory\", \"Endocrine\"). Use plausible and medically accurate descriptions.\n",
    "    - MHSCAT: A medical history subcategory for the medical conditions related to MHCAT (e.g., \"Hypertension\" for Cardiac, \"Asthma\" for Respiratory, \"Diabetes Mellitus\" for Endocrine).\n",
    "\n",
    "    - MHTERM: Verbatim term for medical conditions for the patient, use snowmed codes where possible, or NA if there are no conditions.\n",
    "    - Age: A realistic age for oncology patients (e.g., between 30 and 85).\n",
    "    - Sex: Either \"Male\" or \"Female\".\n",
    "    - Race: A common race/ethnicity (e.g., \"White\", \"Black\", \"Asian\", \"Hispanic\").\n",
    "    - Smoking_Status: One of \"Never Smoker\", \"Former Smoker\", or \"Current Smoker\".\n",
    "    - Alcohol_Consumption: One of \"None\", \"Light\", \"Moderate\", or \"Heavy\".\n",
    "    - Dosage: A plausible dosage for a Phase 1 oncology trial (e.g., \"50 mg\", \"100 mg\", \"150 mg\").\n",
    "    - Treatment_Duration: A plausible treatment duration (e.g., \"21 days\", \"28 days\", \"42 days\").\n",
    "\n",
    "    Specifically:\n",
    "    *   Focus on generating data that is realistic for clinical trial for an oncology drug.\n",
    "    *   When a patient does not experience an adverse event, use NA for adverse event related parameters.\n",
    "    *   Be very sparing in returning \"Yes\" for AESDTH and AESLIFE, especially if AESER is also \"No\"\n",
    "    *   The generated data should contain essential information on the patient, their medical history, and any adverse events experienced.\n",
    "    *   Adhere to the specified data types and value ranges.\n",
    "    *   Ensure logical consistency: if an AETERM and AEDECOD values are defined as NA, ALL other AE columns must also be NA\n",
    "\n",
    "    Return the data in JSON format with the specified keys. Each patient should be represented as a separate JSON object within a JSON array.\n",
    "    '''\n",
    "    return PROMPT\n",
    "\n",
    "def get_extracted_patient_data(drug_name, num_patients):\n",
    "    chat_session = model.start_chat(\n",
    "        history=[\n",
    "            {\n",
    "                \"role\": \"user\",\n",
    "                \"parts\": [prompt_patient_data_generation(drug_name, num_patients)],\n",
    "            },\n",
    "        ],\n",
    "    )\n",
    "    response = chat_session.send_message(prompt_patient_data_generation(drug_name, num_patients))\n",
    "\n",
    "    # Print the raw response text for debugging\n",
    "    print(\"Raw patient data response text:\", response.text)\n",
    "\n",
    "    try:\n",
    "        extracted_data = json.loads(response.text)\n",
    "        if isinstance(extracted_data, list) and extracted_data:\n",
    "            print(\"Extracted patient data:\", extracted_data)\n",
    "            return extracted_data\n",
    "        else:\n",
    "            print(\"Extracted data is not in the expected format or is empty.\")\n",
    "            return None\n",
    "    except json.JSONDecodeError as e:\n",
    "        print(f\"Error parsing JSON: {e}. Response text may be incomplete.\")\n",
    "        try:\n",
    "            # Attempt to fix common JSON errors (e.g., missing closing bracket)\n",
    "            if not response.text.strip().endswith(']'):\n",
    "                repaired_text = response.text.strip() + ']'\n",
    "            else:\n",
    "                repaired_text = response.text.strip()\n",
    "\n",
    "            extracted_data = json.loads(repaired_text) # Attempt to parse fixed JSON\n",
    "            print(\"Successfully parsed recovered JSON\")\n",
    "            return extracted_data\n",
    "\n",
    "        except json.JSONDecodeError as recovery_exception:\n",
    "            print(f\"Failed to recover JSON: {recovery_exception}\")\n",
    "        return None\n",
    "\n",
    "\n",
    "\n",
    "def process_drug(drug_name, batch_size):\n",
    "    try:\n",
    "        total_patients = random.randint(20,50)\n",
    "        report_name = f\"{drug_name}_patient_data\"\n",
    "        all_patient_data = []\n",
    "\n",
    "        print(f\"Generating data for drug: {drug_name} ({total_patients} patients)\")\n",
    "\n",
    "        for i in range(0, total_patients, batch_size):\n",
    "            num_patients = min(batch_size, total_patients - i)\n",
    "            print(f\"Generating batch {i//batch_size + 1} of size {num_patients}\")\n",
    "            patient_data = get_extracted_patient_data(drug_name, num_patients)\n",
    "            if patient_data:\n",
    "                all_patient_data.extend(patient_data)\n",
    "            else:\n",
    "                print(f\"Failed to generate batch {i//batch_size + 1}\")\n",
    "\n",
    "        if all_patient_data:\n",
    "            save_patient_csv(filename=report_name, data=all_patient_data, append=True)\n",
    "            print(f\"Successfully generated and saved data for {drug_name}\")\n",
    "        else:\n",
    "            print(f\"No patient data to save for {drug_name}\")\n",
    "\n",
    "    except Exception as e:\n",
    "        print(f\"Error processing {drug_name}: {e}\")\n",
    "\n",
    "def main_routine(drugs, batch_size, api_key):\n",
    "    start_time = time.time()\n",
    "\n",
    "    # Start threads for all drugs.\n",
    "    num_threads = os.cpu_count()\n",
    "    print(\"Amount of cores for this device:\", num_threads)\n",
    "    with concurrent.futures.ThreadPoolExecutor(max_workers=num_threads) as executor:\n",
    "        executor.map(lambda drug: process_drug(drug, batch_size), drugs) # pass batch_size here\n",
    "\n",
    "    print(f\"The program used {time.time() - start_time} s\")\n",
    "\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    drugs = [\n",
    "\n",
    "         \"Zirabev (Bevcizumab)\",\n",
    "        \"Ziv-Aflibercept\", \"Zofran (Ondansetron Hydrochloride)\", \"Zoledronic Acid\",\n",
    "        \"Zolinza (Vorinostat)\", \"Zometa (Zoledronic Acid)\", \"Zyclara (Imiquimod)\",\n",
    "        \"Zydelig (Idelalisib)\", \"Zykadia (Ceritinib)\", \"Zynlonta (Loncastuximab Tesirine-lpyl)\"\n",
    "    ]\n",
    "    batch_size = 20\n",
    "\n",
    "    main_routine(drugs, batch_size, api_key)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "eef5ff9e-b1e7-40da-ad54-8b385618e2bb",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Abemaciclib\",\n",
      "    \"STUDYID\": \"ABC1234\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"62\",\n",
      "    \"Female_Percentage\": \"98\",\n",
      "    \"Male_Percentage\": \"2\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"15\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"92\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"45\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"15\",\n",
      "    \"Stage_II_Percentage\": \"40\",\n",
      "    \"Stage_III_Percentage\": \"35\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"12\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"3\",\n",
      "    \"Stroke_Percentage\": \"2\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"5\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"4\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"60\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"50\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": \"30\",\n",
      "    \"Letrozole_Percentage\": \"35\",\n",
      "    \"Anastrozole_Percentage\": \"35\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"40\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"25\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"30\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Abemaciclib\",\n",
      "    \"STUDYID\": \"DEF5678\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"97\",\n",
      "    \"Male_Percentage\": \"3\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"18\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"88\",\n",
      "    \"LHRH_Use_Percentage\": \"7\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"33\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"50\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"35\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"37\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"4\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"6\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"28\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"65\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"55\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": \"32\",\n",
      "    \"Letrozole_Percentage\": \"33\",\n",
      "    \"Anastrozole_Percentage\": \"35\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"45\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"30\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"35\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"55\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Abemaciclib\",\n",
      "    \"STUDYID\": \"GHI9012\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"99\",\n",
      "    \"Male_Percentage\": \"1\",\n",
      "    \"Median_BMI\": \"29.0\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"12\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"90\",\n",
      "    \"LHRH_Use_Percentage\": \"6\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"8\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"48\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"8\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"4\",\n",
      "    \"Stage_I_Percentage\": \"12\",\n",
      "    \"Stage_II_Percentage\": \"42\",\n",
      "    \"Stage_III_Percentage\": \"36\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"10\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"2\",\n",
      "    \"Stroke_Percentage\": \"1\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"4\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"3\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"58\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"48\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Doxorubicin\",\n",
      "    \"Tamoxifen_Percentage\": \"28\",\n",
      "    \"Letrozole_Percentage\": \"37\",\n",
      "    \"Anastrozole_Percentage\": \"35\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"38\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"22\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"28\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"25\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"55\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Abemaciclib\",\n",
      "    \"STUDYID\": \"JKL3456\",\n",
      "    \"YEAR\": \"2024\",\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"96\",\n",
      "    \"Male_Percentage\": \"4\",\n",
      "    \"Median_BMI\": \"30.2\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"20\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"8\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"48\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"37\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"11\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"4\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"37\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"5\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"7\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"30\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"70\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"60\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC\",\n",
      "    \"Tamoxifen_Percentage\": \"35\",\n",
      "    \"Letrozole_Percentage\": \"32\",\n",
      "    \"Anastrozole_Percentage\": \"33\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"50\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"35\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"40\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"10\",\n",
      "    \"Beds_200_To_499_Percentage\": \"60\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"75\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3.5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Abemaciclib', 'STUDYID': 'ABC1234', 'YEAR': '2022', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '62', 'Female_Percentage': '98', 'Male_Percentage': '2', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '15', 'Total_ADL_Independence_Percentage': '92', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '10', 'Tumor_Stage_T2_Percentage': '45', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '15', 'Stage_II_Percentage': '40', 'Stage_III_Percentage': '35', 'Diabetes_Mellitus_Percentage': '12', 'Congestive_Heart_Failure_Percentage': '3', 'Stroke_Percentage': '2', 'Atrial_Fibrillation_Percentage': '5', 'Myocardial_Infarction_Percentage': '4', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '60', 'Postoperative_RT_Received_Percentage': '50', 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': '30', 'Letrozole_Percentage': '35', 'Anastrozole_Percentage': '35', 'Antidiarrheal_Agent_Probiotics_Percentage': '40', 'Antiemetic_Agent_Percentage': '25', 'Painkiller_Antipyretic_Percentage': '30', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Abemaciclib', 'STUDYID': 'DEF5678', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '68', 'Female_Percentage': '97', 'Male_Percentage': '3', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '18', 'Total_ADL_Independence_Percentage': '88', 'LHRH_Use_Percentage': '7', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '40', 'Tumor_Stage_T3_Percentage': '33', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '50', 'Nodal_Stage_N1_Percentage': '35', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '37', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '4', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '6', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '28', 'Adjuvant_Chemotherapy_Received_Percentage': '65', 'Postoperative_RT_Received_Percentage': '55', 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel', 'Common_Adjuvant_Regimen_1': 'FEC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': '32', 'Letrozole_Percentage': '33', 'Anastrozole_Percentage': '35', 'Antidiarrheal_Agent_Probiotics_Percentage': '45', 'Antiemetic_Agent_Percentage': '30', 'Painkiller_Antipyretic_Percentage': '35', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '55', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Abemaciclib', 'STUDYID': 'GHI9012', 'YEAR': '2023', 'Country': 'Canada', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '99', 'Male_Percentage': '1', 'Median_BMI': '29.0', 'Smoking_History_Yes_Percentage': '12', 'Total_ADL_Independence_Percentage': '90', 'LHRH_Use_Percentage': '6', 'Tumor_Stage_T1_Percentage': '8', 'Tumor_Stage_T2_Percentage': '48', 'Tumor_Stage_T3_Percentage': '32', 'Tumor_Stage_T4_Percentage': '12', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '8', 'Nodal_Stage_N3_Percentage': '4', 'Stage_I_Percentage': '12', 'Stage_II_Percentage': '42', 'Stage_III_Percentage': '36', 'Diabetes_Mellitus_Percentage': '10', 'Congestive_Heart_Failure_Percentage': '2', 'Stroke_Percentage': '1', 'Atrial_Fibrillation_Percentage': '4', 'Myocardial_Infarction_Percentage': '3', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '58', 'Postoperative_RT_Received_Percentage': '48', 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Cyclophosphamide', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Doxorubicin', 'Tamoxifen_Percentage': '28', 'Letrozole_Percentage': '37', 'Anastrozole_Percentage': '35', 'Antidiarrheal_Agent_Probiotics_Percentage': '38', 'Antiemetic_Agent_Percentage': '22', 'Painkiller_Antipyretic_Percentage': '28', 'Beds_Less_Than_200_Percentage': '25', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '55', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Abemaciclib', 'STUDYID': 'JKL3456', 'YEAR': '2024', 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '70', 'Female_Percentage': '96', 'Male_Percentage': '4', 'Median_BMI': '30.2', 'Smoking_History_Yes_Percentage': '20', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '8', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '38', 'Tumor_Stage_T3_Percentage': '35', 'Tumor_Stage_T4_Percentage': '12', 'Nodal_Stage_N0_Percentage': '48', 'Nodal_Stage_N1_Percentage': '37', 'Nodal_Stage_N2_Percentage': '11', 'Nodal_Stage_N3_Percentage': '4', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '37', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '5', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '7', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '30', 'Adjuvant_Chemotherapy_Received_Percentage': '70', 'Postoperative_RT_Received_Percentage': '60', 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'Taxol', 'Common_Adjuvant_Regimen_2': 'AC', 'Tamoxifen_Percentage': '35', 'Letrozole_Percentage': '32', 'Anastrozole_Percentage': '33', 'Antidiarrheal_Agent_Probiotics_Percentage': '50', 'Antiemetic_Agent_Percentage': '35', 'Painkiller_Antipyretic_Percentage': '40', 'Beds_Less_Than_200_Percentage': '10', 'Beds_200_To_499_Percentage': '60', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '75', 'Months_Between_Surgery_And_Index_Date': '3.5'}]\n",
      "File created: Abemaciclib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Abemaciclib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Abiraterone Acetate\",\n",
      "    \"STUDYID\": \"AA_Study001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 0.5,\n",
      "    \"Male_Percentage\": 99.5,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 85.0,\n",
      "    \"LHRH_Use_Percentage\": 60.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 5.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 15.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 40.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 35.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 7.0,\n",
      "    \"Stage_II_Percentage\": 23.0,\n",
      "    \"Stage_III_Percentage\": 70.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8.0,\n",
      "    \"Stroke_Percentage\": 4.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 6.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 2.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 15.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 25.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 30.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 40.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10.0,\n",
      "    \"Beds_200_To_499_Percentage\": 40.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Abiraterone Acetate\",\n",
      "    \"STUDYID\": \"AA_Study002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 75,\n",
      "    \"Female_Percentage\": 0.2,\n",
      "    \"Male_Percentage\": 99.8,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 80.0,\n",
      "    \"LHRH_Use_Percentage\": 65.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 7.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 13.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 38.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 42.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 42.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 38.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 14.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6.0,\n",
      "    \"Stage_I_Percentage\": 8.0,\n",
      "    \"Stage_II_Percentage\": 22.0,\n",
      "    \"Stage_III_Percentage\": 70.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9.0,\n",
      "    \"Stroke_Percentage\": 5.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 7.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 3.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 17.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 27.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 22.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 32.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 42.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12.0,\n",
      "    \"Beds_200_To_499_Percentage\": 38.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Abiraterone Acetate\",\n",
      "    \"STUDYID\": \"AA_Study003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 0.3,\n",
      "    \"Male_Percentage\": 99.7,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 35.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 82.0,\n",
      "    \"LHRH_Use_Percentage\": 70.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 6.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 14.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 39.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 41.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 44.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 36.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 4.0,\n",
      "    \"Stage_I_Percentage\": 9.0,\n",
      "    \"Stage_II_Percentage\": 21.0,\n",
      "    \"Stage_III_Percentage\": 70.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 19.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7.0,\n",
      "    \"Stroke_Percentage\": 3.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 5.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 4.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 16.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 26.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 21.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 31.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 41.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 11.0,\n",
      "    \"Beds_200_To_499_Percentage\": 39.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 61.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 4\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Abiraterone Acetate', 'STUDYID': 'AA_Study001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 72, 'Female_Percentage': 0.5, 'Male_Percentage': 99.5, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32.0, 'Total_ADL_Independence_Percentage': 85.0, 'LHRH_Use_Percentage': 60.0, 'Tumor_Stage_T1_Percentage': 5.0, 'Tumor_Stage_T2_Percentage': 15.0, 'Tumor_Stage_T3_Percentage': 40.0, 'Tumor_Stage_T4_Percentage': 40.0, 'Nodal_Stage_N0_Percentage': 45.0, 'Nodal_Stage_N1_Percentage': 35.0, 'Nodal_Stage_N2_Percentage': 15.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 7.0, 'Stage_II_Percentage': 23.0, 'Stage_III_Percentage': 70.0, 'Diabetes_Mellitus_Percentage': 18.0, 'Congestive_Heart_Failure_Percentage': 8.0, 'Stroke_Percentage': 4.0, 'Atrial_Fibrillation_Percentage': 10.0, 'Myocardial_Infarction_Percentage': 6.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 2.0, 'Adjuvant_Chemotherapy_Received_Percentage': 15.0, 'Postoperative_RT_Received_Percentage': 25.0, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 20.0, 'Antiemetic_Agent_Percentage': 30.0, 'Painkiller_Antipyretic_Percentage': 40.0, 'Beds_Less_Than_200_Percentage': 10.0, 'Beds_200_To_499_Percentage': 40.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 50.0, 'Designated_Cancer_Hospital_Percentage': 60.0, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Abiraterone Acetate', 'STUDYID': 'AA_Study002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 75, 'Female_Percentage': 0.2, 'Male_Percentage': 99.8, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28.0, 'Total_ADL_Independence_Percentage': 80.0, 'LHRH_Use_Percentage': 65.0, 'Tumor_Stage_T1_Percentage': 7.0, 'Tumor_Stage_T2_Percentage': 13.0, 'Tumor_Stage_T3_Percentage': 38.0, 'Tumor_Stage_T4_Percentage': 42.0, 'Nodal_Stage_N0_Percentage': 42.0, 'Nodal_Stage_N1_Percentage': 38.0, 'Nodal_Stage_N2_Percentage': 14.0, 'Nodal_Stage_N3_Percentage': 6.0, 'Stage_I_Percentage': 8.0, 'Stage_II_Percentage': 22.0, 'Stage_III_Percentage': 70.0, 'Diabetes_Mellitus_Percentage': 20.0, 'Congestive_Heart_Failure_Percentage': 9.0, 'Stroke_Percentage': 5.0, 'Atrial_Fibrillation_Percentage': 11.0, 'Myocardial_Infarction_Percentage': 7.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 3.0, 'Adjuvant_Chemotherapy_Received_Percentage': 17.0, 'Postoperative_RT_Received_Percentage': 27.0, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 22.0, 'Antiemetic_Agent_Percentage': 32.0, 'Painkiller_Antipyretic_Percentage': 42.0, 'Beds_Less_Than_200_Percentage': 12.0, 'Beds_200_To_499_Percentage': 38.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 50.0, 'Designated_Cancer_Hospital_Percentage': 62.0, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Abiraterone Acetate', 'STUDYID': 'AA_Study003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 0.3, 'Male_Percentage': 99.7, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 35.0, 'Total_ADL_Independence_Percentage': 82.0, 'LHRH_Use_Percentage': 70.0, 'Tumor_Stage_T1_Percentage': 6.0, 'Tumor_Stage_T2_Percentage': 14.0, 'Tumor_Stage_T3_Percentage': 39.0, 'Tumor_Stage_T4_Percentage': 41.0, 'Nodal_Stage_N0_Percentage': 44.0, 'Nodal_Stage_N1_Percentage': 36.0, 'Nodal_Stage_N2_Percentage': 16.0, 'Nodal_Stage_N3_Percentage': 4.0, 'Stage_I_Percentage': 9.0, 'Stage_II_Percentage': 21.0, 'Stage_III_Percentage': 70.0, 'Diabetes_Mellitus_Percentage': 19.0, 'Congestive_Heart_Failure_Percentage': 7.0, 'Stroke_Percentage': 3.0, 'Atrial_Fibrillation_Percentage': 9.0, 'Myocardial_Infarction_Percentage': 5.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 4.0, 'Adjuvant_Chemotherapy_Received_Percentage': 16.0, 'Postoperative_RT_Received_Percentage': 26.0, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 21.0, 'Antiemetic_Agent_Percentage': 31.0, 'Painkiller_Antipyretic_Percentage': 41.0, 'Beds_Less_Than_200_Percentage': 11.0, 'Beds_200_To_499_Percentage': 39.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 50.0, 'Designated_Cancer_Hospital_Percentage': 61.0, 'Months_Between_Surgery_And_Index_Date': 4}]\n",
      "File created: Abiraterone Acetate_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Abiraterone Acetate\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Abraxane\",\n",
      "    \"STUDYID\": \"ABX1001\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"62\",\n",
      "    \"Female_Percentage\": \"98\",\n",
      "    \"Male_Percentage\": \"2\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"18\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"2\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"45\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"12\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"3\",\n",
      "    \"Stroke_Percentage\": \"2\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"5\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"4\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"35\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"60\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"45\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": \"25\",\n",
      "    \"Letrozole_Percentage\": \"35\",\n",
      "    \"Anastrozole_Percentage\": \"30\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"40\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"70\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"55\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Abraxane\",\n",
      "    \"STUDYID\": \"ABX1002\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"97\",\n",
      "    \"Male_Percentage\": \"3\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"22\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"1\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"42\",\n",
      "    \"Stage_III_Percentage\": \"31\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"4\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"6\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"38\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"62\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"48\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC\",\n",
      "    \"Tamoxifen_Percentage\": \"28\",\n",
      "    \"Letrozole_Percentage\": \"32\",\n",
      "    \"Anastrozole_Percentage\": \"33\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"42\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"72\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"57\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"52\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1.7\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Abraxane\",\n",
      "    \"STUDYID\": \"ABX1003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"96\",\n",
      "    \"Male_Percentage\": \"4\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"25\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"3\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"4\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"48\",\n",
      "    \"Stage_III_Percentage\": \"26\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"10\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"2\",\n",
      "    \"Stroke_Percentage\": \"1\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"4\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"3\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"32\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"58\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"42\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC-D\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": \"22\",\n",
      "    \"Letrozole_Percentage\": \"38\",\n",
      "    \"Anastrozole_Percentage\": \"28\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"38\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"68\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"52\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"22\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"58\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1.3\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Abraxane', 'STUDYID': 'ABX1001', 'YEAR': '2022', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '62', 'Female_Percentage': '98', 'Male_Percentage': '2', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '18', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '2', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '40', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '45', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '12', 'Congestive_Heart_Failure_Percentage': '3', 'Stroke_Percentage': '2', 'Atrial_Fibrillation_Percentage': '5', 'Myocardial_Infarction_Percentage': '4', 'Neoadjuvant_Chemotherapy_Received_Percentage': '35', 'Adjuvant_Chemotherapy_Received_Percentage': '60', 'Postoperative_RT_Received_Percentage': '45', 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'TC', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': '25', 'Letrozole_Percentage': '35', 'Anastrozole_Percentage': '30', 'Antidiarrheal_Agent_Probiotics_Percentage': '40', 'Antiemetic_Agent_Percentage': '70', 'Painkiller_Antipyretic_Percentage': '55', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '1.5'}, {'Drug_Name': 'Abraxane', 'STUDYID': 'ABX1002', 'YEAR': '2023', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '68', 'Female_Percentage': '97', 'Male_Percentage': '3', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '22', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '1', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '38', 'Tumor_Stage_T3_Percentage': '32', 'Tumor_Stage_T4_Percentage': '12', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '42', 'Stage_III_Percentage': '31', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '4', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '6', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '38', 'Adjuvant_Chemotherapy_Received_Percentage': '62', 'Postoperative_RT_Received_Percentage': '48', 'Common_Neoadjuvant_Regimen_1': 'AC-T', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'AC', 'Tamoxifen_Percentage': '28', 'Letrozole_Percentage': '32', 'Anastrozole_Percentage': '33', 'Antidiarrheal_Agent_Probiotics_Percentage': '42', 'Antiemetic_Agent_Percentage': '72', 'Painkiller_Antipyretic_Percentage': '57', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '52', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '1.7'}, {'Drug_Name': 'Abraxane', 'STUDYID': 'ABX1003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '96', 'Male_Percentage': '4', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '25', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '3', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '42', 'Tumor_Stage_T3_Percentage': '28', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '22', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '4', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '48', 'Stage_III_Percentage': '26', 'Diabetes_Mellitus_Percentage': '10', 'Congestive_Heart_Failure_Percentage': '2', 'Stroke_Percentage': '1', 'Atrial_Fibrillation_Percentage': '4', 'Myocardial_Infarction_Percentage': '3', 'Neoadjuvant_Chemotherapy_Received_Percentage': '32', 'Adjuvant_Chemotherapy_Received_Percentage': '58', 'Postoperative_RT_Received_Percentage': '42', 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'CMF', 'Common_Adjuvant_Regimen_1': 'FEC-D', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': '22', 'Letrozole_Percentage': '38', 'Anastrozole_Percentage': '28', 'Antidiarrheal_Agent_Probiotics_Percentage': '38', 'Antiemetic_Agent_Percentage': '68', 'Painkiller_Antipyretic_Percentage': '52', 'Beds_Less_Than_200_Percentage': '22', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '58', 'Months_Between_Surgery_And_Index_Date': '1.3'}]\n",
      "File created: Abraxane_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Abraxane\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Adriamycin\",\n",
      "    \"STUDYID\": \"ADR1001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 65.0,\n",
      "    \"Male_Percentage\": 35.0,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 88.0,\n",
      "    \"LHRH_Use_Percentage\": 12.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10.0,\n",
      "    \"Stage_I_Percentage\": 25.0,\n",
      "    \"Stage_II_Percentage\": 35.0,\n",
      "    \"Stage_III_Percentage\": 25.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7.0,\n",
      "    \"Stroke_Percentage\": 4.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 5.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 40.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 55.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FAC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"TC\",\n",
      "    \"Tamoxifen_Percentage\": 20.0,\n",
      "    \"Letrozole_Percentage\": 15.0,\n",
      "    \"Anastrozole_Percentage\": 10.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 60.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15.0,\n",
      "    \"Beds_200_To_499_Percentage\": 45.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Adriamycin\",\n",
      "    \"STUDYID\": \"ADR1002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 60.0,\n",
      "    \"Male_Percentage\": 40.0,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 85.0,\n",
      "    \"LHRH_Use_Percentage\": 15.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 33.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 17.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 22.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10.0,\n",
      "    \"Stage_I_Percentage\": 22.0,\n",
      "    \"Stage_II_Percentage\": 33.0,\n",
      "    \"Stage_III_Percentage\": 27.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8.0,\n",
      "    \"Stroke_Percentage\": 5.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 6.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 42.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 52.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 32.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": 22.0,\n",
      "    \"Letrozole_Percentage\": 13.0,\n",
      "    \"Anastrozole_Percentage\": 12.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 32.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 58.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 48.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12.0,\n",
      "    \"Beds_200_To_499_Percentage\": 48.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Adriamycin\",\n",
      "    \"STUDYID\": \"ADR1003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 55.0,\n",
      "    \"Male_Percentage\": 45.0,\n",
      "    \"Median_BMI\": 29.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 35.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 82.0,\n",
      "    \"LHRH_Use_Percentage\": 10.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 22.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 16.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 42.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 26.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 21.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 11.0,\n",
      "    \"Stage_I_Percentage\": 24.0,\n",
      "    \"Stage_II_Percentage\": 31.0,\n",
      "    \"Stage_III_Percentage\": 26.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9.0,\n",
      "    \"Stroke_Percentage\": 6.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 7.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 38.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 58.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CAF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC-D\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 18.0,\n",
      "    \"Letrozole_Percentage\": 17.0,\n",
      "    \"Anastrozole_Percentage\": 11.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 38.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 55.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18.0,\n",
      "    \"Beds_200_To_499_Percentage\": 42.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 58.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Adriamycin', 'STUDYID': 'ADR1001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 65.0, 'Male_Percentage': 35.0, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32.0, 'Total_ADL_Independence_Percentage': 88.0, 'LHRH_Use_Percentage': 12.0, 'Tumor_Stage_T1_Percentage': 20.0, 'Tumor_Stage_T2_Percentage': 35.0, 'Tumor_Stage_T3_Percentage': 30.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 45.0, 'Nodal_Stage_N1_Percentage': 25.0, 'Nodal_Stage_N2_Percentage': 20.0, 'Nodal_Stage_N3_Percentage': 10.0, 'Stage_I_Percentage': 25.0, 'Stage_II_Percentage': 35.0, 'Stage_III_Percentage': 25.0, 'Diabetes_Mellitus_Percentage': 18.0, 'Congestive_Heart_Failure_Percentage': 7.0, 'Stroke_Percentage': 4.0, 'Atrial_Fibrillation_Percentage': 9.0, 'Myocardial_Infarction_Percentage': 5.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 40.0, 'Adjuvant_Chemotherapy_Received_Percentage': 55.0, 'Postoperative_RT_Received_Percentage': 30.0, 'Common_Neoadjuvant_Regimen_1': 'FAC', 'Common_Neoadjuvant_Regimen_2': 'AC', 'Common_Adjuvant_Regimen_1': 'AC-T', 'Common_Adjuvant_Regimen_2': 'TC', 'Tamoxifen_Percentage': 20.0, 'Letrozole_Percentage': 15.0, 'Anastrozole_Percentage': 10.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35.0, 'Antiemetic_Agent_Percentage': 60.0, 'Painkiller_Antipyretic_Percentage': 45.0, 'Beds_Less_Than_200_Percentage': 15.0, 'Beds_200_To_499_Percentage': 45.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 60.0, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Adriamycin', 'STUDYID': 'ADR1002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 60.0, 'Male_Percentage': 40.0, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28.0, 'Total_ADL_Independence_Percentage': 85.0, 'LHRH_Use_Percentage': 15.0, 'Tumor_Stage_T1_Percentage': 18.0, 'Tumor_Stage_T2_Percentage': 32.0, 'Tumor_Stage_T3_Percentage': 33.0, 'Tumor_Stage_T4_Percentage': 17.0, 'Nodal_Stage_N0_Percentage': 40.0, 'Nodal_Stage_N1_Percentage': 28.0, 'Nodal_Stage_N2_Percentage': 22.0, 'Nodal_Stage_N3_Percentage': 10.0, 'Stage_I_Percentage': 22.0, 'Stage_II_Percentage': 33.0, 'Stage_III_Percentage': 27.0, 'Diabetes_Mellitus_Percentage': 20.0, 'Congestive_Heart_Failure_Percentage': 8.0, 'Stroke_Percentage': 5.0, 'Atrial_Fibrillation_Percentage': 10.0, 'Myocardial_Infarction_Percentage': 6.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 42.0, 'Adjuvant_Chemotherapy_Received_Percentage': 52.0, 'Postoperative_RT_Received_Percentage': 32.0, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'TC', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': 22.0, 'Letrozole_Percentage': 13.0, 'Anastrozole_Percentage': 12.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 32.0, 'Antiemetic_Agent_Percentage': 58.0, 'Painkiller_Antipyretic_Percentage': 48.0, 'Beds_Less_Than_200_Percentage': 12.0, 'Beds_200_To_499_Percentage': 48.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 62.0, 'Months_Between_Surgery_And_Index_Date': 1}, {'Drug_Name': 'Adriamycin', 'STUDYID': 'ADR1003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 55.0, 'Male_Percentage': 45.0, 'Median_BMI': 29.0, 'Smoking_History_Yes_Percentage': 35.0, 'Total_ADL_Independence_Percentage': 82.0, 'LHRH_Use_Percentage': 10.0, 'Tumor_Stage_T1_Percentage': 22.0, 'Tumor_Stage_T2_Percentage': 30.0, 'Tumor_Stage_T3_Percentage': 32.0, 'Tumor_Stage_T4_Percentage': 16.0, 'Nodal_Stage_N0_Percentage': 42.0, 'Nodal_Stage_N1_Percentage': 26.0, 'Nodal_Stage_N2_Percentage': 21.0, 'Nodal_Stage_N3_Percentage': 11.0, 'Stage_I_Percentage': 24.0, 'Stage_II_Percentage': 31.0, 'Stage_III_Percentage': 26.0, 'Diabetes_Mellitus_Percentage': 22.0, 'Congestive_Heart_Failure_Percentage': 9.0, 'Stroke_Percentage': 6.0, 'Atrial_Fibrillation_Percentage': 11.0, 'Myocardial_Infarction_Percentage': 7.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 38.0, 'Adjuvant_Chemotherapy_Received_Percentage': 58.0, 'Postoperative_RT_Received_Percentage': 28.0, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'CAF', 'Common_Adjuvant_Regimen_1': 'FEC-D', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 18.0, 'Letrozole_Percentage': 17.0, 'Anastrozole_Percentage': 11.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 38.0, 'Antiemetic_Agent_Percentage': 55.0, 'Painkiller_Antipyretic_Percentage': 50.0, 'Beds_Less_Than_200_Percentage': 18.0, 'Beds_200_To_499_Percentage': 42.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 58.0, 'Months_Between_Surgery_And_Index_Date': 3}]\n",
      "File created: Adriamycin_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Adriamycin\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Afinitor\",\n",
      "    \"STUDYID\": \"AfinitorStudy001\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"35\",\n",
      "    \"Male_Percentage\": \"65\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"42\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"12\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"38\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"45\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC (Doxorubicin + Cyclophosphamide)\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T (Doxorubicin + Cyclophosphamide followed by Paclitaxel)\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"TC (Docetaxel + Cyclophosphamide)\",\n",
      "    \"Tamoxifen_Percentage\": \"25\",\n",
      "    \"Letrozole_Percentage\": \"15\",\n",
      "    \"Anastrozole_Percentage\": \"10\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"30\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"40\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"50\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Afinitor\",\n",
      "    \"STUDYID\": \"AfinitorStudy002\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"40\",\n",
      "    \"Male_Percentage\": \"60\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"38\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"20\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"10\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"14\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"40\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"42\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide)\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"EC (Epirubicin, Cyclophosphamide)\",\n",
      "    \"Tamoxifen_Percentage\": \"20\",\n",
      "    \"Letrozole_Percentage\": \"18\",\n",
      "    \"Anastrozole_Percentage\": \"12\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"32\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"42\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"52\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"42\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Afinitor\",\n",
      "    \"STUDYID\": \"AfinitorStudy003\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"30\",\n",
      "    \"Male_Percentage\": \"70\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"45\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"90\",\n",
      "    \"LHRH_Use_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"20\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"25\",\n",
      "    \"Stage_II_Percentage\": \"30\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"35\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"48\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Taxotere\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide\",\n",
      "    \"Tamoxifen_Percentage\": \"22\",\n",
      "    \"Letrozole_Percentage\": \"13\",\n",
      "    \"Anastrozole_Percentage\": \"15\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"28\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"38\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"48\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"58\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Afinitor\",\n",
      "    \"STUDYID\": \"AfinitorStudy004\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"38\",\n",
      "    \"Male_Percentage\": \"62\",\n",
      "    \"Median_BMI\": \"27.9\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"40\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"16\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"19\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"31\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"26\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"24\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"53\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"21\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"17\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"9\",\n",
      "    \"Stage_I_Percentage\": \"21\",\n",
      "    \"Stage_II_Percentage\": \"34\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"19\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"13\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"21\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"39\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"43\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel + Doxorubicin + Cyclophosphamide\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Epirubicin + Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Fluorouracil + Epirubicin + Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide + Methotrexate + Fluorouracil\",\n",
      "    \"Tamoxifen_Percentage\": \"21\",\n",
      "    \"Letrozole_Percentage\": \"17\",\n",
      "    \"Anastrozole_Percentage\": \"11\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"31\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"41\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"51\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"17\",\n",
      "    \"Beds_200_To_499_Percentage\": \"43\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"61\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.8\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Afinitor', 'STUDYID': 'AfinitorStudy001', 'YEAR': '2022', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '35', 'Male_Percentage': '65', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '42', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '25', 'Tumor_Stage_T4_Percentage': '25', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '20', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '12', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '38', 'Postoperative_RT_Received_Percentage': '45', 'Common_Neoadjuvant_Regimen_1': 'Docetaxel + Carboplatin', 'Common_Neoadjuvant_Regimen_2': 'AC (Doxorubicin + Cyclophosphamide)', 'Common_Adjuvant_Regimen_1': 'AC-T (Doxorubicin + Cyclophosphamide followed by Paclitaxel)', 'Common_Adjuvant_Regimen_2': 'TC (Docetaxel + Cyclophosphamide)', 'Tamoxifen_Percentage': '25', 'Letrozole_Percentage': '15', 'Anastrozole_Percentage': '10', 'Antidiarrheal_Agent_Probiotics_Percentage': '30', 'Antiemetic_Agent_Percentage': '40', 'Painkiller_Antipyretic_Percentage': '50', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Afinitor', 'STUDYID': 'AfinitorStudy002', 'YEAR': '2023', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '40', 'Male_Percentage': '60', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '38', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '18', 'Tumor_Stage_T1_Percentage': '20', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '28', 'Tumor_Stage_T4_Percentage': '22', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '22', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '10', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '14', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '20', 'Adjuvant_Chemotherapy_Received_Percentage': '40', 'Postoperative_RT_Received_Percentage': '42', 'Common_Neoadjuvant_Regimen_1': 'FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide)', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)', 'Common_Adjuvant_Regimen_2': 'EC (Epirubicin, Cyclophosphamide)', 'Tamoxifen_Percentage': '20', 'Letrozole_Percentage': '18', 'Anastrozole_Percentage': '12', 'Antidiarrheal_Agent_Probiotics_Percentage': '32', 'Antiemetic_Agent_Percentage': '42', 'Painkiller_Antipyretic_Percentage': '52', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '42', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Afinitor', 'STUDYID': 'AfinitorStudy003', 'YEAR': '2022', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '30', 'Male_Percentage': '70', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '45', 'Total_ADL_Independence_Percentage': '90', 'LHRH_Use_Percentage': '12', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '35', 'Tumor_Stage_T3_Percentage': '20', 'Tumor_Stage_T4_Percentage': '30', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '18', 'Nodal_Stage_N2_Percentage': '12', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '25', 'Stage_II_Percentage': '30', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '35', 'Postoperative_RT_Received_Percentage': '48', 'Common_Neoadjuvant_Regimen_1': 'Carboplatin + Paclitaxel', 'Common_Neoadjuvant_Regimen_2': 'EC', 'Common_Adjuvant_Regimen_1': 'Taxotere', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide', 'Tamoxifen_Percentage': '22', 'Letrozole_Percentage': '13', 'Anastrozole_Percentage': '15', 'Antidiarrheal_Agent_Probiotics_Percentage': '28', 'Antiemetic_Agent_Percentage': '38', 'Painkiller_Antipyretic_Percentage': '48', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '58', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Afinitor', 'STUDYID': 'AfinitorStudy004', 'YEAR': '2023', 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '70', 'Female_Percentage': '38', 'Male_Percentage': '62', 'Median_BMI': '27.9', 'Smoking_History_Yes_Percentage': '40', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '16', 'Tumor_Stage_T1_Percentage': '19', 'Tumor_Stage_T2_Percentage': '31', 'Tumor_Stage_T3_Percentage': '26', 'Tumor_Stage_T4_Percentage': '24', 'Nodal_Stage_N0_Percentage': '53', 'Nodal_Stage_N1_Percentage': '21', 'Nodal_Stage_N2_Percentage': '17', 'Nodal_Stage_N3_Percentage': '9', 'Stage_I_Percentage': '21', 'Stage_II_Percentage': '34', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '19', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '13', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '21', 'Adjuvant_Chemotherapy_Received_Percentage': '39', 'Postoperative_RT_Received_Percentage': '43', 'Common_Neoadjuvant_Regimen_1': 'Docetaxel + Doxorubicin + Cyclophosphamide', 'Common_Neoadjuvant_Regimen_2': 'Epirubicin + Cyclophosphamide', 'Common_Adjuvant_Regimen_1': 'Fluorouracil + Epirubicin + Cyclophosphamide', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide + Methotrexate + Fluorouracil', 'Tamoxifen_Percentage': '21', 'Letrozole_Percentage': '17', 'Anastrozole_Percentage': '11', 'Antidiarrheal_Agent_Probiotics_Percentage': '31', 'Antiemetic_Agent_Percentage': '41', 'Painkiller_Antipyretic_Percentage': '51', 'Beds_Less_Than_200_Percentage': '17', 'Beds_200_To_499_Percentage': '43', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '61', 'Months_Between_Surgery_And_Index_Date': '2.8'}]\n",
      "File created: Afinitor_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Afinitor\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Alectinib\",\n",
      "    \"STUDYID\": \"ALEC2023-US\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 62,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Postoperative_RT_Received_Percentage\": 38,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Vinorelbine + Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Pemetrexed\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 22,\n",
      "    \"Antiemetic_Agent_Percentage\": 45,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 33,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Alectinib\",\n",
      "    \"STUDYID\": \"ALEC2022-JP\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 24.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 55,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 3,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 28,\n",
      "    \"Tumor_Stage_T4_Percentage\": 22,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 13,\n",
      "    \"Nodal_Stage_N3_Percentage\": 12,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 30,\n",
      "    \"Stage_III_Percentage\": 25,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel + Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Gemcitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 50,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 35,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Alectinib\",\n",
      "    \"STUDYID\": \"ALEC2024-EU\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 55,\n",
      "    \"Male_Percentage\": 45,\n",
      "    \"Median_BMI\": 26.2,\n",
      "    \"Smoking_History_Yes_Percentage\": 48,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 30,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 20,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 2,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 15,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 30,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin + Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 30,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 75,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Alectinib', 'STUDYID': 'ALEC2023-US', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 62, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 25, 'Postoperative_RT_Received_Percentage': 38, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Vinorelbine + Cisplatin', 'Common_Adjuvant_Regimen_2': 'Pemetrexed', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 22, 'Antiemetic_Agent_Percentage': 45, 'Painkiller_Antipyretic_Percentage': 33, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Alectinib', 'STUDYID': 'ALEC2022-JP', 'YEAR': 2022, 'Country': 'Japan', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 24.8, 'Smoking_History_Yes_Percentage': 55, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 3, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 28, 'Tumor_Stage_T4_Percentage': 22, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 13, 'Nodal_Stage_N3_Percentage': 12, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 30, 'Stage_III_Percentage': 25, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 20, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Pemetrexed', 'Common_Adjuvant_Regimen_1': 'Docetaxel + Cisplatin', 'Common_Adjuvant_Regimen_2': 'Gemcitabine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 50, 'Painkiller_Antipyretic_Percentage': 35, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 1.5}, {'Drug_Name': 'Alectinib', 'STUDYID': 'ALEC2024-EU', 'YEAR': 2024, 'Country': 'Germany', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 55, 'Male_Percentage': 45, 'Median_BMI': 26.2, 'Smoking_History_Yes_Percentage': 48, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 25, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 30, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 20, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 2, 'Neoadjuvant_Chemotherapy_Received_Percentage': 15, 'Adjuvant_Chemotherapy_Received_Percentage': 30, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'Carboplatin + Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin + Gemcitabine', 'Common_Adjuvant_Regimen_1': 'Docetaxel + Carboplatin', 'Common_Adjuvant_Regimen_2': 'Vinorelbine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 20, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 30, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 75, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Alectinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Alectinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Axitinib\",\n",
      "    \"STUDYID\": \"AX2023-US-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 32,\n",
      "    \"Male_Percentage\": 68,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 45,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Gemcitabine + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Axitinib\",\n",
      "    \"STUDYID\": \"AX2022-EU-002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 28,\n",
      "    \"Male_Percentage\": 72,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 52,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 30,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Pemetrexed + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CapeOX\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 45,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Axitinib\",\n",
      "    \"STUDYID\": \"AX2024-JP-003\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 35,\n",
      "    \"Male_Percentage\": 65,\n",
      "    \"Median_BMI\": 25.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 38,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 25,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 7,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"S-1 + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + S-1\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"UFT\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine + Oxaliplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 35,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 25,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Axitinib', 'STUDYID': 'AX2023-US-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 32, 'Male_Percentage': 68, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 45, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 25, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'Gemcitabine + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Axitinib', 'STUDYID': 'AX2022-EU-002', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 28, 'Male_Percentage': 72, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 52, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 45, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 30, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Pemetrexed + Carboplatin', 'Common_Adjuvant_Regimen_1': 'FOLFOX', 'Common_Adjuvant_Regimen_2': 'CapeOX', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 45, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Axitinib', 'STUDYID': 'AX2024-JP-003', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 35, 'Male_Percentage': 65, 'Median_BMI': 25.5, 'Smoking_History_Yes_Percentage': 38, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 25, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 7, 'Adjuvant_Chemotherapy_Received_Percentage': 20, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'S-1 + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + S-1', 'Common_Adjuvant_Regimen_1': 'UFT', 'Common_Adjuvant_Regimen_2': 'Capecitabine + Oxaliplatin', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 35, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 25, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Axitinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Axitinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Balversa\",\n",
      "    \"STUDYID\": \"BLV2023-US-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 35,\n",
      "    \"Male_Percentage\": 65,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 42,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 18,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"MVAC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"GC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine/Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"ddMVAC\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Balversa\",\n",
      "    \"STUDYID\": \"BLV2023-EU-002\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 40,\n",
      "    \"Male_Percentage\": 60,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 38,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 25,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Postoperative_RT_Received_Percentage\": 32,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"GC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"MVAC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine/Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin/Gemcitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 45,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Balversa\",\n",
      "    \"STUDYID\": \"BLV2024-JP-003\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 30,\n",
      "    \"Male_Percentage\": 70,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 15,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"GC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"MVAC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine/Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Paclitaxel/Carboplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 35,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 25,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Balversa\",\n",
      "    \"STUDYID\": \"BLV2024-UK-004\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 73,\n",
      "    \"Female_Percentage\": 42,\n",
      "    \"Male_Percentage\": 58,\n",
      "    \"Median_BMI\": 29.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 40,\n",
      "    \"Total_ADL_Independence_Percentage\": 72,\n",
      "    \"LHRH_Use_Percentage\": 13,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 29,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 33,\n",
      "    \"Stage_III_Percentage\": 48,\n",
      "    \"Diabetes_Mellitus_Percentage\": 23,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 19,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 26,\n",
      "    \"Postoperative_RT_Received_Percentage\": 31,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"MVAC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"GC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine/Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel/Cisplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 38,\n",
      "    \"Antiemetic_Agent_Percentage\": 43,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 53,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 34,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 58,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Balversa', 'STUDYID': 'BLV2023-US-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 35, 'Male_Percentage': 65, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 42, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 18, 'Adjuvant_Chemotherapy_Received_Percentage': 25, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'MVAC', 'Common_Neoadjuvant_Regimen_2': 'GC', 'Common_Adjuvant_Regimen_1': 'Gemcitabine/Cisplatin', 'Common_Adjuvant_Regimen_2': 'ddMVAC', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Balversa', 'STUDYID': 'BLV2023-EU-002', 'YEAR': 2023, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 40, 'Male_Percentage': 60, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 38, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 45, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 25, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 28, 'Postoperative_RT_Received_Percentage': 32, 'Common_Neoadjuvant_Regimen_1': 'GC', 'Common_Neoadjuvant_Regimen_2': 'MVAC', 'Common_Adjuvant_Regimen_1': 'Gemcitabine/Cisplatin', 'Common_Adjuvant_Regimen_2': 'Carboplatin/Gemcitabine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 45, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Balversa', 'STUDYID': 'BLV2024-JP-003', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 30, 'Male_Percentage': 70, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 15, 'Adjuvant_Chemotherapy_Received_Percentage': 22, 'Postoperative_RT_Received_Percentage': 28, 'Common_Neoadjuvant_Regimen_1': 'GC', 'Common_Neoadjuvant_Regimen_2': 'MVAC', 'Common_Adjuvant_Regimen_1': 'Gemcitabine/Cisplatin', 'Common_Adjuvant_Regimen_2': 'Paclitaxel/Carboplatin', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 35, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 25, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 2.5}, {'Drug_Name': 'Balversa', 'STUDYID': 'BLV2024-UK-004', 'YEAR': 2024, 'Country': 'UK', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 73, 'Female_Percentage': 42, 'Male_Percentage': 58, 'Median_BMI': 29.0, 'Smoking_History_Yes_Percentage': 40, 'Total_ADL_Independence_Percentage': 72, 'LHRH_Use_Percentage': 13, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 29, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 33, 'Stage_III_Percentage': 48, 'Diabetes_Mellitus_Percentage': 23, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 19, 'Adjuvant_Chemotherapy_Received_Percentage': 26, 'Postoperative_RT_Received_Percentage': 31, 'Common_Neoadjuvant_Regimen_1': 'MVAC', 'Common_Neoadjuvant_Regimen_2': 'GC', 'Common_Adjuvant_Regimen_1': 'Gemcitabine/Cisplatin', 'Common_Adjuvant_Regimen_2': 'Docetaxel/Cisplatin', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 38, 'Antiemetic_Agent_Percentage': 43, 'Painkiller_Antipyretic_Percentage': 53, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 34, 'Designated_Cancer_Hospital_Percentage': 58, 'Months_Between_Surgery_And_Index_Date': 3.5}]\n",
      "File created: Balversa_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Balversa\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Brigatinib\",\n",
      "    \"STUDYID\": \"BRAVO101\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 42.0,\n",
      "    \"Male_Percentage\": 58.0,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 60.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 85.0,\n",
      "    \"LHRH_Use_Percentage\": 5.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10.0,\n",
      "    \"Stage_I_Percentage\": 20.0,\n",
      "    \"Stage_II_Percentage\": 35.0,\n",
      "    \"Stage_III_Percentage\": 30.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8.0,\n",
      "    \"Stroke_Percentage\": 4.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 6.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 55.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CarboTaxol\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Doxorubicin-Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide-Doxorubicin\",\n",
      "    \"Tamoxifen_Percentage\": 12.0,\n",
      "    \"Letrozole_Percentage\": 15.0,\n",
      "    \"Anastrozole_Percentage\": 13.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 65.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15.0,\n",
      "    \"Beds_200_To_499_Percentage\": 45.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Brigatinib\",\n",
      "    \"STUDYID\": \"GLOBAL022\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 38.0,\n",
      "    \"Male_Percentage\": 62.0,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 55.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 78.0,\n",
      "    \"LHRH_Use_Percentage\": 7.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 35.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 17.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 8.0,\n",
      "    \"Stage_I_Percentage\": 18.0,\n",
      "    \"Stage_II_Percentage\": 37.0,\n",
      "    \"Stage_III_Percentage\": 32.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10.0,\n",
      "    \"Stroke_Percentage\": 5.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 7.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 38.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 52.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel-Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"5-FU-Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 10.0,\n",
      "    \"Letrozole_Percentage\": 13.0,\n",
      "    \"Anastrozole_Percentage\": 11.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 62.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 48.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12.0,\n",
      "    \"Beds_200_To_499_Percentage\": 48.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Brigatinib\",\n",
      "    \"STUDYID\": \"ASIA301\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 45.0,\n",
      "    \"Male_Percentage\": 55.0,\n",
      "    \"Median_BMI\": 24.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 45.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 90.0,\n",
      "    \"LHRH_Use_Percentage\": 3.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 28.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 22.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 13.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 12.0,\n",
      "    \"Stage_I_Percentage\": 22.0,\n",
      "    \"Stage_II_Percentage\": 32.0,\n",
      "    \"Stage_III_Percentage\": 28.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6.0,\n",
      "    \"Stroke_Percentage\": 3.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 5.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 28.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 42.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 58.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Paclitaxel-Carboplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel-Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Tamoxifen_Percentage\": 14.0,\n",
      "    \"Letrozole_Percentage\": 17.0,\n",
      "    \"Anastrozole_Percentage\": 15.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 32.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 68.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 52.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18.0,\n",
      "    \"Beds_200_To_499_Percentage\": 42.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Brigatinib', 'STUDYID': 'BRAVO101', 'YEAR': 2022, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 42.0, 'Male_Percentage': 58.0, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 60.0, 'Total_ADL_Independence_Percentage': 85.0, 'LHRH_Use_Percentage': 5.0, 'Tumor_Stage_T1_Percentage': 15.0, 'Tumor_Stage_T2_Percentage': 35.0, 'Tumor_Stage_T3_Percentage': 30.0, 'Tumor_Stage_T4_Percentage': 20.0, 'Nodal_Stage_N0_Percentage': 45.0, 'Nodal_Stage_N1_Percentage': 30.0, 'Nodal_Stage_N2_Percentage': 15.0, 'Nodal_Stage_N3_Percentage': 10.0, 'Stage_I_Percentage': 20.0, 'Stage_II_Percentage': 35.0, 'Stage_III_Percentage': 30.0, 'Diabetes_Mellitus_Percentage': 18.0, 'Congestive_Heart_Failure_Percentage': 8.0, 'Stroke_Percentage': 4.0, 'Atrial_Fibrillation_Percentage': 10.0, 'Myocardial_Infarction_Percentage': 6.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25.0, 'Adjuvant_Chemotherapy_Received_Percentage': 40.0, 'Postoperative_RT_Received_Percentage': 55.0, 'Common_Neoadjuvant_Regimen_1': 'CarboTaxol', 'Common_Neoadjuvant_Regimen_2': 'Doxorubicin-Cyclophosphamide', 'Common_Adjuvant_Regimen_1': 'Taxol', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide-Doxorubicin', 'Tamoxifen_Percentage': 12.0, 'Letrozole_Percentage': 15.0, 'Anastrozole_Percentage': 13.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30.0, 'Antiemetic_Agent_Percentage': 65.0, 'Painkiller_Antipyretic_Percentage': 50.0, 'Beds_Less_Than_200_Percentage': 15.0, 'Beds_200_To_499_Percentage': 45.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 60.0, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Brigatinib', 'STUDYID': 'GLOBAL022', 'YEAR': 2023, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 38.0, 'Male_Percentage': 62.0, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 55.0, 'Total_ADL_Independence_Percentage': 78.0, 'LHRH_Use_Percentage': 7.0, 'Tumor_Stage_T1_Percentage': 12.0, 'Tumor_Stage_T2_Percentage': 38.0, 'Tumor_Stage_T3_Percentage': 32.0, 'Tumor_Stage_T4_Percentage': 18.0, 'Nodal_Stage_N0_Percentage': 40.0, 'Nodal_Stage_N1_Percentage': 35.0, 'Nodal_Stage_N2_Percentage': 17.0, 'Nodal_Stage_N3_Percentage': 8.0, 'Stage_I_Percentage': 18.0, 'Stage_II_Percentage': 37.0, 'Stage_III_Percentage': 32.0, 'Diabetes_Mellitus_Percentage': 20.0, 'Congestive_Heart_Failure_Percentage': 10.0, 'Stroke_Percentage': 5.0, 'Atrial_Fibrillation_Percentage': 12.0, 'Myocardial_Infarction_Percentage': 7.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22.0, 'Adjuvant_Chemotherapy_Received_Percentage': 38.0, 'Postoperative_RT_Received_Percentage': 52.0, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel-Cisplatin', 'Common_Neoadjuvant_Regimen_2': '5-FU-Carboplatin', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 10.0, 'Letrozole_Percentage': 13.0, 'Anastrozole_Percentage': 11.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 28.0, 'Antiemetic_Agent_Percentage': 62.0, 'Painkiller_Antipyretic_Percentage': 48.0, 'Beds_Less_Than_200_Percentage': 12.0, 'Beds_200_To_499_Percentage': 48.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 55.0, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Brigatinib', 'STUDYID': 'ASIA301', 'YEAR': 2023, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 45.0, 'Male_Percentage': 55.0, 'Median_BMI': 24.5, 'Smoking_History_Yes_Percentage': 45.0, 'Total_ADL_Independence_Percentage': 90.0, 'LHRH_Use_Percentage': 3.0, 'Tumor_Stage_T1_Percentage': 18.0, 'Tumor_Stage_T2_Percentage': 32.0, 'Tumor_Stage_T3_Percentage': 28.0, 'Tumor_Stage_T4_Percentage': 22.0, 'Nodal_Stage_N0_Percentage': 50.0, 'Nodal_Stage_N1_Percentage': 25.0, 'Nodal_Stage_N2_Percentage': 13.0, 'Nodal_Stage_N3_Percentage': 12.0, 'Stage_I_Percentage': 22.0, 'Stage_II_Percentage': 32.0, 'Stage_III_Percentage': 28.0, 'Diabetes_Mellitus_Percentage': 15.0, 'Congestive_Heart_Failure_Percentage': 6.0, 'Stroke_Percentage': 3.0, 'Atrial_Fibrillation_Percentage': 8.0, 'Myocardial_Infarction_Percentage': 5.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 28.0, 'Adjuvant_Chemotherapy_Received_Percentage': 42.0, 'Postoperative_RT_Received_Percentage': 58.0, 'Common_Neoadjuvant_Regimen_1': 'Paclitaxel-Carboplatin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel-Cisplatin', 'Common_Adjuvant_Regimen_1': 'Paclitaxel', 'Common_Adjuvant_Regimen_2': 'Carboplatin', 'Tamoxifen_Percentage': 14.0, 'Letrozole_Percentage': 17.0, 'Anastrozole_Percentage': 15.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 32.0, 'Antiemetic_Agent_Percentage': 68.0, 'Painkiller_Antipyretic_Percentage': 52.0, 'Beds_Less_Than_200_Percentage': 18.0, 'Beds_200_To_499_Percentage': 42.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 65.0, 'Months_Between_Surgery_And_Index_Date': 1}]\n",
      "File created: Brigatinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Brigatinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Cabozantinib\",\n",
      "    \"STUDYID\": \"CaboStudy001\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 32,\n",
      "    \"Male_Percentage\": 68,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 45,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 22,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Gemcitabine + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 5,\n",
      "    \"Letrozole_Percentage\": 3,\n",
      "    \"Anastrozole_Percentage\": 2,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Cabozantinib\",\n",
      "    \"STUDYID\": \"CaboStudy002\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 38,\n",
      "    \"Male_Percentage\": 62,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 52,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 25,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 15,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 32,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Pemetrexed + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": 6,\n",
      "    \"Letrozole_Percentage\": 4,\n",
      "    \"Anastrozole_Percentage\": 3,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 45,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Cabozantinib\",\n",
      "    \"STUDYID\": \"CaboStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 40,\n",
      "    \"Male_Percentage\": 60,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 38,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 20,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Etoposide\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Etoposide\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Epirubicin + Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 4,\n",
      "    \"Letrozole_Percentage\": 2,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Cabozantinib\",\n",
      "    \"STUDYID\": \"CaboStudy004\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 35,\n",
      "    \"Male_Percentage\": 65,\n",
      "    \"Median_BMI\": 29.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 48,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 23,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 29,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 33,\n",
      "    \"Stage_III_Percentage\": 48,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 13,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 30,\n",
      "    \"Postoperative_RT_Received_Percentage\": 38,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FOLFIRI\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Oxaliplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Irinotecan\",\n",
      "    \"Tamoxifen_Percentage\": 7,\n",
      "    \"Letrozole_Percentage\": 5,\n",
      "    \"Anastrozole_Percentage\": 4,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 42,\n",
      "    \"Antiemetic_Agent_Percentage\": 62,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 58,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 34,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 63,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Cabozantinib', 'STUDYID': 'CaboStudy001', 'YEAR': 2022, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 32, 'Male_Percentage': 68, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 45, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 22, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 28, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'Gemcitabine + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 5, 'Letrozole_Percentage': 3, 'Anastrozole_Percentage': 2, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Cabozantinib', 'STUDYID': 'CaboStudy002', 'YEAR': 2023, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 38, 'Male_Percentage': 62, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 52, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 25, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 45, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 15, 'Adjuvant_Chemotherapy_Received_Percentage': 32, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Pemetrexed + Carboplatin', 'Common_Adjuvant_Regimen_1': 'Gemcitabine', 'Common_Adjuvant_Regimen_2': 'Vinorelbine', 'Tamoxifen_Percentage': 6, 'Letrozole_Percentage': 4, 'Anastrozole_Percentage': 3, 'Antidiarrheal_Agent_Probiotics_Percentage': 45, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Cabozantinib', 'STUDYID': 'CaboStudy003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 40, 'Male_Percentage': 60, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 38, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 20, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 25, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Etoposide', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Etoposide', 'Common_Adjuvant_Regimen_1': 'Epirubicin + Cyclophosphamide', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 4, 'Letrozole_Percentage': 2, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Cabozantinib', 'STUDYID': 'CaboStudy004', 'YEAR': 2024, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 70, 'Female_Percentage': 35, 'Male_Percentage': 65, 'Median_BMI': 29.0, 'Smoking_History_Yes_Percentage': 48, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 23, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 29, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 33, 'Stage_III_Percentage': 48, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 13, 'Adjuvant_Chemotherapy_Received_Percentage': 30, 'Postoperative_RT_Received_Percentage': 38, 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'FOLFIRI', 'Common_Adjuvant_Regimen_1': 'Oxaliplatin', 'Common_Adjuvant_Regimen_2': 'Irinotecan', 'Tamoxifen_Percentage': 7, 'Letrozole_Percentage': 5, 'Anastrozole_Percentage': 4, 'Antidiarrheal_Agent_Probiotics_Percentage': 42, 'Antiemetic_Agent_Percentage': 62, 'Painkiller_Antipyretic_Percentage': 58, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 34, 'Designated_Cancer_Hospital_Percentage': 63, 'Months_Between_Surgery_And_Index_Date': 3}]\n",
      "File created: Cabozantinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Cabozantinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Capecitabine\",\n",
      "    \"STUDYID\": \"CapeStudy001\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"62\",\n",
      "    \"Male_Percentage\": \"38\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"28\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"45\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"65\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"40\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FAC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Capecitabine + Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"12\",\n",
      "    \"Letrozole_Percentage\": \"8\",\n",
      "    \"Anastrozole_Percentage\": \"10\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"35\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"55\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"45\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Capecitabine\",\n",
      "    \"STUDYID\": \"Study002Cape\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"58\",\n",
      "    \"Male_Percentage\": \"42\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"31\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"7\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"42\",\n",
      "    \"Stage_III_Percentage\": \"33\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"68\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"42\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Capecitabine + Oxaliplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"10\",\n",
      "    \"Letrozole_Percentage\": \"9\",\n",
      "    \"Anastrozole_Percentage\": \"11\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"38\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"58\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"48\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Capecitabine\",\n",
      "    \"STUDYID\": \"CapeStudy003\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"65\",\n",
      "    \"Male_Percentage\": \"35\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"25\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"88\",\n",
      "    \"LHRH_Use_Percentage\": \"6\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"42\",\n",
      "    \"Stage_III_Percentage\": \"28\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"16\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"62\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"38\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Capecitabine + Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"14\",\n",
      "    \"Letrozole_Percentage\": \"7\",\n",
      "    \"Anastrozole_Percentage\": \"9\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"32\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"52\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"42\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"42\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"55\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Capecitabine\",\n",
      "    \"STUDYID\": \"Study004Cape\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"60\",\n",
      "    \"Male_Percentage\": \"40\",\n",
      "    \"Median_BMI\": \"27.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"29\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"84\",\n",
      "    \"LHRH_Use_Percentage\": \"8\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"14\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"39\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"31\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"54\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"26\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"13\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"7\",\n",
      "    \"Stage_I_Percentage\": \"19\",\n",
      "    \"Stage_II_Percentage\": \"43\",\n",
      "    \"Stage_III_Percentage\": \"31\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"19\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"23\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"66\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"41\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Capecitabine + Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"11\",\n",
      "    \"Letrozole_Percentage\": \"8\",\n",
      "    \"Anastrozole_Percentage\": \"10\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"36\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"56\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"46\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"14\",\n",
      "    \"Beds_200_To_499_Percentage\": \"46\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.8\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Capecitabine', 'STUDYID': 'CapeStudy001', 'YEAR': '2022', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '62', 'Male_Percentage': '38', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '28', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '40', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '45', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '65', 'Postoperative_RT_Received_Percentage': '40', 'Common_Neoadjuvant_Regimen_1': 'FAC', 'Common_Neoadjuvant_Regimen_2': 'EC', 'Common_Adjuvant_Regimen_1': 'Capecitabine + Docetaxel', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': '12', 'Letrozole_Percentage': '8', 'Anastrozole_Percentage': '10', 'Antidiarrheal_Agent_Probiotics_Percentage': '35', 'Antiemetic_Agent_Percentage': '55', 'Painkiller_Antipyretic_Percentage': '45', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Capecitabine', 'STUDYID': 'Study002Cape', 'YEAR': '2023', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '58', 'Male_Percentage': '42', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '31', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '7', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '38', 'Tumor_Stage_T3_Percentage': '32', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '42', 'Stage_III_Percentage': '33', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '68', 'Postoperative_RT_Received_Percentage': '42', 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'CMF', 'Common_Adjuvant_Regimen_1': 'Capecitabine + Oxaliplatin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': '10', 'Letrozole_Percentage': '9', 'Anastrozole_Percentage': '11', 'Antidiarrheal_Agent_Probiotics_Percentage': '38', 'Antiemetic_Agent_Percentage': '58', 'Painkiller_Antipyretic_Percentage': '48', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Capecitabine', 'STUDYID': 'CapeStudy003', 'YEAR': '2022', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '65', 'Male_Percentage': '35', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '25', 'Total_ADL_Independence_Percentage': '88', 'LHRH_Use_Percentage': '6', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '35', 'Tumor_Stage_T3_Percentage': '32', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '22', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '42', 'Stage_III_Percentage': '28', 'Diabetes_Mellitus_Percentage': '16', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '20', 'Adjuvant_Chemotherapy_Received_Percentage': '62', 'Postoperative_RT_Received_Percentage': '38', 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'EC', 'Common_Adjuvant_Regimen_1': 'Capecitabine + Cyclophosphamide', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': '14', 'Letrozole_Percentage': '7', 'Anastrozole_Percentage': '9', 'Antidiarrheal_Agent_Probiotics_Percentage': '32', 'Antiemetic_Agent_Percentage': '52', 'Painkiller_Antipyretic_Percentage': '42', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '42', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '55', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Capecitabine', 'STUDYID': 'Study004Cape', 'YEAR': '2023', 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '70', 'Female_Percentage': '60', 'Male_Percentage': '40', 'Median_BMI': '27.8', 'Smoking_History_Yes_Percentage': '29', 'Total_ADL_Independence_Percentage': '84', 'LHRH_Use_Percentage': '8', 'Tumor_Stage_T1_Percentage': '14', 'Tumor_Stage_T2_Percentage': '39', 'Tumor_Stage_T3_Percentage': '31', 'Tumor_Stage_T4_Percentage': '16', 'Nodal_Stage_N0_Percentage': '54', 'Nodal_Stage_N1_Percentage': '26', 'Nodal_Stage_N2_Percentage': '13', 'Nodal_Stage_N3_Percentage': '7', 'Stage_I_Percentage': '19', 'Stage_II_Percentage': '43', 'Stage_III_Percentage': '31', 'Diabetes_Mellitus_Percentage': '19', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '23', 'Adjuvant_Chemotherapy_Received_Percentage': '66', 'Postoperative_RT_Received_Percentage': '41', 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'Capecitabine + Docetaxel', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': '11', 'Letrozole_Percentage': '8', 'Anastrozole_Percentage': '10', 'Antidiarrheal_Agent_Probiotics_Percentage': '36', 'Antiemetic_Agent_Percentage': '56', 'Painkiller_Antipyretic_Percentage': '46', 'Beds_Less_Than_200_Percentage': '14', 'Beds_200_To_499_Percentage': '46', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '2.8'}]\n",
      "File created: Capecitabine_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Capecitabine\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Carboplatin\",\n",
      "    \"STUDYID\": \"CRBP001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 62,\n",
      "    \"Male_Percentage\": 38,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25,\n",
      "    \"Tumor_Stage_T4_Percentage\": 25,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 65,\n",
      "    \"Postoperative_RT_Received_Percentage\": 42,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Paclitaxel/Carboplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel/Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Carboplatin/Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin/Gemcitabine\",\n",
      "    \"Tamoxifen_Percentage\": 5,\n",
      "    \"Letrozole_Percentage\": 3,\n",
      "    \"Anastrozole_Percentage\": 2,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 22,\n",
      "    \"Antiemetic_Agent_Percentage\": 75,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Carboplatin\",\n",
      "    \"STUDYID\": \"CRBP002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 58,\n",
      "    \"Male_Percentage\": 42,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 22,\n",
      "    \"Tumor_Stage_T4_Percentage\": 28,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 35,\n",
      "    \"Nodal_Stage_N2_Percentage\": 18,\n",
      "    \"Nodal_Stage_N3_Percentage\": 7,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 32,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 30,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 62,\n",
      "    \"Postoperative_RT_Received_Percentage\": 45,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel/Carboplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Gemcitabine/Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Carboplatin/Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin/Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": 4,\n",
      "    \"Letrozole_Percentage\": 2,\n",
      "    \"Anastrozole_Percentage\": 4,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 78,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 58,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Carboplatin\",\n",
      "    \"STUDYID\": \"CRBP003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 65,\n",
      "    \"Male_Percentage\": 35,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 28,\n",
      "    \"Tumor_Stage_T4_Percentage\": 22,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 17,\n",
      "    \"Nodal_Stage_N3_Percentage\": 8,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 42,\n",
      "    \"Stage_III_Percentage\": 26,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 70,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin/Gemcitabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel/Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Carboplatin/Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin/Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": 6,\n",
      "    \"Letrozole_Percentage\": 1,\n",
      "    \"Anastrozole_Percentage\": 3,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20,\n",
      "    \"Antiemetic_Agent_Percentage\": 72,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 52,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Carboplatin', 'STUDYID': 'CRBP001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 62, 'Male_Percentage': 38, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 25, 'Tumor_Stage_T4_Percentage': 25, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 28, 'Adjuvant_Chemotherapy_Received_Percentage': 65, 'Postoperative_RT_Received_Percentage': 42, 'Common_Neoadjuvant_Regimen_1': 'Paclitaxel/Carboplatin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel/Carboplatin', 'Common_Adjuvant_Regimen_1': 'Carboplatin/Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Carboplatin/Gemcitabine', 'Tamoxifen_Percentage': 5, 'Letrozole_Percentage': 3, 'Anastrozole_Percentage': 2, 'Antidiarrheal_Agent_Probiotics_Percentage': 22, 'Antiemetic_Agent_Percentage': 75, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Carboplatin', 'STUDYID': 'CRBP002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 58, 'Male_Percentage': 42, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 22, 'Tumor_Stage_T4_Percentage': 28, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 35, 'Nodal_Stage_N2_Percentage': 18, 'Nodal_Stage_N3_Percentage': 7, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 32, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 30, 'Adjuvant_Chemotherapy_Received_Percentage': 62, 'Postoperative_RT_Received_Percentage': 45, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel/Carboplatin', 'Common_Neoadjuvant_Regimen_2': 'Gemcitabine/Carboplatin', 'Common_Adjuvant_Regimen_1': 'Carboplatin/Paclitaxel', 'Common_Adjuvant_Regimen_2': 'Carboplatin/Vinorelbine', 'Tamoxifen_Percentage': 4, 'Letrozole_Percentage': 2, 'Anastrozole_Percentage': 4, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 78, 'Painkiller_Antipyretic_Percentage': 58, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Carboplatin', 'STUDYID': 'CRBP003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 65, 'Male_Percentage': 35, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 28, 'Tumor_Stage_T4_Percentage': 22, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 17, 'Nodal_Stage_N3_Percentage': 8, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 42, 'Stage_III_Percentage': 26, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 70, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'Carboplatin/Gemcitabine', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel/Carboplatin', 'Common_Adjuvant_Regimen_1': 'Carboplatin/Docetaxel', 'Common_Adjuvant_Regimen_2': 'Carboplatin/Vinorelbine', 'Tamoxifen_Percentage': 6, 'Letrozole_Percentage': 1, 'Anastrozole_Percentage': 3, 'Antidiarrheal_Agent_Probiotics_Percentage': 20, 'Antiemetic_Agent_Percentage': 72, 'Painkiller_Antipyretic_Percentage': 52, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Carboplatin_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Carboplatin\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Ceritinib\",\n",
      "    \"STUDYID\": \"CER1001\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"62\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"60\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"58\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"42\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Cisplatin + Vinorelbine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin + Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": \"2\",\n",
      "    \"Letrozole_Percentage\": \"3\",\n",
      "    \"Anastrozole_Percentage\": \"1\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"35\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"65\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"50\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ceritinib\",\n",
      "    \"STUDYID\": \"CER1002\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"55\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"7\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"27\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"60\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"40\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Cisplatin + Etoposide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin + Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": \"1\",\n",
      "    \"Letrozole_Percentage\": \"4\",\n",
      "    \"Anastrozole_Percentage\": \"2\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"40\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"70\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"55\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"10\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ceritinib\",\n",
      "    \"STUDYID\": \"CER1003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"42\",\n",
      "    \"Male_Percentage\": \"58\",\n",
      "    \"Median_BMI\": \"26.9\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"65\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"6\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"16\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"24\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"13\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"19\",\n",
      "    \"Stage_II_Percentage\": \"36\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"17\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"55\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"45\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin + Etoposide\",\n",
      "    \"Tamoxifen_Percentage\": \"3\",\n",
      "    \"Letrozole_Percentage\": \"2\",\n",
      "    \"Anastrozole_Percentage\": \"1\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"30\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"60\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"48\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"40\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"55\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Ceritinib', 'STUDYID': 'CER1001', 'YEAR': '2022', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '62', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '60', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '58', 'Postoperative_RT_Received_Percentage': '42', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Cisplatin + Vinorelbine', 'Common_Adjuvant_Regimen_2': 'Carboplatin + Docetaxel', 'Tamoxifen_Percentage': '2', 'Letrozole_Percentage': '3', 'Anastrozole_Percentage': '1', 'Antidiarrheal_Agent_Probiotics_Percentage': '35', 'Antiemetic_Agent_Percentage': '65', 'Painkiller_Antipyretic_Percentage': '50', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Ceritinib', 'STUDYID': 'CER1002', 'YEAR': '2023', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '68', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '55', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '7', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '38', 'Tumor_Stage_T4_Percentage': '16', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '27', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '20', 'Adjuvant_Chemotherapy_Received_Percentage': '60', 'Postoperative_RT_Received_Percentage': '40', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Gemcitabine', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Pemetrexed', 'Common_Adjuvant_Regimen_1': 'Cisplatin + Etoposide', 'Common_Adjuvant_Regimen_2': 'Carboplatin + Vinorelbine', 'Tamoxifen_Percentage': '1', 'Letrozole_Percentage': '4', 'Anastrozole_Percentage': '2', 'Antidiarrheal_Agent_Probiotics_Percentage': '40', 'Antiemetic_Agent_Percentage': '70', 'Painkiller_Antipyretic_Percentage': '55', 'Beds_Less_Than_200_Percentage': '10', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Ceritinib', 'STUDYID': 'CER1003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '42', 'Male_Percentage': '58', 'Median_BMI': '26.9', 'Smoking_History_Yes_Percentage': '65', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '6', 'Tumor_Stage_T1_Percentage': '16', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '38', 'Tumor_Stage_T4_Percentage': '14', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '24', 'Nodal_Stage_N2_Percentage': '13', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '19', 'Stage_II_Percentage': '36', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '17', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '55', 'Postoperative_RT_Received_Percentage': '45', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Gemcitabine', 'Common_Adjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Carboplatin + Etoposide', 'Tamoxifen_Percentage': '3', 'Letrozole_Percentage': '2', 'Anastrozole_Percentage': '1', 'Antidiarrheal_Agent_Probiotics_Percentage': '30', 'Antiemetic_Agent_Percentage': '60', 'Painkiller_Antipyretic_Percentage': '48', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '40', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '55', 'Months_Between_Surgery_And_Index_Date': '2.5'}]\n",
      "File created: Ceritinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Ceritinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Crizotinib\",\n",
      "    \"STUDYID\": \"CRZ2020-US\",\n",
      "    \"YEAR\": 2020,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 60,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 55,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Cisplatin + Vinorelbine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 45,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Crizotinib\",\n",
      "    \"STUDYID\": \"CRZ2021-EU\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 55,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 35,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32,\n",
      "    \"Nodal_Stage_N2_Percentage\": 23,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 37,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 48,\n",
      "    \"Postoperative_RT_Received_Percentage\": 52,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Cisplatin + Etoposide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin + Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 70,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 35,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 55,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Crizotinib\",\n",
      "    \"STUDYID\": \"CRZ2022-JP\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 55,\n",
      "    \"Male_Percentage\": 45,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 45,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 3,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 17,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 33,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 10,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 42,\n",
      "    \"Postoperative_RT_Received_Percentage\": 60,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin + Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cisplatin + Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Crizotinib\",\n",
      "    \"STUDYID\": \"CRZ2023-CA\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 63,\n",
      "    \"Female_Percentage\": 50,\n",
      "    \"Male_Percentage\": 50,\n",
      "    \"Median_BMI\": 29.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 58,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 36,\n",
      "    \"Tumor_Stage_T3_Percentage\": 31,\n",
      "    \"Tumor_Stage_T4_Percentage\": 19,\n",
      "    \"Nodal_Stage_N0_Percentage\": 38,\n",
      "    \"Nodal_Stage_N1_Percentage\": 31,\n",
      "    \"Nodal_Stage_N2_Percentage\": 22,\n",
      "    \"Nodal_Stage_N3_Percentage\": 9,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 36,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 13,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 11,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 46,\n",
      "    \"Postoperative_RT_Received_Percentage\": 54,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Cisplatin + Vinorelbine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 32,\n",
      "    \"Antiemetic_Agent_Percentage\": 68,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 52,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 38,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.8\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Crizotinib', 'STUDYID': 'CRZ2020-US', 'YEAR': 2020, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 60, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 55, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Cisplatin + Vinorelbine', 'Common_Adjuvant_Regimen_2': 'Carboplatin + Pemetrexed', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 45, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Crizotinib', 'STUDYID': 'CRZ2021-EU', 'YEAR': 2021, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 65, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 55, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 35, 'Nodal_Stage_N1_Percentage': 32, 'Nodal_Stage_N2_Percentage': 23, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 37, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 48, 'Postoperative_RT_Received_Percentage': 52, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Gemcitabine', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Docetaxel', 'Common_Adjuvant_Regimen_1': 'Cisplatin + Etoposide', 'Common_Adjuvant_Regimen_2': 'Carboplatin + Vinorelbine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 70, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 35, 'Beds_Greater_Or_Equal_To_500_Percentage': 55, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 1.5}, {'Drug_Name': 'Crizotinib', 'STUDYID': 'CRZ2022-JP', 'YEAR': 2022, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 68, 'Female_Percentage': 55, 'Male_Percentage': 45, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 45, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 3, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 17, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 33, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 10, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 6, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 42, 'Postoperative_RT_Received_Percentage': 60, 'Common_Neoadjuvant_Regimen_1': 'Carboplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin + Docetaxel', 'Common_Adjuvant_Regimen_1': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_2': 'Cisplatin + Vinorelbine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 2.5}, {'Drug_Name': 'Crizotinib', 'STUDYID': 'CRZ2023-CA', 'YEAR': 2023, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 63, 'Female_Percentage': 50, 'Male_Percentage': 50, 'Median_BMI': 29.0, 'Smoking_History_Yes_Percentage': 58, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 36, 'Tumor_Stage_T3_Percentage': 31, 'Tumor_Stage_T4_Percentage': 19, 'Nodal_Stage_N0_Percentage': 38, 'Nodal_Stage_N1_Percentage': 31, 'Nodal_Stage_N2_Percentage': 22, 'Nodal_Stage_N3_Percentage': 9, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 36, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 13, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 11, 'Adjuvant_Chemotherapy_Received_Percentage': 46, 'Postoperative_RT_Received_Percentage': 54, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Docetaxel', 'Common_Adjuvant_Regimen_1': 'Cisplatin + Vinorelbine', 'Common_Adjuvant_Regimen_2': 'Carboplatin + Pemetrexed', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 32, 'Antiemetic_Agent_Percentage': 68, 'Painkiller_Antipyretic_Percentage': 52, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 38, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 1.8}]\n",
      "File created: Crizotinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Crizotinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Cyclophosphamide\",\n",
      "    \"STUDYID\": \"CYC2023-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 25,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 30,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 65,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FAC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"TC\",\n",
      "    \"Tamoxifen_Percentage\": 20,\n",
      "    \"Letrozole_Percentage\": 15,\n",
      "    \"Anastrozole_Percentage\": 10,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 70,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Cyclophosphamide\",\n",
      "    \"STUDYID\": \"CYC2022-002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 33,\n",
      "    \"Tumor_Stage_T4_Percentage\": 17,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 12,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 33,\n",
      "    \"Stage_III_Percentage\": 27,\n",
      "    \"Diabetes_Mellitus_Percentage\": 21,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 35,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 60,\n",
      "    \"Postoperative_RT_Received_Percentage\": 45,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 22,\n",
      "    \"Letrozole_Percentage\": 13,\n",
      "    \"Anastrozole_Percentage\": 12,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 75,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Cyclophosphamide\",\n",
      "    \"STUDYID\": \"CYC2024-003\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 29.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 22,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 16,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58,\n",
      "    \"Nodal_Stage_N1_Percentage\": 26,\n",
      "    \"Nodal_Stage_N2_Percentage\": 11,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 24,\n",
      "    \"Stage_II_Percentage\": 31,\n",
      "    \"Stage_III_Percentage\": 26,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 62,\n",
      "    \"Postoperative_RT_Received_Percentage\": 38,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CEF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxotere\",\n",
      "    \"Tamoxifen_Percentage\": 18,\n",
      "    \"Letrozole_Percentage\": 17,\n",
      "    \"Anastrozole_Percentage\": 15,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 38,\n",
      "    \"Antiemetic_Agent_Percentage\": 72,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 58,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 50,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Cyclophosphamide', 'STUDYID': 'CYC2023-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 25, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 30, 'Adjuvant_Chemotherapy_Received_Percentage': 65, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'FAC', 'Common_Neoadjuvant_Regimen_2': 'CMF', 'Common_Adjuvant_Regimen_1': 'AC', 'Common_Adjuvant_Regimen_2': 'TC', 'Tamoxifen_Percentage': 20, 'Letrozole_Percentage': 15, 'Anastrozole_Percentage': 10, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 70, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Cyclophosphamide', 'STUDYID': 'CYC2022-002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 33, 'Tumor_Stage_T4_Percentage': 17, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 12, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 33, 'Stage_III_Percentage': 27, 'Diabetes_Mellitus_Percentage': 21, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 35, 'Adjuvant_Chemotherapy_Received_Percentage': 60, 'Postoperative_RT_Received_Percentage': 45, 'Common_Neoadjuvant_Regimen_1': 'CMF', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'AC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 22, 'Letrozole_Percentage': 13, 'Anastrozole_Percentage': 12, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 75, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Cyclophosphamide', 'STUDYID': 'CYC2024-003', 'YEAR': 2024, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 29.0, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 22, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 16, 'Nodal_Stage_N0_Percentage': 58, 'Nodal_Stage_N1_Percentage': 26, 'Nodal_Stage_N2_Percentage': 11, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 24, 'Stage_II_Percentage': 31, 'Stage_III_Percentage': 26, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 28, 'Adjuvant_Chemotherapy_Received_Percentage': 62, 'Postoperative_RT_Received_Percentage': 38, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'CEF', 'Common_Adjuvant_Regimen_2': 'Taxotere', 'Tamoxifen_Percentage': 18, 'Letrozole_Percentage': 17, 'Anastrozole_Percentage': 15, 'Antidiarrheal_Agent_Probiotics_Percentage': 38, 'Antiemetic_Agent_Percentage': 72, 'Painkiller_Antipyretic_Percentage': 58, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 50, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Cyclophosphamide_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Cyclophosphamide\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Cytarabine\",\n",
      "    \"STUDYID\": \"CYT2023-001\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"62\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"26.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"32\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"12\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"5\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"7\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"4\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"60\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"40\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FLT3 Inhibitor + Cytarabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"7+3\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"HiDAC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"MEC\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"35\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"70\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"50\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Cytarabine\",\n",
      "    \"STUDYID\": \"CYT2023-002\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"27.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"38\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"6\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"32\",\n",
      "    \"Stage_III_Percentage\": \"33\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"14\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"58\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"38\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FLT3 Inhibitor + Cytarabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"7+3\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"HiDAC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"MEC\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"38\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"72\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"52\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"34\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"68\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Cytarabine\",\n",
      "    \"STUDYID\": \"CYT2023-003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"50\",\n",
      "    \"Male_Percentage\": \"50\",\n",
      "    \"Median_BMI\": \"28\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"40\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"75\",\n",
      "    \"LHRH_Use_Percentage\": \"7\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"45\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"50\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"8\",\n",
      "    \"Stage_I_Percentage\": \"15\",\n",
      "    \"Stage_II_Percentage\": \"30\",\n",
      "    \"Stage_III_Percentage\": \"35\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"55\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"35\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FLT3 Inhibitor + Cytarabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"7+3\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"HiDAC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"MEC\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"40\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"75\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"55\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Cytarabine', 'STUDYID': 'CYT2023-001', 'YEAR': '2023', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '62', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '26.5', 'Smoking_History_Yes_Percentage': '32', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '12', 'Congestive_Heart_Failure_Percentage': '5', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '7', 'Myocardial_Infarction_Percentage': '4', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '60', 'Postoperative_RT_Received_Percentage': '40', 'Common_Neoadjuvant_Regimen_1': 'FLT3 Inhibitor + Cytarabine', 'Common_Neoadjuvant_Regimen_2': '7+3', 'Common_Adjuvant_Regimen_1': 'HiDAC', 'Common_Adjuvant_Regimen_2': 'MEC', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '35', 'Antiemetic_Agent_Percentage': '70', 'Painkiller_Antipyretic_Percentage': '50', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Cytarabine', 'STUDYID': 'CYT2023-002', 'YEAR': '2023', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '68', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '27.1', 'Smoking_History_Yes_Percentage': '38', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '6', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '42', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '32', 'Stage_III_Percentage': '33', 'Diabetes_Mellitus_Percentage': '14', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '58', 'Postoperative_RT_Received_Percentage': '38', 'Common_Neoadjuvant_Regimen_1': 'FLT3 Inhibitor + Cytarabine', 'Common_Neoadjuvant_Regimen_2': '7+3', 'Common_Adjuvant_Regimen_1': 'HiDAC', 'Common_Adjuvant_Regimen_2': 'MEC', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '38', 'Antiemetic_Agent_Percentage': '72', 'Painkiller_Antipyretic_Percentage': '52', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '34', 'Designated_Cancer_Hospital_Percentage': '68', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Cytarabine', 'STUDYID': 'CYT2023-003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '70', 'Female_Percentage': '50', 'Male_Percentage': '50', 'Median_BMI': '28', 'Smoking_History_Yes_Percentage': '40', 'Total_ADL_Independence_Percentage': '75', 'LHRH_Use_Percentage': '7', 'Tumor_Stage_T1_Percentage': '10', 'Tumor_Stage_T2_Percentage': '25', 'Tumor_Stage_T3_Percentage': '45', 'Tumor_Stage_T4_Percentage': '20', 'Nodal_Stage_N0_Percentage': '50', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '12', 'Nodal_Stage_N3_Percentage': '8', 'Stage_I_Percentage': '15', 'Stage_II_Percentage': '30', 'Stage_III_Percentage': '35', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '20', 'Adjuvant_Chemotherapy_Received_Percentage': '55', 'Postoperative_RT_Received_Percentage': '35', 'Common_Neoadjuvant_Regimen_1': 'FLT3 Inhibitor + Cytarabine', 'Common_Neoadjuvant_Regimen_2': '7+3', 'Common_Adjuvant_Regimen_1': 'HiDAC', 'Common_Adjuvant_Regimen_2': 'MEC', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '40', 'Antiemetic_Agent_Percentage': '75', 'Painkiller_Antipyretic_Percentage': '55', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '3'}]\n",
      "File created: Cytarabine_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Cytarabine\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Dabrafenib\",\n",
      "    \"STUDYID\": \"DBRF1001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": \"65\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"45\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"12\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"5\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"7\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"4\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"10\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"40\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"35\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"DTX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CBDCA+PTX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"PTX+CBDCA\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC\",\n",
      "    \"Tamoxifen_Percentage\": \"2\",\n",
      "    \"Letrozole_Percentage\": \"3\",\n",
      "    \"Anastrozole_Percentage\": \"1\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"25\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"55\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"60\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Dabrafenib\",\n",
      "    \"STUDYID\": \"DBRF1002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"Claim database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": \"52\",\n",
      "    \"Male_Percentage\": \"48\",\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": \"58\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"8\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"40\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"35\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"17\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"8\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"37\",\n",
      "    \"Stage_III_Percentage\": \"25\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"12\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"42\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"38\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": \"4\",\n",
      "    \"Letrozole_Percentage\": \"2\",\n",
      "    \"Anastrozole_Percentage\": \"1\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"28\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"58\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"63\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"42\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Dabrafenib\",\n",
      "    \"STUDYID\": \"DBRF1003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": \"55\",\n",
      "    \"Male_Percentage\": \"45\",\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": \"60\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"6\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"14\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"36\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"29\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"21\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"42\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"32\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"19\",\n",
      "    \"Stage_II_Percentage\": \"36\",\n",
      "    \"Stage_III_Percentage\": \"27\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"14\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"4\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"11\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"41\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"36\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Taxol\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CarboTaxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"EC-T\",\n",
      "    \"Tamoxifen_Percentage\": \"3\",\n",
      "    \"Letrozole_Percentage\": \"1\",\n",
      "    \"Anastrozole_Percentage\": \"2\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"26\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"56\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"61\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"16\",\n",
      "    \"Beds_200_To_499_Percentage\": \"44\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Dabrafenib', 'STUDYID': 'DBRF1001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': '65', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '35', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '20', 'Nodal_Stage_N0_Percentage': '45', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '12', 'Congestive_Heart_Failure_Percentage': '5', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '7', 'Myocardial_Infarction_Percentage': '4', 'Neoadjuvant_Chemotherapy_Received_Percentage': '10', 'Adjuvant_Chemotherapy_Received_Percentage': '40', 'Postoperative_RT_Received_Percentage': '35', 'Common_Neoadjuvant_Regimen_1': 'DTX', 'Common_Neoadjuvant_Regimen_2': 'CBDCA+PTX', 'Common_Adjuvant_Regimen_1': 'PTX+CBDCA', 'Common_Adjuvant_Regimen_2': 'AC', 'Tamoxifen_Percentage': '2', 'Letrozole_Percentage': '3', 'Anastrozole_Percentage': '1', 'Antidiarrheal_Agent_Probiotics_Percentage': '25', 'Antiemetic_Agent_Percentage': '55', 'Painkiller_Antipyretic_Percentage': '60', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Dabrafenib', 'STUDYID': 'DBRF1002', 'YEAR': 2022, 'Country': 'UK', 'Dataset': 'Claim database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': '52', 'Male_Percentage': '48', 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': '58', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '8', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '38', 'Tumor_Stage_T3_Percentage': '28', 'Tumor_Stage_T4_Percentage': '22', 'Nodal_Stage_N0_Percentage': '40', 'Nodal_Stage_N1_Percentage': '35', 'Nodal_Stage_N2_Percentage': '17', 'Nodal_Stage_N3_Percentage': '8', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '37', 'Stage_III_Percentage': '25', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '12', 'Adjuvant_Chemotherapy_Received_Percentage': '42', 'Postoperative_RT_Received_Percentage': '38', 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': '4', 'Letrozole_Percentage': '2', 'Anastrozole_Percentage': '1', 'Antidiarrheal_Agent_Probiotics_Percentage': '28', 'Antiemetic_Agent_Percentage': '58', 'Painkiller_Antipyretic_Percentage': '63', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '42', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Dabrafenib', 'STUDYID': 'DBRF1003', 'YEAR': 2023, 'Country': 'Germany', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': '55', 'Male_Percentage': '45', 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': '60', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '6', 'Tumor_Stage_T1_Percentage': '14', 'Tumor_Stage_T2_Percentage': '36', 'Tumor_Stage_T3_Percentage': '29', 'Tumor_Stage_T4_Percentage': '21', 'Nodal_Stage_N0_Percentage': '42', 'Nodal_Stage_N1_Percentage': '32', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '19', 'Stage_II_Percentage': '36', 'Stage_III_Percentage': '27', 'Diabetes_Mellitus_Percentage': '14', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '4', 'Neoadjuvant_Chemotherapy_Received_Percentage': '11', 'Adjuvant_Chemotherapy_Received_Percentage': '41', 'Postoperative_RT_Received_Percentage': '36', 'Common_Neoadjuvant_Regimen_1': 'Taxol', 'Common_Neoadjuvant_Regimen_2': 'CarboTaxol', 'Common_Adjuvant_Regimen_1': 'FEC-T', 'Common_Adjuvant_Regimen_2': 'EC-T', 'Tamoxifen_Percentage': '3', 'Letrozole_Percentage': '1', 'Anastrozole_Percentage': '2', 'Antidiarrheal_Agent_Probiotics_Percentage': '26', 'Antiemetic_Agent_Percentage': '56', 'Painkiller_Antipyretic_Percentage': '61', 'Beds_Less_Than_200_Percentage': '16', 'Beds_200_To_499_Percentage': '44', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '2.5'}]\n",
      "File created: Dabrafenib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Dabrafenib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Dasatinib\",\n",
      "    \"STUDYID\": \"DasaStudy001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 88,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 48,\n",
      "    \"Postoperative_RT_Received_Percentage\": 55,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"TPF\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DCF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Paclitaxel\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 40,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Dasatinib\",\n",
      "    \"STUDYID\": \"DasaStudy002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 38,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32,\n",
      "    \"Nodal_Stage_N2_Percentage\": 18,\n",
      "    \"Nodal_Stage_N3_Percentage\": 12,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50,\n",
      "    \"Postoperative_RT_Received_Percentage\": 52,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"TPF\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"5-FU + Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Paclitaxel + Trastuzumab\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28,\n",
      "    \"Antiemetic_Agent_Percentage\": 62,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 42,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Dasatinib\",\n",
      "    \"STUDYID\": \"DasaStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 29.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 25,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 18,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 42,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 15,\n",
      "    \"Stage_I_Percentage\": 28,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 6,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 52,\n",
      "    \"Postoperative_RT_Received_Percentage\": 50,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"5-FU + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"TPF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 75,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Dasatinib', 'STUDYID': 'DasaStudy001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 88, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 48, 'Postoperative_RT_Received_Percentage': 55, 'Common_Neoadjuvant_Regimen_1': 'TPF', 'Common_Neoadjuvant_Regimen_2': 'DCF', 'Common_Adjuvant_Regimen_1': 'Docetaxel + Carboplatin', 'Common_Adjuvant_Regimen_2': 'Paclitaxel', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 40, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Dasatinib', 'STUDYID': 'DasaStudy002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 38, 'Nodal_Stage_N1_Percentage': 32, 'Nodal_Stage_N2_Percentage': 18, 'Nodal_Stage_N3_Percentage': 12, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 50, 'Postoperative_RT_Received_Percentage': 52, 'Common_Neoadjuvant_Regimen_1': 'TPF', 'Common_Neoadjuvant_Regimen_2': '5-FU + Cisplatin', 'Common_Adjuvant_Regimen_1': 'Docetaxel + Carboplatin', 'Common_Adjuvant_Regimen_2': 'Paclitaxel + Trastuzumab', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 28, 'Antiemetic_Agent_Percentage': 62, 'Painkiller_Antipyretic_Percentage': 42, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 1}, {'Drug_Name': 'Dasatinib', 'STUDYID': 'DasaStudy003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 29.5, 'Smoking_History_Yes_Percentage': 25, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 18, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 42, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 15, 'Stage_I_Percentage': 28, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 6, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 28, 'Adjuvant_Chemotherapy_Received_Percentage': 52, 'Postoperative_RT_Received_Percentage': 50, 'Common_Neoadjuvant_Regimen_1': '5-FU + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'TPF', 'Common_Adjuvant_Regimen_1': 'Carboplatin + Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 75, 'Months_Between_Surgery_And_Index_Date': 3}]\n",
      "File created: Dasatinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Dasatinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Decitabine\",\n",
      "    \"STUDYID\": \"Decitabine2023-US-01\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 62,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 38,\n",
      "    \"Postoperative_RT_Received_Percentage\": 45,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FLT3 inhibitors\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"7+3 Cytarabine and Daunorubicin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-Azacitidine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"LDAC\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 40,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 55,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": null\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Decitabine\",\n",
      "    \"STUDYID\": \"Decitabine2022-EU-02\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 58,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 14,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 33,\n",
      "    \"Stage_III_Percentage\": 49,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 35,\n",
      "    \"Postoperative_RT_Received_Percentage\": 42,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FLT3 inhibitors\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"7+3 Cytarabine and Daunorubicin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-Azacitidine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"LDAC\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28,\n",
      "    \"Antiemetic_Agent_Percentage\": 62,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 42,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 52,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 36,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 68,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": null\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Decitabine\",\n",
      "    \"STUDYID\": \"Decitabine2024-Asia-03\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 42,\n",
      "    \"Male_Percentage\": 58,\n",
      "    \"Median_BMI\": 25.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 55,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 3,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 38,\n",
      "    \"Tumor_Stage_T4_Percentage\": 12,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58,\n",
      "    \"Nodal_Stage_N1_Percentage\": 22,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16,\n",
      "    \"Nodal_Stage_N3_Percentage\": 4,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 37,\n",
      "    \"Stage_III_Percentage\": 41,\n",
      "    \"Diabetes_Mellitus_Percentage\": 16,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 24,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Postoperative_RT_Received_Percentage\": 47,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FLT3 inhibitors\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"7+3 Cytarabine and Daunorubicin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-Azacitidine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"LDAC\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 23,\n",
      "    \"Antiemetic_Agent_Percentage\": 58,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 38,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 58,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 24,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": null\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Decitabine', 'STUDYID': 'Decitabine2023-US-01', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 62, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 38, 'Postoperative_RT_Received_Percentage': 45, 'Common_Neoadjuvant_Regimen_1': 'FLT3 inhibitors', 'Common_Neoadjuvant_Regimen_2': '7+3 Cytarabine and Daunorubicin', 'Common_Adjuvant_Regimen_1': '5-Azacitidine', 'Common_Adjuvant_Regimen_2': 'LDAC', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 40, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 55, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': None}, {'Drug_Name': 'Decitabine', 'STUDYID': 'Decitabine2022-EU-02', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 58, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 14, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 33, 'Stage_III_Percentage': 49, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 35, 'Postoperative_RT_Received_Percentage': 42, 'Common_Neoadjuvant_Regimen_1': 'FLT3 inhibitors', 'Common_Neoadjuvant_Regimen_2': '7+3 Cytarabine and Daunorubicin', 'Common_Adjuvant_Regimen_1': '5-Azacitidine', 'Common_Adjuvant_Regimen_2': 'LDAC', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 28, 'Antiemetic_Agent_Percentage': 62, 'Painkiller_Antipyretic_Percentage': 42, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 52, 'Beds_Greater_Or_Equal_To_500_Percentage': 36, 'Designated_Cancer_Hospital_Percentage': 68, 'Months_Between_Surgery_And_Index_Date': None}, {'Drug_Name': 'Decitabine', 'STUDYID': 'Decitabine2024-Asia-03', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 42, 'Male_Percentage': 58, 'Median_BMI': 25.5, 'Smoking_History_Yes_Percentage': 55, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 3, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 38, 'Tumor_Stage_T4_Percentage': 12, 'Nodal_Stage_N0_Percentage': 58, 'Nodal_Stage_N1_Percentage': 22, 'Nodal_Stage_N2_Percentage': 16, 'Nodal_Stage_N3_Percentage': 4, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 37, 'Stage_III_Percentage': 41, 'Diabetes_Mellitus_Percentage': 16, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 24, 'Adjuvant_Chemotherapy_Received_Percentage': 40, 'Postoperative_RT_Received_Percentage': 47, 'Common_Neoadjuvant_Regimen_1': 'FLT3 inhibitors', 'Common_Neoadjuvant_Regimen_2': '7+3 Cytarabine and Daunorubicin', 'Common_Adjuvant_Regimen_1': '5-Azacitidine', 'Common_Adjuvant_Regimen_2': 'LDAC', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 23, 'Antiemetic_Agent_Percentage': 58, 'Painkiller_Antipyretic_Percentage': 38, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 58, 'Beds_Greater_Or_Equal_To_500_Percentage': 24, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': None}]\n",
      "File created: Decitabine_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Decitabine\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Docetaxel\",\n",
      "    \"STUDYID\": \"DCTXL001\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"35\",\n",
      "    \"Male_Percentage\": \"65\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"42\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"45\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"60\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"45\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FAC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": \"12\",\n",
      "    \"Letrozole_Percentage\": \"8\",\n",
      "    \"Anastrozole_Percentage\": \"10\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"30\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"70\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"55\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Docetaxel\",\n",
      "    \"STUDYID\": \"DCTXL002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"40\",\n",
      "    \"Male_Percentage\": \"60\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"38\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"40\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"32\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"32\",\n",
      "    \"Stage_III_Percentage\": \"35\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"58\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"42\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel/Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC-T\",\n",
      "    \"Tamoxifen_Percentage\": \"10\",\n",
      "    \"Letrozole_Percentage\": \"9\",\n",
      "    \"Anastrozole_Percentage\": \"11\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"32\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"72\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"58\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"42\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Docetaxel\",\n",
      "    \"STUDYID\": \"DCTXL003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"38\",\n",
      "    \"Male_Percentage\": \"62\",\n",
      "    \"Median_BMI\": \"26.9\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"45\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"20\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"14\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"29\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"41\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"43\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"31\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"19\",\n",
      "    \"Stage_II_Percentage\": \"34\",\n",
      "    \"Stage_III_Percentage\": \"32\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"19\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"24\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"59\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"44\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Taxotere/FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel/Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": \"11\",\n",
      "    \"Letrozole_Percentage\": \"8\",\n",
      "    \"Anastrozole_Percentage\": \"10\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"31\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"71\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"56\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"19\",\n",
      "    \"Beds_200_To_499_Percentage\": \"43\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"38\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"61\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Docetaxel\",\n",
      "    \"STUDYID\": \"DCTXL004\",\n",
      "    \"YEAR\": \"2024\",\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"42\",\n",
      "    \"Male_Percentage\": \"58\",\n",
      "    \"Median_BMI\": \"27.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"40\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"17\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"13\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"27\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"43\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"17\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"39\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"33\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"17\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"11\",\n",
      "    \"Stage_I_Percentage\": \"17\",\n",
      "    \"Stage_II_Percentage\": \"31\",\n",
      "    \"Stage_III_Percentage\": \"36\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"21\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"11\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"23\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"57\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"41\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel/AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel/Doxorubicin/Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC-TH\",\n",
      "    \"Tamoxifen_Percentage\": \"9\",\n",
      "    \"Letrozole_Percentage\": \"10\",\n",
      "    \"Anastrozole_Percentage\": \"12\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"33\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"73\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"59\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"17\",\n",
      "    \"Beds_200_To_499_Percentage\": \"41\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"42\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"63\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.7\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Docetaxel\",\n",
      "    \"STUDYID\": \"DCTXL005\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"France\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"300\",\n",
      "    \"Median_Age\": \"67\",\n",
      "    \"Female_Percentage\": \"36\",\n",
      "    \"Male_Percentage\": \"64\",\n",
      "    \"Median_BMI\": \"27.2\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"43\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"84\",\n",
      "    \"LHRH_Use_Percentage\": \"19\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"16\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"31\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"39\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"44\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"11\",\n",
      "    \"Stage_I_Percentage\": \"21\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"31\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"17\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"26\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"61\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"46\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC-T\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel/Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": \"13\",\n",
      "    \"Letrozole_Percentage\": \"7\",\n",
      "    \"Anastrozole_Percentage\": \"9\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"29\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"69\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"54\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"21\",\n",
      "    \"Beds_200_To_499_Percentage\": \"44\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"59\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.1\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Docetaxel', 'STUDYID': 'DCTXL001', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '35', 'Male_Percentage': '65', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '42', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '45', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '60', 'Postoperative_RT_Received_Percentage': '45', 'Common_Neoadjuvant_Regimen_1': 'FAC', 'Common_Neoadjuvant_Regimen_2': 'AC', 'Common_Adjuvant_Regimen_1': 'TC', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': '12', 'Letrozole_Percentage': '8', 'Anastrozole_Percentage': '10', 'Antidiarrheal_Agent_Probiotics_Percentage': '30', 'Antiemetic_Agent_Percentage': '70', 'Painkiller_Antipyretic_Percentage': '55', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Docetaxel', 'STUDYID': 'DCTXL002', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '40', 'Male_Percentage': '60', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '38', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '18', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '42', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '40', 'Nodal_Stage_N1_Percentage': '32', 'Nodal_Stage_N2_Percentage': '18', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '32', 'Stage_III_Percentage': '35', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '58', 'Postoperative_RT_Received_Percentage': '42', 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'EC', 'Common_Adjuvant_Regimen_1': 'Docetaxel/Cyclophosphamide', 'Common_Adjuvant_Regimen_2': 'AC-T', 'Tamoxifen_Percentage': '10', 'Letrozole_Percentage': '9', 'Anastrozole_Percentage': '11', 'Antidiarrheal_Agent_Probiotics_Percentage': '32', 'Antiemetic_Agent_Percentage': '72', 'Painkiller_Antipyretic_Percentage': '58', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '42', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Docetaxel', 'STUDYID': 'DCTXL003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '38', 'Male_Percentage': '62', 'Median_BMI': '26.9', 'Smoking_History_Yes_Percentage': '45', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '20', 'Tumor_Stage_T1_Percentage': '14', 'Tumor_Stage_T2_Percentage': '29', 'Tumor_Stage_T3_Percentage': '41', 'Tumor_Stage_T4_Percentage': '16', 'Nodal_Stage_N0_Percentage': '43', 'Nodal_Stage_N1_Percentage': '31', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '19', 'Stage_II_Percentage': '34', 'Stage_III_Percentage': '32', 'Diabetes_Mellitus_Percentage': '19', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '24', 'Adjuvant_Chemotherapy_Received_Percentage': '59', 'Postoperative_RT_Received_Percentage': '44', 'Common_Neoadjuvant_Regimen_1': 'Taxotere/FEC', 'Common_Neoadjuvant_Regimen_2': 'EC', 'Common_Adjuvant_Regimen_1': 'Docetaxel/Carboplatin', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': '11', 'Letrozole_Percentage': '8', 'Anastrozole_Percentage': '10', 'Antidiarrheal_Agent_Probiotics_Percentage': '31', 'Antiemetic_Agent_Percentage': '71', 'Painkiller_Antipyretic_Percentage': '56', 'Beds_Less_Than_200_Percentage': '19', 'Beds_200_To_499_Percentage': '43', 'Beds_Greater_Or_Equal_To_500_Percentage': '38', 'Designated_Cancer_Hospital_Percentage': '61', 'Months_Between_Surgery_And_Index_Date': '2.2'}, {'Drug_Name': 'Docetaxel', 'STUDYID': 'DCTXL004', 'YEAR': '2024', 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '70', 'Female_Percentage': '42', 'Male_Percentage': '58', 'Median_BMI': '27.8', 'Smoking_History_Yes_Percentage': '40', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '17', 'Tumor_Stage_T1_Percentage': '13', 'Tumor_Stage_T2_Percentage': '27', 'Tumor_Stage_T3_Percentage': '43', 'Tumor_Stage_T4_Percentage': '17', 'Nodal_Stage_N0_Percentage': '39', 'Nodal_Stage_N1_Percentage': '33', 'Nodal_Stage_N2_Percentage': '17', 'Nodal_Stage_N3_Percentage': '11', 'Stage_I_Percentage': '17', 'Stage_II_Percentage': '31', 'Stage_III_Percentage': '36', 'Diabetes_Mellitus_Percentage': '21', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '11', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '23', 'Adjuvant_Chemotherapy_Received_Percentage': '57', 'Postoperative_RT_Received_Percentage': '41', 'Common_Neoadjuvant_Regimen_1': 'Docetaxel/AC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'Docetaxel/Doxorubicin/Cyclophosphamide', 'Common_Adjuvant_Regimen_2': 'AC-TH', 'Tamoxifen_Percentage': '9', 'Letrozole_Percentage': '10', 'Anastrozole_Percentage': '12', 'Antidiarrheal_Agent_Probiotics_Percentage': '33', 'Antiemetic_Agent_Percentage': '73', 'Painkiller_Antipyretic_Percentage': '59', 'Beds_Less_Than_200_Percentage': '17', 'Beds_200_To_499_Percentage': '41', 'Beds_Greater_Or_Equal_To_500_Percentage': '42', 'Designated_Cancer_Hospital_Percentage': '63', 'Months_Between_Surgery_And_Index_Date': '2.7'}, {'Drug_Name': 'Docetaxel', 'STUDYID': 'DCTXL005', 'YEAR': '2023', 'Country': 'France', 'Dataset': 'MDV', 'Patient_Count': '300', 'Median_Age': '67', 'Female_Percentage': '36', 'Male_Percentage': '64', 'Median_BMI': '27.2', 'Smoking_History_Yes_Percentage': '43', 'Total_ADL_Independence_Percentage': '84', 'LHRH_Use_Percentage': '19', 'Tumor_Stage_T1_Percentage': '16', 'Tumor_Stage_T2_Percentage': '31', 'Tumor_Stage_T3_Percentage': '39', 'Tumor_Stage_T4_Percentage': '14', 'Nodal_Stage_N0_Percentage': '44', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '11', 'Stage_I_Percentage': '21', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '31', 'Diabetes_Mellitus_Percentage': '17', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '26', 'Adjuvant_Chemotherapy_Received_Percentage': '61', 'Postoperative_RT_Received_Percentage': '46', 'Common_Neoadjuvant_Regimen_1': 'FEC-T', 'Common_Neoadjuvant_Regimen_2': 'AC', 'Common_Adjuvant_Regimen_1': 'Docetaxel/Cyclophosphamide', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': '13', 'Letrozole_Percentage': '7', 'Anastrozole_Percentage': '9', 'Antidiarrheal_Agent_Probiotics_Percentage': '29', 'Antiemetic_Agent_Percentage': '69', 'Painkiller_Antipyretic_Percentage': '54', 'Beds_Less_Than_200_Percentage': '21', 'Beds_200_To_499_Percentage': '44', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '59', 'Months_Between_Surgery_And_Index_Date': '2.1'}]\n",
      "File created: Docetaxel_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Docetaxel\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Doxorubicin\",\n",
      "    \"STUDYID\": \"DOX2020-US-01\",\n",
      "    \"YEAR\": 2020,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 55.0,\n",
      "    \"Male_Percentage\": 45.0,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 85.0,\n",
      "    \"LHRH_Use_Percentage\": 12.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 25.0,\n",
      "    \"Stage_II_Percentage\": 40.0,\n",
      "    \"Stage_III_Percentage\": 30.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7.0,\n",
      "    \"Stroke_Percentage\": 3.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 4.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 45.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 55.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 60.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FAC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"TC\",\n",
      "    \"Tamoxifen_Percentage\": 20.0,\n",
      "    \"Letrozole_Percentage\": 15.0,\n",
      "    \"Anastrozole_Percentage\": 10.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 70.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15.0,\n",
      "    \"Beds_200_To_499_Percentage\": 45.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Doxorubicin\",\n",
      "    \"STUDYID\": \"DOX2021-EU-02\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 60.0,\n",
      "    \"Male_Percentage\": 40.0,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 28.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 78.0,\n",
      "    \"LHRH_Use_Percentage\": 15.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 22.0,\n",
      "    \"Stage_II_Percentage\": 38.0,\n",
      "    \"Stage_III_Percentage\": 32.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8.0,\n",
      "    \"Stroke_Percentage\": 4.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 5.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 40.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 60.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 55.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel/Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": 22.0,\n",
      "    \"Letrozole_Percentage\": 18.0,\n",
      "    \"Anastrozole_Percentage\": 12.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 45.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 75.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10.0,\n",
      "    \"Beds_200_To_499_Percentage\": 50.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Doxorubicin\",\n",
      "    \"STUDYID\": \"DOX2022-ASIA-03\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 58.0,\n",
      "    \"Male_Percentage\": 42.0,\n",
      "    \"Median_BMI\": 24.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 25.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 80.0,\n",
      "    \"LHRH_Use_Percentage\": 10.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 22.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 65.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 28.0,\n",
      "    \"Stage_II_Percentage\": 42.0,\n",
      "    \"Stage_III_Percentage\": 25.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6.0,\n",
      "    \"Stroke_Percentage\": 2.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 3.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 50.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 70.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel/Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": 25.0,\n",
      "    \"Letrozole_Percentage\": 20.0,\n",
      "    \"Anastrozole_Percentage\": 15.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 65.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20.0,\n",
      "    \"Beds_200_To_499_Percentage\": 40.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 75.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Doxorubicin\",\n",
      "    \"STUDYID\": \"DOX2023-CA-04\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 300,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 52.0,\n",
      "    \"Male_Percentage\": 48.0,\n",
      "    \"Median_BMI\": 28.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 30.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 82.0,\n",
      "    \"LHRH_Use_Percentage\": 13.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 19.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 33.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 33.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 27.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 24.0,\n",
      "    \"Stage_II_Percentage\": 39.0,\n",
      "    \"Stage_III_Percentage\": 29.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 17.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7.5,\n",
      "    \"Stroke_Percentage\": 3.5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9.5,\n",
      "    \"Myocardial_Infarction_Percentage\": 4.5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 42.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 58.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 62.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol/AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"TC\",\n",
      "    \"Tamoxifen_Percentage\": 21.0,\n",
      "    \"Letrozole_Percentage\": 16.0,\n",
      "    \"Anastrozole_Percentage\": 11.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 41.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 71.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 51.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 14.0,\n",
      "    \"Beds_200_To_499_Percentage\": 46.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 67.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Doxorubicin', 'STUDYID': 'DOX2020-US-01', 'YEAR': 2020, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 55.0, 'Male_Percentage': 45.0, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32.0, 'Total_ADL_Independence_Percentage': 85.0, 'LHRH_Use_Percentage': 12.0, 'Tumor_Stage_T1_Percentage': 20.0, 'Tumor_Stage_T2_Percentage': 35.0, 'Tumor_Stage_T3_Percentage': 30.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 60.0, 'Nodal_Stage_N1_Percentage': 25.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 25.0, 'Stage_II_Percentage': 40.0, 'Stage_III_Percentage': 30.0, 'Diabetes_Mellitus_Percentage': 18.0, 'Congestive_Heart_Failure_Percentage': 7.0, 'Stroke_Percentage': 3.0, 'Atrial_Fibrillation_Percentage': 9.0, 'Myocardial_Infarction_Percentage': 4.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 45.0, 'Adjuvant_Chemotherapy_Received_Percentage': 55.0, 'Postoperative_RT_Received_Percentage': 60.0, 'Common_Neoadjuvant_Regimen_1': 'FAC', 'Common_Neoadjuvant_Regimen_2': 'AC', 'Common_Adjuvant_Regimen_1': 'AC-T', 'Common_Adjuvant_Regimen_2': 'TC', 'Tamoxifen_Percentage': 20.0, 'Letrozole_Percentage': 15.0, 'Anastrozole_Percentage': 10.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 40.0, 'Antiemetic_Agent_Percentage': 70.0, 'Painkiller_Antipyretic_Percentage': 50.0, 'Beds_Less_Than_200_Percentage': 15.0, 'Beds_200_To_499_Percentage': 45.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 65.0, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Doxorubicin', 'STUDYID': 'DOX2021-EU-02', 'YEAR': 2021, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 60.0, 'Male_Percentage': 40.0, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 28.0, 'Total_ADL_Independence_Percentage': 78.0, 'LHRH_Use_Percentage': 15.0, 'Tumor_Stage_T1_Percentage': 18.0, 'Tumor_Stage_T2_Percentage': 32.0, 'Tumor_Stage_T3_Percentage': 35.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 55.0, 'Nodal_Stage_N1_Percentage': 30.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 22.0, 'Stage_II_Percentage': 38.0, 'Stage_III_Percentage': 32.0, 'Diabetes_Mellitus_Percentage': 20.0, 'Congestive_Heart_Failure_Percentage': 8.0, 'Stroke_Percentage': 4.0, 'Atrial_Fibrillation_Percentage': 10.0, 'Myocardial_Infarction_Percentage': 5.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 40.0, 'Adjuvant_Chemotherapy_Received_Percentage': 60.0, 'Postoperative_RT_Received_Percentage': 55.0, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'Docetaxel/Cyclophosphamide', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': 22.0, 'Letrozole_Percentage': 18.0, 'Anastrozole_Percentage': 12.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 45.0, 'Antiemetic_Agent_Percentage': 75.0, 'Painkiller_Antipyretic_Percentage': 55.0, 'Beds_Less_Than_200_Percentage': 10.0, 'Beds_200_To_499_Percentage': 50.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 70.0, 'Months_Between_Surgery_And_Index_Date': 1}, {'Drug_Name': 'Doxorubicin', 'STUDYID': 'DOX2022-ASIA-03', 'YEAR': 2022, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 58.0, 'Male_Percentage': 42.0, 'Median_BMI': 24.5, 'Smoking_History_Yes_Percentage': 25.0, 'Total_ADL_Independence_Percentage': 80.0, 'LHRH_Use_Percentage': 10.0, 'Tumor_Stage_T1_Percentage': 22.0, 'Tumor_Stage_T2_Percentage': 38.0, 'Tumor_Stage_T3_Percentage': 25.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 65.0, 'Nodal_Stage_N1_Percentage': 20.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 28.0, 'Stage_II_Percentage': 42.0, 'Stage_III_Percentage': 25.0, 'Diabetes_Mellitus_Percentage': 15.0, 'Congestive_Heart_Failure_Percentage': 6.0, 'Stroke_Percentage': 2.0, 'Atrial_Fibrillation_Percentage': 8.0, 'Myocardial_Infarction_Percentage': 3.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 50.0, 'Adjuvant_Chemotherapy_Received_Percentage': 50.0, 'Postoperative_RT_Received_Percentage': 70.0, 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'EC', 'Common_Adjuvant_Regimen_1': 'Docetaxel/Cyclophosphamide', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': 25.0, 'Letrozole_Percentage': 20.0, 'Anastrozole_Percentage': 15.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35.0, 'Antiemetic_Agent_Percentage': 65.0, 'Painkiller_Antipyretic_Percentage': 45.0, 'Beds_Less_Than_200_Percentage': 20.0, 'Beds_200_To_499_Percentage': 40.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 75.0, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Doxorubicin', 'STUDYID': 'DOX2023-CA-04', 'YEAR': 2023, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 300, 'Median_Age': 65, 'Female_Percentage': 52.0, 'Male_Percentage': 48.0, 'Median_BMI': 28.0, 'Smoking_History_Yes_Percentage': 30.0, 'Total_ADL_Independence_Percentage': 82.0, 'LHRH_Use_Percentage': 13.0, 'Tumor_Stage_T1_Percentage': 19.0, 'Tumor_Stage_T2_Percentage': 33.0, 'Tumor_Stage_T3_Percentage': 33.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 58.0, 'Nodal_Stage_N1_Percentage': 27.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 24.0, 'Stage_II_Percentage': 39.0, 'Stage_III_Percentage': 29.0, 'Diabetes_Mellitus_Percentage': 17.0, 'Congestive_Heart_Failure_Percentage': 7.5, 'Stroke_Percentage': 3.5, 'Atrial_Fibrillation_Percentage': 9.5, 'Myocardial_Infarction_Percentage': 4.5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 42.0, 'Adjuvant_Chemotherapy_Received_Percentage': 58.0, 'Postoperative_RT_Received_Percentage': 62.0, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Taxol/AC', 'Common_Adjuvant_Regimen_1': 'AC-T', 'Common_Adjuvant_Regimen_2': 'TC', 'Tamoxifen_Percentage': 21.0, 'Letrozole_Percentage': 16.0, 'Anastrozole_Percentage': 11.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 41.0, 'Antiemetic_Agent_Percentage': 71.0, 'Painkiller_Antipyretic_Percentage': 51.0, 'Beds_Less_Than_200_Percentage': 14.0, 'Beds_200_To_499_Percentage': 46.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 67.0, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Doxorubicin_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Doxorubicin\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Enzalutamide\",\n",
      "    \"STUDYID\": \"EnzaStudy001\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"0.5\",\n",
      "    \"Male_Percentage\": \"99.5\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"70\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"15\",\n",
      "    \"Stage_II_Percentage\": \"30\",\n",
      "    \"Stage_III_Percentage\": \"35\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"12\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"5\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"10\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"15\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"10\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"15\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"25\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Enzalutamide\",\n",
      "    \"STUDYID\": \"EnzaStudy002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"75\",\n",
      "    \"Female_Percentage\": \"0.3\",\n",
      "    \"Male_Percentage\": \"99.7\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"38\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"72\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"8\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"22\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"32\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"27\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"9\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"13\",\n",
      "    \"Stage_II_Percentage\": \"28\",\n",
      "    \"Stage_III_Percentage\": \"37\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"22\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"13\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"6\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"11\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"16\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"11\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"16\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"26\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"16\",\n",
      "    \"Beds_200_To_499_Percentage\": \"46\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"38\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"4\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Enzalutamide\",\n",
      "    \"STUDYID\": \"EnzaStudy003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"0.7\",\n",
      "    \"Male_Percentage\": \"99.3\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"32\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"88\",\n",
      "    \"LHRH_Use_Percentage\": \"68\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"62\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"23\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"11\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"4\",\n",
      "    \"Stage_I_Percentage\": \"17\",\n",
      "    \"Stage_II_Percentage\": \"32\",\n",
      "    \"Stage_III_Percentage\": \"33\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"11\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"4\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"9\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"14\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"9\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"14\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"23\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"14\",\n",
      "    \"Beds_200_To_499_Percentage\": \"44\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"42\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"58\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Enzalutamide', 'STUDYID': 'EnzaStudy001', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '72', 'Female_Percentage': '0.5', 'Male_Percentage': '99.5', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '70', 'Tumor_Stage_T1_Percentage': '10', 'Tumor_Stage_T2_Percentage': '25', 'Tumor_Stage_T3_Percentage': '35', 'Tumor_Stage_T4_Percentage': '30', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '15', 'Stage_II_Percentage': '30', 'Stage_III_Percentage': '35', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '12', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '5', 'Adjuvant_Chemotherapy_Received_Percentage': '10', 'Postoperative_RT_Received_Percentage': '15', 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'None', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '10', 'Antiemetic_Agent_Percentage': '15', 'Painkiller_Antipyretic_Percentage': '25', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Enzalutamide', 'STUDYID': 'EnzaStudy002', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '75', 'Female_Percentage': '0.3', 'Male_Percentage': '99.7', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '38', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '72', 'Tumor_Stage_T1_Percentage': '8', 'Tumor_Stage_T2_Percentage': '22', 'Tumor_Stage_T3_Percentage': '38', 'Tumor_Stage_T4_Percentage': '32', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '27', 'Nodal_Stage_N2_Percentage': '9', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '13', 'Stage_II_Percentage': '28', 'Stage_III_Percentage': '37', 'Diabetes_Mellitus_Percentage': '22', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '13', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '6', 'Adjuvant_Chemotherapy_Received_Percentage': '11', 'Postoperative_RT_Received_Percentage': '16', 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'None', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '11', 'Antiemetic_Agent_Percentage': '16', 'Painkiller_Antipyretic_Percentage': '26', 'Beds_Less_Than_200_Percentage': '16', 'Beds_200_To_499_Percentage': '46', 'Beds_Greater_Or_Equal_To_500_Percentage': '38', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '4'}, {'Drug_Name': 'Enzalutamide', 'STUDYID': 'EnzaStudy003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '70', 'Female_Percentage': '0.7', 'Male_Percentage': '99.3', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '32', 'Total_ADL_Independence_Percentage': '88', 'LHRH_Use_Percentage': '68', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '32', 'Tumor_Stage_T4_Percentage': '28', 'Nodal_Stage_N0_Percentage': '62', 'Nodal_Stage_N1_Percentage': '23', 'Nodal_Stage_N2_Percentage': '11', 'Nodal_Stage_N3_Percentage': '4', 'Stage_I_Percentage': '17', 'Stage_II_Percentage': '32', 'Stage_III_Percentage': '33', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '11', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '4', 'Adjuvant_Chemotherapy_Received_Percentage': '9', 'Postoperative_RT_Received_Percentage': '14', 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'None', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '9', 'Antiemetic_Agent_Percentage': '14', 'Painkiller_Antipyretic_Percentage': '23', 'Beds_Less_Than_200_Percentage': '14', 'Beds_200_To_499_Percentage': '44', 'Beds_Greater_Or_Equal_To_500_Percentage': '42', 'Designated_Cancer_Hospital_Percentage': '58', 'Months_Between_Surgery_And_Index_Date': '2'}]\n",
      "File created: Enzalutamide_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Enzalutamide\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Erlotinib\",\n",
      "    \"STUDYID\": \"ERL2023-001\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"26.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"62\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"12\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"38\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"45\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"2\",\n",
      "    \"Letrozole_Percentage\": \"1\",\n",
      "    \"Anastrozole_Percentage\": \"1\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"35\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"55\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"65\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Erlotinib\",\n",
      "    \"STUDYID\": \"ERL2022-002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"27.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"58\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"75\",\n",
      "    \"LHRH_Use_Percentage\": \"6\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"32\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"11\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"14\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"40\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"48\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": \"3\",\n",
      "    \"Letrozole_Percentage\": \"2\",\n",
      "    \"Anastrozole_Percentage\": \"1\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"38\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"58\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"68\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"22\",\n",
      "    \"Beds_200_To_499_Percentage\": \"43\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Erlotinib\",\n",
      "    \"STUDYID\": \"ERL2024-003\",\n",
      "    \"YEAR\": \"2024\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"42\",\n",
      "    \"Male_Percentage\": \"58\",\n",
      "    \"Median_BMI\": \"25.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"65\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"4\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"4\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"37\",\n",
      "    \"Stage_III_Percentage\": \"28\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"16\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"10\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"35\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"42\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin + Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Vinblastine\",\n",
      "    \"Tamoxifen_Percentage\": \"1\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"32\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"52\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"62\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"47\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"58\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Erlotinib\",\n",
      "    \"STUDYID\": \"ERL2023-004\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"46\",\n",
      "    \"Male_Percentage\": \"54\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"60\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"77\",\n",
      "    \"LHRH_Use_Percentage\": \"5.5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"16\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"29\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"39\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"54\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"26\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"21\",\n",
      "    \"Stage_II_Percentage\": \"34\",\n",
      "    \"Stage_III_Percentage\": \"31\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"19\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8.5\",\n",
      "    \"Stroke_Percentage\": \"4.5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10.5\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6.5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"13\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"39\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"46\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Vinorelbine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Vinorelbine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Etoposide\",\n",
      "    \"Tamoxifen_Percentage\": \"2.5\",\n",
      "    \"Letrozole_Percentage\": \"1.5\",\n",
      "    \"Anastrozole_Percentage\": \"0.5\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"36\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"56\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"66\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"21\",\n",
      "    \"Beds_200_To_499_Percentage\": \"44\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"61\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.7\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Erlotinib', 'STUDYID': 'ERL2023-001', 'YEAR': '2023', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '26.5', 'Smoking_History_Yes_Percentage': '62', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '12', 'Adjuvant_Chemotherapy_Received_Percentage': '38', 'Postoperative_RT_Received_Percentage': '45', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Gemcitabine', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Gemcitabine', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': '2', 'Letrozole_Percentage': '1', 'Anastrozole_Percentage': '1', 'Antidiarrheal_Agent_Probiotics_Percentage': '35', 'Antiemetic_Agent_Percentage': '55', 'Painkiller_Antipyretic_Percentage': '65', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Erlotinib', 'STUDYID': 'ERL2022-002', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '27.1', 'Smoking_History_Yes_Percentage': '58', 'Total_ADL_Independence_Percentage': '75', 'LHRH_Use_Percentage': '6', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '38', 'Tumor_Stage_T4_Percentage': '16', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '32', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '11', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '14', 'Adjuvant_Chemotherapy_Received_Percentage': '40', 'Postoperative_RT_Received_Percentage': '48', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Gemcitabine', 'Common_Adjuvant_Regimen_1': 'Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Vinorelbine', 'Tamoxifen_Percentage': '3', 'Letrozole_Percentage': '2', 'Anastrozole_Percentage': '1', 'Antidiarrheal_Agent_Probiotics_Percentage': '38', 'Antiemetic_Agent_Percentage': '58', 'Painkiller_Antipyretic_Percentage': '68', 'Beds_Less_Than_200_Percentage': '22', 'Beds_200_To_499_Percentage': '43', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Erlotinib', 'STUDYID': 'ERL2024-003', 'YEAR': '2024', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '42', 'Male_Percentage': '58', 'Median_BMI': '25.8', 'Smoking_History_Yes_Percentage': '65', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '4', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '42', 'Tumor_Stage_T4_Percentage': '14', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '22', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '4', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '37', 'Stage_III_Percentage': '28', 'Diabetes_Mellitus_Percentage': '16', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '10', 'Adjuvant_Chemotherapy_Received_Percentage': '35', 'Postoperative_RT_Received_Percentage': '42', 'Common_Neoadjuvant_Regimen_1': 'Carboplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin + Docetaxel', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'Vinblastine', 'Tamoxifen_Percentage': '1', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '32', 'Antiemetic_Agent_Percentage': '52', 'Painkiller_Antipyretic_Percentage': '62', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '47', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '58', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Erlotinib', 'STUDYID': 'ERL2023-004', 'YEAR': '2023', 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '70', 'Female_Percentage': '46', 'Male_Percentage': '54', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '60', 'Total_ADL_Independence_Percentage': '77', 'LHRH_Use_Percentage': '5.5', 'Tumor_Stage_T1_Percentage': '16', 'Tumor_Stage_T2_Percentage': '29', 'Tumor_Stage_T3_Percentage': '39', 'Tumor_Stage_T4_Percentage': '16', 'Nodal_Stage_N0_Percentage': '54', 'Nodal_Stage_N1_Percentage': '26', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '21', 'Stage_II_Percentage': '34', 'Stage_III_Percentage': '31', 'Diabetes_Mellitus_Percentage': '19', 'Congestive_Heart_Failure_Percentage': '8.5', 'Stroke_Percentage': '4.5', 'Atrial_Fibrillation_Percentage': '10.5', 'Myocardial_Infarction_Percentage': '6.5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '13', 'Adjuvant_Chemotherapy_Received_Percentage': '39', 'Postoperative_RT_Received_Percentage': '46', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Vinorelbine', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Docetaxel', 'Common_Adjuvant_Regimen_1': 'Vinorelbine', 'Common_Adjuvant_Regimen_2': 'Etoposide', 'Tamoxifen_Percentage': '2.5', 'Letrozole_Percentage': '1.5', 'Anastrozole_Percentage': '0.5', 'Antidiarrheal_Agent_Probiotics_Percentage': '36', 'Antiemetic_Agent_Percentage': '56', 'Painkiller_Antipyretic_Percentage': '66', 'Beds_Less_Than_200_Percentage': '21', 'Beds_200_To_499_Percentage': '44', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '61', 'Months_Between_Surgery_And_Index_Date': '2.7'}]\n",
      "File created: Erlotinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Erlotinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Everolimus\",\n",
      "    \"STUDYID\": \"EVE1001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 35,\n",
      "    \"Male_Percentage\": 65,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 42,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25,\n",
      "    \"Tumor_Stage_T4_Percentage\": 25,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 5,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Postoperative_RT_Received_Percentage\": 22,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": 25,\n",
      "    \"Letrozole_Percentage\": 15,\n",
      "    \"Anastrozole_Percentage\": 10,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Everolimus\",\n",
      "    \"STUDYID\": \"EVE1002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 40,\n",
      "    \"Male_Percentage\": 60,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 38,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 18,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 28,\n",
      "    \"Tumor_Stage_T4_Percentage\": 22,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 35,\n",
      "    \"Nodal_Stage_N2_Percentage\": 17,\n",
      "    \"Nodal_Stage_N3_Percentage\": 8,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 6,\n",
      "    \"Atrial_Fibrillation_Percentage\": 14,\n",
      "    \"Myocardial_Infarction_Percentage\": 9,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 7,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Postoperative_RT_Received_Percentage\": 25,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": 28,\n",
      "    \"Letrozole_Percentage\": 17,\n",
      "    \"Anastrozole_Percentage\": 12,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 45,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Everolimus\",\n",
      "    \"STUDYID\": \"EVE1003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 30,\n",
      "    \"Male_Percentage\": 70,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 45,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 20,\n",
      "    \"Tumor_Stage_T1_Percentage\": 22,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 20,\n",
      "    \"Tumor_Stage_T4_Percentage\": 23,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 13,\n",
      "    \"Nodal_Stage_N3_Percentage\": 12,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 6,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 11,\n",
      "    \"Postoperative_RT_Received_Percentage\": 20,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": 22,\n",
      "    \"Letrozole_Percentage\": 13,\n",
      "    \"Anastrozole_Percentage\": 8,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28,\n",
      "    \"Antiemetic_Agent_Percentage\": 38,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 48,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Everolimus\",\n",
      "    \"STUDYID\": \"EVE1004\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 38,\n",
      "    \"Male_Percentage\": 62,\n",
      "    \"Median_BMI\": 27.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 40,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 17,\n",
      "    \"Tumor_Stage_T1_Percentage\": 19,\n",
      "    \"Tumor_Stage_T2_Percentage\": 33,\n",
      "    \"Tumor_Stage_T3_Percentage\": 26,\n",
      "    \"Tumor_Stage_T4_Percentage\": 22,\n",
      "    \"Nodal_Stage_N0_Percentage\": 43,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16,\n",
      "    \"Nodal_Stage_N3_Percentage\": 9,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 33,\n",
      "    \"Stage_III_Percentage\": 48,\n",
      "    \"Diabetes_Mellitus_Percentage\": 19,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 13,\n",
      "    \"Myocardial_Infarction_Percentage\": 8,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 13,\n",
      "    \"Postoperative_RT_Received_Percentage\": 24,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 27,\n",
      "    \"Letrozole_Percentage\": 16,\n",
      "    \"Anastrozole_Percentage\": 11,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 33,\n",
      "    \"Antiemetic_Agent_Percentage\": 43,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 53,\n",
      "    \"Beds_Less_Than_200_Percentage\": 14,\n",
      "    \"Beds_200_To_499_Percentage\": 46,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3.2\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Everolimus', 'STUDYID': 'EVE1001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 35, 'Male_Percentage': 65, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 42, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 25, 'Tumor_Stage_T4_Percentage': 25, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 5, 'Adjuvant_Chemotherapy_Received_Percentage': 10, 'Postoperative_RT_Received_Percentage': 22, 'Common_Neoadjuvant_Regimen_1': 'None', 'Common_Neoadjuvant_Regimen_2': 'None', 'Common_Adjuvant_Regimen_1': 'AC', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': 25, 'Letrozole_Percentage': 15, 'Anastrozole_Percentage': 10, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Everolimus', 'STUDYID': 'EVE1002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 40, 'Male_Percentage': 60, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 38, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 18, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 28, 'Tumor_Stage_T4_Percentage': 22, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 35, 'Nodal_Stage_N2_Percentage': 17, 'Nodal_Stage_N3_Percentage': 8, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 6, 'Atrial_Fibrillation_Percentage': 14, 'Myocardial_Infarction_Percentage': 9, 'Neoadjuvant_Chemotherapy_Received_Percentage': 7, 'Adjuvant_Chemotherapy_Received_Percentage': 12, 'Postoperative_RT_Received_Percentage': 25, 'Common_Neoadjuvant_Regimen_1': 'None', 'Common_Neoadjuvant_Regimen_2': 'None', 'Common_Adjuvant_Regimen_1': 'AC-T', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': 28, 'Letrozole_Percentage': 17, 'Anastrozole_Percentage': 12, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 45, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Everolimus', 'STUDYID': 'EVE1003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 30, 'Male_Percentage': 70, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 45, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 20, 'Tumor_Stage_T1_Percentage': 22, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 20, 'Tumor_Stage_T4_Percentage': 23, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 13, 'Nodal_Stage_N3_Percentage': 12, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 6, 'Adjuvant_Chemotherapy_Received_Percentage': 11, 'Postoperative_RT_Received_Percentage': 20, 'Common_Neoadjuvant_Regimen_1': 'None', 'Common_Neoadjuvant_Regimen_2': 'None', 'Common_Adjuvant_Regimen_1': 'FEC', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': 22, 'Letrozole_Percentage': 13, 'Anastrozole_Percentage': 8, 'Antidiarrheal_Agent_Probiotics_Percentage': 28, 'Antiemetic_Agent_Percentage': 38, 'Painkiller_Antipyretic_Percentage': 48, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 2.5}, {'Drug_Name': 'Everolimus', 'STUDYID': 'EVE1004', 'YEAR': 2023, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 70, 'Female_Percentage': 38, 'Male_Percentage': 62, 'Median_BMI': 27.9, 'Smoking_History_Yes_Percentage': 40, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 17, 'Tumor_Stage_T1_Percentage': 19, 'Tumor_Stage_T2_Percentage': 33, 'Tumor_Stage_T3_Percentage': 26, 'Tumor_Stage_T4_Percentage': 22, 'Nodal_Stage_N0_Percentage': 43, 'Nodal_Stage_N1_Percentage': 32, 'Nodal_Stage_N2_Percentage': 16, 'Nodal_Stage_N3_Percentage': 9, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 33, 'Stage_III_Percentage': 48, 'Diabetes_Mellitus_Percentage': 19, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 13, 'Myocardial_Infarction_Percentage': 8, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 13, 'Postoperative_RT_Received_Percentage': 24, 'Common_Neoadjuvant_Regimen_1': 'None', 'Common_Neoadjuvant_Regimen_2': 'None', 'Common_Adjuvant_Regimen_1': 'EC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 27, 'Letrozole_Percentage': 16, 'Anastrozole_Percentage': 11, 'Antidiarrheal_Agent_Probiotics_Percentage': 33, 'Antiemetic_Agent_Percentage': 43, 'Painkiller_Antipyretic_Percentage': 53, 'Beds_Less_Than_200_Percentage': 14, 'Beds_200_To_499_Percentage': 46, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 3.2}]\n",
      "File created: Everolimus_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Everolimus\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Fluorouracil\",\n",
      "    \"STUDYID\": \"FU001\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"26.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"32\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"40\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"60\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"45\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU/LV\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CAPOX\",\n",
      "    \"Tamoxifen_Percentage\": \"5\",\n",
      "    \"Letrozole_Percentage\": \"3\",\n",
      "    \"Anastrozole_Percentage\": \"2\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"35\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"70\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"50\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"40\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Fluorouracil\",\n",
      "    \"STUDYID\": \"FU002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"52\",\n",
      "    \"Male_Percentage\": \"48\",\n",
      "    \"Median_BMI\": \"27.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"28\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"42\",\n",
      "    \"Stage_III_Percentage\": \"32\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"28\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"62\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"48\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CAPOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FOLFOX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"5-FU/LV\",\n",
      "    \"Tamoxifen_Percentage\": \"6\",\n",
      "    \"Letrozole_Percentage\": \"4\",\n",
      "    \"Anastrozole_Percentage\": \"3\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"38\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"72\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"52\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"22\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"42\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Fluorouracil\",\n",
      "    \"STUDYID\": \"FU003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"25.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"88\",\n",
      "    \"LHRH_Use_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"8\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"38\",\n",
      "    \"Stage_III_Percentage\": \"35\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"16\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"58\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"42\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU/LV\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CAPOX\",\n",
      "    \"Tamoxifen_Percentage\": \"4\",\n",
      "    \"Letrozole_Percentage\": \"2\",\n",
      "    \"Anastrozole_Percentage\": \"1\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"32\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"68\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"48\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"52\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"38\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Fluorouracil', 'STUDYID': 'FU001', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '26.5', 'Smoking_History_Yes_Percentage': '32', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '12', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '35', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '20', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '40', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '60', 'Postoperative_RT_Received_Percentage': '45', 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'CAPOX', 'Common_Adjuvant_Regimen_1': '5-FU/LV', 'Common_Adjuvant_Regimen_2': 'CAPOX', 'Tamoxifen_Percentage': '5', 'Letrozole_Percentage': '3', 'Anastrozole_Percentage': '2', 'Antidiarrheal_Agent_Probiotics_Percentage': '35', 'Antiemetic_Agent_Percentage': '70', 'Painkiller_Antipyretic_Percentage': '50', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '40', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Fluorouracil', 'STUDYID': 'FU002', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '52', 'Male_Percentage': '48', 'Median_BMI': '27.1', 'Smoking_History_Yes_Percentage': '28', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '38', 'Tumor_Stage_T3_Percentage': '32', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '22', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '42', 'Stage_III_Percentage': '32', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '28', 'Adjuvant_Chemotherapy_Received_Percentage': '62', 'Postoperative_RT_Received_Percentage': '48', 'Common_Neoadjuvant_Regimen_1': 'CAPOX', 'Common_Neoadjuvant_Regimen_2': 'FOLFOX', 'Common_Adjuvant_Regimen_1': 'CAPOX', 'Common_Adjuvant_Regimen_2': '5-FU/LV', 'Tamoxifen_Percentage': '6', 'Letrozole_Percentage': '4', 'Anastrozole_Percentage': '3', 'Antidiarrheal_Agent_Probiotics_Percentage': '38', 'Antiemetic_Agent_Percentage': '72', 'Painkiller_Antipyretic_Percentage': '52', 'Beds_Less_Than_200_Percentage': '22', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '42', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Fluorouracil', 'STUDYID': 'FU003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '25.8', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '88', 'LHRH_Use_Percentage': '10', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '35', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '20', 'Nodal_Stage_N2_Percentage': '12', 'Nodal_Stage_N3_Percentage': '8', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '38', 'Stage_III_Percentage': '35', 'Diabetes_Mellitus_Percentage': '16', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '58', 'Postoperative_RT_Received_Percentage': '42', 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'CAPOX', 'Common_Adjuvant_Regimen_1': '5-FU/LV', 'Common_Adjuvant_Regimen_2': 'CAPOX', 'Tamoxifen_Percentage': '4', 'Letrozole_Percentage': '2', 'Anastrozole_Percentage': '1', 'Antidiarrheal_Agent_Probiotics_Percentage': '32', 'Antiemetic_Agent_Percentage': '68', 'Painkiller_Antipyretic_Percentage': '48', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '52', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '38', 'Months_Between_Surgery_And_Index_Date': '2.5'}]\n",
      "File created: Fluorouracil_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Fluorouracil\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Gemcitabine\",\n",
      "    \"STUDYID\": \"GemStudy001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 26.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 62,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 35,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 48,\n",
      "    \"Postoperative_RT_Received_Percentage\": 55,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Gemcitabine + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Gemcitabine + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Gemcitabine + Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Gemcitabine\",\n",
      "    \"STUDYID\": \"PanCan2022\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 27.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 58,\n",
      "    \"Total_ADL_Independence_Percentage\": 72,\n",
      "    \"LHRH_Use_Percentage\": 8,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32,\n",
      "    \"Nodal_Stage_N2_Percentage\": 18,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 6,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 9,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 30,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 50,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Gemcitabine + Carboplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Gemcitabine + Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"5-FU\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28,\n",
      "    \"Antiemetic_Agent_Percentage\": 68,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Gemcitabine\",\n",
      "    \"STUDYID\": \"AsiaOnco23\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 24.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 45,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 10,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 12,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 52,\n",
      "    \"Postoperative_RT_Received_Percentage\": 60,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Gemcitabine + S-1\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"S-1\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 22,\n",
      "    \"Antiemetic_Agent_Percentage\": 62,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 48,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 52,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Gemcitabine', 'STUDYID': 'GemStudy001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 26.5, 'Smoking_History_Yes_Percentage': 62, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 35, 'Adjuvant_Chemotherapy_Received_Percentage': 48, 'Postoperative_RT_Received_Percentage': 55, 'Common_Neoadjuvant_Regimen_1': 'Gemcitabine + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Gemcitabine + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Gemcitabine', 'Common_Adjuvant_Regimen_2': 'Gemcitabine + Capecitabine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Gemcitabine', 'STUDYID': 'PanCan2022', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 27.1, 'Smoking_History_Yes_Percentage': 58, 'Total_ADL_Independence_Percentage': 72, 'LHRH_Use_Percentage': 8, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 32, 'Nodal_Stage_N2_Percentage': 18, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 6, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 9, 'Neoadjuvant_Chemotherapy_Received_Percentage': 30, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 50, 'Common_Neoadjuvant_Regimen_1': 'Gemcitabine + Carboplatin', 'Common_Neoadjuvant_Regimen_2': 'Gemcitabine + Docetaxel', 'Common_Adjuvant_Regimen_1': 'Gemcitabine', 'Common_Adjuvant_Regimen_2': '5-FU', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 28, 'Antiemetic_Agent_Percentage': 68, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 1.5}, {'Drug_Name': 'Gemcitabine', 'STUDYID': 'AsiaOnco23', 'YEAR': 2023, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 24.8, 'Smoking_History_Yes_Percentage': 45, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 10, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 12, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 40, 'Adjuvant_Chemotherapy_Received_Percentage': 52, 'Postoperative_RT_Received_Percentage': 60, 'Common_Neoadjuvant_Regimen_1': 'Gemcitabine + S-1', 'Common_Neoadjuvant_Regimen_2': 'Gemcitabine', 'Common_Adjuvant_Regimen_1': 'Gemcitabine', 'Common_Adjuvant_Regimen_2': 'S-1', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 22, 'Antiemetic_Agent_Percentage': 62, 'Painkiller_Antipyretic_Percentage': 48, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 52, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Gemcitabine_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Gemcitabine\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Ibrutinib\",\n",
      "    \"STUDYID\": \"IBR12020US\",\n",
      "    \"YEAR\": 2020,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 35,\n",
      "    \"Male_Percentage\": 65,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 42,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Hyper-CVAD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Bendamustine\",\n",
      "    \"Tamoxifen_Percentage\": 2,\n",
      "    \"Letrozole_Percentage\": 1,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20,\n",
      "    \"Antiemetic_Agent_Percentage\": 30,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 40,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ibrutinib\",\n",
      "    \"STUDYID\": \"IBR22021EU\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 75,\n",
      "    \"Female_Percentage\": 40,\n",
      "    \"Male_Percentage\": 60,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 38,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 6,\n",
      "    \"Atrial_Fibrillation_Percentage\": 14,\n",
      "    \"Myocardial_Infarction_Percentage\": 8,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CVP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DHAP\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Chlorambucil\",\n",
      "    \"Tamoxifen_Percentage\": 3,\n",
      "    \"Letrozole_Percentage\": 2,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 22,\n",
      "    \"Antiemetic_Agent_Percentage\": 32,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 42,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ibrutinib\",\n",
      "    \"STUDYID\": \"IBR32022CA\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 38,\n",
      "    \"Male_Percentage\": 62,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 40,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 29,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16,\n",
      "    \"Nodal_Stage_N3_Percentage\": 4,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 33,\n",
      "    \"Stage_III_Percentage\": 48,\n",
      "    \"Diabetes_Mellitus_Percentage\": 19,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 13,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 9,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 23,\n",
      "    \"Postoperative_RT_Received_Percentage\": 29,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Hyper-CVAD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Bendamustine\",\n",
      "    \"Tamoxifen_Percentage\": 2,\n",
      "    \"Letrozole_Percentage\": 1,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 21,\n",
      "    \"Antiemetic_Agent_Percentage\": 31,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 41,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ibrutinib\",\n",
      "    \"STUDYID\": \"IBR42023UK\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 380,\n",
      "    \"Median_Age\": 73,\n",
      "    \"Female_Percentage\": 37,\n",
      "    \"Male_Percentage\": 63,\n",
      "    \"Median_BMI\": 27.2,\n",
      "    \"Smoking_History_Yes_Percentage\": 39,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 13,\n",
      "    \"Tumor_Stage_T2_Percentage\": 27,\n",
      "    \"Tumor_Stage_T3_Percentage\": 44,\n",
      "    \"Tumor_Stage_T4_Percentage\": 16,\n",
      "    \"Nodal_Stage_N0_Percentage\": 51,\n",
      "    \"Nodal_Stage_N1_Percentage\": 29,\n",
      "    \"Nodal_Stage_N2_Percentage\": 17,\n",
      "    \"Nodal_Stage_N3_Percentage\": 3,\n",
      "    \"Stage_I_Percentage\": 17,\n",
      "    \"Stage_II_Percentage\": 31,\n",
      "    \"Stage_III_Percentage\": 52,\n",
      "    \"Diabetes_Mellitus_Percentage\": 21,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 11,\n",
      "    \"Stroke_Percentage\": 7,\n",
      "    \"Atrial_Fibrillation_Percentage\": 15,\n",
      "    \"Myocardial_Infarction_Percentage\": 9,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 7,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 21,\n",
      "    \"Postoperative_RT_Received_Percentage\": 27,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CVP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DHAP\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Chlorambucil\",\n",
      "    \"Tamoxifen_Percentage\": 3,\n",
      "    \"Letrozole_Percentage\": 2,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 23,\n",
      "    \"Antiemetic_Agent_Percentage\": 33,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 43,\n",
      "    \"Beds_Less_Than_200_Percentage\": 9,\n",
      "    \"Beds_200_To_499_Percentage\": 51,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 67,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Ibrutinib', 'STUDYID': 'IBR12020US', 'YEAR': 2020, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 72, 'Female_Percentage': 35, 'Male_Percentage': 65, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 42, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 25, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'Hyper-CVAD', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'Bendamustine', 'Tamoxifen_Percentage': 2, 'Letrozole_Percentage': 1, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 20, 'Antiemetic_Agent_Percentage': 30, 'Painkiller_Antipyretic_Percentage': 40, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Ibrutinib', 'STUDYID': 'IBR22021EU', 'YEAR': 2021, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 75, 'Female_Percentage': 40, 'Male_Percentage': 60, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 38, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 45, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 6, 'Atrial_Fibrillation_Percentage': 14, 'Myocardial_Infarction_Percentage': 8, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 22, 'Postoperative_RT_Received_Percentage': 28, 'Common_Neoadjuvant_Regimen_1': 'R-CVP', 'Common_Neoadjuvant_Regimen_2': 'DHAP', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'Chlorambucil', 'Tamoxifen_Percentage': 3, 'Letrozole_Percentage': 2, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 22, 'Antiemetic_Agent_Percentage': 32, 'Painkiller_Antipyretic_Percentage': 42, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Ibrutinib', 'STUDYID': 'IBR32022CA', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 38, 'Male_Percentage': 62, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 40, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 29, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 16, 'Nodal_Stage_N3_Percentage': 4, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 33, 'Stage_III_Percentage': 48, 'Diabetes_Mellitus_Percentage': 19, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 13, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 9, 'Adjuvant_Chemotherapy_Received_Percentage': 23, 'Postoperative_RT_Received_Percentage': 29, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'Hyper-CVAD', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'Bendamustine', 'Tamoxifen_Percentage': 2, 'Letrozole_Percentage': 1, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 21, 'Antiemetic_Agent_Percentage': 31, 'Painkiller_Antipyretic_Percentage': 41, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 2.5}, {'Drug_Name': 'Ibrutinib', 'STUDYID': 'IBR42023UK', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'Claim Database', 'Patient_Count': 380, 'Median_Age': 73, 'Female_Percentage': 37, 'Male_Percentage': 63, 'Median_BMI': 27.2, 'Smoking_History_Yes_Percentage': 39, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 13, 'Tumor_Stage_T2_Percentage': 27, 'Tumor_Stage_T3_Percentage': 44, 'Tumor_Stage_T4_Percentage': 16, 'Nodal_Stage_N0_Percentage': 51, 'Nodal_Stage_N1_Percentage': 29, 'Nodal_Stage_N2_Percentage': 17, 'Nodal_Stage_N3_Percentage': 3, 'Stage_I_Percentage': 17, 'Stage_II_Percentage': 31, 'Stage_III_Percentage': 52, 'Diabetes_Mellitus_Percentage': 21, 'Congestive_Heart_Failure_Percentage': 11, 'Stroke_Percentage': 7, 'Atrial_Fibrillation_Percentage': 15, 'Myocardial_Infarction_Percentage': 9, 'Neoadjuvant_Chemotherapy_Received_Percentage': 7, 'Adjuvant_Chemotherapy_Received_Percentage': 21, 'Postoperative_RT_Received_Percentage': 27, 'Common_Neoadjuvant_Regimen_1': 'R-CVP', 'Common_Neoadjuvant_Regimen_2': 'DHAP', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'Chlorambucil', 'Tamoxifen_Percentage': 3, 'Letrozole_Percentage': 2, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 23, 'Antiemetic_Agent_Percentage': 33, 'Painkiller_Antipyretic_Percentage': 43, 'Beds_Less_Than_200_Percentage': 9, 'Beds_200_To_499_Percentage': 51, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 67, 'Months_Between_Surgery_And_Index_Date': 3.5}]\n",
      "File created: Ibrutinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Ibrutinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Imatinib\",\n",
      "    \"STUDYID\": \"Gleevec2020\",\n",
      "    \"YEAR\": 2020,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": \"32\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"88\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"25\",\n",
      "    \"Stage_II_Percentage\": \"40\",\n",
      "    \"Stage_III_Percentage\": \"35\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"12\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"4\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"6\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"2\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"10\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"30\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Nil\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Nil\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Nil\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Nil\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"15\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"40\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"50\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"55\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Imatinib\",\n",
      "    \"STUDYID\": \"CMLAdv2021\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": \"28\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"90\",\n",
      "    \"LHRH_Use_Percentage\": \"3\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"65\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"42\",\n",
      "    \"Stage_III_Percentage\": \"36\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"10\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"5\",\n",
      "    \"Stroke_Percentage\": \"2\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"7\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"3\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"8\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"28\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Nil\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Nil\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Nil\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Nil\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"18\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"42\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"52\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"58\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Imatinib\",\n",
      "    \"STUDYID\": \"EuroCML2022\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": \"52\",\n",
      "    \"Male_Percentage\": \"48\",\n",
      "    \"Median_BMI\": 26.9,\n",
      "    \"Smoking_History_Yes_Percentage\": \"30\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"7\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"27\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"9\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"28\",\n",
      "    \"Stage_II_Percentage\": \"38\",\n",
      "    \"Stage_III_Percentage\": \"34\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"14\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"4\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"12\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"28\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"32\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Nil\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Nil\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Nil\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Nil\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"20\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"45\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"55\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"52\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Imatinib', 'STUDYID': 'Gleevec2020', 'YEAR': 2020, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': '32', 'Total_ADL_Independence_Percentage': '88', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '35', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '20', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '25', 'Stage_II_Percentage': '40', 'Stage_III_Percentage': '35', 'Diabetes_Mellitus_Percentage': '12', 'Congestive_Heart_Failure_Percentage': '4', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '6', 'Myocardial_Infarction_Percentage': '2', 'Neoadjuvant_Chemotherapy_Received_Percentage': '10', 'Adjuvant_Chemotherapy_Received_Percentage': '25', 'Postoperative_RT_Received_Percentage': '30', 'Common_Neoadjuvant_Regimen_1': 'Nil', 'Common_Neoadjuvant_Regimen_2': 'Nil', 'Common_Adjuvant_Regimen_1': 'Nil', 'Common_Adjuvant_Regimen_2': 'Nil', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '15', 'Antiemetic_Agent_Percentage': '40', 'Painkiller_Antipyretic_Percentage': '50', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '55', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Imatinib', 'STUDYID': 'CMLAdv2021', 'YEAR': 2021, 'Country': 'UK', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 65, 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': '28', 'Total_ADL_Independence_Percentage': '90', 'LHRH_Use_Percentage': '3', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '38', 'Tumor_Stage_T3_Percentage': '28', 'Tumor_Stage_T4_Percentage': '22', 'Nodal_Stage_N0_Percentage': '65', 'Nodal_Stage_N1_Percentage': '20', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '42', 'Stage_III_Percentage': '36', 'Diabetes_Mellitus_Percentage': '10', 'Congestive_Heart_Failure_Percentage': '5', 'Stroke_Percentage': '2', 'Atrial_Fibrillation_Percentage': '7', 'Myocardial_Infarction_Percentage': '3', 'Neoadjuvant_Chemotherapy_Received_Percentage': '8', 'Adjuvant_Chemotherapy_Received_Percentage': '22', 'Postoperative_RT_Received_Percentage': '28', 'Common_Neoadjuvant_Regimen_1': 'Nil', 'Common_Neoadjuvant_Regimen_2': 'Nil', 'Common_Adjuvant_Regimen_1': 'Nil', 'Common_Adjuvant_Regimen_2': 'Nil', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '18', 'Antiemetic_Agent_Percentage': '42', 'Painkiller_Antipyretic_Percentage': '52', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '58', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '1.5'}, {'Drug_Name': 'Imatinib', 'STUDYID': 'EuroCML2022', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 68, 'Female_Percentage': '52', 'Male_Percentage': '48', 'Median_BMI': 26.9, 'Smoking_History_Yes_Percentage': '30', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '7', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '32', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '27', 'Nodal_Stage_N2_Percentage': '9', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '28', 'Stage_II_Percentage': '38', 'Stage_III_Percentage': '34', 'Diabetes_Mellitus_Percentage': '14', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '4', 'Neoadjuvant_Chemotherapy_Received_Percentage': '12', 'Adjuvant_Chemotherapy_Received_Percentage': '28', 'Postoperative_RT_Received_Percentage': '32', 'Common_Neoadjuvant_Regimen_1': 'Nil', 'Common_Neoadjuvant_Regimen_2': 'Nil', 'Common_Adjuvant_Regimen_1': 'Nil', 'Common_Adjuvant_Regimen_2': 'Nil', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '20', 'Antiemetic_Agent_Percentage': '45', 'Painkiller_Antipyretic_Percentage': '55', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '52', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '2.5'}]\n",
      "File created: Imatinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Imatinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Ixazomib\",\n",
      "    \"STUDYID\": \"IXA2023-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel + Cisplatin + 5-FU\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC (Doxorubicin + Cyclophosphamide)\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": 22,\n",
      "    \"Letrozole_Percentage\": 18,\n",
      "    \"Anastrozole_Percentage\": 20,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ixazomib\",\n",
      "    \"STUDYID\": \"IXA2023-002\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 38,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 42,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 32,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 7,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 8,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 42,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide)\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + Doxorubicin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Anthracycline-based therapy\",\n",
      "    \"Tamoxifen_Percentage\": 25,\n",
      "    \"Letrozole_Percentage\": 20,\n",
      "    \"Anastrozole_Percentage\": 15,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ixazomib\",\n",
      "    \"STUDYID\": \"IXA2023-003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 55,\n",
      "    \"Male_Percentage\": 45,\n",
      "    \"Median_BMI\": 24.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 25,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 12,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 25,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 38,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"S-1 + Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel + Trastuzumab\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Capecitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"HER2 targeted therapy\",\n",
      "    \"Tamoxifen_Percentage\": 20,\n",
      "    \"Letrozole_Percentage\": 15,\n",
      "    \"Anastrozole_Percentage\": 25,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 40,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Ixazomib', 'STUDYID': 'IXA2023-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 40, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel + Cisplatin + 5-FU', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': 'AC (Doxorubicin + Cyclophosphamide)', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': 22, 'Letrozole_Percentage': 18, 'Anastrozole_Percentage': 20, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Ixazomib', 'STUDYID': 'IXA2023-002', 'YEAR': 2023, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 38, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 42, 'Nodal_Stage_N1_Percentage': 32, 'Nodal_Stage_N2_Percentage': 16, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 32, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 7, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 8, 'Neoadjuvant_Chemotherapy_Received_Percentage': 28, 'Adjuvant_Chemotherapy_Received_Percentage': 42, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide)', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + Doxorubicin', 'Common_Adjuvant_Regimen_1': 'CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)', 'Common_Adjuvant_Regimen_2': 'Anthracycline-based therapy', 'Tamoxifen_Percentage': 25, 'Letrozole_Percentage': 20, 'Anastrozole_Percentage': 15, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Ixazomib', 'STUDYID': 'IXA2023-003', 'YEAR': 2023, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 55, 'Male_Percentage': 45, 'Median_BMI': 24.5, 'Smoking_History_Yes_Percentage': 25, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 25, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 12, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 25, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 38, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'S-1 + Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel + Trastuzumab', 'Common_Adjuvant_Regimen_1': 'Capecitabine', 'Common_Adjuvant_Regimen_2': 'HER2 targeted therapy', 'Tamoxifen_Percentage': 20, 'Letrozole_Percentage': 15, 'Anastrozole_Percentage': 25, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 40, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 1}]\n",
      "File created: Ixazomib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Ixazomib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Lapatinib\",\n",
      "    \"STUDYID\": \"LPT1001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 98,\n",
      "    \"Male_Percentage\": 2,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 15,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 10,\n",
      "    \"Tumor_Stage_T2_Percentage\": 45,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 3,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 5,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 60,\n",
      "    \"Postoperative_RT_Received_Percentage\": 50,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": 30,\n",
      "    \"Letrozole_Percentage\": 25,\n",
      "    \"Anastrozole_Percentage\": 20,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 70,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Lapatinib\",\n",
      "    \"STUDYID\": \"LPT1002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 97,\n",
      "    \"Male_Percentage\": 3,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 18,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 42,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 14,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 14,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 32,\n",
      "    \"Diabetes_Mellitus_Percentage\": 14,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 62,\n",
      "    \"Postoperative_RT_Received_Percentage\": 52,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Tamoxifen_Percentage\": 32,\n",
      "    \"Letrozole_Percentage\": 23,\n",
      "    \"Anastrozole_Percentage\": 18,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 42,\n",
      "    \"Antiemetic_Agent_Percentage\": 72,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 57,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 46,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Lapatinib\",\n",
      "    \"STUDYID\": \"LPT1003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 99,\n",
      "    \"Male_Percentage\": 1,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 13,\n",
      "    \"Total_ADL_Independence_Percentage\": 88,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 9,\n",
      "    \"Tumor_Stage_T2_Percentage\": 46,\n",
      "    \"Tumor_Stage_T3_Percentage\": 31,\n",
      "    \"Tumor_Stage_T4_Percentage\": 14,\n",
      "    \"Nodal_Stage_N0_Percentage\": 56,\n",
      "    \"Nodal_Stage_N1_Percentage\": 24,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16,\n",
      "    \"Nodal_Stage_N3_Percentage\": 4,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 41,\n",
      "    \"Stage_III_Percentage\": 29,\n",
      "    \"Diabetes_Mellitus_Percentage\": 11,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 2,\n",
      "    \"Stroke_Percentage\": 1,\n",
      "    \"Atrial_Fibrillation_Percentage\": 4,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 19,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 59,\n",
      "    \"Postoperative_RT_Received_Percentage\": 49,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC-T\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": 29,\n",
      "    \"Letrozole_Percentage\": 26,\n",
      "    \"Anastrozole_Percentage\": 21,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 39,\n",
      "    \"Antiemetic_Agent_Percentage\": 69,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 54,\n",
      "    \"Beds_Less_Than_200_Percentage\": 9,\n",
      "    \"Beds_200_To_499_Percentage\": 39,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 52,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 59,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Lapatinib', 'STUDYID': 'LPT1001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 98, 'Male_Percentage': 2, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 15, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 10, 'Tumor_Stage_T2_Percentage': 45, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 3, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 5, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 60, 'Postoperative_RT_Received_Percentage': 50, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': 30, 'Letrozole_Percentage': 25, 'Anastrozole_Percentage': 20, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 70, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Lapatinib', 'STUDYID': 'LPT1002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 97, 'Male_Percentage': 3, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 18, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 42, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 14, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 14, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 32, 'Diabetes_Mellitus_Percentage': 14, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 6, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 62, 'Postoperative_RT_Received_Percentage': 52, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel', 'Common_Adjuvant_Regimen_1': 'AC-T', 'Common_Adjuvant_Regimen_2': 'FEC', 'Tamoxifen_Percentage': 32, 'Letrozole_Percentage': 23, 'Anastrozole_Percentage': 18, 'Antidiarrheal_Agent_Probiotics_Percentage': 42, 'Antiemetic_Agent_Percentage': 72, 'Painkiller_Antipyretic_Percentage': 57, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 46, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Lapatinib', 'STUDYID': 'LPT1003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 99, 'Male_Percentage': 1, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 13, 'Total_ADL_Independence_Percentage': 88, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 9, 'Tumor_Stage_T2_Percentage': 46, 'Tumor_Stage_T3_Percentage': 31, 'Tumor_Stage_T4_Percentage': 14, 'Nodal_Stage_N0_Percentage': 56, 'Nodal_Stage_N1_Percentage': 24, 'Nodal_Stage_N2_Percentage': 16, 'Nodal_Stage_N3_Percentage': 4, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 41, 'Stage_III_Percentage': 29, 'Diabetes_Mellitus_Percentage': 11, 'Congestive_Heart_Failure_Percentage': 2, 'Stroke_Percentage': 1, 'Atrial_Fibrillation_Percentage': 4, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 19, 'Adjuvant_Chemotherapy_Received_Percentage': 59, 'Postoperative_RT_Received_Percentage': 49, 'Common_Neoadjuvant_Regimen_1': 'FEC-T', 'Common_Neoadjuvant_Regimen_2': 'AC', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': 29, 'Letrozole_Percentage': 26, 'Anastrozole_Percentage': 21, 'Antidiarrheal_Agent_Probiotics_Percentage': 39, 'Antiemetic_Agent_Percentage': 69, 'Painkiller_Antipyretic_Percentage': 54, 'Beds_Less_Than_200_Percentage': 9, 'Beds_200_To_499_Percentage': 39, 'Beds_Greater_Or_Equal_To_500_Percentage': 52, 'Designated_Cancer_Hospital_Percentage': 59, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Lapatinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Lapatinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Lenalidomide\",\n",
      "    \"STUDYID\": \"LEN2023-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 68,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"VRD\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CyBorD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"RVD\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"RD\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 65,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Lenalidomide\",\n",
      "    \"STUDYID\": \"LEN2022-002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 75,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 72,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 28,\n",
      "    \"Tumor_Stage_T4_Percentage\": 22,\n",
      "    \"Nodal_Stage_N0_Percentage\": 38,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32,\n",
      "    \"Nodal_Stage_N2_Percentage\": 18,\n",
      "    \"Nodal_Stage_N3_Percentage\": 12,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 6,\n",
      "    \"Atrial_Fibrillation_Percentage\": 14,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"VRD\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CyBorD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"RVD\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"RD\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 42,\n",
      "    \"Antiemetic_Agent_Percentage\": 58,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 68,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Lenalidomide\",\n",
      "    \"STUDYID\": \"LEN2024-003\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 42,\n",
      "    \"Male_Percentage\": 58,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 70,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 42,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16,\n",
      "    \"Nodal_Stage_N3_Percentage\": 14,\n",
      "    \"Stage_I_Percentage\": 28,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 16,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Postoperative_RT_Received_Percentage\": 32,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"VRD\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CyBorD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"RVD\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"RD\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 38,\n",
      "    \"Antiemetic_Agent_Percentage\": 52,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 62,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 58,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Lenalidomide', 'STUDYID': 'LEN2023-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 72, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 68, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 25, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'VRD', 'Common_Neoadjuvant_Regimen_2': 'CyBorD', 'Common_Adjuvant_Regimen_1': 'RVD', 'Common_Adjuvant_Regimen_2': 'RD', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 65, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Lenalidomide', 'STUDYID': 'LEN2022-002', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 75, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 72, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 28, 'Tumor_Stage_T4_Percentage': 22, 'Nodal_Stage_N0_Percentage': 38, 'Nodal_Stage_N1_Percentage': 32, 'Nodal_Stage_N2_Percentage': 18, 'Nodal_Stage_N3_Percentage': 12, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 6, 'Atrial_Fibrillation_Percentage': 14, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 22, 'Postoperative_RT_Received_Percentage': 28, 'Common_Neoadjuvant_Regimen_1': 'VRD', 'Common_Neoadjuvant_Regimen_2': 'CyBorD', 'Common_Adjuvant_Regimen_1': 'RVD', 'Common_Adjuvant_Regimen_2': 'RD', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 42, 'Antiemetic_Agent_Percentage': 58, 'Painkiller_Antipyretic_Percentage': 68, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Lenalidomide', 'STUDYID': 'LEN2024-003', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 68, 'Female_Percentage': 42, 'Male_Percentage': 58, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 70, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 42, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 16, 'Nodal_Stage_N3_Percentage': 14, 'Stage_I_Percentage': 28, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 16, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 28, 'Postoperative_RT_Received_Percentage': 32, 'Common_Neoadjuvant_Regimen_1': 'VRD', 'Common_Neoadjuvant_Regimen_2': 'CyBorD', 'Common_Adjuvant_Regimen_1': 'RVD', 'Common_Adjuvant_Regimen_2': 'RD', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 38, 'Antiemetic_Agent_Percentage': 52, 'Painkiller_Antipyretic_Percentage': 62, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 58, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Lenalidomide_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Lenalidomide\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Letrozole\",\n",
      "    \"STUDYID\": \"LtzStudy001\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"99.5\",\n",
      "    \"Male_Percentage\": \"0.5\",\n",
      "    \"Median_BMI\": \"28.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"12\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"20\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"30\",\n",
      "    \"Stage_II_Percentage\": \"40\",\n",
      "    \"Stage_III_Percentage\": \"20\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"3\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"8\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"45\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"55\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": \"10\",\n",
      "    \"Letrozole_Percentage\": \"75\",\n",
      "    \"Anastrozole_Percentage\": \"15\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"15\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"25\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"30\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Letrozole\",\n",
      "    \"STUDYID\": \"LtzStudy002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"99.7\",\n",
      "    \"Male_Percentage\": \"0.3\",\n",
      "    \"Median_BMI\": \"30.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"15\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"3\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"22\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"25\",\n",
      "    \"Stage_II_Percentage\": \"45\",\n",
      "    \"Stage_III_Percentage\": \"20\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"11\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"4\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"10\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"50\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"60\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-TH\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxotere\",\n",
      "    \"Tamoxifen_Percentage\": \"8\",\n",
      "    \"Letrozole_Percentage\": \"70\",\n",
      "    \"Anastrozole_Percentage\": \"22\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"18\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"28\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"35\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"55\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Letrozole\",\n",
      "    \"STUDYID\": \"LtzStudy003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"99.6\",\n",
      "    \"Male_Percentage\": \"0.4\",\n",
      "    \"Median_BMI\": \"27.9\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"10\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"90\",\n",
      "    \"LHRH_Use_Percentage\": \"7\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"65\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"35\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"20\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"5\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"2\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"5\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"40\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"50\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC-D\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Doxorubicin\",\n",
      "    \"Tamoxifen_Percentage\": \"12\",\n",
      "    \"Letrozole_Percentage\": \"80\",\n",
      "    \"Anastrozole_Percentage\": \"8\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"12\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"22\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"28\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"25\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"55\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Letrozole\",\n",
      "    \"STUDYID\": \"LtzStudy004\",\n",
      "    \"YEAR\": \"2024\",\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"99.8\",\n",
      "    \"Male_Percentage\": \"0.2\",\n",
      "    \"Median_BMI\": \"29.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"13\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"4\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"27\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"39\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"21\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"13\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"9\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"28\",\n",
      "    \"Stage_II_Percentage\": \"42\",\n",
      "    \"Stage_III_Percentage\": \"20\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"19\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"3\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"9\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"48\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"58\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AT\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Taxol-CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Methotrexate\",\n",
      "    \"Tamoxifen_Percentage\": \"9\",\n",
      "    \"Letrozole_Percentage\": \"72\",\n",
      "    \"Anastrozole_Percentage\": \"19\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"17\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"27\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"33\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"52\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Letrozole', 'STUDYID': 'LtzStudy001', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '99.5', 'Male_Percentage': '0.5', 'Median_BMI': '28.5', 'Smoking_History_Yes_Percentage': '12', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '25', 'Tumor_Stage_T2_Percentage': '40', 'Tumor_Stage_T3_Percentage': '20', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '30', 'Stage_II_Percentage': '40', 'Stage_III_Percentage': '20', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '3', 'Neoadjuvant_Chemotherapy_Received_Percentage': '8', 'Adjuvant_Chemotherapy_Received_Percentage': '45', 'Postoperative_RT_Received_Percentage': '55', 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'TC', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': '10', 'Letrozole_Percentage': '75', 'Anastrozole_Percentage': '15', 'Antidiarrheal_Agent_Probiotics_Percentage': '15', 'Antiemetic_Agent_Percentage': '25', 'Painkiller_Antipyretic_Percentage': '30', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Letrozole', 'STUDYID': 'LtzStudy002', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '99.7', 'Male_Percentage': '0.3', 'Median_BMI': '30.1', 'Smoking_History_Yes_Percentage': '15', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '3', 'Tumor_Stage_T1_Percentage': '28', 'Tumor_Stage_T2_Percentage': '38', 'Tumor_Stage_T3_Percentage': '22', 'Tumor_Stage_T4_Percentage': '12', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '25', 'Stage_II_Percentage': '45', 'Stage_III_Percentage': '20', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '11', 'Myocardial_Infarction_Percentage': '4', 'Neoadjuvant_Chemotherapy_Received_Percentage': '10', 'Adjuvant_Chemotherapy_Received_Percentage': '50', 'Postoperative_RT_Received_Percentage': '60', 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel', 'Common_Adjuvant_Regimen_1': 'AC-TH', 'Common_Adjuvant_Regimen_2': 'Taxotere', 'Tamoxifen_Percentage': '8', 'Letrozole_Percentage': '70', 'Anastrozole_Percentage': '22', 'Antidiarrheal_Agent_Probiotics_Percentage': '18', 'Antiemetic_Agent_Percentage': '28', 'Painkiller_Antipyretic_Percentage': '35', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '55', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Letrozole', 'STUDYID': 'LtzStudy003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '99.6', 'Male_Percentage': '0.4', 'Median_BMI': '27.9', 'Smoking_History_Yes_Percentage': '10', 'Total_ADL_Independence_Percentage': '90', 'LHRH_Use_Percentage': '7', 'Tumor_Stage_T1_Percentage': '30', 'Tumor_Stage_T2_Percentage': '35', 'Tumor_Stage_T3_Percentage': '25', 'Tumor_Stage_T4_Percentage': '10', 'Nodal_Stage_N0_Percentage': '65', 'Nodal_Stage_N1_Percentage': '20', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '35', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '20', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '5', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '2', 'Neoadjuvant_Chemotherapy_Received_Percentage': '5', 'Adjuvant_Chemotherapy_Received_Percentage': '40', 'Postoperative_RT_Received_Percentage': '50', 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'Cyclophosphamide', 'Common_Adjuvant_Regimen_1': 'FEC-D', 'Common_Adjuvant_Regimen_2': 'Doxorubicin', 'Tamoxifen_Percentage': '12', 'Letrozole_Percentage': '80', 'Anastrozole_Percentage': '8', 'Antidiarrheal_Agent_Probiotics_Percentage': '12', 'Antiemetic_Agent_Percentage': '22', 'Painkiller_Antipyretic_Percentage': '28', 'Beds_Less_Than_200_Percentage': '25', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '55', 'Months_Between_Surgery_And_Index_Date': '1'}, {'Drug_Name': 'Letrozole', 'STUDYID': 'LtzStudy004', 'YEAR': '2024', 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '70', 'Female_Percentage': '99.8', 'Male_Percentage': '0.2', 'Median_BMI': '29.5', 'Smoking_History_Yes_Percentage': '13', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '4', 'Tumor_Stage_T1_Percentage': '27', 'Tumor_Stage_T2_Percentage': '39', 'Tumor_Stage_T3_Percentage': '21', 'Tumor_Stage_T4_Percentage': '13', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '9', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '28', 'Stage_II_Percentage': '42', 'Stage_III_Percentage': '20', 'Diabetes_Mellitus_Percentage': '19', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '3', 'Neoadjuvant_Chemotherapy_Received_Percentage': '9', 'Adjuvant_Chemotherapy_Received_Percentage': '48', 'Postoperative_RT_Received_Percentage': '58', 'Common_Neoadjuvant_Regimen_1': 'AT', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'Taxol-CMF', 'Common_Adjuvant_Regimen_2': 'Methotrexate', 'Tamoxifen_Percentage': '9', 'Letrozole_Percentage': '72', 'Anastrozole_Percentage': '19', 'Antidiarrheal_Agent_Probiotics_Percentage': '17', 'Antiemetic_Agent_Percentage': '27', 'Painkiller_Antipyretic_Percentage': '33', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '52', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '2'}]\n",
      "File created: Letrozole_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Letrozole\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Lenvatinib\",\n",
      "    \"STUDYID\": \"LENV2023-US-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 35,\n",
      "    \"Male_Percentage\": 65,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 42,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 25,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 30,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 15,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 30,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 5,\n",
      "    \"Letrozole_Percentage\": 3,\n",
      "    \"Anastrozole_Percentage\": 2,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Lenvatinib\",\n",
      "    \"STUDYID\": \"LENV2022-EU-002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 40,\n",
      "    \"Male_Percentage\": 60,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 38,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 28,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16,\n",
      "    \"Nodal_Stage_N3_Percentage\": 16,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 33,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Gemcitabine + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"XELOX\",\n",
      "    \"Tamoxifen_Percentage\": 6,\n",
      "    \"Letrozole_Percentage\": 4,\n",
      "    \"Anastrozole_Percentage\": 3,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 45,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Lenvatinib\",\n",
      "    \"STUDYID\": \"LENV2024-JP-003\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 30,\n",
      "    \"Male_Percentage\": 70,\n",
      "    \"Median_BMI\": 24.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 22,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 25,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 15,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 28,\n",
      "    \"Stage_III_Percentage\": 32,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Postoperative_RT_Received_Percentage\": 32,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"S-1 + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + 5-FU\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"UFT\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine + Oxaliplatin\",\n",
      "    \"Tamoxifen_Percentage\": 4,\n",
      "    \"Letrozole_Percentage\": 2,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 80,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Lenvatinib', 'STUDYID': 'LENV2023-US-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 35, 'Male_Percentage': 65, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 42, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 25, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 30, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 15, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 30, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 25, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Gemcitabine', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 5, 'Letrozole_Percentage': 3, 'Anastrozole_Percentage': 2, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Lenvatinib', 'STUDYID': 'LENV2022-EU-002', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 40, 'Male_Percentage': 60, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 38, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 28, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 16, 'Nodal_Stage_N3_Percentage': 16, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 33, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 22, 'Postoperative_RT_Received_Percentage': 28, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Gemcitabine + Carboplatin', 'Common_Adjuvant_Regimen_1': 'FOLFOX', 'Common_Adjuvant_Regimen_2': 'XELOX', 'Tamoxifen_Percentage': 6, 'Letrozole_Percentage': 4, 'Anastrozole_Percentage': 3, 'Antidiarrheal_Agent_Probiotics_Percentage': 45, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Lenvatinib', 'STUDYID': 'LENV2024-JP-003', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 30, 'Male_Percentage': 70, 'Median_BMI': 24.5, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 22, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 25, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 15, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 28, 'Stage_III_Percentage': 32, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 28, 'Postoperative_RT_Received_Percentage': 32, 'Common_Neoadjuvant_Regimen_1': 'S-1 + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + 5-FU', 'Common_Adjuvant_Regimen_1': 'UFT', 'Common_Adjuvant_Regimen_2': 'Capecitabine + Oxaliplatin', 'Tamoxifen_Percentage': 4, 'Letrozole_Percentage': 2, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 80, 'Months_Between_Surgery_And_Index_Date': 1}]\n",
      "File created: Lenvatinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Lenvatinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Lorlatinib\",\n",
      "    \"STUDYID\": \"LRLT2023-US\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45.0,\n",
      "    \"Male_Percentage\": 55.0,\n",
      "    \"Median_BMI\": 26.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 60.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 85.0,\n",
      "    \"LHRH_Use_Percentage\": 5.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10.0,\n",
      "    \"Stage_I_Percentage\": 20.0,\n",
      "    \"Stage_II_Percentage\": 35.0,\n",
      "    \"Stage_III_Percentage\": 30.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5.0,\n",
      "    \"Stroke_Percentage\": 3.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 4.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Vinorelbine + Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel + Carboplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 50.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15.0,\n",
      "    \"Beds_200_To_499_Percentage\": 45.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Lorlatinib\",\n",
      "    \"STUDYID\": \"LRLT2022-EU\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 38.0,\n",
      "    \"Male_Percentage\": 62.0,\n",
      "    \"Median_BMI\": 27.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 55.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 78.0,\n",
      "    \"LHRH_Use_Percentage\": 8.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 35.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 23.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10.0,\n",
      "    \"Stage_I_Percentage\": 18.0,\n",
      "    \"Stage_II_Percentage\": 32.0,\n",
      "    \"Stage_III_Percentage\": 35.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7.0,\n",
      "    \"Stroke_Percentage\": 4.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 5.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 38.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Vinorelbine + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel + Cisplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 18.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 48.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 58.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18.0,\n",
      "    \"Beds_200_To_499_Percentage\": 42.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Lorlatinib\",\n",
      "    \"STUDYID\": \"LRLT2024-Asia\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 42.0,\n",
      "    \"Male_Percentage\": 58.0,\n",
      "    \"Median_BMI\": 25.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 48.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 82.0,\n",
      "    \"LHRH_Use_Percentage\": 6.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 36.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 31.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 19.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 38.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 29.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 21.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 12.0,\n",
      "    \"Stage_I_Percentage\": 19.0,\n",
      "    \"Stage_II_Percentage\": 34.0,\n",
      "    \"Stage_III_Percentage\": 32.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 13.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6.0,\n",
      "    \"Stroke_Percentage\": 3.5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 4.5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 24.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 39.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 29.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Vinorelbine + Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Pemetrexed + Cisplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 19.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 49.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 59.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 16.0,\n",
      "    \"Beds_200_To_499_Percentage\": 44.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 68.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Lorlatinib', 'STUDYID': 'LRLT2023-US', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45.0, 'Male_Percentage': 55.0, 'Median_BMI': 26.5, 'Smoking_History_Yes_Percentage': 60.0, 'Total_ADL_Independence_Percentage': 85.0, 'LHRH_Use_Percentage': 5.0, 'Tumor_Stage_T1_Percentage': 15.0, 'Tumor_Stage_T2_Percentage': 35.0, 'Tumor_Stage_T3_Percentage': 30.0, 'Tumor_Stage_T4_Percentage': 20.0, 'Nodal_Stage_N0_Percentage': 40.0, 'Nodal_Stage_N1_Percentage': 30.0, 'Nodal_Stage_N2_Percentage': 20.0, 'Nodal_Stage_N3_Percentage': 10.0, 'Stage_I_Percentage': 20.0, 'Stage_II_Percentage': 35.0, 'Stage_III_Percentage': 30.0, 'Diabetes_Mellitus_Percentage': 12.0, 'Congestive_Heart_Failure_Percentage': 5.0, 'Stroke_Percentage': 3.0, 'Atrial_Fibrillation_Percentage': 7.0, 'Myocardial_Infarction_Percentage': 4.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25.0, 'Adjuvant_Chemotherapy_Received_Percentage': 40.0, 'Postoperative_RT_Received_Percentage': 30.0, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Vinorelbine + Cisplatin', 'Common_Adjuvant_Regimen_2': 'Docetaxel + Carboplatin', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 20.0, 'Antiemetic_Agent_Percentage': 50.0, 'Painkiller_Antipyretic_Percentage': 60.0, 'Beds_Less_Than_200_Percentage': 15.0, 'Beds_200_To_499_Percentage': 45.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 70.0, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Lorlatinib', 'STUDYID': 'LRLT2022-EU', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 38.0, 'Male_Percentage': 62.0, 'Median_BMI': 27.1, 'Smoking_History_Yes_Percentage': 55.0, 'Total_ADL_Independence_Percentage': 78.0, 'LHRH_Use_Percentage': 8.0, 'Tumor_Stage_T1_Percentage': 12.0, 'Tumor_Stage_T2_Percentage': 38.0, 'Tumor_Stage_T3_Percentage': 32.0, 'Tumor_Stage_T4_Percentage': 18.0, 'Nodal_Stage_N0_Percentage': 35.0, 'Nodal_Stage_N1_Percentage': 32.0, 'Nodal_Stage_N2_Percentage': 23.0, 'Nodal_Stage_N3_Percentage': 10.0, 'Stage_I_Percentage': 18.0, 'Stage_II_Percentage': 32.0, 'Stage_III_Percentage': 35.0, 'Diabetes_Mellitus_Percentage': 15.0, 'Congestive_Heart_Failure_Percentage': 7.0, 'Stroke_Percentage': 4.0, 'Atrial_Fibrillation_Percentage': 9.0, 'Myocardial_Infarction_Percentage': 5.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22.0, 'Adjuvant_Chemotherapy_Received_Percentage': 38.0, 'Postoperative_RT_Received_Percentage': 28.0, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Gemcitabine', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Pemetrexed', 'Common_Adjuvant_Regimen_1': 'Vinorelbine + Carboplatin', 'Common_Adjuvant_Regimen_2': 'Docetaxel + Cisplatin', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 18.0, 'Antiemetic_Agent_Percentage': 48.0, 'Painkiller_Antipyretic_Percentage': 58.0, 'Beds_Less_Than_200_Percentage': 18.0, 'Beds_200_To_499_Percentage': 42.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 65.0, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Lorlatinib', 'STUDYID': 'LRLT2024-Asia', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 42.0, 'Male_Percentage': 58.0, 'Median_BMI': 25.8, 'Smoking_History_Yes_Percentage': 48.0, 'Total_ADL_Independence_Percentage': 82.0, 'LHRH_Use_Percentage': 6.0, 'Tumor_Stage_T1_Percentage': 14.0, 'Tumor_Stage_T2_Percentage': 36.0, 'Tumor_Stage_T3_Percentage': 31.0, 'Tumor_Stage_T4_Percentage': 19.0, 'Nodal_Stage_N0_Percentage': 38.0, 'Nodal_Stage_N1_Percentage': 29.0, 'Nodal_Stage_N2_Percentage': 21.0, 'Nodal_Stage_N3_Percentage': 12.0, 'Stage_I_Percentage': 19.0, 'Stage_II_Percentage': 34.0, 'Stage_III_Percentage': 32.0, 'Diabetes_Mellitus_Percentage': 13.0, 'Congestive_Heart_Failure_Percentage': 6.0, 'Stroke_Percentage': 3.5, 'Atrial_Fibrillation_Percentage': 8.0, 'Myocardial_Infarction_Percentage': 4.5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 24.0, 'Adjuvant_Chemotherapy_Received_Percentage': 39.0, 'Postoperative_RT_Received_Percentage': 29.0, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Gemcitabine', 'Common_Adjuvant_Regimen_1': 'Vinorelbine + Docetaxel', 'Common_Adjuvant_Regimen_2': 'Pemetrexed + Cisplatin', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 19.0, 'Antiemetic_Agent_Percentage': 49.0, 'Painkiller_Antipyretic_Percentage': 59.0, 'Beds_Less_Than_200_Percentage': 16.0, 'Beds_200_To_499_Percentage': 44.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 68.0, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Lorlatinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Lorlatinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Methotrexate\",\n",
      "    \"STUDYID\": \"MTX2023-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 25,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 48,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"MTX/5-FU\",\n",
      "    \"Tamoxifen_Percentage\": 15,\n",
      "    \"Letrozole_Percentage\": 10,\n",
      "    \"Anastrozole_Percentage\": 8,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Methotrexate\",\n",
      "    \"STUDYID\": \"MTX2022-002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 22,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"MTX/5-FU\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC\",\n",
      "    \"Tamoxifen_Percentage\": 12,\n",
      "    \"Letrozole_Percentage\": 15,\n",
      "    \"Anastrozole_Percentage\": 10,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 45,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Methotrexate\",\n",
      "    \"STUDYID\": \"MTX2024-003\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 26.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 22,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 65,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 28,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 20,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"MTX\",\n",
      "    \"Tamoxifen_Percentage\": 10,\n",
      "    \"Letrozole_Percentage\": 12,\n",
      "    \"Anastrozole_Percentage\": 5,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 18,\n",
      "    \"Antiemetic_Agent_Percentage\": 38,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Methotrexate', 'STUDYID': 'MTX2023-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 25, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 48, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'CMF', 'Common_Neoadjuvant_Regimen_2': 'AC', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'MTX/5-FU', 'Tamoxifen_Percentage': 15, 'Letrozole_Percentage': 10, 'Anastrozole_Percentage': 8, 'Antidiarrheal_Agent_Probiotics_Percentage': 20, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Methotrexate', 'STUDYID': 'MTX2022-002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 22, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 50, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'MTX/5-FU', 'Common_Adjuvant_Regimen_2': 'AC', 'Tamoxifen_Percentage': 12, 'Letrozole_Percentage': 15, 'Anastrozole_Percentage': 10, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 45, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Methotrexate', 'STUDYID': 'MTX2024-003', 'YEAR': 2024, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 26.9, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 22, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 25, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 65, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 28, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 20, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'CMF', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'MTX', 'Tamoxifen_Percentage': 10, 'Letrozole_Percentage': 12, 'Anastrozole_Percentage': 5, 'Antidiarrheal_Agent_Probiotics_Percentage': 18, 'Antiemetic_Agent_Percentage': 38, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Methotrexate_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Methotrexate\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Neratinib\",\n",
      "    \"STUDYID\": \"NRNB2023001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 58,\n",
      "    \"Female_Percentage\": 99,\n",
      "    \"Male_Percentage\": 1,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 18,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 22,\n",
      "    \"Tumor_Stage_T2_Percentage\": 45,\n",
      "    \"Tumor_Stage_T3_Percentage\": 23,\n",
      "    \"Tumor_Stage_T4_Percentage\": 10,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 3,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 4,\n",
      "    \"Myocardial_Infarction_Percentage\": 1,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 15,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 65,\n",
      "    \"Postoperative_RT_Received_Percentage\": 50,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC\",\n",
      "    \"Tamoxifen_Percentage\": 30,\n",
      "    \"Letrozole_Percentage\": 25,\n",
      "    \"Anastrozole_Percentage\": 20,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 60,\n",
      "    \"Antiemetic_Agent_Percentage\": 45,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 35,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Neratinib\",\n",
      "    \"STUDYID\": \"NRNB2023002\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 98,\n",
      "    \"Male_Percentage\": 2,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 22,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 5,\n",
      "    \"Myocardial_Infarction_Percentage\": 2,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 18,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 60,\n",
      "    \"Postoperative_RT_Received_Percentage\": 45,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"EC\",\n",
      "    \"Tamoxifen_Percentage\": 35,\n",
      "    \"Letrozole_Percentage\": 20,\n",
      "    \"Anastrozole_Percentage\": 15,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 55,\n",
      "    \"Antiemetic_Agent_Percentage\": 50,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 40,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Neratinib\",\n",
      "    \"STUDYID\": \"NRNB2023003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 97,\n",
      "    \"Male_Percentage\": 3,\n",
      "    \"Median_BMI\": 29.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 25,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 25,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 20,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 35,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 55,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Tamoxifen_Percentage\": 40,\n",
      "    \"Letrozole_Percentage\": 15,\n",
      "    \"Anastrozole_Percentage\": 10,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 50,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 50,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 4\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Neratinib\",\n",
      "    \"STUDYID\": \"NRNB2023004\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 380,\n",
      "    \"Median_Age\": 60,\n",
      "    \"Female_Percentage\": 96,\n",
      "    \"Male_Percentage\": 4,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 15,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 8,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 42,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 30,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 25,\n",
      "    \"Diabetes_Mellitus_Percentage\": 10,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 2,\n",
      "    \"Stroke_Percentage\": 1,\n",
      "    \"Atrial_Fibrillation_Percentage\": 3,\n",
      "    \"Myocardial_Infarction_Percentage\": 1,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 70,\n",
      "    \"Postoperative_RT_Received_Percentage\": 55,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 25,\n",
      "    \"Letrozole_Percentage\": 30,\n",
      "    \"Anastrozole_Percentage\": 25,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 65,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 30,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Neratinib', 'STUDYID': 'NRNB2023001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 58, 'Female_Percentage': 99, 'Male_Percentage': 1, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 18, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 22, 'Tumor_Stage_T2_Percentage': 45, 'Tumor_Stage_T3_Percentage': 23, 'Tumor_Stage_T4_Percentage': 10, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 3, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 4, 'Myocardial_Infarction_Percentage': 1, 'Neoadjuvant_Chemotherapy_Received_Percentage': 15, 'Adjuvant_Chemotherapy_Received_Percentage': 65, 'Postoperative_RT_Received_Percentage': 50, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'TC', 'Common_Adjuvant_Regimen_2': 'AC', 'Tamoxifen_Percentage': 30, 'Letrozole_Percentage': 25, 'Anastrozole_Percentage': 20, 'Antidiarrheal_Agent_Probiotics_Percentage': 60, 'Antiemetic_Agent_Percentage': 45, 'Painkiller_Antipyretic_Percentage': 35, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Neratinib', 'STUDYID': 'NRNB2023002', 'YEAR': 2023, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 62, 'Female_Percentage': 98, 'Male_Percentage': 2, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 22, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 25, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 5, 'Myocardial_Infarction_Percentage': 2, 'Neoadjuvant_Chemotherapy_Received_Percentage': 18, 'Adjuvant_Chemotherapy_Received_Percentage': 60, 'Postoperative_RT_Received_Percentage': 45, 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'CMF', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'EC', 'Tamoxifen_Percentage': 35, 'Letrozole_Percentage': 20, 'Anastrozole_Percentage': 15, 'Antidiarrheal_Agent_Probiotics_Percentage': 55, 'Antiemetic_Agent_Percentage': 50, 'Painkiller_Antipyretic_Percentage': 40, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Neratinib', 'STUDYID': 'NRNB2023003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 97, 'Male_Percentage': 3, 'Median_BMI': 29.0, 'Smoking_History_Yes_Percentage': 25, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 25, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 20, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 35, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 6, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 55, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'CMF', 'Common_Adjuvant_Regimen_1': 'Taxol', 'Common_Adjuvant_Regimen_2': 'FEC', 'Tamoxifen_Percentage': 40, 'Letrozole_Percentage': 15, 'Anastrozole_Percentage': 10, 'Antidiarrheal_Agent_Probiotics_Percentage': 50, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 50, 'Months_Between_Surgery_And_Index_Date': 4}, {'Drug_Name': 'Neratinib', 'STUDYID': 'NRNB2023004', 'YEAR': 2023, 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': 380, 'Median_Age': 60, 'Female_Percentage': 96, 'Male_Percentage': 4, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 15, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 8, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 42, 'Tumor_Stage_T3_Percentage': 25, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 30, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 25, 'Diabetes_Mellitus_Percentage': 10, 'Congestive_Heart_Failure_Percentage': 2, 'Stroke_Percentage': 1, 'Atrial_Fibrillation_Percentage': 3, 'Myocardial_Infarction_Percentage': 1, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 70, 'Postoperative_RT_Received_Percentage': 55, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'TC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 25, 'Letrozole_Percentage': 30, 'Anastrozole_Percentage': 25, 'Antidiarrheal_Agent_Probiotics_Percentage': 65, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 30, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 2}]\n",
      "File created: Neratinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Neratinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Olaparib\",\n",
      "    \"STUDYID\": \"OLA2023-US\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 98,\n",
      "    \"Male_Percentage\": 2,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 15,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 10,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 15,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 3,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 5,\n",
      "    \"Myocardial_Infarction_Percentage\": 1,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 55,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Taxol + Carboplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC (Adriamycin + Cyclophosphamide)\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"TC (Taxotere + Cyclophosphamide)\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FEC (5-FU, Epirubicin, Cyclophosphamide)\",\n",
      "    \"Tamoxifen_Percentage\": 30,\n",
      "    \"Letrozole_Percentage\": 25,\n",
      "    \"Anastrozole_Percentage\": 20,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 45,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 70,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 45,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Olaparib\",\n",
      "    \"STUDYID\": \"OLA2022-UK\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 97,\n",
      "    \"Male_Percentage\": 3,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 22,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 32,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 2,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 60,\n",
      "    \"Postoperative_RT_Received_Percentage\": 45,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC (Epirubicin + Cyclophosphamide)\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF (Cyclophosphamide, Methotrexate, 5-FU)\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel + Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC-T (Adriamycin, Cyclophosphamide followed by Taxol)\",\n",
      "    \"Tamoxifen_Percentage\": 35,\n",
      "    \"Letrozole_Percentage\": 20,\n",
      "    \"Anastrozole_Percentage\": 15,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 50,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 75,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 45,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Olaparib\",\n",
      "    \"STUDYID\": \"OLA2024-CA\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 99,\n",
      "    \"Male_Percentage\": 1,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 18,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 8,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 65,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 12,\n",
      "    \"Stage_II_Percentage\": 45,\n",
      "    \"Stage_III_Percentage\": 28,\n",
      "    \"Diabetes_Mellitus_Percentage\": 10,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 1,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6,\n",
      "    \"Myocardial_Infarction_Percentage\": 1,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 18,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC (Adriamycin + Cyclophosphamide)\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol + Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC (5-FU, Epirubicin, Cyclophosphamide)\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxotere + Carboplatin\",\n",
      "    \"Tamoxifen_Percentage\": 25,\n",
      "    \"Letrozole_Percentage\": 30,\n",
      "    \"Anastrozole_Percentage\": 15,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 65,\n",
      "    \"Beds_Less_Than_200_Percentage\": 8,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 42,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Olaparib', 'STUDYID': 'OLA2023-US', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 98, 'Male_Percentage': 2, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 15, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 10, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 15, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 3, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 5, 'Myocardial_Infarction_Percentage': 1, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 55, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'Taxol + Carboplatin', 'Common_Neoadjuvant_Regimen_2': 'AC (Adriamycin + Cyclophosphamide)', 'Common_Adjuvant_Regimen_1': 'TC (Taxotere + Cyclophosphamide)', 'Common_Adjuvant_Regimen_2': 'FEC (5-FU, Epirubicin, Cyclophosphamide)', 'Tamoxifen_Percentage': 30, 'Letrozole_Percentage': 25, 'Anastrozole_Percentage': 20, 'Antidiarrheal_Agent_Probiotics_Percentage': 45, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 70, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 45, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Olaparib', 'STUDYID': 'OLA2022-UK', 'YEAR': 2022, 'Country': 'UK', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 97, 'Male_Percentage': 3, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 22, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 32, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 2, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 60, 'Postoperative_RT_Received_Percentage': 45, 'Common_Neoadjuvant_Regimen_1': 'EC (Epirubicin + Cyclophosphamide)', 'Common_Neoadjuvant_Regimen_2': 'CMF (Cyclophosphamide, Methotrexate, 5-FU)', 'Common_Adjuvant_Regimen_1': 'Docetaxel + Cyclophosphamide', 'Common_Adjuvant_Regimen_2': 'AC-T (Adriamycin, Cyclophosphamide followed by Taxol)', 'Tamoxifen_Percentage': 35, 'Letrozole_Percentage': 20, 'Anastrozole_Percentage': 15, 'Antidiarrheal_Agent_Probiotics_Percentage': 50, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 75, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 45, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Olaparib', 'STUDYID': 'OLA2024-CA', 'YEAR': 2024, 'Country': 'Canada', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 99, 'Male_Percentage': 1, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 18, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 8, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 45, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 65, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 12, 'Stage_II_Percentage': 45, 'Stage_III_Percentage': 28, 'Diabetes_Mellitus_Percentage': 10, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 1, 'Atrial_Fibrillation_Percentage': 6, 'Myocardial_Infarction_Percentage': 1, 'Neoadjuvant_Chemotherapy_Received_Percentage': 18, 'Adjuvant_Chemotherapy_Received_Percentage': 50, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'AC (Adriamycin + Cyclophosphamide)', 'Common_Neoadjuvant_Regimen_2': 'Taxol + Cyclophosphamide', 'Common_Adjuvant_Regimen_1': 'FEC (5-FU, Epirubicin, Cyclophosphamide)', 'Common_Adjuvant_Regimen_2': 'Taxotere + Carboplatin', 'Tamoxifen_Percentage': 25, 'Letrozole_Percentage': 30, 'Anastrozole_Percentage': 15, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 65, 'Beds_Less_Than_200_Percentage': 8, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 42, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Olaparib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Olaparib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Osimertinib\",\n",
      "    \"STUDYID\": \"OsiStudy001\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"52\",\n",
      "    \"Male_Percentage\": \"48\",\n",
      "    \"Median_BMI\": \"26.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"45\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"12\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"10\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"30\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": \"2\",\n",
      "    \"Letrozole_Percentage\": \"3\",\n",
      "    \"Anastrozole_Percentage\": \"1\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"20\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"40\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"50\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"55\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Osimertinib\",\n",
      "    \"STUDYID\": \"OsiStudy002\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"24.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"40\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"3\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"48\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"32\",\n",
      "    \"Stage_III_Percentage\": \"50\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"10\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"14\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"8\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"28\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Gemcitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"1\",\n",
      "    \"Letrozole_Percentage\": \"2\",\n",
      "    \"Anastrozole_Percentage\": \"0.5\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"22\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"42\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"52\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"60\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"20\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Osimertinib\",\n",
      "    \"STUDYID\": \"OsiStudy003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"55\",\n",
      "    \"Male_Percentage\": \"45\",\n",
      "    \"Median_BMI\": \"27.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"30\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"90\",\n",
      "    \"LHRH_Use_Percentage\": \"4\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"50\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"38\",\n",
      "    \"Stage_III_Percentage\": \"40\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"12\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"28\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"32\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin + Etoposide\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": \"3\",\n",
      "    \"Letrozole_Percentage\": \"4\",\n",
      "    \"Anastrozole_Percentage\": \"2\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"18\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"38\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"48\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"10\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Osimertinib', 'STUDYID': 'OsiStudy001', 'YEAR': '2022', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '52', 'Male_Percentage': '48', 'Median_BMI': '26.5', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '45', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '12', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '10', 'Adjuvant_Chemotherapy_Received_Percentage': '25', 'Postoperative_RT_Received_Percentage': '30', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Vinorelbine', 'Tamoxifen_Percentage': '2', 'Letrozole_Percentage': '3', 'Anastrozole_Percentage': '1', 'Antidiarrheal_Agent_Probiotics_Percentage': '20', 'Antiemetic_Agent_Percentage': '40', 'Painkiller_Antipyretic_Percentage': '50', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '55', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Osimertinib', 'STUDYID': 'OsiStudy002', 'YEAR': '2023', 'Country': 'Japan', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '24.8', 'Smoking_History_Yes_Percentage': '40', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '3', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '42', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '48', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '32', 'Stage_III_Percentage': '50', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '10', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '14', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '8', 'Adjuvant_Chemotherapy_Received_Percentage': '22', 'Postoperative_RT_Received_Percentage': '28', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Pemetrexed', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'Gemcitabine', 'Tamoxifen_Percentage': '1', 'Letrozole_Percentage': '2', 'Anastrozole_Percentage': '0.5', 'Antidiarrheal_Agent_Probiotics_Percentage': '22', 'Antiemetic_Agent_Percentage': '42', 'Painkiller_Antipyretic_Percentage': '52', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '60', 'Beds_Greater_Or_Equal_To_500_Percentage': '20', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '1.5'}, {'Drug_Name': 'Osimertinib', 'STUDYID': 'OsiStudy003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '55', 'Male_Percentage': '45', 'Median_BMI': '27.1', 'Smoking_History_Yes_Percentage': '30', 'Total_ADL_Independence_Percentage': '90', 'LHRH_Use_Percentage': '4', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '35', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '50', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '38', 'Stage_III_Percentage': '40', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '12', 'Adjuvant_Chemotherapy_Received_Percentage': '28', 'Postoperative_RT_Received_Percentage': '32', 'Common_Neoadjuvant_Regimen_1': 'Carboplatin + Paclitaxel', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin + Etoposide', 'Common_Adjuvant_Regimen_1': 'Paclitaxel', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': '3', 'Letrozole_Percentage': '4', 'Anastrozole_Percentage': '2', 'Antidiarrheal_Agent_Probiotics_Percentage': '18', 'Antiemetic_Agent_Percentage': '38', 'Painkiller_Antipyretic_Percentage': '48', 'Beds_Less_Than_200_Percentage': '10', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '2.5'}]\n",
      "File created: Osimertinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Osimertinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Paclitaxel\",\n",
      "    \"STUDYID\": \"PTXStudy001\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"62\",\n",
      "    \"Female_Percentage\": \"65\",\n",
      "    \"Male_Percentage\": \"35\",\n",
      "    \"Median_BMI\": \"26.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"28\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"45\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"10\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"3\",\n",
      "    \"Stroke_Percentage\": \"2\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"5\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"4\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"35\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"60\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"45\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol/Carbo\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": \"20\",\n",
      "    \"Letrozole_Percentage\": \"15\",\n",
      "    \"Anastrozole_Percentage\": \"10\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"30\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"70\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"50\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"40\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"45\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Paclitaxel\",\n",
      "    \"STUDYID\": \"PTXStudy002\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"68\",\n",
      "    \"Male_Percentage\": \"32\",\n",
      "    \"Median_BMI\": \"27.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"31\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"43\",\n",
      "    \"Stage_III_Percentage\": \"29\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"12\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"4\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"6\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"38\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"63\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"48\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel/Carbo\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Tamoxifen_Percentage\": \"22\",\n",
      "    \"Letrozole_Percentage\": \"17\",\n",
      "    \"Anastrozole_Percentage\": \"12\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"33\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"73\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"53\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"43\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"39\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"63\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Paclitaxel\",\n",
      "    \"STUDYID\": \"PTXStudy003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"70\",\n",
      "    \"Male_Percentage\": \"30\",\n",
      "    \"Median_BMI\": \"28.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"20\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"50\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"8\",\n",
      "    \"Stage_I_Percentage\": \"25\",\n",
      "    \"Stage_II_Percentage\": \"40\",\n",
      "    \"Stage_III_Percentage\": \"25\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"5\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"7\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"40\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"65\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"50\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol/Herceptin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel/Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"EC\",\n",
      "    \"Tamoxifen_Percentage\": \"25\",\n",
      "    \"Letrozole_Percentage\": \"20\",\n",
      "    \"Anastrozole_Percentage\": \"15\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"35\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"75\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"55\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"4\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Paclitaxel', 'STUDYID': 'PTXStudy001', 'YEAR': '2022', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '62', 'Female_Percentage': '65', 'Male_Percentage': '35', 'Median_BMI': '26.5', 'Smoking_History_Yes_Percentage': '28', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '12', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '40', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '45', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '10', 'Congestive_Heart_Failure_Percentage': '3', 'Stroke_Percentage': '2', 'Atrial_Fibrillation_Percentage': '5', 'Myocardial_Infarction_Percentage': '4', 'Neoadjuvant_Chemotherapy_Received_Percentage': '35', 'Adjuvant_Chemotherapy_Received_Percentage': '60', 'Postoperative_RT_Received_Percentage': '45', 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Taxol/Carbo', 'Common_Adjuvant_Regimen_1': 'TC', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': '20', 'Letrozole_Percentage': '15', 'Anastrozole_Percentage': '10', 'Antidiarrheal_Agent_Probiotics_Percentage': '30', 'Antiemetic_Agent_Percentage': '70', 'Painkiller_Antipyretic_Percentage': '50', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '40', 'Beds_Greater_Or_Equal_To_500_Percentage': '45', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Paclitaxel', 'STUDYID': 'PTXStudy002', 'YEAR': '2023', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '68', 'Female_Percentage': '68', 'Male_Percentage': '32', 'Median_BMI': '27.1', 'Smoking_History_Yes_Percentage': '31', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '38', 'Tumor_Stage_T3_Percentage': '28', 'Tumor_Stage_T4_Percentage': '16', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '43', 'Stage_III_Percentage': '29', 'Diabetes_Mellitus_Percentage': '12', 'Congestive_Heart_Failure_Percentage': '4', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '6', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '38', 'Adjuvant_Chemotherapy_Received_Percentage': '63', 'Postoperative_RT_Received_Percentage': '48', 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel/Carbo', 'Common_Adjuvant_Regimen_1': 'AC-T', 'Common_Adjuvant_Regimen_2': 'FEC', 'Tamoxifen_Percentage': '22', 'Letrozole_Percentage': '17', 'Anastrozole_Percentage': '12', 'Antidiarrheal_Agent_Probiotics_Percentage': '33', 'Antiemetic_Agent_Percentage': '73', 'Painkiller_Antipyretic_Percentage': '53', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '43', 'Beds_Greater_Or_Equal_To_500_Percentage': '39', 'Designated_Cancer_Hospital_Percentage': '63', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Paclitaxel', 'STUDYID': 'PTXStudy003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '70', 'Female_Percentage': '70', 'Male_Percentage': '30', 'Median_BMI': '28.5', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '18', 'Tumor_Stage_T1_Percentage': '20', 'Tumor_Stage_T2_Percentage': '35', 'Tumor_Stage_T3_Percentage': '25', 'Tumor_Stage_T4_Percentage': '20', 'Nodal_Stage_N0_Percentage': '50', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '12', 'Nodal_Stage_N3_Percentage': '8', 'Stage_I_Percentage': '25', 'Stage_II_Percentage': '40', 'Stage_III_Percentage': '25', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '5', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '7', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '40', 'Adjuvant_Chemotherapy_Received_Percentage': '65', 'Postoperative_RT_Received_Percentage': '50', 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'Taxol/Herceptin', 'Common_Adjuvant_Regimen_1': 'Docetaxel/Cyclophosphamide', 'Common_Adjuvant_Regimen_2': 'EC', 'Tamoxifen_Percentage': '25', 'Letrozole_Percentage': '20', 'Anastrozole_Percentage': '15', 'Antidiarrheal_Agent_Probiotics_Percentage': '35', 'Antiemetic_Agent_Percentage': '75', 'Painkiller_Antipyretic_Percentage': '55', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '4'}]\n",
      "File created: Paclitaxel_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Paclitaxel\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Palbociclib\",\n",
      "    \"STUDYID\": \"PALB2023-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 99,\n",
      "    \"Male_Percentage\": 1,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 18,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 45,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 3,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 5,\n",
      "    \"Myocardial_Infarction_Percentage\": 1,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": 25,\n",
      "    \"Letrozole_Percentage\": 35,\n",
      "    \"Anastrozole_Percentage\": 30,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 30,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Palbociclib\",\n",
      "    \"STUDYID\": \"PALB2022-002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 98,\n",
      "    \"Male_Percentage\": 2,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 22,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 33,\n",
      "    \"Nodal_Stage_N2_Percentage\": 11,\n",
      "    \"Nodal_Stage_N3_Percentage\": 4,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 42,\n",
      "    \"Stage_III_Percentage\": 33,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 2,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 48,\n",
      "    \"Postoperative_RT_Received_Percentage\": 38,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC-T\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 28,\n",
      "    \"Letrozole_Percentage\": 32,\n",
      "    \"Anastrozole_Percentage\": 33,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 22,\n",
      "    \"Antiemetic_Agent_Percentage\": 42,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 32,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Palbociclib\",\n",
      "    \"STUDYID\": \"PALB2024-003\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 97,\n",
      "    \"Male_Percentage\": 3,\n",
      "    \"Median_BMI\": 26.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 20,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 42,\n",
      "    \"Tumor_Stage_T3_Percentage\": 28,\n",
      "    \"Tumor_Stage_T4_Percentage\": 16,\n",
      "    \"Nodal_Stage_N0_Percentage\": 54,\n",
      "    \"Nodal_Stage_N1_Percentage\": 31,\n",
      "    \"Nodal_Stage_N2_Percentage\": 9,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 44,\n",
      "    \"Stage_III_Percentage\": 29,\n",
      "    \"Diabetes_Mellitus_Percentage\": 13,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 3.5,\n",
      "    \"Stroke_Percentage\": 2.5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6,\n",
      "    \"Myocardial_Infarction_Percentage\": 1.5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 9,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 46,\n",
      "    \"Postoperative_RT_Received_Percentage\": 36,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC-T\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel/Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": 26,\n",
      "    \"Letrozole_Percentage\": 34,\n",
      "    \"Anastrozole_Percentage\": 31,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 21,\n",
      "    \"Antiemetic_Agent_Percentage\": 41,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 31,\n",
      "    \"Beds_Less_Than_200_Percentage\": 14,\n",
      "    \"Beds_200_To_499_Percentage\": 49,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 37,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Palbociclib\",\n",
      "    \"STUDYID\": \"PALB2023-004\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 380,\n",
      "    \"Median_Age\": 63,\n",
      "    \"Female_Percentage\": 98.5,\n",
      "    \"Male_Percentage\": 1.5,\n",
      "    \"Median_BMI\": 29.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 15,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 4,\n",
      "    \"Tumor_Stage_T1_Percentage\": 16,\n",
      "    \"Tumor_Stage_T2_Percentage\": 39,\n",
      "    \"Tumor_Stage_T3_Percentage\": 29,\n",
      "    \"Tumor_Stage_T4_Percentage\": 16,\n",
      "    \"Nodal_Stage_N0_Percentage\": 56,\n",
      "    \"Nodal_Stage_N1_Percentage\": 29,\n",
      "    \"Nodal_Stage_N2_Percentage\": 12,\n",
      "    \"Nodal_Stage_N3_Percentage\": 3,\n",
      "    \"Stage_I_Percentage\": 21,\n",
      "    \"Stage_II_Percentage\": 43,\n",
      "    \"Stage_III_Percentage\": 28,\n",
      "    \"Diabetes_Mellitus_Percentage\": 11,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 2.5,\n",
      "    \"Stroke_Percentage\": 1.5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 4,\n",
      "    \"Myocardial_Infarction_Percentage\": 0.5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 7,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 44,\n",
      "    \"Postoperative_RT_Received_Percentage\": 34,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol/Herceptin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Tamoxifen_Percentage\": 24,\n",
      "    \"Letrozole_Percentage\": 36,\n",
      "    \"Anastrozole_Percentage\": 29,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 19,\n",
      "    \"Antiemetic_Agent_Percentage\": 39,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 29,\n",
      "    \"Beds_Less_Than_200_Percentage\": 16,\n",
      "    \"Beds_200_To_499_Percentage\": 51,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 33,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 58,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Palbociclib', 'STUDYID': 'PALB2023-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 99, 'Male_Percentage': 1, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 18, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 45, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 3, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 5, 'Myocardial_Infarction_Percentage': 1, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'TC', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': 25, 'Letrozole_Percentage': 35, 'Anastrozole_Percentage': 30, 'Antidiarrheal_Agent_Probiotics_Percentage': 20, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 30, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Palbociclib', 'STUDYID': 'PALB2022-002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 98, 'Male_Percentage': 2, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 22, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 33, 'Nodal_Stage_N2_Percentage': 11, 'Nodal_Stage_N3_Percentage': 4, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 42, 'Stage_III_Percentage': 33, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 2, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 48, 'Postoperative_RT_Received_Percentage': 38, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'AC-T', 'Common_Adjuvant_Regimen_1': 'FEC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 28, 'Letrozole_Percentage': 32, 'Anastrozole_Percentage': 33, 'Antidiarrheal_Agent_Probiotics_Percentage': 22, 'Antiemetic_Agent_Percentage': 42, 'Painkiller_Antipyretic_Percentage': 32, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Palbociclib', 'STUDYID': 'PALB2024-003', 'YEAR': 2024, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 97, 'Male_Percentage': 3, 'Median_BMI': 26.9, 'Smoking_History_Yes_Percentage': 20, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 42, 'Tumor_Stage_T3_Percentage': 28, 'Tumor_Stage_T4_Percentage': 16, 'Nodal_Stage_N0_Percentage': 54, 'Nodal_Stage_N1_Percentage': 31, 'Nodal_Stage_N2_Percentage': 9, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 44, 'Stage_III_Percentage': 29, 'Diabetes_Mellitus_Percentage': 13, 'Congestive_Heart_Failure_Percentage': 3.5, 'Stroke_Percentage': 2.5, 'Atrial_Fibrillation_Percentage': 6, 'Myocardial_Infarction_Percentage': 1.5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 9, 'Adjuvant_Chemotherapy_Received_Percentage': 46, 'Postoperative_RT_Received_Percentage': 36, 'Common_Neoadjuvant_Regimen_1': 'FEC-T', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel/Carboplatin', 'Common_Adjuvant_Regimen_1': 'EC', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': 26, 'Letrozole_Percentage': 34, 'Anastrozole_Percentage': 31, 'Antidiarrheal_Agent_Probiotics_Percentage': 21, 'Antiemetic_Agent_Percentage': 41, 'Painkiller_Antipyretic_Percentage': 31, 'Beds_Less_Than_200_Percentage': 14, 'Beds_200_To_499_Percentage': 49, 'Beds_Greater_Or_Equal_To_500_Percentage': 37, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 2.5}, {'Drug_Name': 'Palbociclib', 'STUDYID': 'PALB2023-004', 'YEAR': 2023, 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': 380, 'Median_Age': 63, 'Female_Percentage': 98.5, 'Male_Percentage': 1.5, 'Median_BMI': 29.0, 'Smoking_History_Yes_Percentage': 15, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 4, 'Tumor_Stage_T1_Percentage': 16, 'Tumor_Stage_T2_Percentage': 39, 'Tumor_Stage_T3_Percentage': 29, 'Tumor_Stage_T4_Percentage': 16, 'Nodal_Stage_N0_Percentage': 56, 'Nodal_Stage_N1_Percentage': 29, 'Nodal_Stage_N2_Percentage': 12, 'Nodal_Stage_N3_Percentage': 3, 'Stage_I_Percentage': 21, 'Stage_II_Percentage': 43, 'Stage_III_Percentage': 28, 'Diabetes_Mellitus_Percentage': 11, 'Congestive_Heart_Failure_Percentage': 2.5, 'Stroke_Percentage': 1.5, 'Atrial_Fibrillation_Percentage': 4, 'Myocardial_Infarction_Percentage': 0.5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 7, 'Adjuvant_Chemotherapy_Received_Percentage': 44, 'Postoperative_RT_Received_Percentage': 34, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Taxol/Herceptin', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'FEC', 'Tamoxifen_Percentage': 24, 'Letrozole_Percentage': 36, 'Anastrozole_Percentage': 29, 'Antidiarrheal_Agent_Probiotics_Percentage': 19, 'Antiemetic_Agent_Percentage': 39, 'Painkiller_Antipyretic_Percentage': 29, 'Beds_Less_Than_200_Percentage': 16, 'Beds_200_To_499_Percentage': 51, 'Beds_Greater_Or_Equal_To_500_Percentage': 33, 'Designated_Cancer_Hospital_Percentage': 58, 'Months_Between_Surgery_And_Index_Date': 1.5}]\n",
      "File created: Palbociclib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Palbociclib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Pemetrexed\",\n",
      "    \"STUDYID\": \"PMTX101\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"26.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"60\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"50\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"12\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"65\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"50\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"20\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"70\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"55\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Pemetrexed\",\n",
      "    \"STUDYID\": \"PMTX102\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"52\",\n",
      "    \"Male_Percentage\": \"48\",\n",
      "    \"Median_BMI\": \"27.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"55\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"3\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"45\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"48\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"27\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"9\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"49\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"10\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"14\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"68\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"52\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"22\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"72\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"58\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Pemetrexed\",\n",
      "    \"STUDYID\": \"PMTX103\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"25.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"65\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"90\",\n",
      "    \"LHRH_Use_Percentage\": \"7\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"23\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"11\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"37\",\n",
      "    \"Stage_III_Percentage\": \"41\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"16\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"11\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"28\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"62\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"48\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Vinorelbine + Cisplatin\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"18\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"68\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"52\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"42\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"55\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1.8\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Pemetrexed\",\n",
      "    \"STUDYID\": \"PMTX104\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"50\",\n",
      "    \"Male_Percentage\": \"50\",\n",
      "    \"Median_BMI\": \"26.9\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"58\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"4\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"14\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"29\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"49\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"26\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"17\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"8\",\n",
      "    \"Stage_I_Percentage\": \"19\",\n",
      "    \"Stage_II_Percentage\": \"34\",\n",
      "    \"Stage_III_Percentage\": \"47\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"19\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"13\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"24\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"66\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"51\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin + Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"21\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"71\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"57\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"13\",\n",
      "    \"Beds_200_To_499_Percentage\": \"47\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.3\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Pemetrexed', 'STUDYID': 'PMTX101', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '26.5', 'Smoking_History_Yes_Percentage': '60', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '50', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '12', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '65', 'Postoperative_RT_Received_Percentage': '50', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Pemetrexed', 'Common_Adjuvant_Regimen_1': 'Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Cisplatin + Pemetrexed', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '20', 'Antiemetic_Agent_Percentage': '70', 'Painkiller_Antipyretic_Percentage': '55', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Pemetrexed', 'STUDYID': 'PMTX102', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '52', 'Male_Percentage': '48', 'Median_BMI': '27.1', 'Smoking_History_Yes_Percentage': '55', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '3', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '45', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '48', 'Nodal_Stage_N1_Percentage': '27', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '9', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '49', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '10', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '14', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '68', 'Postoperative_RT_Received_Percentage': '52', 'Common_Neoadjuvant_Regimen_1': 'Carboplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin + Gemcitabine', 'Common_Adjuvant_Regimen_1': 'Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Carboplatin + Pemetrexed', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '22', 'Antiemetic_Agent_Percentage': '72', 'Painkiller_Antipyretic_Percentage': '58', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Pemetrexed', 'STUDYID': 'PMTX103', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '25.8', 'Smoking_History_Yes_Percentage': '65', 'Total_ADL_Independence_Percentage': '90', 'LHRH_Use_Percentage': '7', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '35', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '23', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '11', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '37', 'Stage_III_Percentage': '41', 'Diabetes_Mellitus_Percentage': '16', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '11', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '28', 'Adjuvant_Chemotherapy_Received_Percentage': '62', 'Postoperative_RT_Received_Percentage': '48', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Vinorelbine + Cisplatin', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '18', 'Antiemetic_Agent_Percentage': '68', 'Painkiller_Antipyretic_Percentage': '52', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '42', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '55', 'Months_Between_Surgery_And_Index_Date': '1.8'}, {'Drug_Name': 'Pemetrexed', 'STUDYID': 'PMTX104', 'YEAR': '2023', 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '70', 'Female_Percentage': '50', 'Male_Percentage': '50', 'Median_BMI': '26.9', 'Smoking_History_Yes_Percentage': '58', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '4', 'Tumor_Stage_T1_Percentage': '14', 'Tumor_Stage_T2_Percentage': '29', 'Tumor_Stage_T3_Percentage': '42', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '49', 'Nodal_Stage_N1_Percentage': '26', 'Nodal_Stage_N2_Percentage': '17', 'Nodal_Stage_N3_Percentage': '8', 'Stage_I_Percentage': '19', 'Stage_II_Percentage': '34', 'Stage_III_Percentage': '47', 'Diabetes_Mellitus_Percentage': '19', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '13', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '24', 'Adjuvant_Chemotherapy_Received_Percentage': '66', 'Postoperative_RT_Received_Percentage': '51', 'Common_Neoadjuvant_Regimen_1': 'Carboplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin + Docetaxel', 'Common_Adjuvant_Regimen_1': 'Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '21', 'Antiemetic_Agent_Percentage': '71', 'Painkiller_Antipyretic_Percentage': '57', 'Beds_Less_Than_200_Percentage': '13', 'Beds_200_To_499_Percentage': '47', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '2.3'}]\n",
      "File created: Pemetrexed_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Pemetrexed\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Ribociclib\",\n",
      "    \"STUDYID\": \"RiboStudy001\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 98,\n",
      "    \"Male_Percentage\": 2,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 15,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 10,\n",
      "    \"Tumor_Stage_T2_Percentage\": 45,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 15,\n",
      "    \"Stage_II_Percentage\": 50,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 3,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 5,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": 20,\n",
      "    \"Letrozole_Percentage\": 35,\n",
      "    \"Anastrozole_Percentage\": 40,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 50,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 55,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ribociclib\",\n",
      "    \"STUDYID\": \"RiboStudy002\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 97,\n",
      "    \"Male_Percentage\": 3,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 18,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 33,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 45,\n",
      "    \"Stage_III_Percentage\": 37,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 25,\n",
      "    \"Letrozole_Percentage\": 30,\n",
      "    \"Anastrozole_Percentage\": 45,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 65,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ribociclib\",\n",
      "    \"STUDYID\": \"RiboStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 59,\n",
      "    \"Female_Percentage\": 99,\n",
      "    \"Male_Percentage\": 1,\n",
      "    \"Median_BMI\": 26.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 12,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 3,\n",
      "    \"Tumor_Stage_T1_Percentage\": 8,\n",
      "    \"Tumor_Stage_T2_Percentage\": 48,\n",
      "    \"Tumor_Stage_T3_Percentage\": 28,\n",
      "    \"Tumor_Stage_T4_Percentage\": 16,\n",
      "    \"Nodal_Stage_N0_Percentage\": 65,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 8,\n",
      "    \"Nodal_Stage_N3_Percentage\": 7,\n",
      "    \"Stage_I_Percentage\": 12,\n",
      "    \"Stage_II_Percentage\": 55,\n",
      "    \"Stage_III_Percentage\": 33,\n",
      "    \"Diabetes_Mellitus_Percentage\": 10,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 2,\n",
      "    \"Stroke_Percentage\": 1,\n",
      "    \"Atrial_Fibrillation_Percentage\": 4,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 6,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Postoperative_RT_Received_Percentage\": 25,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC-T\",\n",
      "    \"Tamoxifen_Percentage\": 15,\n",
      "    \"Letrozole_Percentage\": 40,\n",
      "    \"Anastrozole_Percentage\": 35,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20,\n",
      "    \"Antiemetic_Agent_Percentage\": 45,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 8,\n",
      "    \"Beds_200_To_499_Percentage\": 60,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 32,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 75,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ribociclib\",\n",
      "    \"STUDYID\": \"RiboStudy004\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 71,\n",
      "    \"Female_Percentage\": 96,\n",
      "    \"Male_Percentage\": 4,\n",
      "    \"Median_BMI\": 29.3,\n",
      "    \"Smoking_History_Yes_Percentage\": 20,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 9,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 13,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 35,\n",
      "    \"Nodal_Stage_N2_Percentage\": 9,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 55,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Taxane-based\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Anthracycline-based\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AI\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide\",\n",
      "    \"Tamoxifen_Percentage\": 30,\n",
      "    \"Letrozole_Percentage\": 25,\n",
      "    \"Anastrozole_Percentage\": 45,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 70,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 4\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Ribociclib', 'STUDYID': 'RiboStudy001', 'YEAR': 2022, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 98, 'Male_Percentage': 2, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 15, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 10, 'Tumor_Stage_T2_Percentage': 45, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 15, 'Stage_II_Percentage': 50, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 3, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 5, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'TC', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': 20, 'Letrozole_Percentage': 35, 'Anastrozole_Percentage': 40, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 50, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 55, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Ribociclib', 'STUDYID': 'RiboStudy002', 'YEAR': 2023, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 97, 'Male_Percentage': 3, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 18, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 33, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 45, 'Stage_III_Percentage': 37, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 50, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'AC-T', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'AC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 25, 'Letrozole_Percentage': 30, 'Anastrozole_Percentage': 45, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 65, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Ribociclib', 'STUDYID': 'RiboStudy003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 59, 'Female_Percentage': 99, 'Male_Percentage': 1, 'Median_BMI': 26.9, 'Smoking_History_Yes_Percentage': 12, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 3, 'Tumor_Stage_T1_Percentage': 8, 'Tumor_Stage_T2_Percentage': 48, 'Tumor_Stage_T3_Percentage': 28, 'Tumor_Stage_T4_Percentage': 16, 'Nodal_Stage_N0_Percentage': 65, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 8, 'Nodal_Stage_N3_Percentage': 7, 'Stage_I_Percentage': 12, 'Stage_II_Percentage': 55, 'Stage_III_Percentage': 33, 'Diabetes_Mellitus_Percentage': 10, 'Congestive_Heart_Failure_Percentage': 2, 'Stroke_Percentage': 1, 'Atrial_Fibrillation_Percentage': 4, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 6, 'Adjuvant_Chemotherapy_Received_Percentage': 40, 'Postoperative_RT_Received_Percentage': 25, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'CMF', 'Common_Adjuvant_Regimen_1': 'FEC-T', 'Common_Adjuvant_Regimen_2': 'AC-T', 'Tamoxifen_Percentage': 15, 'Letrozole_Percentage': 40, 'Anastrozole_Percentage': 35, 'Antidiarrheal_Agent_Probiotics_Percentage': 20, 'Antiemetic_Agent_Percentage': 45, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 8, 'Beds_200_To_499_Percentage': 60, 'Beds_Greater_Or_Equal_To_500_Percentage': 32, 'Designated_Cancer_Hospital_Percentage': 75, 'Months_Between_Surgery_And_Index_Date': 1}, {'Drug_Name': 'Ribociclib', 'STUDYID': 'RiboStudy004', 'YEAR': 2024, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 71, 'Female_Percentage': 96, 'Male_Percentage': 4, 'Median_BMI': 29.3, 'Smoking_History_Yes_Percentage': 20, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 9, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 13, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 35, 'Nodal_Stage_N2_Percentage': 9, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 55, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'Taxane-based', 'Common_Neoadjuvant_Regimen_2': 'Anthracycline-based', 'Common_Adjuvant_Regimen_1': 'AI', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide', 'Tamoxifen_Percentage': 30, 'Letrozole_Percentage': 25, 'Anastrozole_Percentage': 45, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 70, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 4}]\n",
      "File created: Ribociclib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Ribociclib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Sorafenib\",\n",
      "    \"STUDYID\": \"Sora2023-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 32.0,\n",
      "    \"Male_Percentage\": 68.0,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 45.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 85.0,\n",
      "    \"LHRH_Use_Percentage\": 12.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 20.0,\n",
      "    \"Stage_II_Percentage\": 35.0,\n",
      "    \"Stage_III_Percentage\": 45.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7.0,\n",
      "    \"Stroke_Percentage\": 4.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 6.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 5.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 22.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"NA\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"NA\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 40.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20.0,\n",
      "    \"Beds_200_To_499_Percentage\": 50.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Sorafenib\",\n",
      "    \"STUDYID\": \"Sora2022-002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 38.0,\n",
      "    \"Male_Percentage\": 62.0,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 52.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 78.0,\n",
      "    \"LHRH_Use_Percentage\": 15.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 18.0,\n",
      "    \"Stage_II_Percentage\": 32.0,\n",
      "    \"Stage_III_Percentage\": 50.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9.0,\n",
      "    \"Stroke_Percentage\": 5.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 7.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 7.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 25.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"NA\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"NA\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Oxaliplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 45.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 25.0,\n",
      "    \"Beds_200_To_499_Percentage\": 45.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Sorafenib\",\n",
      "    \"STUDYID\": \"Sora2024-003\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 28.0,\n",
      "    \"Male_Percentage\": 72.0,\n",
      "    \"Median_BMI\": 24.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 38.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 90.0,\n",
      "    \"LHRH_Use_Percentage\": 10.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 65.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 22.0,\n",
      "    \"Stage_II_Percentage\": 38.0,\n",
      "    \"Stage_III_Percentage\": 40.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6.0,\n",
      "    \"Stroke_Percentage\": 3.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 5.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 4.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 20.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"NA\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"NA\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"S-1\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 35.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15.0,\n",
      "    \"Beds_200_To_499_Percentage\": 55.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Sorafenib', 'STUDYID': 'Sora2023-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 32.0, 'Male_Percentage': 68.0, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 45.0, 'Total_ADL_Independence_Percentage': 85.0, 'LHRH_Use_Percentage': 12.0, 'Tumor_Stage_T1_Percentage': 15.0, 'Tumor_Stage_T2_Percentage': 30.0, 'Tumor_Stage_T3_Percentage': 40.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 60.0, 'Nodal_Stage_N1_Percentage': 25.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 20.0, 'Stage_II_Percentage': 35.0, 'Stage_III_Percentage': 45.0, 'Diabetes_Mellitus_Percentage': 18.0, 'Congestive_Heart_Failure_Percentage': 7.0, 'Stroke_Percentage': 4.0, 'Atrial_Fibrillation_Percentage': 9.0, 'Myocardial_Infarction_Percentage': 6.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 5.0, 'Adjuvant_Chemotherapy_Received_Percentage': 22.0, 'Postoperative_RT_Received_Percentage': 30.0, 'Common_Neoadjuvant_Regimen_1': 'NA', 'Common_Neoadjuvant_Regimen_2': 'NA', 'Common_Adjuvant_Regimen_1': 'Gemcitabine', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35.0, 'Antiemetic_Agent_Percentage': 40.0, 'Painkiller_Antipyretic_Percentage': 55.0, 'Beds_Less_Than_200_Percentage': 20.0, 'Beds_200_To_499_Percentage': 50.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 30.0, 'Designated_Cancer_Hospital_Percentage': 60.0, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Sorafenib', 'STUDYID': 'Sora2022-002', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 38.0, 'Male_Percentage': 62.0, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 52.0, 'Total_ADL_Independence_Percentage': 78.0, 'LHRH_Use_Percentage': 15.0, 'Tumor_Stage_T1_Percentage': 12.0, 'Tumor_Stage_T2_Percentage': 28.0, 'Tumor_Stage_T3_Percentage': 45.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 55.0, 'Nodal_Stage_N1_Percentage': 30.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 18.0, 'Stage_II_Percentage': 32.0, 'Stage_III_Percentage': 50.0, 'Diabetes_Mellitus_Percentage': 22.0, 'Congestive_Heart_Failure_Percentage': 9.0, 'Stroke_Percentage': 5.0, 'Atrial_Fibrillation_Percentage': 11.0, 'Myocardial_Infarction_Percentage': 7.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 7.0, 'Adjuvant_Chemotherapy_Received_Percentage': 25.0, 'Postoperative_RT_Received_Percentage': 35.0, 'Common_Neoadjuvant_Regimen_1': 'NA', 'Common_Neoadjuvant_Regimen_2': 'NA', 'Common_Adjuvant_Regimen_1': 'Gemcitabine', 'Common_Adjuvant_Regimen_2': 'Oxaliplatin', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 40.0, 'Antiemetic_Agent_Percentage': 45.0, 'Painkiller_Antipyretic_Percentage': 60.0, 'Beds_Less_Than_200_Percentage': 25.0, 'Beds_200_To_499_Percentage': 45.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 30.0, 'Designated_Cancer_Hospital_Percentage': 55.0, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Sorafenib', 'STUDYID': 'Sora2024-003', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 28.0, 'Male_Percentage': 72.0, 'Median_BMI': 24.5, 'Smoking_History_Yes_Percentage': 38.0, 'Total_ADL_Independence_Percentage': 90.0, 'LHRH_Use_Percentage': 10.0, 'Tumor_Stage_T1_Percentage': 18.0, 'Tumor_Stage_T2_Percentage': 32.0, 'Tumor_Stage_T3_Percentage': 35.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 65.0, 'Nodal_Stage_N1_Percentage': 20.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 22.0, 'Stage_II_Percentage': 38.0, 'Stage_III_Percentage': 40.0, 'Diabetes_Mellitus_Percentage': 15.0, 'Congestive_Heart_Failure_Percentage': 6.0, 'Stroke_Percentage': 3.0, 'Atrial_Fibrillation_Percentage': 8.0, 'Myocardial_Infarction_Percentage': 5.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 4.0, 'Adjuvant_Chemotherapy_Received_Percentage': 20.0, 'Postoperative_RT_Received_Percentage': 28.0, 'Common_Neoadjuvant_Regimen_1': 'NA', 'Common_Neoadjuvant_Regimen_2': 'NA', 'Common_Adjuvant_Regimen_1': 'S-1', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30.0, 'Antiemetic_Agent_Percentage': 35.0, 'Painkiller_Antipyretic_Percentage': 50.0, 'Beds_Less_Than_200_Percentage': 15.0, 'Beds_200_To_499_Percentage': 55.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 30.0, 'Designated_Cancer_Hospital_Percentage': 70.0, 'Months_Between_Surgery_And_Index_Date': 2}]\n",
      "File created: Sorafenib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Sorafenib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Sunitinib\",\n",
      "    \"STUDYID\": \"SUN1001\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"62\",\n",
      "    \"Female_Percentage\": \"35\",\n",
      "    \"Male_Percentage\": \"65\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"42\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"88\",\n",
      "    \"LHRH_Use_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"30\",\n",
      "    \"Stage_III_Percentage\": \"35\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"10\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"30\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Gemcitabine + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"20\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"45\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"55\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"40\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"45\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Sunitinib\",\n",
      "    \"STUDYID\": \"SUN1002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"38\",\n",
      "    \"Male_Percentage\": \"62\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"38\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"32\",\n",
      "    \"Stage_III_Percentage\": \"33\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"12\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"28\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"32\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Gemcitabine + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"22\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"48\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"58\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"38\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"50\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Sunitinib\",\n",
      "    \"STUDYID\": \"SUN1003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"40\",\n",
      "    \"Male_Percentage\": \"60\",\n",
      "    \"Median_BMI\": \"29.0\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"13\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"7\",\n",
      "    \"Stage_I_Percentage\": \"15\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"38\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"22\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"11\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"15\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"30\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"35\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Gemcitabine + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"25\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"50\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"60\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"10\",\n",
      "    \"Beds_200_To_499_Percentage\": \"35\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"55\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Sunitinib\",\n",
      "    \"STUDYID\": \"SUN1004\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"33\",\n",
      "    \"Male_Percentage\": \"67\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"45\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"90\",\n",
      "    \"LHRH_Use_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"22\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"32\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"62\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"13\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"7\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"28\",\n",
      "    \"Stage_III_Percentage\": \"32\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"16\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"2\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"4\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"8\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"28\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Gemcitabine + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"18\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"42\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"52\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"17\",\n",
      "    \"Beds_200_To_499_Percentage\": \"42\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"41\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"58\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1.8\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Sunitinib\",\n",
      "    \"STUDYID\": \"SUN1005\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"300\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"28\",\n",
      "    \"Male_Percentage\": \"72\",\n",
      "    \"Median_BMI\": \"24.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"50\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"20\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"20\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"20\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"50\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"25\",\n",
      "    \"Stage_II_Percentage\": \"25\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"25\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"10\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"12\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"35\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"40\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Gemcitabine + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"30\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"55\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"65\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"8\",\n",
      "    \"Beds_200_To_499_Percentage\": \"30\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"62\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"75\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3.5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Sunitinib', 'STUDYID': 'SUN1001', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '62', 'Female_Percentage': '35', 'Male_Percentage': '65', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '42', 'Total_ADL_Independence_Percentage': '88', 'LHRH_Use_Percentage': '12', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '25', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '30', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '20', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '30', 'Stage_III_Percentage': '35', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '10', 'Adjuvant_Chemotherapy_Received_Percentage': '25', 'Postoperative_RT_Received_Percentage': '30', 'Common_Neoadjuvant_Regimen_1': 'Gemcitabine + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '20', 'Antiemetic_Agent_Percentage': '45', 'Painkiller_Antipyretic_Percentage': '55', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '40', 'Beds_Greater_Or_Equal_To_500_Percentage': '45', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Sunitinib', 'STUDYID': 'SUN1002', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '68', 'Female_Percentage': '38', 'Male_Percentage': '62', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '38', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '32', 'Tumor_Stage_T4_Percentage': '28', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '22', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '32', 'Stage_III_Percentage': '33', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '12', 'Adjuvant_Chemotherapy_Received_Percentage': '28', 'Postoperative_RT_Received_Percentage': '32', 'Common_Neoadjuvant_Regimen_1': 'Gemcitabine + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '22', 'Antiemetic_Agent_Percentage': '48', 'Painkiller_Antipyretic_Percentage': '58', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '38', 'Beds_Greater_Or_Equal_To_500_Percentage': '50', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Sunitinib', 'STUDYID': 'SUN1003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '70', 'Female_Percentage': '40', 'Male_Percentage': '60', 'Median_BMI': '29.0', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '18', 'Tumor_Stage_T1_Percentage': '10', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '35', 'Tumor_Stage_T4_Percentage': '25', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '13', 'Nodal_Stage_N3_Percentage': '7', 'Stage_I_Percentage': '15', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '38', 'Diabetes_Mellitus_Percentage': '22', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '11', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '15', 'Adjuvant_Chemotherapy_Received_Percentage': '30', 'Postoperative_RT_Received_Percentage': '35', 'Common_Neoadjuvant_Regimen_1': 'Gemcitabine + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '25', 'Antiemetic_Agent_Percentage': '50', 'Painkiller_Antipyretic_Percentage': '60', 'Beds_Less_Than_200_Percentage': '10', 'Beds_200_To_499_Percentage': '35', 'Beds_Greater_Or_Equal_To_500_Percentage': '55', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Sunitinib', 'STUDYID': 'SUN1004', 'YEAR': '2023', 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '65', 'Female_Percentage': '33', 'Male_Percentage': '67', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '45', 'Total_ADL_Independence_Percentage': '90', 'LHRH_Use_Percentage': '10', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '22', 'Tumor_Stage_T3_Percentage': '28', 'Tumor_Stage_T4_Percentage': '32', 'Nodal_Stage_N0_Percentage': '62', 'Nodal_Stage_N1_Percentage': '18', 'Nodal_Stage_N2_Percentage': '13', 'Nodal_Stage_N3_Percentage': '7', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '28', 'Stage_III_Percentage': '32', 'Diabetes_Mellitus_Percentage': '16', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '2', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '4', 'Neoadjuvant_Chemotherapy_Received_Percentage': '8', 'Adjuvant_Chemotherapy_Received_Percentage': '22', 'Postoperative_RT_Received_Percentage': '28', 'Common_Neoadjuvant_Regimen_1': 'Gemcitabine + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '18', 'Antiemetic_Agent_Percentage': '42', 'Painkiller_Antipyretic_Percentage': '52', 'Beds_Less_Than_200_Percentage': '17', 'Beds_200_To_499_Percentage': '42', 'Beds_Greater_Or_Equal_To_500_Percentage': '41', 'Designated_Cancer_Hospital_Percentage': '58', 'Months_Between_Surgery_And_Index_Date': '1.8'}, {'Drug_Name': 'Sunitinib', 'STUDYID': 'SUN1005', 'YEAR': '2022', 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': '300', 'Median_Age': '72', 'Female_Percentage': '28', 'Male_Percentage': '72', 'Median_BMI': '24.5', 'Smoking_History_Yes_Percentage': '50', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '20', 'Tumor_Stage_T1_Percentage': '20', 'Tumor_Stage_T2_Percentage': '20', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '30', 'Nodal_Stage_N0_Percentage': '50', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '25', 'Stage_II_Percentage': '25', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '25', 'Congestive_Heart_Failure_Percentage': '10', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '12', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '20', 'Adjuvant_Chemotherapy_Received_Percentage': '35', 'Postoperative_RT_Received_Percentage': '40', 'Common_Neoadjuvant_Regimen_1': 'Gemcitabine + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '30', 'Antiemetic_Agent_Percentage': '55', 'Painkiller_Antipyretic_Percentage': '65', 'Beds_Less_Than_200_Percentage': '8', 'Beds_200_To_499_Percentage': '30', 'Beds_Greater_Or_Equal_To_500_Percentage': '62', 'Designated_Cancer_Hospital_Percentage': '75', 'Months_Between_Surgery_And_Index_Date': '3.5'}]\n",
      "File created: Sunitinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Sunitinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Tamoxifen\",\n",
      "    \"STUDYID\": \"TAMO101\",\n",
      "    \"YEAR\": 2018,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 99.5,\n",
      "    \"Male_Percentage\": 0.5,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 18.2,\n",
      "    \"Total_ADL_Independence_Percentage\": 85.1,\n",
      "    \"LHRH_Use_Percentage\": 5.3,\n",
      "    \"Tumor_Stage_T1_Percentage\": 25.6,\n",
      "    \"Tumor_Stage_T2_Percentage\": 45.2,\n",
      "    \"Tumor_Stage_T3_Percentage\": 20.1,\n",
      "    \"Tumor_Stage_T4_Percentage\": 9.1,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60.3,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25.7,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.2,\n",
      "    \"Nodal_Stage_N3_Percentage\": 3.8,\n",
      "    \"Stage_I_Percentage\": 30.5,\n",
      "    \"Stage_II_Percentage\": 40.2,\n",
      "    \"Stage_III_Percentage\": 20.3,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12.5,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4.2,\n",
      "    \"Stroke_Percentage\": 2.1,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6.3,\n",
      "    \"Myocardial_Infarction_Percentage\": 3.5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 15.4,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 55.2,\n",
      "    \"Postoperative_RT_Received_Percentage\": 65.3,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": 80.5,\n",
      "    \"Letrozole_Percentage\": 8.2,\n",
      "    \"Anastrozole_Percentage\": 6.3,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 15.2,\n",
      "    \"Antiemetic_Agent_Percentage\": 25.3,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 35.4,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15.2,\n",
      "    \"Beds_200_To_499_Percentage\": 45.3,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 39.5,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60.2,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Tamoxifen\",\n",
      "    \"STUDYID\": \"TAMO202\",\n",
      "    \"YEAR\": 2019,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 99.1,\n",
      "    \"Male_Percentage\": 0.9,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 21.5,\n",
      "    \"Total_ADL_Independence_Percentage\": 78.6,\n",
      "    \"LHRH_Use_Percentage\": 7.8,\n",
      "    \"Tumor_Stage_T1_Percentage\": 28.7,\n",
      "    \"Tumor_Stage_T2_Percentage\": 42.3,\n",
      "    \"Tumor_Stage_T3_Percentage\": 18.9,\n",
      "    \"Tumor_Stage_T4_Percentage\": 10.1,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58.2,\n",
      "    \"Nodal_Stage_N1_Percentage\": 27.1,\n",
      "    \"Nodal_Stage_N2_Percentage\": 11.5,\n",
      "    \"Nodal_Stage_N3_Percentage\": 3.2,\n",
      "    \"Stage_I_Percentage\": 32.1,\n",
      "    \"Stage_II_Percentage\": 38.5,\n",
      "    \"Stage_III_Percentage\": 19.7,\n",
      "    \"Diabetes_Mellitus_Percentage\": 14.8,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5.9,\n",
      "    \"Stroke_Percentage\": 2.8,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7.5,\n",
      "    \"Myocardial_Infarction_Percentage\": 4.1,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 13.2,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 52.9,\n",
      "    \"Postoperative_RT_Received_Percentage\": 62.4,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 75.3,\n",
      "    \"Letrozole_Percentage\": 10.5,\n",
      "    \"Anastrozole_Percentage\": 7.9,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 17.8,\n",
      "    \"Antiemetic_Agent_Percentage\": 28.1,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 38.5,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12.5,\n",
      "    \"Beds_200_To_499_Percentage\": 42.8,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 44.7,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65.4,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.0\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Tamoxifen\",\n",
      "    \"STUDYID\": \"TAMO303\",\n",
      "    \"YEAR\": 2020,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 98.9,\n",
      "    \"Male_Percentage\": 1.1,\n",
      "    \"Median_BMI\": 29.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 25.3,\n",
      "    \"Total_ADL_Independence_Percentage\": 75.2,\n",
      "    \"LHRH_Use_Percentage\": 9.5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 30.5,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40.1,\n",
      "    \"Tumor_Stage_T3_Percentage\": 17.2,\n",
      "    \"Tumor_Stage_T4_Percentage\": 12.2,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55.1,\n",
      "    \"Nodal_Stage_N1_Percentage\": 29.5,\n",
      "    \"Nodal_Stage_N2_Percentage\": 12.8,\n",
      "    \"Nodal_Stage_N3_Percentage\": 2.6,\n",
      "    \"Stage_I_Percentage\": 33.7,\n",
      "    \"Stage_II_Percentage\": 36.8,\n",
      "    \"Stage_III_Percentage\": 18.5,\n",
      "    \"Diabetes_Mellitus_Percentage\": 16.2,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7.1,\n",
      "    \"Stroke_Percentage\": 3.5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8.7,\n",
      "    \"Myocardial_Infarction_Percentage\": 4.8,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 11.5,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50.6,\n",
      "    \"Postoperative_RT_Received_Percentage\": 60.1,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide\",\n",
      "    \"Tamoxifen_Percentage\": 70.2,\n",
      "    \"Letrozole_Percentage\": 12.8,\n",
      "    \"Anastrozole_Percentage\": 9.5,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20.1,\n",
      "    \"Antiemetic_Agent_Percentage\": 30.5,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 40.2,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10.3,\n",
      "    \"Beds_200_To_499_Percentage\": 40.5,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 49.2,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70.5,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Tamoxifen\",\n",
      "    \"STUDYID\": \"TAMO404\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 99.3,\n",
      "    \"Male_Percentage\": 0.7,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 15.8,\n",
      "    \"Total_ADL_Independence_Percentage\": 88.4,\n",
      "    \"LHRH_Use_Percentage\": 6.2,\n",
      "    \"Tumor_Stage_T1_Percentage\": 23.4,\n",
      "    \"Tumor_Stage_T2_Percentage\": 47.5,\n",
      "    \"Tumor_Stage_T3_Percentage\": 19.3,\n",
      "    \"Tumor_Stage_T4_Percentage\": 9.8,\n",
      "    \"Nodal_Stage_N0_Percentage\": 62.5,\n",
      "    \"Nodal_Stage_N1_Percentage\": 24.3,\n",
      "    \"Nodal_Stage_N2_Percentage\": 9.6,\n",
      "    \"Nodal_Stage_N3_Percentage\": 3.6,\n",
      "    \"Stage_I_Percentage\": 31.2,\n",
      "    \"Stage_II_Percentage\": 41.8,\n",
      "    \"Stage_III_Percentage\": 19.1,\n",
      "    \"Diabetes_Mellitus_Percentage\": 11.2,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 3.8,\n",
      "    \"Stroke_Percentage\": 1.9,\n",
      "    \"Atrial_Fibrillation_Percentage\": 5.9,\n",
      "    \"Myocardial_Infarction_Percentage\": 3.2,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 16.5,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 56.8,\n",
      "    \"Postoperative_RT_Received_Percentage\": 66.5,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Tamoxifen_Percentage\": 82.7,\n",
      "    \"Letrozole_Percentage\": 7.1,\n",
      "    \"Anastrozole_Percentage\": 5.2,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 14.5,\n",
      "    \"Antiemetic_Agent_Percentage\": 24.6,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 34.7,\n",
      "    \"Beds_Less_Than_200_Percentage\": 16.8,\n",
      "    \"Beds_200_To_499_Percentage\": 46.5,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 36.7,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 58.9,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.8\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Tamoxifen\",\n",
      "    \"STUDYID\": \"TAMO505\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 310,\n",
      "    \"Median_Age\": 67,\n",
      "    \"Female_Percentage\": 99.0,\n",
      "    \"Male_Percentage\": 1.0,\n",
      "    \"Median_BMI\": 28.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 20.1,\n",
      "    \"Total_ADL_Independence_Percentage\": 80.3,\n",
      "    \"LHRH_Use_Percentage\": 8.4,\n",
      "    \"Tumor_Stage_T1_Percentage\": 27.6,\n",
      "    \"Tumor_Stage_T2_Percentage\": 43.9,\n",
      "    \"Tumor_Stage_T3_Percentage\": 18.1,\n",
      "    \"Tumor_Stage_T4_Percentage\": 10.4,\n",
      "    \"Nodal_Stage_N0_Percentage\": 59.8,\n",
      "    \"Nodal_Stage_N1_Percentage\": 26.4,\n",
      "    \"Nodal_Stage_N2_Percentage\": 11.9,\n",
      "    \"Nodal_Stage_N3_Percentage\": 1.9,\n",
      "    \"Stage_I_Percentage\": 32.8,\n",
      "    \"Stage_II_Percentage\": 39.2,\n",
      "    \"Stage_III_Percentage\": 18.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 13.5,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5.1,\n",
      "    \"Stroke_Percentage\": 2.5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6.8,\n",
      "    \"Myocardial_Infarction_Percentage\": 3.9,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 14.3,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 54.5,\n",
      "    \"Postoperative_RT_Received_Percentage\": 64.2,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": 77.9,\n",
      "    \"Letrozole_Percentage\": 9.4,\n",
      "    \"Anastrozole_Percentage\": 6.7,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 16.3,\n",
      "    \"Antiemetic_Agent_Percentage\": 26.4,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 36.5,\n",
      "    \"Beds_Less_Than_200_Percentage\": 13.9,\n",
      "    \"Beds_200_To_499_Percentage\": 44.1,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 42.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 63.1,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.2\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Tamoxifen', 'STUDYID': 'TAMO101', 'YEAR': 2018, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 99.5, 'Male_Percentage': 0.5, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 18.2, 'Total_ADL_Independence_Percentage': 85.1, 'LHRH_Use_Percentage': 5.3, 'Tumor_Stage_T1_Percentage': 25.6, 'Tumor_Stage_T2_Percentage': 45.2, 'Tumor_Stage_T3_Percentage': 20.1, 'Tumor_Stage_T4_Percentage': 9.1, 'Nodal_Stage_N0_Percentage': 60.3, 'Nodal_Stage_N1_Percentage': 25.7, 'Nodal_Stage_N2_Percentage': 10.2, 'Nodal_Stage_N3_Percentage': 3.8, 'Stage_I_Percentage': 30.5, 'Stage_II_Percentage': 40.2, 'Stage_III_Percentage': 20.3, 'Diabetes_Mellitus_Percentage': 12.5, 'Congestive_Heart_Failure_Percentage': 4.2, 'Stroke_Percentage': 2.1, 'Atrial_Fibrillation_Percentage': 6.3, 'Myocardial_Infarction_Percentage': 3.5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 15.4, 'Adjuvant_Chemotherapy_Received_Percentage': 55.2, 'Postoperative_RT_Received_Percentage': 65.3, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'TC', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': 80.5, 'Letrozole_Percentage': 8.2, 'Anastrozole_Percentage': 6.3, 'Antidiarrheal_Agent_Probiotics_Percentage': 15.2, 'Antiemetic_Agent_Percentage': 25.3, 'Painkiller_Antipyretic_Percentage': 35.4, 'Beds_Less_Than_200_Percentage': 15.2, 'Beds_200_To_499_Percentage': 45.3, 'Beds_Greater_Or_Equal_To_500_Percentage': 39.5, 'Designated_Cancer_Hospital_Percentage': 60.2, 'Months_Between_Surgery_And_Index_Date': 1.5}, {'Drug_Name': 'Tamoxifen', 'STUDYID': 'TAMO202', 'YEAR': 2019, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 99.1, 'Male_Percentage': 0.9, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 21.5, 'Total_ADL_Independence_Percentage': 78.6, 'LHRH_Use_Percentage': 7.8, 'Tumor_Stage_T1_Percentage': 28.7, 'Tumor_Stage_T2_Percentage': 42.3, 'Tumor_Stage_T3_Percentage': 18.9, 'Tumor_Stage_T4_Percentage': 10.1, 'Nodal_Stage_N0_Percentage': 58.2, 'Nodal_Stage_N1_Percentage': 27.1, 'Nodal_Stage_N2_Percentage': 11.5, 'Nodal_Stage_N3_Percentage': 3.2, 'Stage_I_Percentage': 32.1, 'Stage_II_Percentage': 38.5, 'Stage_III_Percentage': 19.7, 'Diabetes_Mellitus_Percentage': 14.8, 'Congestive_Heart_Failure_Percentage': 5.9, 'Stroke_Percentage': 2.8, 'Atrial_Fibrillation_Percentage': 7.5, 'Myocardial_Infarction_Percentage': 4.1, 'Neoadjuvant_Chemotherapy_Received_Percentage': 13.2, 'Adjuvant_Chemotherapy_Received_Percentage': 52.9, 'Postoperative_RT_Received_Percentage': 62.4, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 75.3, 'Letrozole_Percentage': 10.5, 'Anastrozole_Percentage': 7.9, 'Antidiarrheal_Agent_Probiotics_Percentage': 17.8, 'Antiemetic_Agent_Percentage': 28.1, 'Painkiller_Antipyretic_Percentage': 38.5, 'Beds_Less_Than_200_Percentage': 12.5, 'Beds_200_To_499_Percentage': 42.8, 'Beds_Greater_Or_Equal_To_500_Percentage': 44.7, 'Designated_Cancer_Hospital_Percentage': 65.4, 'Months_Between_Surgery_And_Index_Date': 2.0}, {'Drug_Name': 'Tamoxifen', 'STUDYID': 'TAMO303', 'YEAR': 2020, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 98.9, 'Male_Percentage': 1.1, 'Median_BMI': 29.5, 'Smoking_History_Yes_Percentage': 25.3, 'Total_ADL_Independence_Percentage': 75.2, 'LHRH_Use_Percentage': 9.5, 'Tumor_Stage_T1_Percentage': 30.5, 'Tumor_Stage_T2_Percentage': 40.1, 'Tumor_Stage_T3_Percentage': 17.2, 'Tumor_Stage_T4_Percentage': 12.2, 'Nodal_Stage_N0_Percentage': 55.1, 'Nodal_Stage_N1_Percentage': 29.5, 'Nodal_Stage_N2_Percentage': 12.8, 'Nodal_Stage_N3_Percentage': 2.6, 'Stage_I_Percentage': 33.7, 'Stage_II_Percentage': 36.8, 'Stage_III_Percentage': 18.5, 'Diabetes_Mellitus_Percentage': 16.2, 'Congestive_Heart_Failure_Percentage': 7.1, 'Stroke_Percentage': 3.5, 'Atrial_Fibrillation_Percentage': 8.7, 'Myocardial_Infarction_Percentage': 4.8, 'Neoadjuvant_Chemotherapy_Received_Percentage': 11.5, 'Adjuvant_Chemotherapy_Received_Percentage': 50.6, 'Postoperative_RT_Received_Percentage': 60.1, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide', 'Tamoxifen_Percentage': 70.2, 'Letrozole_Percentage': 12.8, 'Anastrozole_Percentage': 9.5, 'Antidiarrheal_Agent_Probiotics_Percentage': 20.1, 'Antiemetic_Agent_Percentage': 30.5, 'Painkiller_Antipyretic_Percentage': 40.2, 'Beds_Less_Than_200_Percentage': 10.3, 'Beds_200_To_499_Percentage': 40.5, 'Beds_Greater_Or_Equal_To_500_Percentage': 49.2, 'Designated_Cancer_Hospital_Percentage': 70.5, 'Months_Between_Surgery_And_Index_Date': 2.5}, {'Drug_Name': 'Tamoxifen', 'STUDYID': 'TAMO404', 'YEAR': 2021, 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 65, 'Female_Percentage': 99.3, 'Male_Percentage': 0.7, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 15.8, 'Total_ADL_Independence_Percentage': 88.4, 'LHRH_Use_Percentage': 6.2, 'Tumor_Stage_T1_Percentage': 23.4, 'Tumor_Stage_T2_Percentage': 47.5, 'Tumor_Stage_T3_Percentage': 19.3, 'Tumor_Stage_T4_Percentage': 9.8, 'Nodal_Stage_N0_Percentage': 62.5, 'Nodal_Stage_N1_Percentage': 24.3, 'Nodal_Stage_N2_Percentage': 9.6, 'Nodal_Stage_N3_Percentage': 3.6, 'Stage_I_Percentage': 31.2, 'Stage_II_Percentage': 41.8, 'Stage_III_Percentage': 19.1, 'Diabetes_Mellitus_Percentage': 11.2, 'Congestive_Heart_Failure_Percentage': 3.8, 'Stroke_Percentage': 1.9, 'Atrial_Fibrillation_Percentage': 5.9, 'Myocardial_Infarction_Percentage': 3.2, 'Neoadjuvant_Chemotherapy_Received_Percentage': 16.5, 'Adjuvant_Chemotherapy_Received_Percentage': 56.8, 'Postoperative_RT_Received_Percentage': 66.5, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'FEC', 'Tamoxifen_Percentage': 82.7, 'Letrozole_Percentage': 7.1, 'Anastrozole_Percentage': 5.2, 'Antidiarrheal_Agent_Probiotics_Percentage': 14.5, 'Antiemetic_Agent_Percentage': 24.6, 'Painkiller_Antipyretic_Percentage': 34.7, 'Beds_Less_Than_200_Percentage': 16.8, 'Beds_200_To_499_Percentage': 46.5, 'Beds_Greater_Or_Equal_To_500_Percentage': 36.7, 'Designated_Cancer_Hospital_Percentage': 58.9, 'Months_Between_Surgery_And_Index_Date': 1.8}, {'Drug_Name': 'Tamoxifen', 'STUDYID': 'TAMO505', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'MDV', 'Patient_Count': 310, 'Median_Age': 67, 'Female_Percentage': 99.0, 'Male_Percentage': 1.0, 'Median_BMI': 28.8, 'Smoking_History_Yes_Percentage': 20.1, 'Total_ADL_Independence_Percentage': 80.3, 'LHRH_Use_Percentage': 8.4, 'Tumor_Stage_T1_Percentage': 27.6, 'Tumor_Stage_T2_Percentage': 43.9, 'Tumor_Stage_T3_Percentage': 18.1, 'Tumor_Stage_T4_Percentage': 10.4, 'Nodal_Stage_N0_Percentage': 59.8, 'Nodal_Stage_N1_Percentage': 26.4, 'Nodal_Stage_N2_Percentage': 11.9, 'Nodal_Stage_N3_Percentage': 1.9, 'Stage_I_Percentage': 32.8, 'Stage_II_Percentage': 39.2, 'Stage_III_Percentage': 18.0, 'Diabetes_Mellitus_Percentage': 13.5, 'Congestive_Heart_Failure_Percentage': 5.1, 'Stroke_Percentage': 2.5, 'Atrial_Fibrillation_Percentage': 6.8, 'Myocardial_Infarction_Percentage': 3.9, 'Neoadjuvant_Chemotherapy_Received_Percentage': 14.3, 'Adjuvant_Chemotherapy_Received_Percentage': 54.5, 'Postoperative_RT_Received_Percentage': 64.2, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'AC', 'Common_Adjuvant_Regimen_1': 'FEC', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': 77.9, 'Letrozole_Percentage': 9.4, 'Anastrozole_Percentage': 6.7, 'Antidiarrheal_Agent_Probiotics_Percentage': 16.3, 'Antiemetic_Agent_Percentage': 26.4, 'Painkiller_Antipyretic_Percentage': 36.5, 'Beds_Less_Than_200_Percentage': 13.9, 'Beds_200_To_499_Percentage': 44.1, 'Beds_Greater_Or_Equal_To_500_Percentage': 42.0, 'Designated_Cancer_Hospital_Percentage': 63.1, 'Months_Between_Surgery_And_Index_Date': 2.2}]\n",
      "File created: Tamoxifen_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Tamoxifen\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Temozolomide\",\n",
      "    \"STUDYID\": \"TMZ2020USA\",\n",
      "    \"YEAR\": 2020,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 26.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 75,\n",
      "    \"Postoperative_RT_Received_Percentage\": 60,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"N/A\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"N/A\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Temozolomide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Temozolomide + Procarbazine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 80,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 65,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Temozolomide\",\n",
      "    \"STUDYID\": \"TMZ2021EUR\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 27.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58,\n",
      "    \"Nodal_Stage_N1_Percentage\": 27,\n",
      "    \"Nodal_Stage_N2_Percentage\": 9,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 33,\n",
      "    \"Stage_III_Percentage\": 49,\n",
      "    \"Diabetes_Mellitus_Percentage\": 14,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 72,\n",
      "    \"Postoperative_RT_Received_Percentage\": 58,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"N/A\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"N/A\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Temozolomide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Temozolomide + Bevacizumab\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28,\n",
      "    \"Antiemetic_Agent_Percentage\": 78,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 68,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Temozolomide\",\n",
      "    \"STUDYID\": \"TMZ2022ASIA\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 42,\n",
      "    \"Male_Percentage\": 58,\n",
      "    \"Median_BMI\": 25.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 88,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 38,\n",
      "    \"Tumor_Stage_T4_Percentage\": 12,\n",
      "    \"Nodal_Stage_N0_Percentage\": 62,\n",
      "    \"Nodal_Stage_N1_Percentage\": 23,\n",
      "    \"Nodal_Stage_N2_Percentage\": 11,\n",
      "    \"Nodal_Stage_N3_Percentage\": 4,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 37,\n",
      "    \"Stage_III_Percentage\": 41,\n",
      "    \"Diabetes_Mellitus_Percentage\": 10,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 78,\n",
      "    \"Postoperative_RT_Received_Percentage\": 62,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"N/A\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"N/A\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Temozolomide\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Temozolomide + Nimustine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 22,\n",
      "    \"Antiemetic_Agent_Percentage\": 82,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 62,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 58,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Temozolomide', 'STUDYID': 'TMZ2020USA', 'YEAR': 2020, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 26.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 0, 'Adjuvant_Chemotherapy_Received_Percentage': 75, 'Postoperative_RT_Received_Percentage': 60, 'Common_Neoadjuvant_Regimen_1': 'N/A', 'Common_Neoadjuvant_Regimen_2': 'N/A', 'Common_Adjuvant_Regimen_1': 'Temozolomide', 'Common_Adjuvant_Regimen_2': 'Temozolomide + Procarbazine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 80, 'Painkiller_Antipyretic_Percentage': 65, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 1}, {'Drug_Name': 'Temozolomide', 'STUDYID': 'TMZ2021EUR', 'YEAR': 2021, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 65, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 27.1, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 58, 'Nodal_Stage_N1_Percentage': 27, 'Nodal_Stage_N2_Percentage': 9, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 33, 'Stage_III_Percentage': 49, 'Diabetes_Mellitus_Percentage': 14, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 0, 'Adjuvant_Chemotherapy_Received_Percentage': 72, 'Postoperative_RT_Received_Percentage': 58, 'Common_Neoadjuvant_Regimen_1': 'N/A', 'Common_Neoadjuvant_Regimen_2': 'N/A', 'Common_Adjuvant_Regimen_1': 'Temozolomide', 'Common_Adjuvant_Regimen_2': 'Temozolomide + Bevacizumab', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 28, 'Antiemetic_Agent_Percentage': 78, 'Painkiller_Antipyretic_Percentage': 68, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 1}, {'Drug_Name': 'Temozolomide', 'STUDYID': 'TMZ2022ASIA', 'YEAR': 2022, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 68, 'Female_Percentage': 42, 'Male_Percentage': 58, 'Median_BMI': 25.8, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 88, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 38, 'Tumor_Stage_T4_Percentage': 12, 'Nodal_Stage_N0_Percentage': 62, 'Nodal_Stage_N1_Percentage': 23, 'Nodal_Stage_N2_Percentage': 11, 'Nodal_Stage_N3_Percentage': 4, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 37, 'Stage_III_Percentage': 41, 'Diabetes_Mellitus_Percentage': 10, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 6, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 0, 'Adjuvant_Chemotherapy_Received_Percentage': 78, 'Postoperative_RT_Received_Percentage': 62, 'Common_Neoadjuvant_Regimen_1': 'N/A', 'Common_Neoadjuvant_Regimen_2': 'N/A', 'Common_Adjuvant_Regimen_1': 'Temozolomide', 'Common_Adjuvant_Regimen_2': 'Temozolomide + Nimustine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 22, 'Antiemetic_Agent_Percentage': 82, 'Painkiller_Antipyretic_Percentage': 62, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 58, 'Months_Between_Surgery_And_Index_Date': 1}]\n",
      "File created: Temozolomide_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Temozolomide\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Thalidomide\",\n",
      "    \"STUDYID\": \"ThalStudy001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 42,\n",
      "    \"Male_Percentage\": 58,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Postoperative_RT_Received_Percentage\": 55,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel + Cisplatin + 5-FU\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Capecitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide + Doxorubicin\",\n",
      "    \"Tamoxifen_Percentage\": 15,\n",
      "    \"Letrozole_Percentage\": 10,\n",
      "    \"Anastrozole_Percentage\": 8,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 22,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 70,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Thalidomide\",\n",
      "    \"STUDYID\": \"ThalStudy002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 38,\n",
      "    \"Male_Percentage\": 62,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 48,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 14,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 44,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 6,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 8,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 42,\n",
      "    \"Postoperative_RT_Received_Percentage\": 52,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel + Cisplatin + 5-FU\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Capecitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide + Doxorubicin\",\n",
      "    \"Tamoxifen_Percentage\": 12,\n",
      "    \"Letrozole_Percentage\": 13,\n",
      "    \"Anastrozole_Percentage\": 5,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 62,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 68,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 58,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Thalidomide\",\n",
      "    \"STUDYID\": \"ThalStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 46,\n",
      "    \"Diabetes_Mellitus_Percentage\": 16,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 38,\n",
      "    \"Postoperative_RT_Received_Percentage\": 58,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel + Cisplatin + 5-FU\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Capecitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide + Doxorubicin\",\n",
      "    \"Tamoxifen_Percentage\": 18,\n",
      "    \"Letrozole_Percentage\": 7,\n",
      "    \"Anastrozole_Percentage\": 10,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20,\n",
      "    \"Antiemetic_Agent_Percentage\": 68,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 72,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Thalidomide', 'STUDYID': 'ThalStudy001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 42, 'Male_Percentage': 58, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 40, 'Postoperative_RT_Received_Percentage': 55, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel + Cisplatin + 5-FU', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': 'Capecitabine', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide + Doxorubicin', 'Tamoxifen_Percentage': 15, 'Letrozole_Percentage': 10, 'Anastrozole_Percentage': 8, 'Antidiarrheal_Agent_Probiotics_Percentage': 22, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 70, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Thalidomide', 'STUDYID': 'ThalStudy002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 38, 'Male_Percentage': 62, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 48, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 14, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 44, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 6, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 8, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 42, 'Postoperative_RT_Received_Percentage': 52, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel + Cisplatin + 5-FU', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': 'Capecitabine', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide + Doxorubicin', 'Tamoxifen_Percentage': 12, 'Letrozole_Percentage': 13, 'Anastrozole_Percentage': 5, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 62, 'Painkiller_Antipyretic_Percentage': 68, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 58, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Thalidomide', 'STUDYID': 'ThalStudy003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 46, 'Diabetes_Mellitus_Percentage': 16, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 28, 'Adjuvant_Chemotherapy_Received_Percentage': 38, 'Postoperative_RT_Received_Percentage': 58, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel + Cisplatin + 5-FU', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': 'Capecitabine', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide + Doxorubicin', 'Tamoxifen_Percentage': 18, 'Letrozole_Percentage': 7, 'Anastrozole_Percentage': 10, 'Antidiarrheal_Agent_Probiotics_Percentage': 20, 'Antiemetic_Agent_Percentage': 68, 'Painkiller_Antipyretic_Percentage': 72, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 2}]\n",
      "File created: Thalidomide_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Thalidomide\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Venetoclax\",\n",
      "    \"STUDYID\": \"VtxStudy001\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 68,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 23,\n",
      "    \"Nodal_Stage_N0_Percentage\": 48,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 17,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 15,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 47,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 15,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 42,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DA-EPOCH-R\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 2,\n",
      "    \"Letrozole_Percentage\": 1,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 40,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 45,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Venetoclax\",\n",
      "    \"STUDYID\": \"VtxStudy002\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 75,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 72,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 10,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 22,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 12,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 48,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 14,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 38,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Hyper-CVAD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 3,\n",
      "    \"Letrozole_Percentage\": 2,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28,\n",
      "    \"Antiemetic_Agent_Percentage\": 58,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 42,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 46,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Venetoclax\",\n",
      "    \"STUDYID\": \"VtxStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 65,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 33,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 24,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 11,\n",
      "    \"Stage_I_Percentage\": 14,\n",
      "    \"Stage_II_Percentage\": 36,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 17,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 14,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Postoperative_RT_Received_Percentage\": 33,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DA-EPOCH-R\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 2,\n",
      "    \"Letrozole_Percentage\": 1,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 26,\n",
      "    \"Antiemetic_Agent_Percentage\": 56,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 41,\n",
      "    \"Beds_Less_Than_200_Percentage\": 8,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 44,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 58,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Venetoclax\",\n",
      "    \"STUDYID\": \"VtxStudy004\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 73,\n",
      "    \"Female_Percentage\": 47,\n",
      "    \"Male_Percentage\": 53,\n",
      "    \"Median_BMI\": 27.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 30,\n",
      "    \"Total_ADL_Independence_Percentage\": 70,\n",
      "    \"LHRH_Use_Percentage\": 8,\n",
      "    \"Tumor_Stage_T1_Percentage\": 11,\n",
      "    \"Tumor_Stage_T2_Percentage\": 37,\n",
      "    \"Tumor_Stage_T3_Percentage\": 31,\n",
      "    \"Tumor_Stage_T4_Percentage\": 21,\n",
      "    \"Nodal_Stage_N0_Percentage\": 51,\n",
      "    \"Nodal_Stage_N1_Percentage\": 23,\n",
      "    \"Nodal_Stage_N2_Percentage\": 17,\n",
      "    \"Nodal_Stage_N3_Percentage\": 9,\n",
      "    \"Stage_I_Percentage\": 13,\n",
      "    \"Stage_II_Percentage\": 39,\n",
      "    \"Stage_III_Percentage\": 48,\n",
      "    \"Diabetes_Mellitus_Percentage\": 19,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 11,\n",
      "    \"Stroke_Percentage\": 6,\n",
      "    \"Atrial_Fibrillation_Percentage\": 13,\n",
      "    \"Myocardial_Infarction_Percentage\": 8,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 13,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 44,\n",
      "    \"Postoperative_RT_Received_Percentage\": 37,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Hyper-CVAD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 3,\n",
      "    \"Letrozole_Percentage\": 2,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 27,\n",
      "    \"Antiemetic_Agent_Percentage\": 57,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 43,\n",
      "    \"Beds_Less_Than_200_Percentage\": 11,\n",
      "    \"Beds_200_To_499_Percentage\": 43,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 46,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 63,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Venetoclax', 'STUDYID': 'VtxStudy001', 'YEAR': 2022, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 72, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 68, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 23, 'Nodal_Stage_N0_Percentage': 48, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 17, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 15, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 47, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 15, 'Adjuvant_Chemotherapy_Received_Percentage': 42, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'DA-EPOCH-R', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 2, 'Letrozole_Percentage': 1, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 40, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 45, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Venetoclax', 'STUDYID': 'VtxStudy002', 'YEAR': 2023, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 75, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 72, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 10, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 22, 'Nodal_Stage_N2_Percentage': 16, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 12, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 48, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 14, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 38, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'Hyper-CVAD', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 3, 'Letrozole_Percentage': 2, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 28, 'Antiemetic_Agent_Percentage': 58, 'Painkiller_Antipyretic_Percentage': 42, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 46, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Venetoclax', 'STUDYID': 'VtxStudy003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 65, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 33, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 24, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 11, 'Stage_I_Percentage': 14, 'Stage_II_Percentage': 36, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 17, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 14, 'Adjuvant_Chemotherapy_Received_Percentage': 40, 'Postoperative_RT_Received_Percentage': 33, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'DA-EPOCH-R', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 2, 'Letrozole_Percentage': 1, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 26, 'Antiemetic_Agent_Percentage': 56, 'Painkiller_Antipyretic_Percentage': 41, 'Beds_Less_Than_200_Percentage': 8, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 44, 'Designated_Cancer_Hospital_Percentage': 58, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Venetoclax', 'STUDYID': 'VtxStudy004', 'YEAR': 2024, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 73, 'Female_Percentage': 47, 'Male_Percentage': 53, 'Median_BMI': 27.9, 'Smoking_History_Yes_Percentage': 30, 'Total_ADL_Independence_Percentage': 70, 'LHRH_Use_Percentage': 8, 'Tumor_Stage_T1_Percentage': 11, 'Tumor_Stage_T2_Percentage': 37, 'Tumor_Stage_T3_Percentage': 31, 'Tumor_Stage_T4_Percentage': 21, 'Nodal_Stage_N0_Percentage': 51, 'Nodal_Stage_N1_Percentage': 23, 'Nodal_Stage_N2_Percentage': 17, 'Nodal_Stage_N3_Percentage': 9, 'Stage_I_Percentage': 13, 'Stage_II_Percentage': 39, 'Stage_III_Percentage': 48, 'Diabetes_Mellitus_Percentage': 19, 'Congestive_Heart_Failure_Percentage': 11, 'Stroke_Percentage': 6, 'Atrial_Fibrillation_Percentage': 13, 'Myocardial_Infarction_Percentage': 8, 'Neoadjuvant_Chemotherapy_Received_Percentage': 13, 'Adjuvant_Chemotherapy_Received_Percentage': 44, 'Postoperative_RT_Received_Percentage': 37, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'Hyper-CVAD', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 3, 'Letrozole_Percentage': 2, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 27, 'Antiemetic_Agent_Percentage': 57, 'Painkiller_Antipyretic_Percentage': 43, 'Beds_Less_Than_200_Percentage': 11, 'Beds_200_To_499_Percentage': 43, 'Beds_Greater_Or_Equal_To_500_Percentage': 46, 'Designated_Cancer_Hospital_Percentage': 63, 'Months_Between_Surgery_And_Index_Date': 3}]\n",
      "File created: Venetoclax_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Venetoclax\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Vismodegib\",\n",
      "    \"STUDYID\": \"VISMO001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 35.0,\n",
      "    \"Male_Percentage\": 65.0,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 42.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 85.0,\n",
      "    \"LHRH_Use_Percentage\": 0.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 20.0,\n",
      "    \"Stage_II_Percentage\": 35.0,\n",
      "    \"Stage_III_Percentage\": 45.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8.0,\n",
      "    \"Stroke_Percentage\": 5.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 7.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 5.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 10.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 25.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + 5-FU\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 40.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20.0,\n",
      "    \"Beds_200_To_499_Percentage\": 50.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 40.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Vismodegib\",\n",
      "    \"STUDYID\": \"VISMO002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 75,\n",
      "    \"Female_Percentage\": 40.0,\n",
      "    \"Male_Percentage\": 60.0,\n",
      "    \"Median_BMI\": 28.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 38.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 80.0,\n",
      "    \"LHRH_Use_Percentage\": 0.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 18.0,\n",
      "    \"Stage_II_Percentage\": 32.0,\n",
      "    \"Stage_III_Percentage\": 50.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10.0,\n",
      "    \"Stroke_Percentage\": 6.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 14.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 8.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 7.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 12.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin + Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 45.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15.0,\n",
      "    \"Beds_200_To_499_Percentage\": 55.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 45.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Vismodegib\",\n",
      "    \"STUDYID\": \"VISMO003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 30.0,\n",
      "    \"Male_Percentage\": 70.0,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 45.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 90.0,\n",
      "    \"LHRH_Use_Percentage\": 0.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 65.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 22.0,\n",
      "    \"Stage_II_Percentage\": 38.0,\n",
      "    \"Stage_III_Percentage\": 40.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7.0,\n",
      "    \"Stroke_Percentage\": 4.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 6.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 3.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 8.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 22.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Capecitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 35.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 25.0,\n",
      "    \"Beds_200_To_499_Percentage\": 45.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 35.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Vismodegib\",\n",
      "    \"STUDYID\": \"VISMO004\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 73,\n",
      "    \"Female_Percentage\": 38.0,\n",
      "    \"Male_Percentage\": 62.0,\n",
      "    \"Median_BMI\": 29.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 40.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 82.0,\n",
      "    \"LHRH_Use_Percentage\": 0.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 29.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 27.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 19.0,\n",
      "    \"Stage_II_Percentage\": 34.0,\n",
      "    \"Stage_III_Percentage\": 47.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 19.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9.0,\n",
      "    \"Stroke_Percentage\": 5.5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 13.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 7.5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 6.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 11.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 26.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Paclitaxel\",\n",
      "    \"Tamoxifen_Percentage\": 0.0,\n",
      "    \"Letrozole_Percentage\": 0.0,\n",
      "    \"Anastrozole_Percentage\": 0.0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 32.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 42.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 52.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18.0,\n",
      "    \"Beds_200_To_499_Percentage\": 52.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 42.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Vismodegib', 'STUDYID': 'VISMO001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 72, 'Female_Percentage': 35.0, 'Male_Percentage': 65.0, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 42.0, 'Total_ADL_Independence_Percentage': 85.0, 'LHRH_Use_Percentage': 0.0, 'Tumor_Stage_T1_Percentage': 15.0, 'Tumor_Stage_T2_Percentage': 30.0, 'Tumor_Stage_T3_Percentage': 40.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 60.0, 'Nodal_Stage_N1_Percentage': 25.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 20.0, 'Stage_II_Percentage': 35.0, 'Stage_III_Percentage': 45.0, 'Diabetes_Mellitus_Percentage': 18.0, 'Congestive_Heart_Failure_Percentage': 8.0, 'Stroke_Percentage': 5.0, 'Atrial_Fibrillation_Percentage': 12.0, 'Myocardial_Infarction_Percentage': 7.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 5.0, 'Adjuvant_Chemotherapy_Received_Percentage': 10.0, 'Postoperative_RT_Received_Percentage': 25.0, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + 5-FU', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': '5-FU', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30.0, 'Antiemetic_Agent_Percentage': 40.0, 'Painkiller_Antipyretic_Percentage': 50.0, 'Beds_Less_Than_200_Percentage': 20.0, 'Beds_200_To_499_Percentage': 50.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 30.0, 'Designated_Cancer_Hospital_Percentage': 40.0, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Vismodegib', 'STUDYID': 'VISMO002', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 75, 'Female_Percentage': 40.0, 'Male_Percentage': 60.0, 'Median_BMI': 28.0, 'Smoking_History_Yes_Percentage': 38.0, 'Total_ADL_Independence_Percentage': 80.0, 'LHRH_Use_Percentage': 0.0, 'Tumor_Stage_T1_Percentage': 12.0, 'Tumor_Stage_T2_Percentage': 28.0, 'Tumor_Stage_T3_Percentage': 45.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 55.0, 'Nodal_Stage_N1_Percentage': 30.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 18.0, 'Stage_II_Percentage': 32.0, 'Stage_III_Percentage': 50.0, 'Diabetes_Mellitus_Percentage': 20.0, 'Congestive_Heart_Failure_Percentage': 10.0, 'Stroke_Percentage': 6.0, 'Atrial_Fibrillation_Percentage': 14.0, 'Myocardial_Infarction_Percentage': 8.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 7.0, 'Adjuvant_Chemotherapy_Received_Percentage': 12.0, 'Postoperative_RT_Received_Percentage': 28.0, 'Common_Neoadjuvant_Regimen_1': 'Carboplatin + Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin + Gemcitabine', 'Common_Adjuvant_Regimen_1': 'Gemcitabine', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35.0, 'Antiemetic_Agent_Percentage': 45.0, 'Painkiller_Antipyretic_Percentage': 55.0, 'Beds_Less_Than_200_Percentage': 15.0, 'Beds_200_To_499_Percentage': 55.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 30.0, 'Designated_Cancer_Hospital_Percentage': 45.0, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Vismodegib', 'STUDYID': 'VISMO003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 30.0, 'Male_Percentage': 70.0, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 45.0, 'Total_ADL_Independence_Percentage': 90.0, 'LHRH_Use_Percentage': 0.0, 'Tumor_Stage_T1_Percentage': 18.0, 'Tumor_Stage_T2_Percentage': 32.0, 'Tumor_Stage_T3_Percentage': 35.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 65.0, 'Nodal_Stage_N1_Percentage': 20.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 22.0, 'Stage_II_Percentage': 38.0, 'Stage_III_Percentage': 40.0, 'Diabetes_Mellitus_Percentage': 15.0, 'Congestive_Heart_Failure_Percentage': 7.0, 'Stroke_Percentage': 4.0, 'Atrial_Fibrillation_Percentage': 10.0, 'Myocardial_Infarction_Percentage': 6.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 3.0, 'Adjuvant_Chemotherapy_Received_Percentage': 8.0, 'Postoperative_RT_Received_Percentage': 22.0, 'Common_Neoadjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Pemetrexed', 'Common_Adjuvant_Regimen_1': 'Capecitabine', 'Common_Adjuvant_Regimen_2': 'Vinorelbine', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 25.0, 'Antiemetic_Agent_Percentage': 35.0, 'Painkiller_Antipyretic_Percentage': 45.0, 'Beds_Less_Than_200_Percentage': 25.0, 'Beds_200_To_499_Percentage': 45.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 30.0, 'Designated_Cancer_Hospital_Percentage': 35.0, 'Months_Between_Surgery_And_Index_Date': 1}, {'Drug_Name': 'Vismodegib', 'STUDYID': 'VISMO004', 'YEAR': 2024, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 73, 'Female_Percentage': 38.0, 'Male_Percentage': 62.0, 'Median_BMI': 29.0, 'Smoking_History_Yes_Percentage': 40.0, 'Total_ADL_Independence_Percentage': 82.0, 'LHRH_Use_Percentage': 0.0, 'Tumor_Stage_T1_Percentage': 14.0, 'Tumor_Stage_T2_Percentage': 29.0, 'Tumor_Stage_T3_Percentage': 42.0, 'Tumor_Stage_T4_Percentage': 15.0, 'Nodal_Stage_N0_Percentage': 58.0, 'Nodal_Stage_N1_Percentage': 27.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 19.0, 'Stage_II_Percentage': 34.0, 'Stage_III_Percentage': 47.0, 'Diabetes_Mellitus_Percentage': 19.0, 'Congestive_Heart_Failure_Percentage': 9.0, 'Stroke_Percentage': 5.5, 'Atrial_Fibrillation_Percentage': 13.0, 'Myocardial_Infarction_Percentage': 7.5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 6.0, 'Adjuvant_Chemotherapy_Received_Percentage': 11.0, 'Postoperative_RT_Received_Percentage': 26.0, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Gemcitabine', 'Common_Adjuvant_Regimen_1': 'Gemcitabine', 'Common_Adjuvant_Regimen_2': 'Paclitaxel', 'Tamoxifen_Percentage': 0.0, 'Letrozole_Percentage': 0.0, 'Anastrozole_Percentage': 0.0, 'Antidiarrheal_Agent_Probiotics_Percentage': 32.0, 'Antiemetic_Agent_Percentage': 42.0, 'Painkiller_Antipyretic_Percentage': 52.0, 'Beds_Less_Than_200_Percentage': 18.0, 'Beds_200_To_499_Percentage': 52.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 30.0, 'Designated_Cancer_Hospital_Percentage': 42.0, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Vismodegib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Vismodegib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Vorinostat\",\n",
      "    \"STUDYID\": \"VORI1001\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"32\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"38\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"45\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EPOCH\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"R-CVP\",\n",
      "    \"Tamoxifen_Percentage\": \"5\",\n",
      "    \"Letrozole_Percentage\": \"3\",\n",
      "    \"Anastrozole_Percentage\": \"2\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"25\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"60\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"70\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"55\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Vorinostat\",\n",
      "    \"STUDYID\": \"VORI1002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"28\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"32\",\n",
      "    \"Stage_III_Percentage\": \"50\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"10\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"12\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"40\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"48\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"ICE\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Bendamustine\",\n",
      "    \"Tamoxifen_Percentage\": \"6\",\n",
      "    \"Letrozole_Percentage\": \"4\",\n",
      "    \"Anastrozole_Percentage\": \"3\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"28\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"65\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"75\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"58\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Vorinostat\",\n",
      "    \"STUDYID\": \"VORI1003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"52\",\n",
      "    \"Male_Percentage\": \"48\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"88\",\n",
      "    \"LHRH_Use_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"38\",\n",
      "    \"Stage_III_Percentage\": \"40\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"16\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"35\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"42\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DHAP\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Rituximab\",\n",
      "    \"Tamoxifen_Percentage\": \"4\",\n",
      "    \"Letrozole_Percentage\": \"2\",\n",
      "    \"Anastrozole_Percentage\": \"1\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"22\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"55\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"65\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"52\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1.8\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Vorinostat', 'STUDYID': 'VORI1001', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '32', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '12', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '38', 'Postoperative_RT_Received_Percentage': '45', 'Common_Neoadjuvant_Regimen_1': 'CHOP', 'Common_Neoadjuvant_Regimen_2': 'EPOCH', 'Common_Adjuvant_Regimen_1': 'R-CHOP', 'Common_Adjuvant_Regimen_2': 'R-CVP', 'Tamoxifen_Percentage': '5', 'Letrozole_Percentage': '3', 'Anastrozole_Percentage': '2', 'Antidiarrheal_Agent_Probiotics_Percentage': '25', 'Antiemetic_Agent_Percentage': '60', 'Painkiller_Antipyretic_Percentage': '70', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '55', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Vorinostat', 'STUDYID': 'VORI1002', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '28', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '42', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '32', 'Stage_III_Percentage': '50', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '10', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '12', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '40', 'Postoperative_RT_Received_Percentage': '48', 'Common_Neoadjuvant_Regimen_1': 'CHOP', 'Common_Neoadjuvant_Regimen_2': 'ICE', 'Common_Adjuvant_Regimen_1': 'R-CHOP', 'Common_Adjuvant_Regimen_2': 'Bendamustine', 'Tamoxifen_Percentage': '6', 'Letrozole_Percentage': '4', 'Anastrozole_Percentage': '3', 'Antidiarrheal_Agent_Probiotics_Percentage': '28', 'Antiemetic_Agent_Percentage': '65', 'Painkiller_Antipyretic_Percentage': '75', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '58', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Vorinostat', 'STUDYID': 'VORI1003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '52', 'Male_Percentage': '48', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '88', 'LHRH_Use_Percentage': '10', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '38', 'Tumor_Stage_T4_Percentage': '12', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '22', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '38', 'Stage_III_Percentage': '40', 'Diabetes_Mellitus_Percentage': '16', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '20', 'Adjuvant_Chemotherapy_Received_Percentage': '35', 'Postoperative_RT_Received_Percentage': '42', 'Common_Neoadjuvant_Regimen_1': 'CHOP', 'Common_Neoadjuvant_Regimen_2': 'DHAP', 'Common_Adjuvant_Regimen_1': 'R-CHOP', 'Common_Adjuvant_Regimen_2': 'Rituximab', 'Tamoxifen_Percentage': '4', 'Letrozole_Percentage': '2', 'Anastrozole_Percentage': '1', 'Antidiarrheal_Agent_Probiotics_Percentage': '22', 'Antiemetic_Agent_Percentage': '55', 'Painkiller_Antipyretic_Percentage': '65', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '52', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '1.8'}]\n",
      "File created: Vorinostat_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Vorinostat\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Welireg (Belzutifan)\",\n",
      "    \"STUDYID\": \"WLRG2023-US-01\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 88,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 15,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 15,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 45,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Welireg (Belzutifan)\",\n",
      "    \"STUDYID\": \"WLRG2023-EU-02\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 38,\n",
      "    \"Male_Percentage\": 62,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 41,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 42,\n",
      "    \"Stage_III_Percentage\": 32,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Postoperative_RT_Received_Percentage\": 38,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Oxaliplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 18,\n",
      "    \"Antiemetic_Agent_Percentage\": 42,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 58,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Welireg (Belzutifan)\",\n",
      "    \"STUDYID\": \"WLRG2024-JP-03\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 24.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 25,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 65,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 45,\n",
      "    \"Stage_III_Percentage\": 25,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"S-1 + Cisplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"UFT\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 12,\n",
      "    \"Antiemetic_Agent_Percentage\": 38,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 52,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 55,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 25,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 75,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Welireg (Belzutifan)\",\n",
      "    \"STUDYID\": \"WLRG2024-CA-04\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 380,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 28.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 13,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 36,\n",
      "    \"Tumor_Stage_T3_Percentage\": 28,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58,\n",
      "    \"Nodal_Stage_N1_Percentage\": 27,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 28,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 14,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 26,\n",
      "    \"Postoperative_RT_Received_Percentage\": 33,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"5-FU + Leucovorin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Capecitabine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 16,\n",
      "    \"Antiemetic_Agent_Percentage\": 41,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 56,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 68,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.8\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Welireg (Belzutifan)', 'STUDYID': 'WLRG2023-US-01', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 88, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 15, 'Adjuvant_Chemotherapy_Received_Percentage': 28, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Gemcitabine', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 15, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 45, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Welireg (Belzutifan)', 'STUDYID': 'WLRG2023-EU-02', 'YEAR': 2023, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 38, 'Male_Percentage': 62, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 41, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 42, 'Stage_III_Percentage': 32, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 25, 'Postoperative_RT_Received_Percentage': 38, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Pemetrexed', 'Common_Adjuvant_Regimen_1': '5-FU + Oxaliplatin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 18, 'Antiemetic_Agent_Percentage': 42, 'Painkiller_Antipyretic_Percentage': 58, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 1.5}, {'Drug_Name': 'Welireg (Belzutifan)', 'STUDYID': 'WLRG2024-JP-03', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 24.5, 'Smoking_History_Yes_Percentage': 25, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 25, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 65, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 45, 'Stage_III_Percentage': 25, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 22, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'S-1 + Cisplatin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': 'UFT', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 12, 'Antiemetic_Agent_Percentage': 38, 'Painkiller_Antipyretic_Percentage': 52, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 55, 'Beds_Greater_Or_Equal_To_500_Percentage': 25, 'Designated_Cancer_Hospital_Percentage': 75, 'Months_Between_Surgery_And_Index_Date': 2.5}, {'Drug_Name': 'Welireg (Belzutifan)', 'STUDYID': 'WLRG2024-CA-04', 'YEAR': 2024, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 380, 'Median_Age': 65, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 28.0, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 13, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 36, 'Tumor_Stage_T3_Percentage': 28, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 58, 'Nodal_Stage_N1_Percentage': 27, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 28, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 14, 'Adjuvant_Chemotherapy_Received_Percentage': 26, 'Postoperative_RT_Received_Percentage': 33, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Gemcitabine', 'Common_Neoadjuvant_Regimen_2': 'Paclitaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': '5-FU + Leucovorin', 'Common_Adjuvant_Regimen_2': 'Capecitabine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 16, 'Antiemetic_Agent_Percentage': 41, 'Painkiller_Antipyretic_Percentage': 56, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 68, 'Months_Between_Surgery_And_Index_Date': 1.8}]\n",
      "File created: Welireg (Belzutifan)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Welireg (Belzutifan)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Xalkori (Crizotinib)\",\n",
      "    \"STUDYID\": \"ALKStudy001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 60,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cisplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xalkori (Crizotinib)\",\n",
      "    \"STUDYID\": \"XALK2022EU\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 55,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58,\n",
      "    \"Nodal_Stage_N1_Percentage\": 22,\n",
      "    \"Nodal_Stage_N2_Percentage\": 14,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Vinorelbine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 70,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xalkori (Crizotinib)\",\n",
      "    \"STUDYID\": \"JapanALK23\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 25.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 40,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 12,\n",
      "    \"Nodal_Stage_N3_Percentage\": 8,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 10,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin + Vinorelbine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Pemetrexed + Bevacizumab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 80,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Xalkori (Crizotinib)', 'STUDYID': 'ALKStudy001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 60, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 25, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Cisplatin', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Xalkori (Crizotinib)', 'STUDYID': 'XALK2022EU', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 55, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 58, 'Nodal_Stage_N1_Percentage': 22, 'Nodal_Stage_N2_Percentage': 14, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 22, 'Postoperative_RT_Received_Percentage': 28, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Gemcitabine', 'Common_Adjuvant_Regimen_1': 'Gemcitabine', 'Common_Adjuvant_Regimen_2': 'Vinorelbine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 70, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 1.5}, {'Drug_Name': 'Xalkori (Crizotinib)', 'STUDYID': 'JapanALK23', 'YEAR': 2023, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 25.5, 'Smoking_History_Yes_Percentage': 40, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 12, 'Nodal_Stage_N3_Percentage': 8, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 10, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 6, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 28, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'Carboplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin + Vinorelbine', 'Common_Adjuvant_Regimen_1': 'Pemetrexed + Bevacizumab', 'Common_Adjuvant_Regimen_2': 'Carboplatin', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 80, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Xalkori (Crizotinib)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Xalkori (Crizotinib)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Xatmep\",\n",
      "    \"STUDYID\": \"XM2023-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 88,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 25,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 20,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 30,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 25,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 48,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Tamoxifen_Percentage\": 18,\n",
      "    \"Letrozole_Percentage\": 15,\n",
      "    \"Anastrozole_Percentage\": 12,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 65,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xatmep\",\n",
      "    \"STUDYID\": \"XM2023-002\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25,\n",
      "    \"Tumor_Stage_T4_Percentage\": 25,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 30,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 52,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": 20,\n",
      "    \"Letrozole_Percentage\": 18,\n",
      "    \"Anastrozole_Percentage\": 14,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 70,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xatmep\",\n",
      "    \"STUDYID\": \"XM2023-003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 26.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 30,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 15,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 65,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 35,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 15,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC-T\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"ECF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Gemcitabine\",\n",
      "    \"Tamoxifen_Percentage\": 22,\n",
      "    \"Letrozole_Percentage\": 20,\n",
      "    \"Anastrozole_Percentage\": 16,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 32,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 75,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 60,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xatmep\",\n",
      "    \"STUDYID\": \"XM2023-004\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 55,\n",
      "    \"Male_Percentage\": 45,\n",
      "    \"Median_BMI\": 27.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 30,\n",
      "    \"Total_ADL_Independence_Percentage\": 86,\n",
      "    \"LHRH_Use_Percentage\": 13,\n",
      "    \"Tumor_Stage_T1_Percentage\": 22,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 18,\n",
      "    \"Tumor_Stage_T4_Percentage\": 22,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 9,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 28,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 28,\n",
      "    \"Diabetes_Mellitus_Percentage\": 16,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3.5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7.5,\n",
      "    \"Myocardial_Infarction_Percentage\": 4.5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 23,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50,\n",
      "    \"Postoperative_RT_Received_Percentage\": 38,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"PET\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"TECF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Doxorubicin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide\",\n",
      "    \"Tamoxifen_Percentage\": 19,\n",
      "    \"Letrozole_Percentage\": 17,\n",
      "    \"Anastrozole_Percentage\": 13,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 29,\n",
      "    \"Antiemetic_Agent_Percentage\": 58,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 68,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.8\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Xatmep', 'STUDYID': 'XM2023-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 88, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 25, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 20, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 30, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 25, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 48, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'CMF', 'Common_Neoadjuvant_Regimen_2': 'AC', 'Common_Adjuvant_Regimen_1': 'TC', 'Common_Adjuvant_Regimen_2': 'FEC', 'Tamoxifen_Percentage': 18, 'Letrozole_Percentage': 15, 'Anastrozole_Percentage': 12, 'Antidiarrheal_Agent_Probiotics_Percentage': 28, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 65, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Xatmep', 'STUDYID': 'XM2023-002', 'YEAR': 2023, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 25, 'Tumor_Stage_T4_Percentage': 25, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 30, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 52, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'AC-T', 'Common_Neoadjuvant_Regimen_2': 'EC', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': 20, 'Letrozole_Percentage': 18, 'Anastrozole_Percentage': 14, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 70, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Xatmep', 'STUDYID': 'XM2023-003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 26.9, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 30, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 15, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 65, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 35, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 15, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'FEC-T', 'Common_Neoadjuvant_Regimen_2': 'ECF', 'Common_Adjuvant_Regimen_1': 'Carboplatin', 'Common_Adjuvant_Regimen_2': 'Gemcitabine', 'Tamoxifen_Percentage': 22, 'Letrozole_Percentage': 20, 'Anastrozole_Percentage': 16, 'Antidiarrheal_Agent_Probiotics_Percentage': 32, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 75, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 60, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 2.5}, {'Drug_Name': 'Xatmep', 'STUDYID': 'XM2023-004', 'YEAR': 2023, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 65, 'Female_Percentage': 55, 'Male_Percentage': 45, 'Median_BMI': 27.8, 'Smoking_History_Yes_Percentage': 30, 'Total_ADL_Independence_Percentage': 86, 'LHRH_Use_Percentage': 13, 'Tumor_Stage_T1_Percentage': 22, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 18, 'Tumor_Stage_T4_Percentage': 22, 'Nodal_Stage_N0_Percentage': 58, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 9, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 28, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 28, 'Diabetes_Mellitus_Percentage': 16, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3.5, 'Atrial_Fibrillation_Percentage': 7.5, 'Myocardial_Infarction_Percentage': 4.5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 23, 'Adjuvant_Chemotherapy_Received_Percentage': 50, 'Postoperative_RT_Received_Percentage': 38, 'Common_Neoadjuvant_Regimen_1': 'PET', 'Common_Neoadjuvant_Regimen_2': 'TECF', 'Common_Adjuvant_Regimen_1': 'Doxorubicin', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide', 'Tamoxifen_Percentage': 19, 'Letrozole_Percentage': 17, 'Anastrozole_Percentage': 13, 'Antidiarrheal_Agent_Probiotics_Percentage': 29, 'Antiemetic_Agent_Percentage': 58, 'Painkiller_Antipyretic_Percentage': 68, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 2.8}]\n",
      "File created: Xatmep (Methotrexate Sodium)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Xatmep (Methotrexate Sodium)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Xeloda (Capecitabine)\",\n",
      "    \"STUDYID\": \"XelodaStudy001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 62,\n",
      "    \"Male_Percentage\": 38,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 45,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 68,\n",
      "    \"Postoperative_RT_Received_Percentage\": 45,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC\",\n",
      "    \"Tamoxifen_Percentage\": 25,\n",
      "    \"Letrozole_Percentage\": 35,\n",
      "    \"Anastrozole_Percentage\": 30,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 65,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xeloda (Capecitabine)\",\n",
      "    \"STUDYID\": \"XelodaStudy002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 58,\n",
      "    \"Male_Percentage\": 42,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 42,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 70,\n",
      "    \"Postoperative_RT_Received_Percentage\": 48,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CAF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AT\",\n",
      "    \"Tamoxifen_Percentage\": 28,\n",
      "    \"Letrozole_Percentage\": 32,\n",
      "    \"Anastrozole_Percentage\": 33,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 45,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 70,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xeloda (Capecitabine)\",\n",
      "    \"STUDYID\": \"XelodaStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 60,\n",
      "    \"Male_Percentage\": 40,\n",
      "    \"Median_BMI\": 26.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 30,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 39,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16,\n",
      "    \"Nodal_Stage_N3_Percentage\": 4,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 43,\n",
      "    \"Stage_III_Percentage\": 33,\n",
      "    \"Diabetes_Mellitus_Percentage\": 19,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 23,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 69,\n",
      "    \"Postoperative_RT_Received_Percentage\": 46,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CEF\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Doxetacel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FAC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"TC\",\n",
      "    \"Tamoxifen_Percentage\": 26,\n",
      "    \"Letrozole_Percentage\": 34,\n",
      "    \"Anastrozole_Percentage\": 31,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 42,\n",
      "    \"Antiemetic_Agent_Percentage\": 57,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 67,\n",
      "    \"Beds_Less_Than_200_Percentage\": 16,\n",
      "    \"Beds_200_To_499_Percentage\": 44,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Xeloda (Capecitabine)', 'STUDYID': 'XelodaStudy001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 62, 'Male_Percentage': 38, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 45, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 68, 'Postoperative_RT_Received_Percentage': 45, 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'AC', 'Tamoxifen_Percentage': 25, 'Letrozole_Percentage': 35, 'Anastrozole_Percentage': 30, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 65, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Xeloda (Capecitabine)', 'STUDYID': 'XelodaStudy002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 58, 'Male_Percentage': 42, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 42, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 70, 'Postoperative_RT_Received_Percentage': 48, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'CAF', 'Common_Adjuvant_Regimen_2': 'AT', 'Tamoxifen_Percentage': 28, 'Letrozole_Percentage': 32, 'Anastrozole_Percentage': 33, 'Antidiarrheal_Agent_Probiotics_Percentage': 45, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 70, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Xeloda (Capecitabine)', 'STUDYID': 'XelodaStudy003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 60, 'Male_Percentage': 40, 'Median_BMI': 26.9, 'Smoking_History_Yes_Percentage': 30, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 39, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 16, 'Nodal_Stage_N3_Percentage': 4, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 43, 'Stage_III_Percentage': 33, 'Diabetes_Mellitus_Percentage': 19, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 23, 'Adjuvant_Chemotherapy_Received_Percentage': 69, 'Postoperative_RT_Received_Percentage': 46, 'Common_Neoadjuvant_Regimen_1': 'CEF', 'Common_Neoadjuvant_Regimen_2': 'Doxetacel', 'Common_Adjuvant_Regimen_1': 'FAC', 'Common_Adjuvant_Regimen_2': 'TC', 'Tamoxifen_Percentage': 26, 'Letrozole_Percentage': 34, 'Anastrozole_Percentage': 31, 'Antidiarrheal_Agent_Probiotics_Percentage': 42, 'Antiemetic_Agent_Percentage': 57, 'Painkiller_Antipyretic_Percentage': 67, 'Beds_Less_Than_200_Percentage': 16, 'Beds_200_To_499_Percentage': 44, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 2}]\n",
      "File created: Xeloda (Capecitabine)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Xeloda (Capecitabine)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Xgeva (Denosumab)\",\n",
      "    \"STUDYID\": \"XgevaStudy001\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"32\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"12\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"10\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"35\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel + Cyclophosphamide\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC (Adriamycin + Cyclophosphamide)\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T (Adriamycin + Cyclophosphamide followed by Taxol)\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"TC (Docetaxel + Cyclophosphamide)\",\n",
      "    \"Tamoxifen_Percentage\": \"15\",\n",
      "    \"Letrozole_Percentage\": \"25\",\n",
      "    \"Anastrozole_Percentage\": \"30\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"22\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"40\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"55\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xgeva (Denosumab)\",\n",
      "    \"STUDYID\": \"XgevaStudy002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"52\",\n",
      "    \"Male_Percentage\": \"48\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"28\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"50\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"17\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"32\",\n",
      "    \"Stage_III_Percentage\": \"35\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"10\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"14\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"12\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"38\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide)\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol + Trastuzumab\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Taxol + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)\",\n",
      "    \"Tamoxifen_Percentage\": \"18\",\n",
      "    \"Letrozole_Percentage\": \"28\",\n",
      "    \"Anastrozole_Percentage\": \"32\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"25\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"45\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"60\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"10\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xgeva (Denosumab)\",\n",
      "    \"STUDYID\": \"XgevaStudy003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"26.9\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"90\",\n",
      "    \"LHRH_Use_Percentage\": \"22\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"13\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"38\",\n",
      "    \"Stage_III_Percentage\": \"25\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"8\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"18\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"32\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC (Epirubicin, Cyclophosphamide)\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + Pertuzumab + Trastuzumab\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC-D (5-Fluorouracil, Epirubicin, Cyclophosphamide followed by Docetaxel)\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC (Adriamycin + Cyclophosphamide)\",\n",
      "    \"Tamoxifen_Percentage\": \"12\",\n",
      "    \"Letrozole_Percentage\": \"22\",\n",
      "    \"Anastrozole_Percentage\": \"28\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"20\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"35\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"50\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"40\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"55\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xgeva (Denosumab)\",\n",
      "    \"STUDYID\": \"XgevaStudy004\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"55\",\n",
      "    \"Male_Percentage\": \"45\",\n",
      "    \"Median_BMI\": \"29.0\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"30\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"14\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"29\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"41\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"26\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"19\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"33\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"22\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"13\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"11\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"21\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"37\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC-TH (Adriamycin + Cyclophosphamide followed by Paclitaxel + Trastuzumab)\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab)\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"TC (Docetaxel + Cyclophosphamide)\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC-T (Adriamycin + Cyclophosphamide followed by Taxol)\",\n",
      "    \"Tamoxifen_Percentage\": \"16\",\n",
      "    \"Letrozole_Percentage\": \"26\",\n",
      "    \"Anastrozole_Percentage\": \"31\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"23\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"42\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"58\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.8\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Xgeva (Denosumab)', 'STUDYID': 'XgevaStudy001', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '32', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '25', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '12', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '10', 'Adjuvant_Chemotherapy_Received_Percentage': '20', 'Postoperative_RT_Received_Percentage': '35', 'Common_Neoadjuvant_Regimen_1': 'Docetaxel + Cyclophosphamide', 'Common_Neoadjuvant_Regimen_2': 'AC (Adriamycin + Cyclophosphamide)', 'Common_Adjuvant_Regimen_1': 'AC-T (Adriamycin + Cyclophosphamide followed by Taxol)', 'Common_Adjuvant_Regimen_2': 'TC (Docetaxel + Cyclophosphamide)', 'Tamoxifen_Percentage': '15', 'Letrozole_Percentage': '25', 'Anastrozole_Percentage': '30', 'Antidiarrheal_Agent_Probiotics_Percentage': '22', 'Antiemetic_Agent_Percentage': '40', 'Painkiller_Antipyretic_Percentage': '55', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Xgeva (Denosumab)', 'STUDYID': 'XgevaStudy002', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '52', 'Male_Percentage': '48', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '28', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '30', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '42', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '50', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '17', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '32', 'Stage_III_Percentage': '35', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '10', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '14', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '12', 'Adjuvant_Chemotherapy_Received_Percentage': '22', 'Postoperative_RT_Received_Percentage': '38', 'Common_Neoadjuvant_Regimen_1': 'FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide)', 'Common_Neoadjuvant_Regimen_2': 'Taxol + Trastuzumab', 'Common_Adjuvant_Regimen_1': 'Taxol + Carboplatin', 'Common_Adjuvant_Regimen_2': 'CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)', 'Tamoxifen_Percentage': '18', 'Letrozole_Percentage': '28', 'Anastrozole_Percentage': '32', 'Antidiarrheal_Agent_Probiotics_Percentage': '25', 'Antiemetic_Agent_Percentage': '45', 'Painkiller_Antipyretic_Percentage': '60', 'Beds_Less_Than_200_Percentage': '10', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Xgeva (Denosumab)', 'STUDYID': 'XgevaStudy003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '26.9', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '90', 'LHRH_Use_Percentage': '22', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '38', 'Tumor_Stage_T4_Percentage': '12', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '22', 'Nodal_Stage_N2_Percentage': '13', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '38', 'Stage_III_Percentage': '25', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '8', 'Adjuvant_Chemotherapy_Received_Percentage': '18', 'Postoperative_RT_Received_Percentage': '32', 'Common_Neoadjuvant_Regimen_1': 'EC (Epirubicin, Cyclophosphamide)', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + Pertuzumab + Trastuzumab', 'Common_Adjuvant_Regimen_1': 'FEC-D (5-Fluorouracil, Epirubicin, Cyclophosphamide followed by Docetaxel)', 'Common_Adjuvant_Regimen_2': 'AC (Adriamycin + Cyclophosphamide)', 'Tamoxifen_Percentage': '12', 'Letrozole_Percentage': '22', 'Anastrozole_Percentage': '28', 'Antidiarrheal_Agent_Probiotics_Percentage': '20', 'Antiemetic_Agent_Percentage': '35', 'Painkiller_Antipyretic_Percentage': '50', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '40', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '55', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Xgeva (Denosumab)', 'STUDYID': 'XgevaStudy004', 'YEAR': '2023', 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '70', 'Female_Percentage': '55', 'Male_Percentage': '45', 'Median_BMI': '29.0', 'Smoking_History_Yes_Percentage': '30', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '28', 'Tumor_Stage_T1_Percentage': '14', 'Tumor_Stage_T2_Percentage': '29', 'Tumor_Stage_T3_Percentage': '41', 'Tumor_Stage_T4_Percentage': '16', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '26', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '19', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '33', 'Diabetes_Mellitus_Percentage': '22', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '13', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '11', 'Adjuvant_Chemotherapy_Received_Percentage': '21', 'Postoperative_RT_Received_Percentage': '37', 'Common_Neoadjuvant_Regimen_1': 'AC-TH (Adriamycin + Cyclophosphamide followed by Paclitaxel + Trastuzumab)', 'Common_Neoadjuvant_Regimen_2': 'TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab)', 'Common_Adjuvant_Regimen_1': 'TC (Docetaxel + Cyclophosphamide)', 'Common_Adjuvant_Regimen_2': 'AC-T (Adriamycin + Cyclophosphamide followed by Taxol)', 'Tamoxifen_Percentage': '16', 'Letrozole_Percentage': '26', 'Anastrozole_Percentage': '31', 'Antidiarrheal_Agent_Probiotics_Percentage': '23', 'Antiemetic_Agent_Percentage': '42', 'Painkiller_Antipyretic_Percentage': '58', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '2.8'}]\n",
      "File created: Xgeva (Denosumab)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Xgeva (Denosumab)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Xofigo (Radium 223 Dichloride)\",\n",
      "    \"STUDYID\": \"XofigoStudy001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 2,\n",
      "    \"Male_Percentage\": 98,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 60,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 85,\n",
      "    \"Tumor_Stage_T1_Percentage\": 5,\n",
      "    \"Tumor_Stage_T2_Percentage\": 15,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 40,\n",
      "    \"Nodal_Stage_N0_Percentage\": 30,\n",
      "    \"Nodal_Stage_N1_Percentage\": 40,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 2,\n",
      "    \"Stage_II_Percentage\": 8,\n",
      "    \"Stage_III_Percentage\": 20,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 8,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 5,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 15,\n",
      "    \"Postoperative_RT_Received_Percentage\": 25,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Abiraterone\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Enzalutamide\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 18\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xofigo (Radium 223 Dichloride)\",\n",
      "    \"STUDYID\": \"XofigoStudy002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 75,\n",
      "    \"Female_Percentage\": 3,\n",
      "    \"Male_Percentage\": 97,\n",
      "    \"Median_BMI\": 28.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 55,\n",
      "    \"Total_ADL_Independence_Percentage\": 70,\n",
      "    \"LHRH_Use_Percentage\": 80,\n",
      "    \"Tumor_Stage_T1_Percentage\": 7,\n",
      "    \"Tumor_Stage_T2_Percentage\": 13,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 45,\n",
      "    \"Nodal_Stage_N0_Percentage\": 35,\n",
      "    \"Nodal_Stage_N1_Percentage\": 35,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 3,\n",
      "    \"Stage_II_Percentage\": 7,\n",
      "    \"Stage_III_Percentage\": 18,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 12,\n",
      "    \"Stroke_Percentage\": 6,\n",
      "    \"Atrial_Fibrillation_Percentage\": 14,\n",
      "    \"Myocardial_Infarction_Percentage\": 9,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 7,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 17,\n",
      "    \"Postoperative_RT_Received_Percentage\": 27,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Abiraterone\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Enzalutamide\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 32,\n",
      "    \"Antiemetic_Agent_Percentage\": 42,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 52,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 46,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 20\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xofigo (Radium 223 Dichloride)\",\n",
      "    \"STUDYID\": \"XofigoStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 1,\n",
      "    \"Male_Percentage\": 99,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 50,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 90,\n",
      "    \"Tumor_Stage_T1_Percentage\": 3,\n",
      "    \"Tumor_Stage_T2_Percentage\": 17,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 38,\n",
      "    \"Nodal_Stage_N0_Percentage\": 28,\n",
      "    \"Nodal_Stage_N1_Percentage\": 42,\n",
      "    \"Nodal_Stage_N2_Percentage\": 22,\n",
      "    \"Nodal_Stage_N3_Percentage\": 8,\n",
      "    \"Stage_I_Percentage\": 1,\n",
      "    \"Stage_II_Percentage\": 9,\n",
      "    \"Stage_III_Percentage\": 22,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 3,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 13,\n",
      "    \"Postoperative_RT_Received_Percentage\": 23,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Abiraterone\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Enzalutamide\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28,\n",
      "    \"Antiemetic_Agent_Percentage\": 38,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 48,\n",
      "    \"Beds_Less_Than_200_Percentage\": 8,\n",
      "    \"Beds_200_To_499_Percentage\": 38,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 54,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 58,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 16\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xofigo (Radium 223 Dichloride)\",\n",
      "    \"STUDYID\": \"XofigoStudy004\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 73,\n",
      "    \"Female_Percentage\": 4,\n",
      "    \"Male_Percentage\": 96,\n",
      "    \"Median_BMI\": 27.2,\n",
      "    \"Smoking_History_Yes_Percentage\": 58,\n",
      "    \"Total_ADL_Independence_Percentage\": 73,\n",
      "    \"LHRH_Use_Percentage\": 83,\n",
      "    \"Tumor_Stage_T1_Percentage\": 6,\n",
      "    \"Tumor_Stage_T2_Percentage\": 14,\n",
      "    \"Tumor_Stage_T3_Percentage\": 37,\n",
      "    \"Tumor_Stage_T4_Percentage\": 43,\n",
      "    \"Nodal_Stage_N0_Percentage\": 33,\n",
      "    \"Nodal_Stage_N1_Percentage\": 37,\n",
      "    \"Nodal_Stage_N2_Percentage\": 18,\n",
      "    \"Nodal_Stage_N3_Percentage\": 12,\n",
      "    \"Stage_I_Percentage\": 2,\n",
      "    \"Stage_II_Percentage\": 8,\n",
      "    \"Stage_III_Percentage\": 19,\n",
      "    \"Diabetes_Mellitus_Percentage\": 21,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 11,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 13,\n",
      "    \"Myocardial_Infarction_Percentage\": 8,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 6,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 16,\n",
      "    \"Postoperative_RT_Received_Percentage\": 26,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Abiraterone\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Enzalutamide\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 31,\n",
      "    \"Antiemetic_Agent_Percentage\": 41,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 51,\n",
      "    \"Beds_Less_Than_200_Percentage\": 11,\n",
      "    \"Beds_200_To_499_Percentage\": 41,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 48,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 61,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 19\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Xofigo (Radium 223 Dichloride)', 'STUDYID': 'XofigoStudy001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 72, 'Female_Percentage': 2, 'Male_Percentage': 98, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 60, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 85, 'Tumor_Stage_T1_Percentage': 5, 'Tumor_Stage_T2_Percentage': 15, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 40, 'Nodal_Stage_N0_Percentage': 30, 'Nodal_Stage_N1_Percentage': 40, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 2, 'Stage_II_Percentage': 8, 'Stage_III_Percentage': 20, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 8, 'Neoadjuvant_Chemotherapy_Received_Percentage': 5, 'Adjuvant_Chemotherapy_Received_Percentage': 15, 'Postoperative_RT_Received_Percentage': 25, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'Abiraterone', 'Common_Adjuvant_Regimen_2': 'Enzalutamide', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 18}, {'Drug_Name': 'Xofigo (Radium 223 Dichloride)', 'STUDYID': 'XofigoStudy002', 'YEAR': 2022, 'Country': 'UK', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 75, 'Female_Percentage': 3, 'Male_Percentage': 97, 'Median_BMI': 28.0, 'Smoking_History_Yes_Percentage': 55, 'Total_ADL_Independence_Percentage': 70, 'LHRH_Use_Percentage': 80, 'Tumor_Stage_T1_Percentage': 7, 'Tumor_Stage_T2_Percentage': 13, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 45, 'Nodal_Stage_N0_Percentage': 35, 'Nodal_Stage_N1_Percentage': 35, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 3, 'Stage_II_Percentage': 7, 'Stage_III_Percentage': 18, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 12, 'Stroke_Percentage': 6, 'Atrial_Fibrillation_Percentage': 14, 'Myocardial_Infarction_Percentage': 9, 'Neoadjuvant_Chemotherapy_Received_Percentage': 7, 'Adjuvant_Chemotherapy_Received_Percentage': 17, 'Postoperative_RT_Received_Percentage': 27, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin', 'Common_Adjuvant_Regimen_1': 'Abiraterone', 'Common_Adjuvant_Regimen_2': 'Enzalutamide', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 32, 'Antiemetic_Agent_Percentage': 42, 'Painkiller_Antipyretic_Percentage': 52, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 46, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 20}, {'Drug_Name': 'Xofigo (Radium 223 Dichloride)', 'STUDYID': 'XofigoStudy003', 'YEAR': 2023, 'Country': 'Canada', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 1, 'Male_Percentage': 99, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 50, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 90, 'Tumor_Stage_T1_Percentage': 3, 'Tumor_Stage_T2_Percentage': 17, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 38, 'Nodal_Stage_N0_Percentage': 28, 'Nodal_Stage_N1_Percentage': 42, 'Nodal_Stage_N2_Percentage': 22, 'Nodal_Stage_N3_Percentage': 8, 'Stage_I_Percentage': 1, 'Stage_II_Percentage': 9, 'Stage_III_Percentage': 22, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 3, 'Adjuvant_Chemotherapy_Received_Percentage': 13, 'Postoperative_RT_Received_Percentage': 23, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'Abiraterone', 'Common_Adjuvant_Regimen_2': 'Enzalutamide', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 28, 'Antiemetic_Agent_Percentage': 38, 'Painkiller_Antipyretic_Percentage': 48, 'Beds_Less_Than_200_Percentage': 8, 'Beds_200_To_499_Percentage': 38, 'Beds_Greater_Or_Equal_To_500_Percentage': 54, 'Designated_Cancer_Hospital_Percentage': 58, 'Months_Between_Surgery_And_Index_Date': 16}, {'Drug_Name': 'Xofigo (Radium 223 Dichloride)', 'STUDYID': 'XofigoStudy004', 'YEAR': 2024, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 73, 'Female_Percentage': 4, 'Male_Percentage': 96, 'Median_BMI': 27.2, 'Smoking_History_Yes_Percentage': 58, 'Total_ADL_Independence_Percentage': 73, 'LHRH_Use_Percentage': 83, 'Tumor_Stage_T1_Percentage': 6, 'Tumor_Stage_T2_Percentage': 14, 'Tumor_Stage_T3_Percentage': 37, 'Tumor_Stage_T4_Percentage': 43, 'Nodal_Stage_N0_Percentage': 33, 'Nodal_Stage_N1_Percentage': 37, 'Nodal_Stage_N2_Percentage': 18, 'Nodal_Stage_N3_Percentage': 12, 'Stage_I_Percentage': 2, 'Stage_II_Percentage': 8, 'Stage_III_Percentage': 19, 'Diabetes_Mellitus_Percentage': 21, 'Congestive_Heart_Failure_Percentage': 11, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 13, 'Myocardial_Infarction_Percentage': 8, 'Neoadjuvant_Chemotherapy_Received_Percentage': 6, 'Adjuvant_Chemotherapy_Received_Percentage': 16, 'Postoperative_RT_Received_Percentage': 26, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin', 'Common_Adjuvant_Regimen_1': 'Abiraterone', 'Common_Adjuvant_Regimen_2': 'Enzalutamide', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 31, 'Antiemetic_Agent_Percentage': 41, 'Painkiller_Antipyretic_Percentage': 51, 'Beds_Less_Than_200_Percentage': 11, 'Beds_200_To_499_Percentage': 41, 'Beds_Greater_Or_Equal_To_500_Percentage': 48, 'Designated_Cancer_Hospital_Percentage': 61, 'Months_Between_Surgery_And_Index_Date': 19}]\n",
      "File created: Xofigo (Radium 223 Dichloride)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Xofigo (Radium 223 Dichloride)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Xospata\",\n",
      "    \"STUDYID\": \"XOSPATA2023US\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 28.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 62,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 5,\n",
      "    \"Tumor_Stage_T2_Percentage\": 15,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 40,\n",
      "    \"Nodal_Stage_N0_Percentage\": 35,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 15,\n",
      "    \"Stage_I_Percentage\": 10,\n",
      "    \"Stage_II_Percentage\": 25,\n",
      "    \"Stage_III_Percentage\": 65,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 15,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"7+3\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FLAG-Ida\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"High-dose Ara-C\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"5+2\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": null\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xospata\",\n",
      "    \"STUDYID\": \"XOSPATA2022EU\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 51,\n",
      "    \"Male_Percentage\": 49,\n",
      "    \"Median_BMI\": 27.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 58,\n",
      "    \"Total_ADL_Independence_Percentage\": 70,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 8,\n",
      "    \"Tumor_Stage_T2_Percentage\": 12,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 45,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 15,\n",
      "    \"Stage_I_Percentage\": 12,\n",
      "    \"Stage_II_Percentage\": 28,\n",
      "    \"Stage_III_Percentage\": 60,\n",
      "    \"Diabetes_Mellitus_Percentage\": 25,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 7,\n",
      "    \"Atrial_Fibrillation_Percentage\": 15,\n",
      "    \"Myocardial_Infarction_Percentage\": 9,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"7+3\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FLAG-Ida\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"High-dose Ara-C\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"5+2\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 35,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": null\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xospata\",\n",
      "    \"STUDYID\": \"XOSPATA2024JP\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 26.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 45,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 10,\n",
      "    \"Tumor_Stage_T2_Percentage\": 20,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 40,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 20,\n",
      "    \"Stage_I_Percentage\": 15,\n",
      "    \"Stage_II_Percentage\": 30,\n",
      "    \"Stage_III_Percentage\": 55,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 18,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"7+3\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FLAG-Ida\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"High-dose Ara-C\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"5+2\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 30,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 75,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": null\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Xospata', 'STUDYID': 'XOSPATA2023US', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 28.5, 'Smoking_History_Yes_Percentage': 62, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 5, 'Tumor_Stage_T2_Percentage': 15, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 40, 'Nodal_Stage_N0_Percentage': 35, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 15, 'Stage_I_Percentage': 10, 'Stage_II_Percentage': 25, 'Stage_III_Percentage': 65, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 15, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': '7+3', 'Common_Neoadjuvant_Regimen_2': 'FLAG-Ida', 'Common_Adjuvant_Regimen_1': 'High-dose Ara-C', 'Common_Adjuvant_Regimen_2': '5+2', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': None}, {'Drug_Name': 'Xospata', 'STUDYID': 'XOSPATA2022EU', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 51, 'Male_Percentage': 49, 'Median_BMI': 27.9, 'Smoking_History_Yes_Percentage': 58, 'Total_ADL_Independence_Percentage': 70, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 8, 'Tumor_Stage_T2_Percentage': 12, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 45, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 15, 'Stage_I_Percentage': 12, 'Stage_II_Percentage': 28, 'Stage_III_Percentage': 60, 'Diabetes_Mellitus_Percentage': 25, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 7, 'Atrial_Fibrillation_Percentage': 15, 'Myocardial_Infarction_Percentage': 9, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 40, 'Postoperative_RT_Received_Percentage': 28, 'Common_Neoadjuvant_Regimen_1': '7+3', 'Common_Neoadjuvant_Regimen_2': 'FLAG-Ida', 'Common_Adjuvant_Regimen_1': 'High-dose Ara-C', 'Common_Adjuvant_Regimen_2': '5+2', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 35, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': None}, {'Drug_Name': 'Xospata', 'STUDYID': 'XOSPATA2024JP', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 26.5, 'Smoking_History_Yes_Percentage': 45, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 10, 'Tumor_Stage_T2_Percentage': 20, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 40, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 20, 'Stage_I_Percentage': 15, 'Stage_II_Percentage': 30, 'Stage_III_Percentage': 55, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 18, 'Adjuvant_Chemotherapy_Received_Percentage': 50, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': '7+3', 'Common_Neoadjuvant_Regimen_2': 'FLAG-Ida', 'Common_Adjuvant_Regimen_1': 'High-dose Ara-C', 'Common_Adjuvant_Regimen_2': '5+2', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 30, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 75, 'Months_Between_Surgery_And_Index_Date': None}]\n",
      "File created: Xospata (Gilteritinib Fumarate)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Xospata (Gilteritinib Fumarate)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Xpovio (Selinexor)\",\n",
      "    \"STUDYID\": \"XP1001\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"65\",\n",
      "    \"LHRH_Use_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"22\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"18\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"42\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"58\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cyclophosphamide + Doxorubicin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": \"15\",\n",
      "    \"Letrozole_Percentage\": \"20\",\n",
      "    \"Anastrozole_Percentage\": \"18\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"30\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"60\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"45\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xpovio (Selinexor)\",\n",
      "    \"STUDYID\": \"XP1002\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"75\",\n",
      "    \"Female_Percentage\": \"51\",\n",
      "    \"Male_Percentage\": \"49\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"38\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"62\",\n",
      "    \"LHRH_Use_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"49\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"24\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"11\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"40\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"60\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxotere + Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": \"17\",\n",
      "    \"Letrozole_Percentage\": \"18\",\n",
      "    \"Anastrozole_Percentage\": \"20\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"32\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"62\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"47\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xpovio (Selinexor)\",\n",
      "    \"STUDYID\": \"XP1003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"40\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"70\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"38\",\n",
      "    \"Stage_III_Percentage\": \"40\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"15\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"45\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"55\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide\",\n",
      "    \"Tamoxifen_Percentage\": \"13\",\n",
      "    \"Letrozole_Percentage\": \"22\",\n",
      "    \"Anastrozole_Percentage\": \"15\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"28\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"58\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"42\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"42\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"58\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1.8\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Xpovio (Selinexor)', 'STUDYID': 'XP1001', 'YEAR': '2022', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '72', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '65', 'LHRH_Use_Percentage': '12', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '22', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '18', 'Adjuvant_Chemotherapy_Received_Percentage': '42', 'Postoperative_RT_Received_Percentage': '58', 'Common_Neoadjuvant_Regimen_1': 'Cyclophosphamide + Doxorubicin', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel + Carboplatin', 'Common_Adjuvant_Regimen_1': 'AC-T', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': '15', 'Letrozole_Percentage': '20', 'Anastrozole_Percentage': '18', 'Antidiarrheal_Agent_Probiotics_Percentage': '30', 'Antiemetic_Agent_Percentage': '60', 'Painkiller_Antipyretic_Percentage': '45', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Xpovio (Selinexor)', 'STUDYID': 'XP1002', 'YEAR': '2023', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '75', 'Female_Percentage': '51', 'Male_Percentage': '49', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '38', 'Total_ADL_Independence_Percentage': '62', 'LHRH_Use_Percentage': '10', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '42', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '49', 'Diabetes_Mellitus_Percentage': '24', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '11', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '20', 'Adjuvant_Chemotherapy_Received_Percentage': '40', 'Postoperative_RT_Received_Percentage': '60', 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'Taxotere + Cyclophosphamide', 'Common_Adjuvant_Regimen_1': 'TC', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': '17', 'Letrozole_Percentage': '18', 'Anastrozole_Percentage': '20', 'Antidiarrheal_Agent_Probiotics_Percentage': '32', 'Antiemetic_Agent_Percentage': '62', 'Painkiller_Antipyretic_Percentage': '47', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Xpovio (Selinexor)', 'STUDYID': 'XP1003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '70', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '40', 'Total_ADL_Independence_Percentage': '70', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '35', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '20', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '38', 'Stage_III_Percentage': '40', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '15', 'Adjuvant_Chemotherapy_Received_Percentage': '45', 'Postoperative_RT_Received_Percentage': '55', 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'CMF', 'Common_Adjuvant_Regimen_1': 'Docetaxel', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide', 'Tamoxifen_Percentage': '13', 'Letrozole_Percentage': '22', 'Anastrozole_Percentage': '15', 'Antidiarrheal_Agent_Probiotics_Percentage': '28', 'Antiemetic_Agent_Percentage': '58', 'Painkiller_Antipyretic_Percentage': '42', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '42', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '58', 'Months_Between_Surgery_And_Index_Date': '1.8'}]\n",
      "File created: Xpovio (Selinexor)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Xpovio (Selinexor)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Xtandi (Enzalutamide)\",\n",
      "    \"STUDYID\": \"XtandiStudy001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 0.5,\n",
      "    \"Male_Percentage\": 99.5,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 85.0,\n",
      "    \"LHRH_Use_Percentage\": 70.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 10.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 25.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 30.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 12.0,\n",
      "    \"Stage_II_Percentage\": 28.0,\n",
      "    \"Stage_III_Percentage\": 35.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7.0,\n",
      "    \"Stroke_Percentage\": 4.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 5.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 2.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 8.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 15.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 0.1,\n",
      "    \"Letrozole_Percentage\": 0.1,\n",
      "    \"Anastrozole_Percentage\": 0.1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 12.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 18.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 25.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15.0,\n",
      "    \"Beds_200_To_499_Percentage\": 45.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xtandi (Enzalutamide)\",\n",
      "    \"STUDYID\": \"XtandiStudy002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 75,\n",
      "    \"Female_Percentage\": 0.3,\n",
      "    \"Male_Percentage\": 99.7,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 80.0,\n",
      "    \"LHRH_Use_Percentage\": 75.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 8.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 22.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 38.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 32.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 10.0,\n",
      "    \"Stage_II_Percentage\": 25.0,\n",
      "    \"Stage_III_Percentage\": 40.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8.0,\n",
      "    \"Stroke_Percentage\": 5.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 6.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 3.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 7.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 12.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 0.1,\n",
      "    \"Letrozole_Percentage\": 0.1,\n",
      "    \"Anastrozole_Percentage\": 0.1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 15.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 20.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 28.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18.0,\n",
      "    \"Beds_200_To_499_Percentage\": 42.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 4\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Xtandi (Enzalutamide)\",\n",
      "    \"STUDYID\": \"XtandiStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 0.4,\n",
      "    \"Male_Percentage\": 99.6,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 35.0,\n",
      "    \"Total_ADL_Independence_Percentage\": 90.0,\n",
      "    \"LHRH_Use_Percentage\": 65.0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12.0,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28.0,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32.0,\n",
      "    \"Tumor_Stage_T4_Percentage\": 28.0,\n",
      "    \"Nodal_Stage_N0_Percentage\": 65.0,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20.0,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10.0,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.0,\n",
      "    \"Stage_I_Percentage\": 15.0,\n",
      "    \"Stage_II_Percentage\": 30.0,\n",
      "    \"Stage_III_Percentage\": 30.0,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15.0,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6.0,\n",
      "    \"Stroke_Percentage\": 3.0,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8.0,\n",
      "    \"Myocardial_Infarction_Percentage\": 4.0,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 1.0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 9.0,\n",
      "    \"Postoperative_RT_Received_Percentage\": 18.0,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 0.1,\n",
      "    \"Letrozole_Percentage\": 0.1,\n",
      "    \"Anastrozole_Percentage\": 0.1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 10.0,\n",
      "    \"Antiemetic_Agent_Percentage\": 15.0,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 22.0,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20.0,\n",
      "    \"Beds_200_To_499_Percentage\": 50.0,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30.0,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60.0,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Xtandi (Enzalutamide)', 'STUDYID': 'XtandiStudy001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 72, 'Female_Percentage': 0.5, 'Male_Percentage': 99.5, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32.0, 'Total_ADL_Independence_Percentage': 85.0, 'LHRH_Use_Percentage': 70.0, 'Tumor_Stage_T1_Percentage': 10.0, 'Tumor_Stage_T2_Percentage': 25.0, 'Tumor_Stage_T3_Percentage': 35.0, 'Tumor_Stage_T4_Percentage': 30.0, 'Nodal_Stage_N0_Percentage': 60.0, 'Nodal_Stage_N1_Percentage': 25.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 12.0, 'Stage_II_Percentage': 28.0, 'Stage_III_Percentage': 35.0, 'Diabetes_Mellitus_Percentage': 18.0, 'Congestive_Heart_Failure_Percentage': 7.0, 'Stroke_Percentage': 4.0, 'Atrial_Fibrillation_Percentage': 9.0, 'Myocardial_Infarction_Percentage': 5.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 2.0, 'Adjuvant_Chemotherapy_Received_Percentage': 8.0, 'Postoperative_RT_Received_Percentage': 15.0, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'None', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 0.1, 'Letrozole_Percentage': 0.1, 'Anastrozole_Percentage': 0.1, 'Antidiarrheal_Agent_Probiotics_Percentage': 12.0, 'Antiemetic_Agent_Percentage': 18.0, 'Painkiller_Antipyretic_Percentage': 25.0, 'Beds_Less_Than_200_Percentage': 15.0, 'Beds_200_To_499_Percentage': 45.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 65.0, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Xtandi (Enzalutamide)', 'STUDYID': 'XtandiStudy002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 75, 'Female_Percentage': 0.3, 'Male_Percentage': 99.7, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28.0, 'Total_ADL_Independence_Percentage': 80.0, 'LHRH_Use_Percentage': 75.0, 'Tumor_Stage_T1_Percentage': 8.0, 'Tumor_Stage_T2_Percentage': 22.0, 'Tumor_Stage_T3_Percentage': 38.0, 'Tumor_Stage_T4_Percentage': 32.0, 'Nodal_Stage_N0_Percentage': 55.0, 'Nodal_Stage_N1_Percentage': 30.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 10.0, 'Stage_II_Percentage': 25.0, 'Stage_III_Percentage': 40.0, 'Diabetes_Mellitus_Percentage': 20.0, 'Congestive_Heart_Failure_Percentage': 8.0, 'Stroke_Percentage': 5.0, 'Atrial_Fibrillation_Percentage': 10.0, 'Myocardial_Infarction_Percentage': 6.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 3.0, 'Adjuvant_Chemotherapy_Received_Percentage': 7.0, 'Postoperative_RT_Received_Percentage': 12.0, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'None', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 0.1, 'Letrozole_Percentage': 0.1, 'Anastrozole_Percentage': 0.1, 'Antidiarrheal_Agent_Probiotics_Percentage': 15.0, 'Antiemetic_Agent_Percentage': 20.0, 'Painkiller_Antipyretic_Percentage': 28.0, 'Beds_Less_Than_200_Percentage': 18.0, 'Beds_200_To_499_Percentage': 42.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 40.0, 'Designated_Cancer_Hospital_Percentage': 70.0, 'Months_Between_Surgery_And_Index_Date': 4}, {'Drug_Name': 'Xtandi (Enzalutamide)', 'STUDYID': 'XtandiStudy003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 0.4, 'Male_Percentage': 99.6, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 35.0, 'Total_ADL_Independence_Percentage': 90.0, 'LHRH_Use_Percentage': 65.0, 'Tumor_Stage_T1_Percentage': 12.0, 'Tumor_Stage_T2_Percentage': 28.0, 'Tumor_Stage_T3_Percentage': 32.0, 'Tumor_Stage_T4_Percentage': 28.0, 'Nodal_Stage_N0_Percentage': 65.0, 'Nodal_Stage_N1_Percentage': 20.0, 'Nodal_Stage_N2_Percentage': 10.0, 'Nodal_Stage_N3_Percentage': 5.0, 'Stage_I_Percentage': 15.0, 'Stage_II_Percentage': 30.0, 'Stage_III_Percentage': 30.0, 'Diabetes_Mellitus_Percentage': 15.0, 'Congestive_Heart_Failure_Percentage': 6.0, 'Stroke_Percentage': 3.0, 'Atrial_Fibrillation_Percentage': 8.0, 'Myocardial_Infarction_Percentage': 4.0, 'Neoadjuvant_Chemotherapy_Received_Percentage': 1.0, 'Adjuvant_Chemotherapy_Received_Percentage': 9.0, 'Postoperative_RT_Received_Percentage': 18.0, 'Common_Neoadjuvant_Regimen_1': 'Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin', 'Common_Adjuvant_Regimen_1': 'None', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 0.1, 'Letrozole_Percentage': 0.1, 'Anastrozole_Percentage': 0.1, 'Antidiarrheal_Agent_Probiotics_Percentage': 10.0, 'Antiemetic_Agent_Percentage': 15.0, 'Painkiller_Antipyretic_Percentage': 22.0, 'Beds_Less_Than_200_Percentage': 20.0, 'Beds_200_To_499_Percentage': 50.0, 'Beds_Greater_Or_Equal_To_500_Percentage': 30.0, 'Designated_Cancer_Hospital_Percentage': 60.0, 'Months_Between_Surgery_And_Index_Date': 2}]\n",
      "File created: Xtandi (Enzalutamide)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Xtandi (Enzalutamide)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zaltrap\",\n",
      "    \"STUDYID\": \"ZALTRAP2023US001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 42,\n",
      "    \"Male_Percentage\": 58,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 10,\n",
      "    \"Tumor_Stage_T2_Percentage\": 25,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 25,\n",
      "    \"Nodal_Stage_N0_Percentage\": 30,\n",
      "    \"Nodal_Stage_N1_Percentage\": 35,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 15,\n",
      "    \"Stage_I_Percentage\": 15,\n",
      "    \"Stage_II_Percentage\": 30,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FOLFOX\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zaltrap\",\n",
      "    \"STUDYID\": \"ZALTRAP2022EU002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 38,\n",
      "    \"Male_Percentage\": 62,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 40,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 8,\n",
      "    \"Tumor_Stage_T2_Percentage\": 22,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45,\n",
      "    \"Tumor_Stage_T4_Percentage\": 25,\n",
      "    \"Nodal_Stage_N0_Percentage\": 28,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32,\n",
      "    \"Nodal_Stage_N2_Percentage\": 25,\n",
      "    \"Nodal_Stage_N3_Percentage\": 15,\n",
      "    \"Stage_I_Percentage\": 12,\n",
      "    \"Stage_II_Percentage\": 28,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 6,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 8,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FOLFIRI\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FOLFOX\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 45,\n",
      "    \"Antiemetic_Agent_Percentage\": 70,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zaltrap\",\n",
      "    \"STUDYID\": \"ZALTRAP2024JP003\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 24.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 25,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 25,\n",
      "    \"Nodal_Stage_N0_Percentage\": 35,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 15,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50,\n",
      "    \"Postoperative_RT_Received_Percentage\": 25,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"XELOX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"XELOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FOLFOX\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zaltrap', 'STUDYID': 'ZALTRAP2023US001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 42, 'Male_Percentage': 58, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 10, 'Tumor_Stage_T2_Percentage': 25, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 25, 'Nodal_Stage_N0_Percentage': 30, 'Nodal_Stage_N1_Percentage': 35, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 15, 'Stage_I_Percentage': 15, 'Stage_II_Percentage': 30, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'CAPOX', 'Common_Adjuvant_Regimen_1': 'CAPOX', 'Common_Adjuvant_Regimen_2': 'FOLFOX', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zaltrap', 'STUDYID': 'ZALTRAP2022EU002', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 38, 'Male_Percentage': 62, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 40, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 8, 'Tumor_Stage_T2_Percentage': 22, 'Tumor_Stage_T3_Percentage': 45, 'Tumor_Stage_T4_Percentage': 25, 'Nodal_Stage_N0_Percentage': 28, 'Nodal_Stage_N1_Percentage': 32, 'Nodal_Stage_N2_Percentage': 25, 'Nodal_Stage_N3_Percentage': 15, 'Stage_I_Percentage': 12, 'Stage_II_Percentage': 28, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 6, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 8, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 40, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'FOLFIRI', 'Common_Adjuvant_Regimen_1': 'CAPOX', 'Common_Adjuvant_Regimen_2': 'FOLFOX', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 45, 'Antiemetic_Agent_Percentage': 70, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Zaltrap', 'STUDYID': 'ZALTRAP2024JP003', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 24.5, 'Smoking_History_Yes_Percentage': 25, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 25, 'Nodal_Stage_N0_Percentage': 35, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 15, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 50, 'Postoperative_RT_Received_Percentage': 25, 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'XELOX', 'Common_Adjuvant_Regimen_1': 'XELOX', 'Common_Adjuvant_Regimen_2': 'FOLFOX', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 1.5}]\n",
      "File created: Zaltrap (Ziv-Aflibercept)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zaltrap (Ziv-Aflibercept)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zanubrutinib\",\n",
      "    \"STUDYID\": \"Zanu2023-US-01\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 35,\n",
      "    \"Male_Percentage\": 65,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 42,\n",
      "    \"Total_ADL_Independence_Percentage\": 88,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 38,\n",
      "    \"Postoperative_RT_Received_Percentage\": 45,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DA-EPOCH-R\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"BR\",\n",
      "    \"Tamoxifen_Percentage\": 8,\n",
      "    \"Letrozole_Percentage\": 5,\n",
      "    \"Anastrozole_Percentage\": 7,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 30,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zanubrutinib\",\n",
      "    \"STUDYID\": \"Zanu2023-EU-02\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 40,\n",
      "    \"Male_Percentage\": 60,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 38,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 14,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 35,\n",
      "    \"Postoperative_RT_Received_Percentage\": 42,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CVP\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Bendamustine\",\n",
      "    \"Tamoxifen_Percentage\": 7,\n",
      "    \"Letrozole_Percentage\": 6,\n",
      "    \"Anastrozole_Percentage\": 9,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28,\n",
      "    \"Antiemetic_Agent_Percentage\": 42,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 32,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zanubrutinib\",\n",
      "    \"STUDYID\": \"Zanu2022-JP-03\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 30,\n",
      "    \"Male_Percentage\": 70,\n",
      "    \"Median_BMI\": 24.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 50,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 38,\n",
      "    \"Tumor_Stage_T4_Percentage\": 12,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 22,\n",
      "    \"Nodal_Stage_N2_Percentage\": 12,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Postoperative_RT_Received_Percentage\": 48,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Hyper-CVAD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CVP\",\n",
      "    \"Tamoxifen_Percentage\": 9,\n",
      "    \"Letrozole_Percentage\": 4,\n",
      "    \"Anastrozole_Percentage\": 6,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 22,\n",
      "    \"Antiemetic_Agent_Percentage\": 38,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 28,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zanubrutinib\",\n",
      "    \"STUDYID\": \"Zanu2024-CA-04\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 38,\n",
      "    \"Male_Percentage\": 62,\n",
      "    \"Median_BMI\": 28.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 40,\n",
      "    \"Total_ADL_Independence_Percentage\": 87,\n",
      "    \"LHRH_Use_Percentage\": 13,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 29,\n",
      "    \"Tumor_Stage_T3_Percentage\": 41,\n",
      "    \"Tumor_Stage_T4_Percentage\": 16,\n",
      "    \"Nodal_Stage_N0_Percentage\": 54,\n",
      "    \"Nodal_Stage_N1_Percentage\": 26,\n",
      "    \"Nodal_Stage_N2_Percentage\": 16,\n",
      "    \"Nodal_Stage_N3_Percentage\": 4,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 34,\n",
      "    \"Stage_III_Percentage\": 47,\n",
      "    \"Diabetes_Mellitus_Percentage\": 19,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 21,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 37,\n",
      "    \"Postoperative_RT_Received_Percentage\": 44,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Bendamustine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"BR\",\n",
      "    \"Tamoxifen_Percentage\": 8,\n",
      "    \"Letrozole_Percentage\": 5,\n",
      "    \"Anastrozole_Percentage\": 7,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 26,\n",
      "    \"Antiemetic_Agent_Percentage\": 41,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 31,\n",
      "    \"Beds_Less_Than_200_Percentage\": 14,\n",
      "    \"Beds_200_To_499_Percentage\": 46,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zanubrutinib', 'STUDYID': 'Zanu2023-US-01', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 35, 'Male_Percentage': 65, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 42, 'Total_ADL_Independence_Percentage': 88, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 38, 'Postoperative_RT_Received_Percentage': 45, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'DA-EPOCH-R', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'BR', 'Tamoxifen_Percentage': 8, 'Letrozole_Percentage': 5, 'Anastrozole_Percentage': 7, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 30, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zanubrutinib', 'STUDYID': 'Zanu2023-EU-02', 'YEAR': 2023, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 40, 'Male_Percentage': 60, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 38, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 14, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 35, 'Postoperative_RT_Received_Percentage': 42, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'CVP', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'Bendamustine', 'Tamoxifen_Percentage': 7, 'Letrozole_Percentage': 6, 'Anastrozole_Percentage': 9, 'Antidiarrheal_Agent_Probiotics_Percentage': 28, 'Antiemetic_Agent_Percentage': 42, 'Painkiller_Antipyretic_Percentage': 32, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Zanubrutinib', 'STUDYID': 'Zanu2022-JP-03', 'YEAR': 2022, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 30, 'Male_Percentage': 70, 'Median_BMI': 24.5, 'Smoking_History_Yes_Percentage': 50, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 38, 'Tumor_Stage_T4_Percentage': 12, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 22, 'Nodal_Stage_N2_Percentage': 12, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 40, 'Postoperative_RT_Received_Percentage': 48, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'Hyper-CVAD', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'CVP', 'Tamoxifen_Percentage': 9, 'Letrozole_Percentage': 4, 'Anastrozole_Percentage': 6, 'Antidiarrheal_Agent_Probiotics_Percentage': 22, 'Antiemetic_Agent_Percentage': 38, 'Painkiller_Antipyretic_Percentage': 28, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 1}, {'Drug_Name': 'Zanubrutinib', 'STUDYID': 'Zanu2024-CA-04', 'YEAR': 2024, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 70, 'Female_Percentage': 38, 'Male_Percentage': 62, 'Median_BMI': 28.0, 'Smoking_History_Yes_Percentage': 40, 'Total_ADL_Independence_Percentage': 87, 'LHRH_Use_Percentage': 13, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 29, 'Tumor_Stage_T3_Percentage': 41, 'Tumor_Stage_T4_Percentage': 16, 'Nodal_Stage_N0_Percentage': 54, 'Nodal_Stage_N1_Percentage': 26, 'Nodal_Stage_N2_Percentage': 16, 'Nodal_Stage_N3_Percentage': 4, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 34, 'Stage_III_Percentage': 47, 'Diabetes_Mellitus_Percentage': 19, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 21, 'Adjuvant_Chemotherapy_Received_Percentage': 37, 'Postoperative_RT_Received_Percentage': 44, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'Bendamustine', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'BR', 'Tamoxifen_Percentage': 8, 'Letrozole_Percentage': 5, 'Anastrozole_Percentage': 7, 'Antidiarrheal_Agent_Probiotics_Percentage': 26, 'Antiemetic_Agent_Percentage': 41, 'Painkiller_Antipyretic_Percentage': 31, 'Beds_Less_Than_200_Percentage': 14, 'Beds_200_To_499_Percentage': 46, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 2}]\n",
      "File created: Zanubrutinib_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zanubrutinib\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zarxio\",\n",
      "    \"STUDYID\": \"ZarxioStudy001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 25,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 20,\n",
      "    \"Tumor_Stage_T4_Percentage\": 10,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 30,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 20,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 48,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FAC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": 28,\n",
      "    \"Letrozole_Percentage\": 32,\n",
      "    \"Anastrozole_Percentage\": 25,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 18,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zarxio\",\n",
      "    \"STUDYID\": \"ZarxioStudy002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 25,\n",
      "    \"Tumor_Stage_T4_Percentage\": 5,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 45,\n",
      "    \"Stage_III_Percentage\": 25,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 52,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"TC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": 30,\n",
      "    \"Letrozole_Percentage\": 35,\n",
      "    \"Anastrozole_Percentage\": 20,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20,\n",
      "    \"Antiemetic_Agent_Percentage\": 70,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zarxio\",\n",
      "    \"STUDYID\": \"ZarxioStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 26.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 18,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 7,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 35,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 42,\n",
      "    \"Stage_III_Percentage\": 28,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 12,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 55,\n",
      "    \"Postoperative_RT_Received_Percentage\": 42,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Tamoxifen_Percentage\": 32,\n",
      "    \"Letrozole_Percentage\": 38,\n",
      "    \"Anastrozole_Percentage\": 18,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 22,\n",
      "    \"Antiemetic_Agent_Percentage\": 72,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 62,\n",
      "    \"Beds_Less_Than_200_Percentage\": 8,\n",
      "    \"Beds_200_To_499_Percentage\": 52,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 4\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zarxio', 'STUDYID': 'ZarxioStudy001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 25, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 20, 'Tumor_Stage_T4_Percentage': 10, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 30, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 20, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 48, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'FAC', 'Common_Neoadjuvant_Regimen_2': 'TC', 'Common_Adjuvant_Regimen_1': 'AC', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': 28, 'Letrozole_Percentage': 32, 'Anastrozole_Percentage': 25, 'Antidiarrheal_Agent_Probiotics_Percentage': 18, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zarxio', 'STUDYID': 'ZarxioStudy002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 25, 'Tumor_Stage_T4_Percentage': 5, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 45, 'Stage_III_Percentage': 25, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 52, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'TC', 'Common_Neoadjuvant_Regimen_2': 'EC', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': 30, 'Letrozole_Percentage': 35, 'Anastrozole_Percentage': 20, 'Antidiarrheal_Agent_Probiotics_Percentage': 20, 'Antiemetic_Agent_Percentage': 70, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Zarxio', 'STUDYID': 'ZarxioStudy003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 26.9, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 18, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 7, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 35, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 42, 'Stage_III_Percentage': 28, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 12, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 28, 'Adjuvant_Chemotherapy_Received_Percentage': 55, 'Postoperative_RT_Received_Percentage': 42, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel', 'Common_Adjuvant_Regimen_1': 'Taxol', 'Common_Adjuvant_Regimen_2': 'FEC', 'Tamoxifen_Percentage': 32, 'Letrozole_Percentage': 38, 'Anastrozole_Percentage': 18, 'Antidiarrheal_Agent_Probiotics_Percentage': 22, 'Antiemetic_Agent_Percentage': 72, 'Painkiller_Antipyretic_Percentage': 62, 'Beds_Less_Than_200_Percentage': 8, 'Beds_200_To_499_Percentage': 52, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 4}]\n",
      "File created: Zarxio (Filgrastim)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zarxio (Filgrastim)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zejula (Niraparib Tosylate Monohydrate)\",\n",
      "    \"STUDYID\": \"ZejulaStudy001\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"62\",\n",
      "    \"Female_Percentage\": \"99\",\n",
      "    \"Male_Percentage\": \"1\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"15\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"15\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"50\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"12\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"3\",\n",
      "    \"Stroke_Percentage\": \"2\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"5\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"1\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"65\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"30\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Paclitaxel/Carboplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Doxorubicin/Cyclophosphamide\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Carboplatin/Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Paclitaxel\",\n",
      "    \"Tamoxifen_Percentage\": \"2\",\n",
      "    \"Letrozole_Percentage\": \"1\",\n",
      "    \"Anastrozole_Percentage\": \"1\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"25\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"70\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"40\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"10\",\n",
      "    \"Beds_200_To_499_Percentage\": \"40\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"50\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zejula (Niraparib Tosylate Monohydrate)\",\n",
      "    \"STUDYID\": \"ZejulaStudy002\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"98\",\n",
      "    \"Male_Percentage\": \"2\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"18\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"7\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"27\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"9\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"13\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"54\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"14\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"4\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"6\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"2\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"63\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"32\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin/Docetaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Gemcitabine/Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": \"3\",\n",
      "    \"Letrozole_Percentage\": \"2\",\n",
      "    \"Anastrozole_Percentage\": \"2\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"27\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"72\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"42\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"38\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"50\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"72\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zejula (Niraparib Tosylate Monohydrate)\",\n",
      "    \"STUDYID\": \"ZejulaStudy003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"97\",\n",
      "    \"Male_Percentage\": \"3\",\n",
      "    \"Median_BMI\": \"26.9\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"20\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"75\",\n",
      "    \"LHRH_Use_Percentage\": \"6\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"11\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"29\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"39\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"21\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"59\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"26\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"11\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"4\",\n",
      "    \"Stage_I_Percentage\": \"14\",\n",
      "    \"Stage_II_Percentage\": \"34\",\n",
      "    \"Stage_III_Percentage\": \"52\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"13\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"5\",\n",
      "    \"Stroke_Percentage\": \"1\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"4\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"3\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"21\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"64\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"31\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Taxol/Carboplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Carboplatin/Pemetrexed\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel/Cyclophosphamide\",\n",
      "    \"Tamoxifen_Percentage\": \"4\",\n",
      "    \"Letrozole_Percentage\": \"3\",\n",
      "    \"Anastrozole_Percentage\": \"3\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"26\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"71\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"41\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"11\",\n",
      "    \"Beds_200_To_499_Percentage\": \"39\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"50\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"71\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"4\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zejula (Niraparib Tosylate Monohydrate)\",\n",
      "    \"STUDYID\": \"ZejulaStudy004\",\n",
      "    \"YEAR\": \"2024\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"300\",\n",
      "    \"Median_Age\": \"63\",\n",
      "    \"Female_Percentage\": \"96\",\n",
      "    \"Male_Percentage\": \"4\",\n",
      "    \"Median_BMI\": \"27.2\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"17\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"8\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"9\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"31\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"41\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"19\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"61\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"24\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"3\",\n",
      "    \"Stage_I_Percentage\": \"16\",\n",
      "    \"Stage_II_Percentage\": \"36\",\n",
      "    \"Stage_III_Percentage\": \"48\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"2\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"7\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"1\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"23\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"62\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"33\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin/Paclitaxel\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Pemetrexed/Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Cyclophosphamide\",\n",
      "    \"Tamoxifen_Percentage\": \"5\",\n",
      "    \"Letrozole_Percentage\": \"4\",\n",
      "    \"Anastrozole_Percentage\": \"4\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"28\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"73\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"43\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"13\",\n",
      "    \"Beds_200_To_499_Percentage\": \"37\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"50\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"73\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zejula (Niraparib Tosylate Monohydrate)', 'STUDYID': 'ZejulaStudy001', 'YEAR': '2022', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '62', 'Female_Percentage': '99', 'Male_Percentage': '1', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '15', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '10', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '20', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '15', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '50', 'Diabetes_Mellitus_Percentage': '12', 'Congestive_Heart_Failure_Percentage': '3', 'Stroke_Percentage': '2', 'Atrial_Fibrillation_Percentage': '5', 'Myocardial_Infarction_Percentage': '1', 'Neoadjuvant_Chemotherapy_Received_Percentage': '20', 'Adjuvant_Chemotherapy_Received_Percentage': '65', 'Postoperative_RT_Received_Percentage': '30', 'Common_Neoadjuvant_Regimen_1': 'Paclitaxel/Carboplatin', 'Common_Neoadjuvant_Regimen_2': 'Doxorubicin/Cyclophosphamide', 'Common_Adjuvant_Regimen_1': 'Carboplatin/Gemcitabine', 'Common_Adjuvant_Regimen_2': 'Paclitaxel', 'Tamoxifen_Percentage': '2', 'Letrozole_Percentage': '1', 'Anastrozole_Percentage': '1', 'Antidiarrheal_Agent_Probiotics_Percentage': '25', 'Antiemetic_Agent_Percentage': '70', 'Painkiller_Antipyretic_Percentage': '40', 'Beds_Less_Than_200_Percentage': '10', 'Beds_200_To_499_Percentage': '40', 'Beds_Greater_Or_Equal_To_500_Percentage': '50', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Zejula (Niraparib Tosylate Monohydrate)', 'STUDYID': 'ZejulaStudy002', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '68', 'Female_Percentage': '98', 'Male_Percentage': '2', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '18', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '7', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '38', 'Tumor_Stage_T4_Percentage': '22', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '27', 'Nodal_Stage_N2_Percentage': '9', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '13', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '54', 'Diabetes_Mellitus_Percentage': '14', 'Congestive_Heart_Failure_Percentage': '4', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '6', 'Myocardial_Infarction_Percentage': '2', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '63', 'Postoperative_RT_Received_Percentage': '32', 'Common_Neoadjuvant_Regimen_1': 'Carboplatin/Docetaxel', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'Gemcitabine/Cisplatin', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': '3', 'Letrozole_Percentage': '2', 'Anastrozole_Percentage': '2', 'Antidiarrheal_Agent_Probiotics_Percentage': '27', 'Antiemetic_Agent_Percentage': '72', 'Painkiller_Antipyretic_Percentage': '42', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '38', 'Beds_Greater_Or_Equal_To_500_Percentage': '50', 'Designated_Cancer_Hospital_Percentage': '72', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Zejula (Niraparib Tosylate Monohydrate)', 'STUDYID': 'ZejulaStudy003', 'YEAR': '2023', 'Country': 'Germany', 'Dataset': 'MDV', 'Patient_Count': '480', 'Median_Age': '65', 'Female_Percentage': '97', 'Male_Percentage': '3', 'Median_BMI': '26.9', 'Smoking_History_Yes_Percentage': '20', 'Total_ADL_Independence_Percentage': '75', 'LHRH_Use_Percentage': '6', 'Tumor_Stage_T1_Percentage': '11', 'Tumor_Stage_T2_Percentage': '29', 'Tumor_Stage_T3_Percentage': '39', 'Tumor_Stage_T4_Percentage': '21', 'Nodal_Stage_N0_Percentage': '59', 'Nodal_Stage_N1_Percentage': '26', 'Nodal_Stage_N2_Percentage': '11', 'Nodal_Stage_N3_Percentage': '4', 'Stage_I_Percentage': '14', 'Stage_II_Percentage': '34', 'Stage_III_Percentage': '52', 'Diabetes_Mellitus_Percentage': '13', 'Congestive_Heart_Failure_Percentage': '5', 'Stroke_Percentage': '1', 'Atrial_Fibrillation_Percentage': '4', 'Myocardial_Infarction_Percentage': '3', 'Neoadjuvant_Chemotherapy_Received_Percentage': '21', 'Adjuvant_Chemotherapy_Received_Percentage': '64', 'Postoperative_RT_Received_Percentage': '31', 'Common_Neoadjuvant_Regimen_1': 'Taxol/Carboplatin', 'Common_Neoadjuvant_Regimen_2': 'EC', 'Common_Adjuvant_Regimen_1': 'Carboplatin/Pemetrexed', 'Common_Adjuvant_Regimen_2': 'Docetaxel/Cyclophosphamide', 'Tamoxifen_Percentage': '4', 'Letrozole_Percentage': '3', 'Anastrozole_Percentage': '3', 'Antidiarrheal_Agent_Probiotics_Percentage': '26', 'Antiemetic_Agent_Percentage': '71', 'Painkiller_Antipyretic_Percentage': '41', 'Beds_Less_Than_200_Percentage': '11', 'Beds_200_To_499_Percentage': '39', 'Beds_Greater_Or_Equal_To_500_Percentage': '50', 'Designated_Cancer_Hospital_Percentage': '71', 'Months_Between_Surgery_And_Index_Date': '4'}, {'Drug_Name': 'Zejula (Niraparib Tosylate Monohydrate)', 'STUDYID': 'ZejulaStudy004', 'YEAR': '2024', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '300', 'Median_Age': '63', 'Female_Percentage': '96', 'Male_Percentage': '4', 'Median_BMI': '27.2', 'Smoking_History_Yes_Percentage': '17', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '8', 'Tumor_Stage_T1_Percentage': '9', 'Tumor_Stage_T2_Percentage': '31', 'Tumor_Stage_T3_Percentage': '41', 'Tumor_Stage_T4_Percentage': '19', 'Nodal_Stage_N0_Percentage': '61', 'Nodal_Stage_N1_Percentage': '24', 'Nodal_Stage_N2_Percentage': '12', 'Nodal_Stage_N3_Percentage': '3', 'Stage_I_Percentage': '16', 'Stage_II_Percentage': '36', 'Stage_III_Percentage': '48', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '2', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '7', 'Myocardial_Infarction_Percentage': '1', 'Neoadjuvant_Chemotherapy_Received_Percentage': '23', 'Adjuvant_Chemotherapy_Received_Percentage': '62', 'Postoperative_RT_Received_Percentage': '33', 'Common_Neoadjuvant_Regimen_1': 'Carboplatin/Paclitaxel', 'Common_Neoadjuvant_Regimen_2': 'AC', 'Common_Adjuvant_Regimen_1': 'Pemetrexed/Cisplatin', 'Common_Adjuvant_Regimen_2': 'Cyclophosphamide', 'Tamoxifen_Percentage': '5', 'Letrozole_Percentage': '4', 'Anastrozole_Percentage': '4', 'Antidiarrheal_Agent_Probiotics_Percentage': '28', 'Antiemetic_Agent_Percentage': '73', 'Painkiller_Antipyretic_Percentage': '43', 'Beds_Less_Than_200_Percentage': '13', 'Beds_200_To_499_Percentage': '37', 'Beds_Greater_Or_Equal_To_500_Percentage': '50', 'Designated_Cancer_Hospital_Percentage': '73', 'Months_Between_Surgery_And_Index_Date': '5'}]\n",
      "File created: Zejula (Niraparib Tosylate Monohydrate)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zejula (Niraparib Tosylate Monohydrate)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zelboraf (Vemurafenib)\",\n",
      "    \"STUDYID\": \"Zelb2020US\",\n",
      "    \"YEAR\": 2020,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 40,\n",
      "    \"Male_Percentage\": 60,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 65,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Postoperative_RT_Received_Percentage\": 25,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": null,\n",
      "    \"Common_Neoadjuvant_Regimen_2\": null,\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Dacarbazine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Interferon alfa-2b\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 40,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zelboraf (Vemurafenib)\",\n",
      "    \"STUDYID\": \"Zelb2021EU\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 35,\n",
      "    \"Male_Percentage\": 65,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 70,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Postoperative_RT_Received_Percentage\": 28,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": null,\n",
      "    \"Common_Neoadjuvant_Regimen_2\": null,\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Dacarbazine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"High-dose Interferon alfa-2b\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 45,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zelboraf (Vemurafenib)\",\n",
      "    \"STUDYID\": \"Zelb2022JP\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 25.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 55,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 70,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 5,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 10,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Postoperative_RT_Received_Percentage\": 22,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": null,\n",
      "    \"Common_Neoadjuvant_Regimen_2\": null,\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Dacarbazine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Nivolumab\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 35,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 25,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 35,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zelboraf (Vemurafenib)\",\n",
      "    \"STUDYID\": \"Zelb2023CA\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 380,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 38,\n",
      "    \"Male_Percentage\": 62,\n",
      "    \"Median_BMI\": 28.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 60,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 0,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 29,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 9,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 33,\n",
      "    \"Stage_III_Percentage\": 48,\n",
      "    \"Diabetes_Mellitus_Percentage\": 13,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 0,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 11,\n",
      "    \"Postoperative_RT_Received_Percentage\": 26,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": null,\n",
      "    \"Common_Neoadjuvant_Regimen_2\": null,\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Dacarbazine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Ipilimumab\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 32,\n",
      "    \"Antiemetic_Agent_Percentage\": 42,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 52,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 34,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.8\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zelboraf (Vemurafenib)', 'STUDYID': 'Zelb2020US', 'YEAR': 2020, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 40, 'Male_Percentage': 60, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 65, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 0, 'Adjuvant_Chemotherapy_Received_Percentage': 10, 'Postoperative_RT_Received_Percentage': 25, 'Common_Neoadjuvant_Regimen_1': None, 'Common_Neoadjuvant_Regimen_2': None, 'Common_Adjuvant_Regimen_1': 'Dacarbazine', 'Common_Adjuvant_Regimen_2': 'Interferon alfa-2b', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 40, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zelboraf (Vemurafenib)', 'STUDYID': 'Zelb2021EU', 'YEAR': 2021, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 35, 'Male_Percentage': 65, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 70, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 45, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 0, 'Adjuvant_Chemotherapy_Received_Percentage': 12, 'Postoperative_RT_Received_Percentage': 28, 'Common_Neoadjuvant_Regimen_1': None, 'Common_Neoadjuvant_Regimen_2': None, 'Common_Adjuvant_Regimen_1': 'Dacarbazine', 'Common_Adjuvant_Regimen_2': 'High-dose Interferon alfa-2b', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 45, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 1.5}, {'Drug_Name': 'Zelboraf (Vemurafenib)', 'STUDYID': 'Zelb2022JP', 'YEAR': 2022, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 25.5, 'Smoking_History_Yes_Percentage': 55, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 70, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 5, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 10, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 6, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 0, 'Adjuvant_Chemotherapy_Received_Percentage': 8, 'Postoperative_RT_Received_Percentage': 22, 'Common_Neoadjuvant_Regimen_1': None, 'Common_Neoadjuvant_Regimen_2': None, 'Common_Adjuvant_Regimen_1': 'Dacarbazine', 'Common_Adjuvant_Regimen_2': 'Nivolumab', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 35, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 25, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 35, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 2.5}, {'Drug_Name': 'Zelboraf (Vemurafenib)', 'STUDYID': 'Zelb2023CA', 'YEAR': 2023, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 380, 'Median_Age': 65, 'Female_Percentage': 38, 'Male_Percentage': 62, 'Median_BMI': 28.0, 'Smoking_History_Yes_Percentage': 60, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 0, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 29, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 58, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 9, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 33, 'Stage_III_Percentage': 48, 'Diabetes_Mellitus_Percentage': 13, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 0, 'Adjuvant_Chemotherapy_Received_Percentage': 11, 'Postoperative_RT_Received_Percentage': 26, 'Common_Neoadjuvant_Regimen_1': None, 'Common_Neoadjuvant_Regimen_2': None, 'Common_Adjuvant_Regimen_1': 'Dacarbazine', 'Common_Adjuvant_Regimen_2': 'Ipilimumab', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 32, 'Antiemetic_Agent_Percentage': 42, 'Painkiller_Antipyretic_Percentage': 52, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 34, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 1.8}]\n",
      "File created: Zelboraf (Vemurafenib)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zelboraf (Vemurafenib)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zepzelca (Lurbinectedin)\",\n",
      "    \"STUDYID\": \"ZEP2021-US-001\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"26.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"62\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"78\",\n",
      "    \"LHRH_Use_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"45\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"35\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"40\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Etoposide\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Etoposide + Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Irinotecan + Cisplatin\",\n",
      "    \"Tamoxifen_Percentage\": \"5\",\n",
      "    \"Letrozole_Percentage\": \"3\",\n",
      "    \"Anastrozole_Percentage\": \"2\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"20\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"60\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"50\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zepzelca (Lurbinectedin)\",\n",
      "    \"STUDYID\": \"ZEP2022-EU-002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"27.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"58\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"75\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"42\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"32\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"49\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"10\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"12\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"38\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"38\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Etoposide\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Etoposide\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Etoposide + Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Tamoxifen_Percentage\": \"6\",\n",
      "    \"Letrozole_Percentage\": \"4\",\n",
      "    \"Anastrozole_Percentage\": \"3\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"22\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"62\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"52\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"52\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zepzelca (Lurbinectedin)\",\n",
      "    \"STUDYID\": \"ZEP2023-UK-003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"46\",\n",
      "    \"Male_Percentage\": \"54\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"60\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"77\",\n",
      "    \"LHRH_Use_Percentage\": \"14\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"14\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"29\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"41\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"44\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"31\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"19\",\n",
      "    \"Stage_II_Percentage\": \"34\",\n",
      "    \"Stage_III_Percentage\": \"47\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"19\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"11\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"24\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"36\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"39\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Etoposide\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Etoposide + Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Irinotecan + Cisplatin\",\n",
      "    \"Tamoxifen_Percentage\": \"5\",\n",
      "    \"Letrozole_Percentage\": \"3\",\n",
      "    \"Anastrozole_Percentage\": \"2\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"21\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"61\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"51\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"19\",\n",
      "    \"Beds_200_To_499_Percentage\": \"51\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"61\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zepzelca (Lurbinectedin)', 'STUDYID': 'ZEP2021-US-001', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '26.5', 'Smoking_History_Yes_Percentage': '62', 'Total_ADL_Independence_Percentage': '78', 'LHRH_Use_Percentage': '12', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '45', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '35', 'Postoperative_RT_Received_Percentage': '40', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Etoposide', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Etoposide + Cisplatin', 'Common_Adjuvant_Regimen_2': 'Irinotecan + Cisplatin', 'Tamoxifen_Percentage': '5', 'Letrozole_Percentage': '3', 'Anastrozole_Percentage': '2', 'Antidiarrheal_Agent_Probiotics_Percentage': '20', 'Antiemetic_Agent_Percentage': '60', 'Painkiller_Antipyretic_Percentage': '50', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Zepzelca (Lurbinectedin)', 'STUDYID': 'ZEP2022-EU-002', 'YEAR': '2022', 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '27.1', 'Smoking_History_Yes_Percentage': '58', 'Total_ADL_Independence_Percentage': '75', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '42', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '42', 'Nodal_Stage_N1_Percentage': '32', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '49', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '10', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '12', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '38', 'Postoperative_RT_Received_Percentage': '38', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Etoposide', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Etoposide', 'Common_Adjuvant_Regimen_1': 'Etoposide + Cisplatin', 'Common_Adjuvant_Regimen_2': 'Paclitaxel + Carboplatin', 'Tamoxifen_Percentage': '6', 'Letrozole_Percentage': '4', 'Anastrozole_Percentage': '3', 'Antidiarrheal_Agent_Probiotics_Percentage': '22', 'Antiemetic_Agent_Percentage': '62', 'Painkiller_Antipyretic_Percentage': '52', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '52', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Zepzelca (Lurbinectedin)', 'STUDYID': 'ZEP2023-UK-003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '70', 'Female_Percentage': '46', 'Male_Percentage': '54', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '60', 'Total_ADL_Independence_Percentage': '77', 'LHRH_Use_Percentage': '14', 'Tumor_Stage_T1_Percentage': '14', 'Tumor_Stage_T2_Percentage': '29', 'Tumor_Stage_T3_Percentage': '41', 'Tumor_Stage_T4_Percentage': '16', 'Nodal_Stage_N0_Percentage': '44', 'Nodal_Stage_N1_Percentage': '31', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '19', 'Stage_II_Percentage': '34', 'Stage_III_Percentage': '47', 'Diabetes_Mellitus_Percentage': '19', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '11', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '24', 'Adjuvant_Chemotherapy_Received_Percentage': '36', 'Postoperative_RT_Received_Percentage': '39', 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Etoposide', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Etoposide + Cisplatin', 'Common_Adjuvant_Regimen_2': 'Irinotecan + Cisplatin', 'Tamoxifen_Percentage': '5', 'Letrozole_Percentage': '3', 'Anastrozole_Percentage': '2', 'Antidiarrheal_Agent_Probiotics_Percentage': '21', 'Antiemetic_Agent_Percentage': '61', 'Painkiller_Antipyretic_Percentage': '51', 'Beds_Less_Than_200_Percentage': '19', 'Beds_200_To_499_Percentage': '51', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '61', 'Months_Between_Surgery_And_Index_Date': '2.5'}]\n",
      "File created: Zepzelca (Lurbinectedin)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zepzelca (Lurbinectedin)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zevalin (Ibritumomab Tiuxetan)\",\n",
      "    \"STUDYID\": \"ZevalinStudy001\",\n",
      "    \"YEAR\": 2019,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 10,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CVP\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Rituximab\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 15,\n",
      "    \"Antiemetic_Agent_Percentage\": 50,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 40,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zevalin (Ibritumomab Tiuxetan)\",\n",
      "    \"STUDYID\": \"ZevalinStudy002\",\n",
      "    \"YEAR\": 2020,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 58,\n",
      "    \"Nodal_Stage_N1_Percentage\": 27,\n",
      "    \"Nodal_Stage_N2_Percentage\": 9,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 42,\n",
      "    \"Stage_III_Percentage\": 36,\n",
      "    \"Diabetes_Mellitus_Percentage\": 14,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 42,\n",
      "    \"Postoperative_RT_Received_Percentage\": 32,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CVP\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Rituximab\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 17,\n",
      "    \"Antiemetic_Agent_Percentage\": 52,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 62,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 52,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 42,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zevalin (Ibritumomab Tiuxetan)\",\n",
      "    \"STUDYID\": \"ZevalinStudy003\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 50,\n",
      "    \"Male_Percentage\": 50,\n",
      "    \"Median_BMI\": 29.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 38,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 10,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 34,\n",
      "    \"Tumor_Stage_T4_Percentage\": 16,\n",
      "    \"Nodal_Stage_N0_Percentage\": 56,\n",
      "    \"Nodal_Stage_N1_Percentage\": 29,\n",
      "    \"Nodal_Stage_N2_Percentage\": 8,\n",
      "    \"Nodal_Stage_N3_Percentage\": 7,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 44,\n",
      "    \"Stage_III_Percentage\": 36,\n",
      "    \"Diabetes_Mellitus_Percentage\": 16,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 14,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 44,\n",
      "    \"Postoperative_RT_Received_Percentage\": 34,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CVP\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Rituximab\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 19,\n",
      "    \"Antiemetic_Agent_Percentage\": 54,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 64,\n",
      "    \"Beds_Less_Than_200_Percentage\": 16,\n",
      "    \"Beds_200_To_499_Percentage\": 54,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 44,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 4\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zevalin (Ibritumomab Tiuxetan)\",\n",
      "    \"STUDYID\": \"ZevalinStudy004\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 47,\n",
      "    \"Male_Percentage\": 53,\n",
      "    \"Median_BMI\": 27.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 33,\n",
      "    \"Total_ADL_Independence_Percentage\": 83,\n",
      "    \"LHRH_Use_Percentage\": 5.5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 13,\n",
      "    \"Tumor_Stage_T2_Percentage\": 37,\n",
      "    \"Tumor_Stage_T3_Percentage\": 31,\n",
      "    \"Tumor_Stage_T4_Percentage\": 19,\n",
      "    \"Nodal_Stage_N0_Percentage\": 59,\n",
      "    \"Nodal_Stage_N1_Percentage\": 26,\n",
      "    \"Nodal_Stage_N2_Percentage\": 9.5,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5.5,\n",
      "    \"Stage_I_Percentage\": 23,\n",
      "    \"Stage_II_Percentage\": 41,\n",
      "    \"Stage_III_Percentage\": 36,\n",
      "    \"Diabetes_Mellitus_Percentage\": 13,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5.5,\n",
      "    \"Stroke_Percentage\": 3.5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7.5,\n",
      "    \"Myocardial_Infarction_Percentage\": 4.5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 11,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 41,\n",
      "    \"Postoperative_RT_Received_Percentage\": 31,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CVP\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Rituximab\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 16,\n",
      "    \"Antiemetic_Agent_Percentage\": 51,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 61,\n",
      "    \"Beds_Less_Than_200_Percentage\": 19,\n",
      "    \"Beds_200_To_499_Percentage\": 51,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 41,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zevalin (Ibritumomab Tiuxetan)', 'STUDYID': 'ZevalinStudy001', 'YEAR': 2019, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 10, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 40, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'CHOP', 'Common_Neoadjuvant_Regimen_2': 'CVP', 'Common_Adjuvant_Regimen_1': 'R-CHOP', 'Common_Adjuvant_Regimen_2': 'Rituximab', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 15, 'Antiemetic_Agent_Percentage': 50, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 40, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zevalin (Ibritumomab Tiuxetan)', 'STUDYID': 'ZevalinStudy002', 'YEAR': 2020, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 58, 'Nodal_Stage_N1_Percentage': 27, 'Nodal_Stage_N2_Percentage': 9, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 42, 'Stage_III_Percentage': 36, 'Diabetes_Mellitus_Percentage': 14, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 42, 'Postoperative_RT_Received_Percentage': 32, 'Common_Neoadjuvant_Regimen_1': 'CHOP', 'Common_Neoadjuvant_Regimen_2': 'CVP', 'Common_Adjuvant_Regimen_1': 'R-CHOP', 'Common_Adjuvant_Regimen_2': 'Rituximab', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 17, 'Antiemetic_Agent_Percentage': 52, 'Painkiller_Antipyretic_Percentage': 62, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 52, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 42, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Zevalin (Ibritumomab Tiuxetan)', 'STUDYID': 'ZevalinStudy003', 'YEAR': 2021, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 50, 'Male_Percentage': 50, 'Median_BMI': 29.0, 'Smoking_History_Yes_Percentage': 38, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 10, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 34, 'Tumor_Stage_T4_Percentage': 16, 'Nodal_Stage_N0_Percentage': 56, 'Nodal_Stage_N1_Percentage': 29, 'Nodal_Stage_N2_Percentage': 8, 'Nodal_Stage_N3_Percentage': 7, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 44, 'Stage_III_Percentage': 36, 'Diabetes_Mellitus_Percentage': 16, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 14, 'Adjuvant_Chemotherapy_Received_Percentage': 44, 'Postoperative_RT_Received_Percentage': 34, 'Common_Neoadjuvant_Regimen_1': 'CHOP', 'Common_Neoadjuvant_Regimen_2': 'CVP', 'Common_Adjuvant_Regimen_1': 'R-CHOP', 'Common_Adjuvant_Regimen_2': 'Rituximab', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 19, 'Antiemetic_Agent_Percentage': 54, 'Painkiller_Antipyretic_Percentage': 64, 'Beds_Less_Than_200_Percentage': 16, 'Beds_200_To_499_Percentage': 54, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 44, 'Months_Between_Surgery_And_Index_Date': 4}, {'Drug_Name': 'Zevalin (Ibritumomab Tiuxetan)', 'STUDYID': 'ZevalinStudy004', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 65, 'Female_Percentage': 47, 'Male_Percentage': 53, 'Median_BMI': 27.8, 'Smoking_History_Yes_Percentage': 33, 'Total_ADL_Independence_Percentage': 83, 'LHRH_Use_Percentage': 5.5, 'Tumor_Stage_T1_Percentage': 13, 'Tumor_Stage_T2_Percentage': 37, 'Tumor_Stage_T3_Percentage': 31, 'Tumor_Stage_T4_Percentage': 19, 'Nodal_Stage_N0_Percentage': 59, 'Nodal_Stage_N1_Percentage': 26, 'Nodal_Stage_N2_Percentage': 9.5, 'Nodal_Stage_N3_Percentage': 5.5, 'Stage_I_Percentage': 23, 'Stage_II_Percentage': 41, 'Stage_III_Percentage': 36, 'Diabetes_Mellitus_Percentage': 13, 'Congestive_Heart_Failure_Percentage': 5.5, 'Stroke_Percentage': 3.5, 'Atrial_Fibrillation_Percentage': 7.5, 'Myocardial_Infarction_Percentage': 4.5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 11, 'Adjuvant_Chemotherapy_Received_Percentage': 41, 'Postoperative_RT_Received_Percentage': 31, 'Common_Neoadjuvant_Regimen_1': 'CHOP', 'Common_Neoadjuvant_Regimen_2': 'CVP', 'Common_Adjuvant_Regimen_1': 'R-CHOP', 'Common_Adjuvant_Regimen_2': 'Rituximab', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 16, 'Antiemetic_Agent_Percentage': 51, 'Painkiller_Antipyretic_Percentage': 61, 'Beds_Less_Than_200_Percentage': 19, 'Beds_200_To_499_Percentage': 51, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 41, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Zevalin (Ibritumomab Tiuxetan)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zevalin (Ibritumomab Tiuxetan)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zinecard (Dexrazoxane Hydrochloride)\",\n",
      "    \"STUDYID\": \"ZinecardStudy001\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 65,\n",
      "    \"Male_Percentage\": 35,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 22,\n",
      "    \"Total_ADL_Independence_Percentage\": 88,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 40,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 45,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 10,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 3,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 5,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 35,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 60,\n",
      "    \"Postoperative_RT_Received_Percentage\": 45,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": 25,\n",
      "    \"Letrozole_Percentage\": 30,\n",
      "    \"Anastrozole_Percentage\": 20,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 15,\n",
      "    \"Antiemetic_Agent_Percentage\": 70,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 50,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zinecard (Dexrazoxane Hydrochloride)\",\n",
      "    \"STUDYID\": \"ZinecardStudy002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 60,\n",
      "    \"Male_Percentage\": 40,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 25,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 12,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 14,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 43,\n",
      "    \"Stage_III_Percentage\": 31,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 38,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 62,\n",
      "    \"Postoperative_RT_Received_Percentage\": 48,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 28,\n",
      "    \"Letrozole_Percentage\": 32,\n",
      "    \"Anastrozole_Percentage\": 18,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 18,\n",
      "    \"Antiemetic_Agent_Percentage\": 72,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 58,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 46,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zinecard (Dexrazoxane Hydrochloride)\",\n",
      "    \"STUDYID\": \"ZinecardStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 55,\n",
      "    \"Male_Percentage\": 45,\n",
      "    \"Median_BMI\": 29.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 18,\n",
      "    \"Tumor_Stage_T1_Percentage\": 20,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 33,\n",
      "    \"Tumor_Stage_T4_Percentage\": 12,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 40,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 65,\n",
      "    \"Postoperative_RT_Received_Percentage\": 50,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CEF\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Anthracycline\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Taxane\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin\",\n",
      "    \"Tamoxifen_Percentage\": 30,\n",
      "    \"Letrozole_Percentage\": 35,\n",
      "    \"Anastrozole_Percentage\": 15,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20,\n",
      "    \"Antiemetic_Agent_Percentage\": 75,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 4\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zinecard (Dexrazoxane Hydrochloride)', 'STUDYID': 'ZinecardStudy001', 'YEAR': 2021, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 65, 'Male_Percentage': 35, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 22, 'Total_ADL_Independence_Percentage': 88, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 40, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 45, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 10, 'Congestive_Heart_Failure_Percentage': 3, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 5, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 35, 'Adjuvant_Chemotherapy_Received_Percentage': 60, 'Postoperative_RT_Received_Percentage': 45, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'TC', 'Common_Adjuvant_Regimen_1': 'AC-T', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': 25, 'Letrozole_Percentage': 30, 'Anastrozole_Percentage': 20, 'Antidiarrheal_Agent_Probiotics_Percentage': 15, 'Antiemetic_Agent_Percentage': 70, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 50, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zinecard (Dexrazoxane Hydrochloride)', 'STUDYID': 'ZinecardStudy002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 60, 'Male_Percentage': 40, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 25, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 12, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 14, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 43, 'Stage_III_Percentage': 31, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 6, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 38, 'Adjuvant_Chemotherapy_Received_Percentage': 62, 'Postoperative_RT_Received_Percentage': 48, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'FEC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 28, 'Letrozole_Percentage': 32, 'Anastrozole_Percentage': 18, 'Antidiarrheal_Agent_Probiotics_Percentage': 18, 'Antiemetic_Agent_Percentage': 72, 'Painkiller_Antipyretic_Percentage': 58, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 46, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Zinecard (Dexrazoxane Hydrochloride)', 'STUDYID': 'ZinecardStudy003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 55, 'Male_Percentage': 45, 'Median_BMI': 29.0, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 18, 'Tumor_Stage_T1_Percentage': 20, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 33, 'Tumor_Stage_T4_Percentage': 12, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 40, 'Adjuvant_Chemotherapy_Received_Percentage': 65, 'Postoperative_RT_Received_Percentage': 50, 'Common_Neoadjuvant_Regimen_1': 'CEF', 'Common_Neoadjuvant_Regimen_2': 'Anthracycline', 'Common_Adjuvant_Regimen_1': 'Taxane', 'Common_Adjuvant_Regimen_2': 'Carboplatin', 'Tamoxifen_Percentage': 30, 'Letrozole_Percentage': 35, 'Anastrozole_Percentage': 15, 'Antidiarrheal_Agent_Probiotics_Percentage': 20, 'Antiemetic_Agent_Percentage': 75, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 4}]\n",
      "File created: Zinecard (Dexrazoxane Hydrochloride)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zinecard (Dexrazoxane Hydrochloride)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zirabev\",\n",
      "    \"STUDYID\": \"ZIRABEV2023US\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 42,\n",
      "    \"Male_Percentage\": 58,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 48,\n",
      "    \"Postoperative_RT_Received_Percentage\": 33,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"5-FU/LV\",\n",
      "    \"Tamoxifen_Percentage\": 5,\n",
      "    \"Letrozole_Percentage\": 3,\n",
      "    \"Anastrozole_Percentage\": 2,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 40,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zirabev\",\n",
      "    \"STUDYID\": \"ZIRABEV2022EU\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 38,\n",
      "    \"Male_Percentage\": 62,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 40,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 50,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 22,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 9,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 11,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 52,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"XELOX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"XELOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"5-FU/FA\",\n",
      "    \"Tamoxifen_Percentage\": 6,\n",
      "    \"Letrozole_Percentage\": 4,\n",
      "    \"Anastrozole_Percentage\": 3,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zirabev\",\n",
      "    \"STUDYID\": \"ZIRABEV2024JP\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 24.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 25,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 2,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"mFOLFOX6\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"mFOLFOX6\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CapeOX\",\n",
      "    \"Tamoxifen_Percentage\": 4,\n",
      "    \"Letrozole_Percentage\": 2,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 20,\n",
      "    \"Antiemetic_Agent_Percentage\": 55,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 35,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zirabev\",\n",
      "    \"STUDYID\": \"ZIRABEV2023CA\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 380,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 40,\n",
      "    \"Male_Percentage\": 60,\n",
      "    \"Median_BMI\": 28.0,\n",
      "    \"Smoking_History_Yes_Percentage\": 38,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 13,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 29,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 53,\n",
      "    \"Nodal_Stage_N1_Percentage\": 27,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 33,\n",
      "    \"Stage_III_Percentage\": 48,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 23,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50,\n",
      "    \"Postoperative_RT_Received_Percentage\": 34,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CAPOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FOLFOX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CapeOX\",\n",
      "    \"Tamoxifen_Percentage\": 5,\n",
      "    \"Letrozole_Percentage\": 3,\n",
      "    \"Anastrozole_Percentage\": 2,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 28,\n",
      "    \"Antiemetic_Agent_Percentage\": 63,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 43,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zirabev', 'STUDYID': 'ZIRABEV2023US', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 42, 'Male_Percentage': 58, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 48, 'Postoperative_RT_Received_Percentage': 33, 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'CAPOX', 'Common_Adjuvant_Regimen_1': 'CAPOX', 'Common_Adjuvant_Regimen_2': '5-FU/LV', 'Tamoxifen_Percentage': 5, 'Letrozole_Percentage': 3, 'Anastrozole_Percentage': 2, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 40, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zirabev', 'STUDYID': 'ZIRABEV2022EU', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 38, 'Male_Percentage': 62, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 40, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 45, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 50, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 22, 'Congestive_Heart_Failure_Percentage': 9, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 11, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 52, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'XELOX', 'Common_Adjuvant_Regimen_1': 'XELOX', 'Common_Adjuvant_Regimen_2': '5-FU/FA', 'Tamoxifen_Percentage': 6, 'Letrozole_Percentage': 4, 'Anastrozole_Percentage': 3, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 1}, {'Drug_Name': 'Zirabev', 'STUDYID': 'ZIRABEV2024JP', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 24.5, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 25, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 2, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'mFOLFOX6', 'Common_Adjuvant_Regimen_1': 'mFOLFOX6', 'Common_Adjuvant_Regimen_2': 'CapeOX', 'Tamoxifen_Percentage': 4, 'Letrozole_Percentage': 2, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 20, 'Antiemetic_Agent_Percentage': 55, 'Painkiller_Antipyretic_Percentage': 35, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Zirabev', 'STUDYID': 'ZIRABEV2023CA', 'YEAR': 2023, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 380, 'Median_Age': 70, 'Female_Percentage': 40, 'Male_Percentage': 60, 'Median_BMI': 28.0, 'Smoking_History_Yes_Percentage': 38, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 13, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 29, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 53, 'Nodal_Stage_N1_Percentage': 27, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 33, 'Stage_III_Percentage': 48, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 23, 'Adjuvant_Chemotherapy_Received_Percentage': 50, 'Postoperative_RT_Received_Percentage': 34, 'Common_Neoadjuvant_Regimen_1': 'CAPOX', 'Common_Neoadjuvant_Regimen_2': 'FOLFOX', 'Common_Adjuvant_Regimen_1': 'FOLFOX', 'Common_Adjuvant_Regimen_2': 'CapeOX', 'Tamoxifen_Percentage': 5, 'Letrozole_Percentage': 3, 'Anastrozole_Percentage': 2, 'Antidiarrheal_Agent_Probiotics_Percentage': 28, 'Antiemetic_Agent_Percentage': 63, 'Painkiller_Antipyretic_Percentage': 43, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 2}]\n",
      "File created: Zirabev (Bevcizumab)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zirabev (Bevcizumab)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Ziv-Aflibercept\",\n",
      "    \"STUDYID\": \"ZAFL2023-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 25,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 30,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 30,\n",
      "    \"Stage_III_Percentage\": 35,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 48,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"XELOX\",\n",
      "    \"Tamoxifen_Percentage\": 5,\n",
      "    \"Letrozole_Percentage\": 3,\n",
      "    \"Anastrozole_Percentage\": 2,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ziv-Aflibercept\",\n",
      "    \"STUDYID\": \"ZAFL2022-002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 28,\n",
      "    \"Nodal_Stage_N0_Percentage\": 38,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32,\n",
      "    \"Nodal_Stage_N2_Percentage\": 18,\n",
      "    \"Nodal_Stage_N3_Percentage\": 12,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 38,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 6,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 8,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 50,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FOLFIRI\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"XELOX\",\n",
      "    \"Tamoxifen_Percentage\": 6,\n",
      "    \"Letrozole_Percentage\": 4,\n",
      "    \"Anastrozole_Percentage\": 3,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 45,\n",
      "    \"Antiemetic_Agent_Percentage\": 70,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Ziv-Aflibercept\",\n",
      "    \"STUDYID\": \"ZAFL2024-003\",\n",
      "    \"YEAR\": 2024,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 42,\n",
      "    \"Male_Percentage\": 58,\n",
      "    \"Median_BMI\": 25.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 25,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 22,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 25,\n",
      "    \"Nodal_Stage_N0_Percentage\": 42,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 15,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 28,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 20,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 30,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FOLFOX\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CAPOX\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"XELOX\",\n",
      "    \"Tamoxifen_Percentage\": 4,\n",
      "    \"Letrozole_Percentage\": 2,\n",
      "    \"Anastrozole_Percentage\": 1,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Ziv-Aflibercept', 'STUDYID': 'ZAFL2023-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 25, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 30, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 30, 'Stage_III_Percentage': 35, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 48, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'CAPOX', 'Common_Adjuvant_Regimen_1': 'CAPOX', 'Common_Adjuvant_Regimen_2': 'XELOX', 'Tamoxifen_Percentage': 5, 'Letrozole_Percentage': 3, 'Anastrozole_Percentage': 2, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Ziv-Aflibercept', 'STUDYID': 'ZAFL2022-002', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 28, 'Nodal_Stage_N0_Percentage': 38, 'Nodal_Stage_N1_Percentage': 32, 'Nodal_Stage_N2_Percentage': 18, 'Nodal_Stage_N3_Percentage': 12, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 38, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 6, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 8, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 50, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'FOLFIRI', 'Common_Adjuvant_Regimen_1': 'CAPOX', 'Common_Adjuvant_Regimen_2': 'XELOX', 'Tamoxifen_Percentage': 6, 'Letrozole_Percentage': 4, 'Anastrozole_Percentage': 3, 'Antidiarrheal_Agent_Probiotics_Percentage': 45, 'Antiemetic_Agent_Percentage': 70, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Ziv-Aflibercept', 'STUDYID': 'ZAFL2024-003', 'YEAR': 2024, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 42, 'Male_Percentage': 58, 'Median_BMI': 25.5, 'Smoking_History_Yes_Percentage': 25, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 22, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 25, 'Nodal_Stage_N0_Percentage': 42, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 15, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 28, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 20, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 30, 'Common_Neoadjuvant_Regimen_1': 'FOLFOX', 'Common_Neoadjuvant_Regimen_2': 'CAPOX', 'Common_Adjuvant_Regimen_1': 'CAPOX', 'Common_Adjuvant_Regimen_2': 'XELOX', 'Tamoxifen_Percentage': 4, 'Letrozole_Percentage': 2, 'Anastrozole_Percentage': 1, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Ziv-Aflibercept_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Ziv-Aflibercept\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zofran (Ondansetron Hydrochloride)\",\n",
      "    \"STUDYID\": \"ZOFRAN101\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"62\",\n",
      "    \"Female_Percentage\": \"55\",\n",
      "    \"Male_Percentage\": \"45\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"32\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"20\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"25\",\n",
      "    \"Stage_II_Percentage\": \"40\",\n",
      "    \"Stage_III_Percentage\": \"35\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"28\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"65\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"52\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FAC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"TC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": \"22\",\n",
      "    \"Letrozole_Percentage\": \"15\",\n",
      "    \"Anastrozole_Percentage\": \"18\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"25\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"95\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"70\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zofran (Ondansetron Hydrochloride)\",\n",
      "    \"STUDYID\": \"ZOFRAN102\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"60\",\n",
      "    \"Male_Percentage\": \"40\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"28\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"38\",\n",
      "    \"Stage_III_Percentage\": \"40\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"10\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"12\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"30\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"60\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"50\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"TC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"EC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": \"20\",\n",
      "    \"Letrozole_Percentage\": \"17\",\n",
      "    \"Anastrozole_Percentage\": \"13\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"28\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"92\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"72\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"10\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zofran (Ondansetron Hydrochloride)\",\n",
      "    \"STUDYID\": \"ZOFRAN103\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"52\",\n",
      "    \"Male_Percentage\": \"48\",\n",
      "    \"Median_BMI\": \"26.9\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"75\",\n",
      "    \"LHRH_Use_Percentage\": \"8\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"22\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"65\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"10\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"28\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"37\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"22\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"12\",\n",
      "    \"Stroke_Percentage\": \"6\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"14\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"8\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"70\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"55\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"AC\",\n",
      "    \"Tamoxifen_Percentage\": \"25\",\n",
      "    \"Letrozole_Percentage\": \"12\",\n",
      "    \"Anastrozole_Percentage\": \"15\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"30\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"90\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"68\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"40\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zofran (Ondansetron Hydrochloride)\",\n",
      "    \"STUDYID\": \"ZOFRAN104\",\n",
      "    \"YEAR\": \"2024\",\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"58\",\n",
      "    \"Male_Percentage\": \"42\",\n",
      "    \"Median_BMI\": \"29.0\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"30\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"19\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"33\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"9\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"24\",\n",
      "    \"Stage_II_Percentage\": \"39\",\n",
      "    \"Stage_III_Percentage\": \"37\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"19\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"4.5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"11\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6.5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"27\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"63\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"51\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": \"21\",\n",
      "    \"Letrozole_Percentage\": \"16\",\n",
      "    \"Anastrozole_Percentage\": \"17\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"26\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"93\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"71\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"62\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.7\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zofran (Ondansetron Hydrochloride)', 'STUDYID': 'ZOFRAN101', 'YEAR': '2022', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '62', 'Female_Percentage': '55', 'Male_Percentage': '45', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '32', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '12', 'Tumor_Stage_T1_Percentage': '20', 'Tumor_Stage_T2_Percentage': '35', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '25', 'Stage_II_Percentage': '40', 'Stage_III_Percentage': '35', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '28', 'Adjuvant_Chemotherapy_Received_Percentage': '65', 'Postoperative_RT_Received_Percentage': '52', 'Common_Neoadjuvant_Regimen_1': 'FAC', 'Common_Neoadjuvant_Regimen_2': 'TC', 'Common_Adjuvant_Regimen_1': 'AC', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': '22', 'Letrozole_Percentage': '15', 'Anastrozole_Percentage': '18', 'Antidiarrheal_Agent_Probiotics_Percentage': '25', 'Antiemetic_Agent_Percentage': '95', 'Painkiller_Antipyretic_Percentage': '70', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Zofran (Ondansetron Hydrochloride)', 'STUDYID': 'ZOFRAN102', 'YEAR': '2023', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '68', 'Female_Percentage': '60', 'Male_Percentage': '40', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '28', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '10', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '35', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '38', 'Stage_III_Percentage': '40', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '10', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '12', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '30', 'Adjuvant_Chemotherapy_Received_Percentage': '60', 'Postoperative_RT_Received_Percentage': '50', 'Common_Neoadjuvant_Regimen_1': 'TC', 'Common_Neoadjuvant_Regimen_2': 'EC', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': '20', 'Letrozole_Percentage': '17', 'Anastrozole_Percentage': '13', 'Antidiarrheal_Agent_Probiotics_Percentage': '28', 'Antiemetic_Agent_Percentage': '92', 'Painkiller_Antipyretic_Percentage': '72', 'Beds_Less_Than_200_Percentage': '10', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Zofran (Ondansetron Hydrochloride)', 'STUDYID': 'ZOFRAN103', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '70', 'Female_Percentage': '52', 'Male_Percentage': '48', 'Median_BMI': '26.9', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '75', 'LHRH_Use_Percentage': '8', 'Tumor_Stage_T1_Percentage': '22', 'Tumor_Stage_T2_Percentage': '38', 'Tumor_Stage_T3_Percentage': '25', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '65', 'Nodal_Stage_N1_Percentage': '20', 'Nodal_Stage_N2_Percentage': '10', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '28', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '37', 'Diabetes_Mellitus_Percentage': '22', 'Congestive_Heart_Failure_Percentage': '12', 'Stroke_Percentage': '6', 'Atrial_Fibrillation_Percentage': '14', 'Myocardial_Infarction_Percentage': '8', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '70', 'Postoperative_RT_Received_Percentage': '55', 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'Taxol', 'Common_Adjuvant_Regimen_2': 'AC', 'Tamoxifen_Percentage': '25', 'Letrozole_Percentage': '12', 'Anastrozole_Percentage': '15', 'Antidiarrheal_Agent_Probiotics_Percentage': '30', 'Antiemetic_Agent_Percentage': '90', 'Painkiller_Antipyretic_Percentage': '68', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '40', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Zofran (Ondansetron Hydrochloride)', 'STUDYID': 'ZOFRAN104', 'YEAR': '2024', 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '65', 'Female_Percentage': '58', 'Male_Percentage': '42', 'Median_BMI': '29.0', 'Smoking_History_Yes_Percentage': '30', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '19', 'Tumor_Stage_T2_Percentage': '33', 'Tumor_Stage_T3_Percentage': '32', 'Tumor_Stage_T4_Percentage': '16', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '9', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '24', 'Stage_II_Percentage': '39', 'Stage_III_Percentage': '37', 'Diabetes_Mellitus_Percentage': '19', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '4.5', 'Atrial_Fibrillation_Percentage': '11', 'Myocardial_Infarction_Percentage': '6.5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '27', 'Adjuvant_Chemotherapy_Received_Percentage': '63', 'Postoperative_RT_Received_Percentage': '51', 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'AC', 'Common_Adjuvant_Regimen_1': 'AC', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': '21', 'Letrozole_Percentage': '16', 'Anastrozole_Percentage': '17', 'Antidiarrheal_Agent_Probiotics_Percentage': '26', 'Antiemetic_Agent_Percentage': '93', 'Painkiller_Antipyretic_Percentage': '71', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '62', 'Months_Between_Surgery_And_Index_Date': '2.7'}]\n",
      "File created: Zofran (Ondansetron Hydrochloride)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zofran (Ondansetron Hydrochloride)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zoledronic Acid\",\n",
      "    \"STUDYID\": \"ZA2023-001\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 62,\n",
      "    \"Male_Percentage\": 38,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 28,\n",
      "    \"Total_ADL_Independence_Percentage\": 85,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 35,\n",
      "    \"Tumor_Stage_T3_Percentage\": 30,\n",
      "    \"Tumor_Stage_T4_Percentage\": 20,\n",
      "    \"Nodal_Stage_N0_Percentage\": 55,\n",
      "    \"Nodal_Stage_N1_Percentage\": 25,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 40,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 10,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 45,\n",
      "    \"Postoperative_RT_Received_Percentage\": 55,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": 30,\n",
      "    \"Letrozole_Percentage\": 25,\n",
      "    \"Anastrozole_Percentage\": 20,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 15,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 70,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zoledronic Acid\",\n",
      "    \"STUDYID\": \"ZA2022-002\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 58,\n",
      "    \"Male_Percentage\": 42,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 15,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 38,\n",
      "    \"Tumor_Stage_T3_Percentage\": 32,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 52,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 14,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 42,\n",
      "    \"Stage_III_Percentage\": 32,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 48,\n",
      "    \"Postoperative_RT_Received_Percentage\": 58,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 32,\n",
      "    \"Letrozole_Percentage\": 23,\n",
      "    \"Anastrozole_Percentage\": 18,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 17,\n",
      "    \"Antiemetic_Agent_Percentage\": 62,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 72,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 42,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 62,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zoledronic Acid\",\n",
      "    \"STUDYID\": \"ZA2023-003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 65,\n",
      "    \"Female_Percentage\": 65,\n",
      "    \"Male_Percentage\": 35,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 25,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 28,\n",
      "    \"Tumor_Stage_T4_Percentage\": 22,\n",
      "    \"Nodal_Stage_N0_Percentage\": 60,\n",
      "    \"Nodal_Stage_N1_Percentage\": 22,\n",
      "    \"Nodal_Stage_N2_Percentage\": 12,\n",
      "    \"Nodal_Stage_N3_Percentage\": 6,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 30,\n",
      "    \"Diabetes_Mellitus_Percentage\": 16,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 42,\n",
      "    \"Postoperative_RT_Received_Percentage\": 52,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Tamoxifen_Percentage\": 35,\n",
      "    \"Letrozole_Percentage\": 20,\n",
      "    \"Anastrozole_Percentage\": 15,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 12,\n",
      "    \"Antiemetic_Agent_Percentage\": 58,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 68,\n",
      "    \"Beds_Less_Than_200_Percentage\": 12,\n",
      "    \"Beds_200_To_499_Percentage\": 48,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 58,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zoledronic Acid\",\n",
      "    \"STUDYID\": \"ZA2022-004\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 480,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 60,\n",
      "    \"Male_Percentage\": 40,\n",
      "    \"Median_BMI\": 27.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 30,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 13,\n",
      "    \"Tumor_Stage_T1_Percentage\": 14,\n",
      "    \"Tumor_Stage_T2_Percentage\": 36,\n",
      "    \"Tumor_Stage_T3_Percentage\": 31,\n",
      "    \"Tumor_Stage_T4_Percentage\": 19,\n",
      "    \"Nodal_Stage_N0_Percentage\": 54,\n",
      "    \"Nodal_Stage_N1_Percentage\": 26,\n",
      "    \"Nodal_Stage_N2_Percentage\": 13,\n",
      "    \"Nodal_Stage_N3_Percentage\": 7,\n",
      "    \"Stage_I_Percentage\": 19,\n",
      "    \"Stage_II_Percentage\": 41,\n",
      "    \"Stage_III_Percentage\": 31,\n",
      "    \"Diabetes_Mellitus_Percentage\": 19,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 11,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 46,\n",
      "    \"Postoperative_RT_Received_Percentage\": 56,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Tamoxifen_Percentage\": 31,\n",
      "    \"Letrozole_Percentage\": 24,\n",
      "    \"Anastrozole_Percentage\": 19,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 16,\n",
      "    \"Antiemetic_Agent_Percentage\": 61,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 71,\n",
      "    \"Beds_Less_Than_200_Percentage\": 17,\n",
      "    \"Beds_200_To_499_Percentage\": 43,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 61,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.8\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zoledronic Acid', 'STUDYID': 'ZA2023-001', 'YEAR': 2023, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 62, 'Male_Percentage': 38, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 28, 'Total_ADL_Independence_Percentage': 85, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 35, 'Tumor_Stage_T3_Percentage': 30, 'Tumor_Stage_T4_Percentage': 20, 'Nodal_Stage_N0_Percentage': 55, 'Nodal_Stage_N1_Percentage': 25, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 40, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 10, 'Adjuvant_Chemotherapy_Received_Percentage': 45, 'Postoperative_RT_Received_Percentage': 55, 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': 30, 'Letrozole_Percentage': 25, 'Anastrozole_Percentage': 20, 'Antidiarrheal_Agent_Probiotics_Percentage': 15, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 70, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zoledronic Acid', 'STUDYID': 'ZA2022-002', 'YEAR': 2022, 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 58, 'Male_Percentage': 42, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 15, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 38, 'Tumor_Stage_T3_Percentage': 32, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 52, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 14, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 42, 'Stage_III_Percentage': 32, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 12, 'Adjuvant_Chemotherapy_Received_Percentage': 48, 'Postoperative_RT_Received_Percentage': 58, 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'Docetaxel', 'Common_Adjuvant_Regimen_1': 'AC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': 32, 'Letrozole_Percentage': 23, 'Anastrozole_Percentage': 18, 'Antidiarrheal_Agent_Probiotics_Percentage': 17, 'Antiemetic_Agent_Percentage': 62, 'Painkiller_Antipyretic_Percentage': 72, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 42, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 62, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Zoledronic Acid', 'STUDYID': 'ZA2023-003', 'YEAR': 2023, 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 65, 'Female_Percentage': 65, 'Male_Percentage': 35, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 25, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 28, 'Tumor_Stage_T4_Percentage': 22, 'Nodal_Stage_N0_Percentage': 60, 'Nodal_Stage_N1_Percentage': 22, 'Nodal_Stage_N2_Percentage': 12, 'Nodal_Stage_N3_Percentage': 6, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 30, 'Diabetes_Mellitus_Percentage': 16, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 42, 'Postoperative_RT_Received_Percentage': 52, 'Common_Neoadjuvant_Regimen_1': 'FEC', 'Common_Neoadjuvant_Regimen_2': 'CMF', 'Common_Adjuvant_Regimen_1': 'FEC', 'Common_Adjuvant_Regimen_2': 'CMF', 'Tamoxifen_Percentage': 35, 'Letrozole_Percentage': 20, 'Anastrozole_Percentage': 15, 'Antidiarrheal_Agent_Probiotics_Percentage': 12, 'Antiemetic_Agent_Percentage': 58, 'Painkiller_Antipyretic_Percentage': 68, 'Beds_Less_Than_200_Percentage': 12, 'Beds_200_To_499_Percentage': 48, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 58, 'Months_Between_Surgery_And_Index_Date': 2.5}, {'Drug_Name': 'Zoledronic Acid', 'STUDYID': 'ZA2022-004', 'YEAR': 2022, 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': 480, 'Median_Age': 70, 'Female_Percentage': 60, 'Male_Percentage': 40, 'Median_BMI': 27.9, 'Smoking_History_Yes_Percentage': 30, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 13, 'Tumor_Stage_T1_Percentage': 14, 'Tumor_Stage_T2_Percentage': 36, 'Tumor_Stage_T3_Percentage': 31, 'Tumor_Stage_T4_Percentage': 19, 'Nodal_Stage_N0_Percentage': 54, 'Nodal_Stage_N1_Percentage': 26, 'Nodal_Stage_N2_Percentage': 13, 'Nodal_Stage_N3_Percentage': 7, 'Stage_I_Percentage': 19, 'Stage_II_Percentage': 41, 'Stage_III_Percentage': 31, 'Diabetes_Mellitus_Percentage': 19, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 11, 'Adjuvant_Chemotherapy_Received_Percentage': 46, 'Postoperative_RT_Received_Percentage': 56, 'Common_Neoadjuvant_Regimen_1': 'AC-T', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'AC-T', 'Common_Adjuvant_Regimen_2': 'FEC', 'Tamoxifen_Percentage': 31, 'Letrozole_Percentage': 24, 'Anastrozole_Percentage': 19, 'Antidiarrheal_Agent_Probiotics_Percentage': 16, 'Antiemetic_Agent_Percentage': 61, 'Painkiller_Antipyretic_Percentage': 71, 'Beds_Less_Than_200_Percentage': 17, 'Beds_200_To_499_Percentage': 43, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 61, 'Months_Between_Surgery_And_Index_Date': 2.8}]\n",
      "File created: Zoledronic Acid_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zoledronic Acid\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zolinza (Vorinostat)\",\n",
      "    \"STUDYID\": \"VZ501\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"32\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"35\",\n",
      "    \"Stage_III_Percentage\": \"45\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"38\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"42\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"ICE\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"ABVD\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"EPOCH\",\n",
      "    \"Tamoxifen_Percentage\": \"10\",\n",
      "    \"Letrozole_Percentage\": \"8\",\n",
      "    \"Anastrozole_Percentage\": \"7\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"25\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"55\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"40\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zolinza (Vorinostat)\",\n",
      "    \"STUDYID\": \"VZ502\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"48\",\n",
      "    \"Male_Percentage\": \"52\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"42\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"18\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"14\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"33\",\n",
      "    \"Stage_III_Percentage\": \"49\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"40\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"45\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EPOCH\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Hyper-CVAD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"ABVD\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"BEACOPP\",\n",
      "    \"Tamoxifen_Percentage\": \"12\",\n",
      "    \"Letrozole_Percentage\": \"9\",\n",
      "    \"Anastrozole_Percentage\": \"8\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"28\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"58\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"42\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"52\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zolinza (Vorinostat)\",\n",
      "    \"STUDYID\": \"VZ503\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"52\",\n",
      "    \"Male_Percentage\": \"48\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"30\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"88\",\n",
      "    \"LHRH_Use_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"38\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"12\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"58\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"4\",\n",
      "    \"Stage_I_Percentage\": \"22\",\n",
      "    \"Stage_II_Percentage\": \"37\",\n",
      "    \"Stage_III_Percentage\": \"41\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"16\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"35\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"40\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"ICE\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DHAP\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"BEACOPP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"ABVD\",\n",
      "    \"Tamoxifen_Percentage\": \"9\",\n",
      "    \"Letrozole_Percentage\": \"7\",\n",
      "    \"Anastrozole_Percentage\": \"6\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"23\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"53\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"38\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"22\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"30\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"55\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zolinza (Vorinostat)', 'STUDYID': 'VZ501', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '32', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '12', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '30', 'Tumor_Stage_T3_Percentage': '40', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '35', 'Stage_III_Percentage': '45', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '38', 'Postoperative_RT_Received_Percentage': '42', 'Common_Neoadjuvant_Regimen_1': 'CHOP', 'Common_Neoadjuvant_Regimen_2': 'ICE', 'Common_Adjuvant_Regimen_1': 'ABVD', 'Common_Adjuvant_Regimen_2': 'EPOCH', 'Tamoxifen_Percentage': '10', 'Letrozole_Percentage': '8', 'Anastrozole_Percentage': '7', 'Antidiarrheal_Agent_Probiotics_Percentage': '25', 'Antiemetic_Agent_Percentage': '55', 'Painkiller_Antipyretic_Percentage': '40', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Zolinza (Vorinostat)', 'STUDYID': 'VZ502', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '48', 'Male_Percentage': '52', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '42', 'Tumor_Stage_T4_Percentage': '18', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '14', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '33', 'Stage_III_Percentage': '49', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '40', 'Postoperative_RT_Received_Percentage': '45', 'Common_Neoadjuvant_Regimen_1': 'EPOCH', 'Common_Neoadjuvant_Regimen_2': 'Hyper-CVAD', 'Common_Adjuvant_Regimen_1': 'ABVD', 'Common_Adjuvant_Regimen_2': 'BEACOPP', 'Tamoxifen_Percentage': '12', 'Letrozole_Percentage': '9', 'Anastrozole_Percentage': '8', 'Antidiarrheal_Agent_Probiotics_Percentage': '28', 'Antiemetic_Agent_Percentage': '58', 'Painkiller_Antipyretic_Percentage': '42', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '52', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Zolinza (Vorinostat)', 'STUDYID': 'VZ503', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '52', 'Male_Percentage': '48', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '30', 'Total_ADL_Independence_Percentage': '88', 'LHRH_Use_Percentage': '10', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '38', 'Tumor_Stage_T4_Percentage': '12', 'Nodal_Stage_N0_Percentage': '58', 'Nodal_Stage_N1_Percentage': '22', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '4', 'Stage_I_Percentage': '22', 'Stage_II_Percentage': '37', 'Stage_III_Percentage': '41', 'Diabetes_Mellitus_Percentage': '16', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '20', 'Adjuvant_Chemotherapy_Received_Percentage': '35', 'Postoperative_RT_Received_Percentage': '40', 'Common_Neoadjuvant_Regimen_1': 'ICE', 'Common_Neoadjuvant_Regimen_2': 'DHAP', 'Common_Adjuvant_Regimen_1': 'BEACOPP', 'Common_Adjuvant_Regimen_2': 'ABVD', 'Tamoxifen_Percentage': '9', 'Letrozole_Percentage': '7', 'Anastrozole_Percentage': '6', 'Antidiarrheal_Agent_Probiotics_Percentage': '23', 'Antiemetic_Agent_Percentage': '53', 'Painkiller_Antipyretic_Percentage': '38', 'Beds_Less_Than_200_Percentage': '22', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '30', 'Designated_Cancer_Hospital_Percentage': '55', 'Months_Between_Surgery_And_Index_Date': '2.5'}]\n",
      "File created: Zolinza (Vorinostat)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zolinza (Vorinostat)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zometa\",\n",
      "    \"STUDYID\": \"ZometaStudy001\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"65\",\n",
      "    \"Male_Percentage\": \"35\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"28\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"85\",\n",
      "    \"LHRH_Use_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"35\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"55\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"25\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"20\",\n",
      "    \"Stage_II_Percentage\": \"40\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"3\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"48\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"55\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Taxol\",\n",
      "    \"Tamoxifen_Percentage\": \"25\",\n",
      "    \"Letrozole_Percentage\": \"35\",\n",
      "    \"Anastrozole_Percentage\": \"20\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"15\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"60\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"70\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zometa\",\n",
      "    \"STUDYID\": \"ZometaStudy002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"70\",\n",
      "    \"Male_Percentage\": \"30\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"25\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"80\",\n",
      "    \"LHRH_Use_Percentage\": \"15\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"18\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"32\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"22\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"50\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"17\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"38\",\n",
      "    \"Stage_III_Percentage\": \"34\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"4\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"50\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"60\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": \"28\",\n",
      "    \"Letrozole_Percentage\": \"32\",\n",
      "    \"Anastrozole_Percentage\": \"18\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"18\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"65\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"75\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"12\",\n",
      "    \"Beds_200_To_499_Percentage\": \"48\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"65\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zometa\",\n",
      "    \"STUDYID\": \"ZometaStudy003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"60\",\n",
      "    \"Male_Percentage\": \"40\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"30\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"90\",\n",
      "    \"LHRH_Use_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"20\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"40\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"60\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"15\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"5\",\n",
      "    \"Stage_I_Percentage\": \"25\",\n",
      "    \"Stage_II_Percentage\": \"45\",\n",
      "    \"Stage_III_Percentage\": \"25\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"6\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"8\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"2\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"20\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"45\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"50\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"EC\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"CMF\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": \"22\",\n",
      "    \"Letrozole_Percentage\": \"38\",\n",
      "    \"Anastrozole_Percentage\": \"25\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"12\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"55\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"65\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"18\",\n",
      "    \"Beds_200_To_499_Percentage\": \"42\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zometa\",\n",
      "    \"STUDYID\": \"ZometaStudy004\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"480\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"68\",\n",
      "    \"Male_Percentage\": \"32\",\n",
      "    \"Median_BMI\": \"29.0\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"22\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"82\",\n",
      "    \"LHRH_Use_Percentage\": \"13\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"16\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"34\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"29\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"21\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"52\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"26\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"16\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"6\",\n",
      "    \"Stage_I_Percentage\": \"19\",\n",
      "    \"Stage_II_Percentage\": \"39\",\n",
      "    \"Stage_III_Percentage\": \"32\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"19\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"9\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"3\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"23\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"49\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"58\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"AC-T\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"FEC\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"AC\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": \"26\",\n",
      "    \"Letrozole_Percentage\": \"34\",\n",
      "    \"Anastrozole_Percentage\": \"19\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"17\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"62\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"72\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"14\",\n",
      "    \"Beds_200_To_499_Percentage\": \"46\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"40\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"63\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.8\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zometa', 'STUDYID': 'ZometaStudy001', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '65', 'Male_Percentage': '35', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '28', 'Total_ADL_Independence_Percentage': '85', 'LHRH_Use_Percentage': '12', 'Tumor_Stage_T1_Percentage': '15', 'Tumor_Stage_T2_Percentage': '35', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '20', 'Nodal_Stage_N0_Percentage': '55', 'Nodal_Stage_N1_Percentage': '25', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '20', 'Stage_II_Percentage': '40', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '3', 'Neoadjuvant_Chemotherapy_Received_Percentage': '22', 'Adjuvant_Chemotherapy_Received_Percentage': '48', 'Postoperative_RT_Received_Percentage': '55', 'Common_Neoadjuvant_Regimen_1': 'AC', 'Common_Neoadjuvant_Regimen_2': 'Taxol', 'Common_Adjuvant_Regimen_1': 'CMF', 'Common_Adjuvant_Regimen_2': 'Taxol', 'Tamoxifen_Percentage': '25', 'Letrozole_Percentage': '35', 'Anastrozole_Percentage': '20', 'Antidiarrheal_Agent_Probiotics_Percentage': '15', 'Antiemetic_Agent_Percentage': '60', 'Painkiller_Antipyretic_Percentage': '70', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Zometa', 'STUDYID': 'ZometaStudy002', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '70', 'Male_Percentage': '30', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '25', 'Total_ADL_Independence_Percentage': '80', 'LHRH_Use_Percentage': '15', 'Tumor_Stage_T1_Percentage': '18', 'Tumor_Stage_T2_Percentage': '32', 'Tumor_Stage_T3_Percentage': '28', 'Tumor_Stage_T4_Percentage': '22', 'Nodal_Stage_N0_Percentage': '50', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '17', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '38', 'Stage_III_Percentage': '34', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '4', 'Neoadjuvant_Chemotherapy_Received_Percentage': '25', 'Adjuvant_Chemotherapy_Received_Percentage': '50', 'Postoperative_RT_Received_Percentage': '60', 'Common_Neoadjuvant_Regimen_1': 'AC-T', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'AC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': '28', 'Letrozole_Percentage': '32', 'Anastrozole_Percentage': '18', 'Antidiarrheal_Agent_Probiotics_Percentage': '18', 'Antiemetic_Agent_Percentage': '65', 'Painkiller_Antipyretic_Percentage': '75', 'Beds_Less_Than_200_Percentage': '12', 'Beds_200_To_499_Percentage': '48', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '65', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Zometa', 'STUDYID': 'ZometaStudy003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '60', 'Male_Percentage': '40', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '30', 'Total_ADL_Independence_Percentage': '90', 'LHRH_Use_Percentage': '10', 'Tumor_Stage_T1_Percentage': '20', 'Tumor_Stage_T2_Percentage': '40', 'Tumor_Stage_T3_Percentage': '25', 'Tumor_Stage_T4_Percentage': '15', 'Nodal_Stage_N0_Percentage': '60', 'Nodal_Stage_N1_Percentage': '20', 'Nodal_Stage_N2_Percentage': '15', 'Nodal_Stage_N3_Percentage': '5', 'Stage_I_Percentage': '25', 'Stage_II_Percentage': '45', 'Stage_III_Percentage': '25', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '6', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '8', 'Myocardial_Infarction_Percentage': '2', 'Neoadjuvant_Chemotherapy_Received_Percentage': '20', 'Adjuvant_Chemotherapy_Received_Percentage': '45', 'Postoperative_RT_Received_Percentage': '50', 'Common_Neoadjuvant_Regimen_1': 'EC', 'Common_Neoadjuvant_Regimen_2': 'CMF', 'Common_Adjuvant_Regimen_1': 'FEC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': '22', 'Letrozole_Percentage': '38', 'Anastrozole_Percentage': '25', 'Antidiarrheal_Agent_Probiotics_Percentage': '12', 'Antiemetic_Agent_Percentage': '55', 'Painkiller_Antipyretic_Percentage': '65', 'Beds_Less_Than_200_Percentage': '18', 'Beds_200_To_499_Percentage': '42', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '2.5'}, {'Drug_Name': 'Zometa', 'STUDYID': 'ZometaStudy004', 'YEAR': '2023', 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': '480', 'Median_Age': '70', 'Female_Percentage': '68', 'Male_Percentage': '32', 'Median_BMI': '29.0', 'Smoking_History_Yes_Percentage': '22', 'Total_ADL_Independence_Percentage': '82', 'LHRH_Use_Percentage': '13', 'Tumor_Stage_T1_Percentage': '16', 'Tumor_Stage_T2_Percentage': '34', 'Tumor_Stage_T3_Percentage': '29', 'Tumor_Stage_T4_Percentage': '21', 'Nodal_Stage_N0_Percentage': '52', 'Nodal_Stage_N1_Percentage': '26', 'Nodal_Stage_N2_Percentage': '16', 'Nodal_Stage_N3_Percentage': '6', 'Stage_I_Percentage': '19', 'Stage_II_Percentage': '39', 'Stage_III_Percentage': '32', 'Diabetes_Mellitus_Percentage': '19', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '9', 'Myocardial_Infarction_Percentage': '3', 'Neoadjuvant_Chemotherapy_Received_Percentage': '23', 'Adjuvant_Chemotherapy_Received_Percentage': '49', 'Postoperative_RT_Received_Percentage': '58', 'Common_Neoadjuvant_Regimen_1': 'AC-T', 'Common_Neoadjuvant_Regimen_2': 'FEC', 'Common_Adjuvant_Regimen_1': 'AC', 'Common_Adjuvant_Regimen_2': 'Docetaxel', 'Tamoxifen_Percentage': '26', 'Letrozole_Percentage': '34', 'Anastrozole_Percentage': '19', 'Antidiarrheal_Agent_Probiotics_Percentage': '17', 'Antiemetic_Agent_Percentage': '62', 'Painkiller_Antipyretic_Percentage': '72', 'Beds_Less_Than_200_Percentage': '14', 'Beds_200_To_499_Percentage': '46', 'Beds_Greater_Or_Equal_To_500_Percentage': '40', 'Designated_Cancer_Hospital_Percentage': '63', 'Months_Between_Surgery_And_Index_Date': '2.8'}]\n",
      "File created: Zometa (Zoledronic Acid)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zometa (Zoledronic Acid)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zyclara (Imiquimod)\",\n",
      "    \"STUDYID\": \"ZCL2020USA\",\n",
      "    \"YEAR\": 2020,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 32,\n",
      "    \"Total_ADL_Independence_Percentage\": 92,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 55,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 10,\n",
      "    \"Tumor_Stage_T4_Percentage\": 5,\n",
      "    \"Nodal_Stage_N0_Percentage\": 70,\n",
      "    \"Nodal_Stage_N1_Percentage\": 20,\n",
      "    \"Nodal_Stage_N2_Percentage\": 7,\n",
      "    \"Nodal_Stage_N3_Percentage\": 3,\n",
      "    \"Stage_I_Percentage\": 60,\n",
      "    \"Stage_II_Percentage\": 25,\n",
      "    \"Stage_III_Percentage\": 15,\n",
      "    \"Diabetes_Mellitus_Percentage\": 12,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 4,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 6,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 8,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 15,\n",
      "    \"Postoperative_RT_Received_Percentage\": 20,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 10,\n",
      "    \"Antiemetic_Agent_Percentage\": 5,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 25,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 15,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zyclara (Imiquimod)\",\n",
      "    \"STUDYID\": \"ZCL2021CAN\",\n",
      "    \"YEAR\": 2021,\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 28.1,\n",
      "    \"Smoking_History_Yes_Percentage\": 35,\n",
      "    \"Total_ADL_Independence_Percentage\": 90,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 60,\n",
      "    \"Tumor_Stage_T2_Percentage\": 25,\n",
      "    \"Tumor_Stage_T3_Percentage\": 10,\n",
      "    \"Tumor_Stage_T4_Percentage\": 5,\n",
      "    \"Nodal_Stage_N0_Percentage\": 75,\n",
      "    \"Nodal_Stage_N1_Percentage\": 15,\n",
      "    \"Nodal_Stage_N2_Percentage\": 6,\n",
      "    \"Nodal_Stage_N3_Percentage\": 4,\n",
      "    \"Stage_I_Percentage\": 65,\n",
      "    \"Stage_II_Percentage\": 20,\n",
      "    \"Stage_III_Percentage\": 15,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 5,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 7,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 7,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 12,\n",
      "    \"Postoperative_RT_Received_Percentage\": 18,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 12,\n",
      "    \"Antiemetic_Agent_Percentage\": 6,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 28,\n",
      "    \"Beds_Less_Than_200_Percentage\": 25,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 18,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 1.5\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zyclara (Imiquimod)\",\n",
      "    \"STUDYID\": \"ZCL2022EUR\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 26.9,\n",
      "    \"Smoking_History_Yes_Percentage\": 30,\n",
      "    \"Total_ADL_Independence_Percentage\": 88,\n",
      "    \"LHRH_Use_Percentage\": 6,\n",
      "    \"Tumor_Stage_T1_Percentage\": 58,\n",
      "    \"Tumor_Stage_T2_Percentage\": 27,\n",
      "    \"Tumor_Stage_T3_Percentage\": 9,\n",
      "    \"Tumor_Stage_T4_Percentage\": 6,\n",
      "    \"Nodal_Stage_N0_Percentage\": 72,\n",
      "    \"Nodal_Stage_N1_Percentage\": 18,\n",
      "    \"Nodal_Stage_N2_Percentage\": 5,\n",
      "    \"Nodal_Stage_N3_Percentage\": 5,\n",
      "    \"Stage_I_Percentage\": 62,\n",
      "    \"Stage_II_Percentage\": 23,\n",
      "    \"Stage_III_Percentage\": 15,\n",
      "    \"Diabetes_Mellitus_Percentage\": 14,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 9,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 14,\n",
      "    \"Postoperative_RT_Received_Percentage\": 22,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"None\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"None\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 11,\n",
      "    \"Antiemetic_Agent_Percentage\": 7,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 27,\n",
      "    \"Beds_Less_Than_200_Percentage\": 18,\n",
      "    \"Beds_200_To_499_Percentage\": 52,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 30,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 20,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zyclara (Imiquimod)', 'STUDYID': 'ZCL2020USA', 'YEAR': 2020, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 32, 'Total_ADL_Independence_Percentage': 92, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 55, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 10, 'Tumor_Stage_T4_Percentage': 5, 'Nodal_Stage_N0_Percentage': 70, 'Nodal_Stage_N1_Percentage': 20, 'Nodal_Stage_N2_Percentage': 7, 'Nodal_Stage_N3_Percentage': 3, 'Stage_I_Percentage': 60, 'Stage_II_Percentage': 25, 'Stage_III_Percentage': 15, 'Diabetes_Mellitus_Percentage': 12, 'Congestive_Heart_Failure_Percentage': 4, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 6, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 8, 'Adjuvant_Chemotherapy_Received_Percentage': 15, 'Postoperative_RT_Received_Percentage': 20, 'Common_Neoadjuvant_Regimen_1': 'None', 'Common_Neoadjuvant_Regimen_2': 'None', 'Common_Adjuvant_Regimen_1': 'None', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 10, 'Antiemetic_Agent_Percentage': 5, 'Painkiller_Antipyretic_Percentage': 25, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 15, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zyclara (Imiquimod)', 'STUDYID': 'ZCL2021CAN', 'YEAR': 2021, 'Country': 'Canada', 'Dataset': 'Claim database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 28.1, 'Smoking_History_Yes_Percentage': 35, 'Total_ADL_Independence_Percentage': 90, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 60, 'Tumor_Stage_T2_Percentage': 25, 'Tumor_Stage_T3_Percentage': 10, 'Tumor_Stage_T4_Percentage': 5, 'Nodal_Stage_N0_Percentage': 75, 'Nodal_Stage_N1_Percentage': 15, 'Nodal_Stage_N2_Percentage': 6, 'Nodal_Stage_N3_Percentage': 4, 'Stage_I_Percentage': 65, 'Stage_II_Percentage': 20, 'Stage_III_Percentage': 15, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 5, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 7, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 7, 'Adjuvant_Chemotherapy_Received_Percentage': 12, 'Postoperative_RT_Received_Percentage': 18, 'Common_Neoadjuvant_Regimen_1': 'None', 'Common_Neoadjuvant_Regimen_2': 'None', 'Common_Adjuvant_Regimen_1': 'None', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 12, 'Antiemetic_Agent_Percentage': 6, 'Painkiller_Antipyretic_Percentage': 28, 'Beds_Less_Than_200_Percentage': 25, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 18, 'Months_Between_Surgery_And_Index_Date': 1.5}, {'Drug_Name': 'Zyclara (Imiquimod)', 'STUDYID': 'ZCL2022EUR', 'YEAR': 2022, 'Country': 'Germany', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 26.9, 'Smoking_History_Yes_Percentage': 30, 'Total_ADL_Independence_Percentage': 88, 'LHRH_Use_Percentage': 6, 'Tumor_Stage_T1_Percentage': 58, 'Tumor_Stage_T2_Percentage': 27, 'Tumor_Stage_T3_Percentage': 9, 'Tumor_Stage_T4_Percentage': 6, 'Nodal_Stage_N0_Percentage': 72, 'Nodal_Stage_N1_Percentage': 18, 'Nodal_Stage_N2_Percentage': 5, 'Nodal_Stage_N3_Percentage': 5, 'Stage_I_Percentage': 62, 'Stage_II_Percentage': 23, 'Stage_III_Percentage': 15, 'Diabetes_Mellitus_Percentage': 14, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 9, 'Adjuvant_Chemotherapy_Received_Percentage': 14, 'Postoperative_RT_Received_Percentage': 22, 'Common_Neoadjuvant_Regimen_1': 'None', 'Common_Neoadjuvant_Regimen_2': 'None', 'Common_Adjuvant_Regimen_1': 'None', 'Common_Adjuvant_Regimen_2': 'None', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 11, 'Antiemetic_Agent_Percentage': 7, 'Painkiller_Antipyretic_Percentage': 27, 'Beds_Less_Than_200_Percentage': 18, 'Beds_200_To_499_Percentage': 52, 'Beds_Greater_Or_Equal_To_500_Percentage': 30, 'Designated_Cancer_Hospital_Percentage': 20, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Zyclara (Imiquimod)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zyclara (Imiquimod)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zydelig (Idelalisib)\",\n",
      "    \"STUDYID\": \"ZYD1001\",\n",
      "    \"YEAR\": \"2021\",\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"350\",\n",
      "    \"Median_Age\": \"68\",\n",
      "    \"Female_Percentage\": \"42\",\n",
      "    \"Male_Percentage\": \"58\",\n",
      "    \"Median_BMI\": \"27.5\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"35\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"70\",\n",
      "    \"LHRH_Use_Percentage\": \"5\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"10\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"25\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"30\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"35\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"40\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"30\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"20\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"15\",\n",
      "    \"Stage_II_Percentage\": \"25\",\n",
      "    \"Stage_III_Percentage\": \"30\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"18\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"8\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"12\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"15\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"25\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"30\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Hyper-CVAD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Bendamustine\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"45\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"35\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"50\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"20\",\n",
      "    \"Beds_200_To_499_Percentage\": \"45\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"60\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zydelig (Idelalisib)\",\n",
      "    \"STUDYID\": \"ZYD1002\",\n",
      "    \"YEAR\": \"2022\",\n",
      "    \"Country\": \"Canada\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"420\",\n",
      "    \"Median_Age\": \"72\",\n",
      "    \"Female_Percentage\": \"38\",\n",
      "    \"Male_Percentage\": \"62\",\n",
      "    \"Median_BMI\": \"28.1\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"40\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"65\",\n",
      "    \"LHRH_Use_Percentage\": \"7\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"8\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"22\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"33\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"37\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"35\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"32\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"23\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"12\",\n",
      "    \"Stage_II_Percentage\": \"28\",\n",
      "    \"Stage_III_Percentage\": \"32\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"20\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"10\",\n",
      "    \"Stroke_Percentage\": \"5\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"14\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"7\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"12\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"28\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"33\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DA-EPOCH-R\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Obinutuzumab\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"50\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"40\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"55\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"25\",\n",
      "    \"Beds_200_To_499_Percentage\": \"40\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"55\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"3\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zydelig (Idelalisib)\",\n",
      "    \"STUDYID\": \"ZYD1003\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"UK\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": \"280\",\n",
      "    \"Median_Age\": \"65\",\n",
      "    \"Female_Percentage\": \"45\",\n",
      "    \"Male_Percentage\": \"55\",\n",
      "    \"Median_BMI\": \"26.8\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"30\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"75\",\n",
      "    \"LHRH_Use_Percentage\": \"3\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"12\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"28\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"32\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"45\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"28\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"17\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"18\",\n",
      "    \"Stage_II_Percentage\": \"22\",\n",
      "    \"Stage_III_Percentage\": \"35\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"15\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"7\",\n",
      "    \"Stroke_Percentage\": \"3\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"10\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"5\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"18\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"22\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"28\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CVP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Hyper-CVAD\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Bendamustine\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"40\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"30\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"45\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"15\",\n",
      "    \"Beds_200_To_499_Percentage\": \"50\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"70\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"1\"\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zydelig (Idelalisib)\",\n",
      "    \"STUDYID\": \"ZYD1004\",\n",
      "    \"YEAR\": \"2023\",\n",
      "    \"Country\": \"Australia\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": \"380\",\n",
      "    \"Median_Age\": \"70\",\n",
      "    \"Female_Percentage\": \"40\",\n",
      "    \"Male_Percentage\": \"60\",\n",
      "    \"Median_BMI\": \"29.0\",\n",
      "    \"Smoking_History_Yes_Percentage\": \"38\",\n",
      "    \"Total_ADL_Independence_Percentage\": \"68\",\n",
      "    \"LHRH_Use_Percentage\": \"6\",\n",
      "    \"Tumor_Stage_T1_Percentage\": \"9\",\n",
      "    \"Tumor_Stage_T2_Percentage\": \"24\",\n",
      "    \"Tumor_Stage_T3_Percentage\": \"31\",\n",
      "    \"Tumor_Stage_T4_Percentage\": \"36\",\n",
      "    \"Nodal_Stage_N0_Percentage\": \"38\",\n",
      "    \"Nodal_Stage_N1_Percentage\": \"31\",\n",
      "    \"Nodal_Stage_N2_Percentage\": \"21\",\n",
      "    \"Nodal_Stage_N3_Percentage\": \"10\",\n",
      "    \"Stage_I_Percentage\": \"14\",\n",
      "    \"Stage_II_Percentage\": \"26\",\n",
      "    \"Stage_III_Percentage\": \"31\",\n",
      "    \"Diabetes_Mellitus_Percentage\": \"19\",\n",
      "    \"Congestive_Heart_Failure_Percentage\": \"9\",\n",
      "    \"Stroke_Percentage\": \"4\",\n",
      "    \"Atrial_Fibrillation_Percentage\": \"13\",\n",
      "    \"Myocardial_Infarction_Percentage\": \"6\",\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": \"14\",\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": \"26\",\n",
      "    \"Postoperative_RT_Received_Percentage\": \"32\",\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DA-EPOCH-R\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Rituximab\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Obinutuzumab\",\n",
      "    \"Tamoxifen_Percentage\": \"0\",\n",
      "    \"Letrozole_Percentage\": \"0\",\n",
      "    \"Anastrozole_Percentage\": \"0\",\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": \"48\",\n",
      "    \"Antiemetic_Agent_Percentage\": \"38\",\n",
      "    \"Painkiller_Antipyretic_Percentage\": \"53\",\n",
      "    \"Beds_Less_Than_200_Percentage\": \"22\",\n",
      "    \"Beds_200_To_499_Percentage\": \"43\",\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": \"35\",\n",
      "    \"Designated_Cancer_Hospital_Percentage\": \"58\",\n",
      "    \"Months_Between_Surgery_And_Index_Date\": \"2.5\"\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zydelig (Idelalisib)', 'STUDYID': 'ZYD1001', 'YEAR': '2021', 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': '350', 'Median_Age': '68', 'Female_Percentage': '42', 'Male_Percentage': '58', 'Median_BMI': '27.5', 'Smoking_History_Yes_Percentage': '35', 'Total_ADL_Independence_Percentage': '70', 'LHRH_Use_Percentage': '5', 'Tumor_Stage_T1_Percentage': '10', 'Tumor_Stage_T2_Percentage': '25', 'Tumor_Stage_T3_Percentage': '30', 'Tumor_Stage_T4_Percentage': '35', 'Nodal_Stage_N0_Percentage': '40', 'Nodal_Stage_N1_Percentage': '30', 'Nodal_Stage_N2_Percentage': '20', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '15', 'Stage_II_Percentage': '25', 'Stage_III_Percentage': '30', 'Diabetes_Mellitus_Percentage': '18', 'Congestive_Heart_Failure_Percentage': '8', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '12', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '15', 'Adjuvant_Chemotherapy_Received_Percentage': '25', 'Postoperative_RT_Received_Percentage': '30', 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'Hyper-CVAD', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'Bendamustine', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '45', 'Antiemetic_Agent_Percentage': '35', 'Painkiller_Antipyretic_Percentage': '50', 'Beds_Less_Than_200_Percentage': '20', 'Beds_200_To_499_Percentage': '45', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '60', 'Months_Between_Surgery_And_Index_Date': '2'}, {'Drug_Name': 'Zydelig (Idelalisib)', 'STUDYID': 'ZYD1002', 'YEAR': '2022', 'Country': 'Canada', 'Dataset': 'Claim Database', 'Patient_Count': '420', 'Median_Age': '72', 'Female_Percentage': '38', 'Male_Percentage': '62', 'Median_BMI': '28.1', 'Smoking_History_Yes_Percentage': '40', 'Total_ADL_Independence_Percentage': '65', 'LHRH_Use_Percentage': '7', 'Tumor_Stage_T1_Percentage': '8', 'Tumor_Stage_T2_Percentage': '22', 'Tumor_Stage_T3_Percentage': '33', 'Tumor_Stage_T4_Percentage': '37', 'Nodal_Stage_N0_Percentage': '35', 'Nodal_Stage_N1_Percentage': '32', 'Nodal_Stage_N2_Percentage': '23', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '12', 'Stage_II_Percentage': '28', 'Stage_III_Percentage': '32', 'Diabetes_Mellitus_Percentage': '20', 'Congestive_Heart_Failure_Percentage': '10', 'Stroke_Percentage': '5', 'Atrial_Fibrillation_Percentage': '14', 'Myocardial_Infarction_Percentage': '7', 'Neoadjuvant_Chemotherapy_Received_Percentage': '12', 'Adjuvant_Chemotherapy_Received_Percentage': '28', 'Postoperative_RT_Received_Percentage': '33', 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'DA-EPOCH-R', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'Obinutuzumab', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '50', 'Antiemetic_Agent_Percentage': '40', 'Painkiller_Antipyretic_Percentage': '55', 'Beds_Less_Than_200_Percentage': '25', 'Beds_200_To_499_Percentage': '40', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '55', 'Months_Between_Surgery_And_Index_Date': '3'}, {'Drug_Name': 'Zydelig (Idelalisib)', 'STUDYID': 'ZYD1003', 'YEAR': '2023', 'Country': 'UK', 'Dataset': 'MDV', 'Patient_Count': '280', 'Median_Age': '65', 'Female_Percentage': '45', 'Male_Percentage': '55', 'Median_BMI': '26.8', 'Smoking_History_Yes_Percentage': '30', 'Total_ADL_Independence_Percentage': '75', 'LHRH_Use_Percentage': '3', 'Tumor_Stage_T1_Percentage': '12', 'Tumor_Stage_T2_Percentage': '28', 'Tumor_Stage_T3_Percentage': '28', 'Tumor_Stage_T4_Percentage': '32', 'Nodal_Stage_N0_Percentage': '45', 'Nodal_Stage_N1_Percentage': '28', 'Nodal_Stage_N2_Percentage': '17', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '18', 'Stage_II_Percentage': '22', 'Stage_III_Percentage': '35', 'Diabetes_Mellitus_Percentage': '15', 'Congestive_Heart_Failure_Percentage': '7', 'Stroke_Percentage': '3', 'Atrial_Fibrillation_Percentage': '10', 'Myocardial_Infarction_Percentage': '5', 'Neoadjuvant_Chemotherapy_Received_Percentage': '18', 'Adjuvant_Chemotherapy_Received_Percentage': '22', 'Postoperative_RT_Received_Percentage': '28', 'Common_Neoadjuvant_Regimen_1': 'R-CVP', 'Common_Neoadjuvant_Regimen_2': 'Hyper-CVAD', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'Bendamustine', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '40', 'Antiemetic_Agent_Percentage': '30', 'Painkiller_Antipyretic_Percentage': '45', 'Beds_Less_Than_200_Percentage': '15', 'Beds_200_To_499_Percentage': '50', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '70', 'Months_Between_Surgery_And_Index_Date': '1'}, {'Drug_Name': 'Zydelig (Idelalisib)', 'STUDYID': 'ZYD1004', 'YEAR': '2023', 'Country': 'Australia', 'Dataset': 'Claim Database', 'Patient_Count': '380', 'Median_Age': '70', 'Female_Percentage': '40', 'Male_Percentage': '60', 'Median_BMI': '29.0', 'Smoking_History_Yes_Percentage': '38', 'Total_ADL_Independence_Percentage': '68', 'LHRH_Use_Percentage': '6', 'Tumor_Stage_T1_Percentage': '9', 'Tumor_Stage_T2_Percentage': '24', 'Tumor_Stage_T3_Percentage': '31', 'Tumor_Stage_T4_Percentage': '36', 'Nodal_Stage_N0_Percentage': '38', 'Nodal_Stage_N1_Percentage': '31', 'Nodal_Stage_N2_Percentage': '21', 'Nodal_Stage_N3_Percentage': '10', 'Stage_I_Percentage': '14', 'Stage_II_Percentage': '26', 'Stage_III_Percentage': '31', 'Diabetes_Mellitus_Percentage': '19', 'Congestive_Heart_Failure_Percentage': '9', 'Stroke_Percentage': '4', 'Atrial_Fibrillation_Percentage': '13', 'Myocardial_Infarction_Percentage': '6', 'Neoadjuvant_Chemotherapy_Received_Percentage': '14', 'Adjuvant_Chemotherapy_Received_Percentage': '26', 'Postoperative_RT_Received_Percentage': '32', 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'DA-EPOCH-R', 'Common_Adjuvant_Regimen_1': 'Rituximab', 'Common_Adjuvant_Regimen_2': 'Obinutuzumab', 'Tamoxifen_Percentage': '0', 'Letrozole_Percentage': '0', 'Anastrozole_Percentage': '0', 'Antidiarrheal_Agent_Probiotics_Percentage': '48', 'Antiemetic_Agent_Percentage': '38', 'Painkiller_Antipyretic_Percentage': '53', 'Beds_Less_Than_200_Percentage': '22', 'Beds_200_To_499_Percentage': '43', 'Beds_Greater_Or_Equal_To_500_Percentage': '35', 'Designated_Cancer_Hospital_Percentage': '58', 'Months_Between_Surgery_And_Index_Date': '2.5'}]\n",
      "File created: Zydelig (Idelalisib)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zydelig (Idelalisib)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zykadia (Ceritinib)\",\n",
      "    \"STUDYID\": \"ZykadiaStudy001\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 62,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 60,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 12,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 4,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 55,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Cisplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Carboplatin + Paclitaxel\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Vinorelbine + Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Docetaxel + Carboplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zykadia (Ceritinib)\",\n",
      "    \"STUDYID\": \"ZykadiaStudy002\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 55,\n",
      "    \"Total_ADL_Independence_Percentage\": 70,\n",
      "    \"LHRH_Use_Percentage\": 10,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 42,\n",
      "    \"Tumor_Stage_T4_Percentage\": 18,\n",
      "    \"Nodal_Stage_N0_Percentage\": 38,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32,\n",
      "    \"Nodal_Stage_N2_Percentage\": 18,\n",
      "    \"Nodal_Stage_N3_Percentage\": 12,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 58,\n",
      "    \"Postoperative_RT_Received_Percentage\": 38,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Carboplatin + Pemetrexed\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Cisplatin + Gemcitabine\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Paclitaxel + Carboplatin\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Gemcitabine + Cisplatin\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 40,\n",
      "    \"Antiemetic_Agent_Percentage\": 70,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zykadia (Ceritinib)\",\n",
      "    \"STUDYID\": \"ZykadiaStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 42,\n",
      "    \"Male_Percentage\": 58,\n",
      "    \"Median_BMI\": 25.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 45,\n",
      "    \"Total_ADL_Independence_Percentage\": 80,\n",
      "    \"LHRH_Use_Percentage\": 8,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 42,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 15,\n",
      "    \"Nodal_Stage_N3_Percentage\": 15,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 6,\n",
      "    \"Stroke_Percentage\": 2,\n",
      "    \"Atrial_Fibrillation_Percentage\": 8,\n",
      "    \"Myocardial_Infarction_Percentage\": 3,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 52,\n",
      "    \"Postoperative_RT_Received_Percentage\": 42,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"Pemetrexed + Carboplatin\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"Gemcitabine + Cisplatin\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"Cisplatin + Vinorelbine\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"Carboplatin + Docetaxel\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 60,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 45,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 55,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zykadia (Ceritinib)', 'STUDYID': 'ZykadiaStudy001', 'YEAR': 2022, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 62, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 60, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 12, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 4, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 55, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'Cisplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Carboplatin + Paclitaxel', 'Common_Adjuvant_Regimen_1': 'Vinorelbine + Cisplatin', 'Common_Adjuvant_Regimen_2': 'Docetaxel + Carboplatin', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zykadia (Ceritinib)', 'STUDYID': 'ZykadiaStudy002', 'YEAR': 2023, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 68, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 55, 'Total_ADL_Independence_Percentage': 70, 'LHRH_Use_Percentage': 10, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 42, 'Tumor_Stage_T4_Percentage': 18, 'Nodal_Stage_N0_Percentage': 38, 'Nodal_Stage_N1_Percentage': 32, 'Nodal_Stage_N2_Percentage': 18, 'Nodal_Stage_N3_Percentage': 12, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 58, 'Postoperative_RT_Received_Percentage': 38, 'Common_Neoadjuvant_Regimen_1': 'Carboplatin + Pemetrexed', 'Common_Neoadjuvant_Regimen_2': 'Cisplatin + Gemcitabine', 'Common_Adjuvant_Regimen_1': 'Paclitaxel + Carboplatin', 'Common_Adjuvant_Regimen_2': 'Gemcitabine + Cisplatin', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 40, 'Antiemetic_Agent_Percentage': 70, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Zykadia (Ceritinib)', 'STUDYID': 'ZykadiaStudy003', 'YEAR': 2023, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 42, 'Male_Percentage': 58, 'Median_BMI': 25.5, 'Smoking_History_Yes_Percentage': 45, 'Total_ADL_Independence_Percentage': 80, 'LHRH_Use_Percentage': 8, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 42, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 15, 'Nodal_Stage_N3_Percentage': 15, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 6, 'Stroke_Percentage': 2, 'Atrial_Fibrillation_Percentage': 8, 'Myocardial_Infarction_Percentage': 3, 'Neoadjuvant_Chemotherapy_Received_Percentage': 28, 'Adjuvant_Chemotherapy_Received_Percentage': 52, 'Postoperative_RT_Received_Percentage': 42, 'Common_Neoadjuvant_Regimen_1': 'Pemetrexed + Carboplatin', 'Common_Neoadjuvant_Regimen_2': 'Gemcitabine + Cisplatin', 'Common_Adjuvant_Regimen_1': 'Cisplatin + Vinorelbine', 'Common_Adjuvant_Regimen_2': 'Carboplatin + Docetaxel', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 60, 'Painkiller_Antipyretic_Percentage': 45, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 55, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Zykadia (Ceritinib)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zykadia (Ceritinib)\n",
      "Raw patient data response text: [\n",
      "  {\n",
      "    \"Drug_Name\": \"Zynlonta (Loncastuximab Tesirine-lpyl)\",\n",
      "    \"STUDYID\": \"ZynlontaStudy001\",\n",
      "    \"YEAR\": 2022,\n",
      "    \"Country\": \"USA\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 350,\n",
      "    \"Median_Age\": 68,\n",
      "    \"Female_Percentage\": 45,\n",
      "    \"Male_Percentage\": 55,\n",
      "    \"Median_BMI\": 27.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 62,\n",
      "    \"Total_ADL_Independence_Percentage\": 78,\n",
      "    \"LHRH_Use_Percentage\": 5,\n",
      "    \"Tumor_Stage_T1_Percentage\": 15,\n",
      "    \"Tumor_Stage_T2_Percentage\": 30,\n",
      "    \"Tumor_Stage_T3_Percentage\": 40,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 40,\n",
      "    \"Nodal_Stage_N1_Percentage\": 30,\n",
      "    \"Nodal_Stage_N2_Percentage\": 20,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 20,\n",
      "    \"Stage_II_Percentage\": 35,\n",
      "    \"Stage_III_Percentage\": 45,\n",
      "    \"Diabetes_Mellitus_Percentage\": 18,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 8,\n",
      "    \"Stroke_Percentage\": 4,\n",
      "    \"Atrial_Fibrillation_Percentage\": 10,\n",
      "    \"Myocardial_Infarction_Percentage\": 6,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 25,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 60,\n",
      "    \"Postoperative_RT_Received_Percentage\": 40,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DA-EPOCH-R\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"R-CVP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"R-Bendamustine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 30,\n",
      "    \"Antiemetic_Agent_Percentage\": 70,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 55,\n",
      "    \"Beds_Less_Than_200_Percentage\": 15,\n",
      "    \"Beds_200_To_499_Percentage\": 45,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 65,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zynlonta (Loncastuximab Tesirine-lpyl)\",\n",
      "    \"STUDYID\": \"ZynlontaStudy002\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Germany\",\n",
      "    \"Dataset\": \"Claim Database\",\n",
      "    \"Patient_Count\": 420,\n",
      "    \"Median_Age\": 72,\n",
      "    \"Female_Percentage\": 52,\n",
      "    \"Male_Percentage\": 48,\n",
      "    \"Median_BMI\": 26.8,\n",
      "    \"Smoking_History_Yes_Percentage\": 58,\n",
      "    \"Total_ADL_Independence_Percentage\": 75,\n",
      "    \"LHRH_Use_Percentage\": 7,\n",
      "    \"Tumor_Stage_T1_Percentage\": 12,\n",
      "    \"Tumor_Stage_T2_Percentage\": 28,\n",
      "    \"Tumor_Stage_T3_Percentage\": 45,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 35,\n",
      "    \"Nodal_Stage_N1_Percentage\": 32,\n",
      "    \"Nodal_Stage_N2_Percentage\": 23,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 18,\n",
      "    \"Stage_II_Percentage\": 32,\n",
      "    \"Stage_III_Percentage\": 50,\n",
      "    \"Diabetes_Mellitus_Percentage\": 20,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 10,\n",
      "    \"Stroke_Percentage\": 5,\n",
      "    \"Atrial_Fibrillation_Percentage\": 12,\n",
      "    \"Myocardial_Infarction_Percentage\": 7,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 28,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 65,\n",
      "    \"Postoperative_RT_Received_Percentage\": 45,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DA-EPOCH-R\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"R-CVP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"R-Bendamustine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 35,\n",
      "    \"Antiemetic_Agent_Percentage\": 75,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 60,\n",
      "    \"Beds_Less_Than_200_Percentage\": 10,\n",
      "    \"Beds_200_To_499_Percentage\": 50,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 70,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 3\n",
      "  },\n",
      "  {\n",
      "    \"Drug_Name\": \"Zynlonta (Loncastuximab Tesirine-lpyl)\",\n",
      "    \"STUDYID\": \"ZynlontaStudy003\",\n",
      "    \"YEAR\": 2023,\n",
      "    \"Country\": \"Japan\",\n",
      "    \"Dataset\": \"MDV\",\n",
      "    \"Patient_Count\": 280,\n",
      "    \"Median_Age\": 70,\n",
      "    \"Female_Percentage\": 48,\n",
      "    \"Male_Percentage\": 52,\n",
      "    \"Median_BMI\": 25.5,\n",
      "    \"Smoking_History_Yes_Percentage\": 45,\n",
      "    \"Total_ADL_Independence_Percentage\": 82,\n",
      "    \"LHRH_Use_Percentage\": 3,\n",
      "    \"Tumor_Stage_T1_Percentage\": 18,\n",
      "    \"Tumor_Stage_T2_Percentage\": 32,\n",
      "    \"Tumor_Stage_T3_Percentage\": 35,\n",
      "    \"Tumor_Stage_T4_Percentage\": 15,\n",
      "    \"Nodal_Stage_N0_Percentage\": 45,\n",
      "    \"Nodal_Stage_N1_Percentage\": 28,\n",
      "    \"Nodal_Stage_N2_Percentage\": 17,\n",
      "    \"Nodal_Stage_N3_Percentage\": 10,\n",
      "    \"Stage_I_Percentage\": 22,\n",
      "    \"Stage_II_Percentage\": 38,\n",
      "    \"Stage_III_Percentage\": 40,\n",
      "    \"Diabetes_Mellitus_Percentage\": 15,\n",
      "    \"Congestive_Heart_Failure_Percentage\": 7,\n",
      "    \"Stroke_Percentage\": 3,\n",
      "    \"Atrial_Fibrillation_Percentage\": 9,\n",
      "    \"Myocardial_Infarction_Percentage\": 5,\n",
      "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": 22,\n",
      "    \"Adjuvant_Chemotherapy_Received_Percentage\": 55,\n",
      "    \"Postoperative_RT_Received_Percentage\": 35,\n",
      "    \"Common_Neoadjuvant_Regimen_1\": \"R-CHOP\",\n",
      "    \"Common_Neoadjuvant_Regimen_2\": \"DA-EPOCH-R\",\n",
      "    \"Common_Adjuvant_Regimen_1\": \"R-CVP\",\n",
      "    \"Common_Adjuvant_Regimen_2\": \"R-Bendamustine\",\n",
      "    \"Tamoxifen_Percentage\": 0,\n",
      "    \"Letrozole_Percentage\": 0,\n",
      "    \"Anastrozole_Percentage\": 0,\n",
      "    \"Antidiarrheal_Agent_Probiotics_Percentage\": 25,\n",
      "    \"Antiemetic_Agent_Percentage\": 65,\n",
      "    \"Painkiller_Antipyretic_Percentage\": 50,\n",
      "    \"Beds_Less_Than_200_Percentage\": 20,\n",
      "    \"Beds_200_To_499_Percentage\": 40,\n",
      "    \"Beds_Greater_Or_Equal_To_500_Percentage\": 40,\n",
      "    \"Designated_Cancer_Hospital_Percentage\": 60,\n",
      "    \"Months_Between_Surgery_And_Index_Date\": 2.5\n",
      "  }\n",
      "]\n",
      "Extracted patient data: [{'Drug_Name': 'Zynlonta (Loncastuximab Tesirine-lpyl)', 'STUDYID': 'ZynlontaStudy001', 'YEAR': 2022, 'Country': 'USA', 'Dataset': 'MDV', 'Patient_Count': 350, 'Median_Age': 68, 'Female_Percentage': 45, 'Male_Percentage': 55, 'Median_BMI': 27.5, 'Smoking_History_Yes_Percentage': 62, 'Total_ADL_Independence_Percentage': 78, 'LHRH_Use_Percentage': 5, 'Tumor_Stage_T1_Percentage': 15, 'Tumor_Stage_T2_Percentage': 30, 'Tumor_Stage_T3_Percentage': 40, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 40, 'Nodal_Stage_N1_Percentage': 30, 'Nodal_Stage_N2_Percentage': 20, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 20, 'Stage_II_Percentage': 35, 'Stage_III_Percentage': 45, 'Diabetes_Mellitus_Percentage': 18, 'Congestive_Heart_Failure_Percentage': 8, 'Stroke_Percentage': 4, 'Atrial_Fibrillation_Percentage': 10, 'Myocardial_Infarction_Percentage': 6, 'Neoadjuvant_Chemotherapy_Received_Percentage': 25, 'Adjuvant_Chemotherapy_Received_Percentage': 60, 'Postoperative_RT_Received_Percentage': 40, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'DA-EPOCH-R', 'Common_Adjuvant_Regimen_1': 'R-CVP', 'Common_Adjuvant_Regimen_2': 'R-Bendamustine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 30, 'Antiemetic_Agent_Percentage': 70, 'Painkiller_Antipyretic_Percentage': 55, 'Beds_Less_Than_200_Percentage': 15, 'Beds_200_To_499_Percentage': 45, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 65, 'Months_Between_Surgery_And_Index_Date': 2}, {'Drug_Name': 'Zynlonta (Loncastuximab Tesirine-lpyl)', 'STUDYID': 'ZynlontaStudy002', 'YEAR': 2023, 'Country': 'Germany', 'Dataset': 'Claim Database', 'Patient_Count': 420, 'Median_Age': 72, 'Female_Percentage': 52, 'Male_Percentage': 48, 'Median_BMI': 26.8, 'Smoking_History_Yes_Percentage': 58, 'Total_ADL_Independence_Percentage': 75, 'LHRH_Use_Percentage': 7, 'Tumor_Stage_T1_Percentage': 12, 'Tumor_Stage_T2_Percentage': 28, 'Tumor_Stage_T3_Percentage': 45, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 35, 'Nodal_Stage_N1_Percentage': 32, 'Nodal_Stage_N2_Percentage': 23, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 18, 'Stage_II_Percentage': 32, 'Stage_III_Percentage': 50, 'Diabetes_Mellitus_Percentage': 20, 'Congestive_Heart_Failure_Percentage': 10, 'Stroke_Percentage': 5, 'Atrial_Fibrillation_Percentage': 12, 'Myocardial_Infarction_Percentage': 7, 'Neoadjuvant_Chemotherapy_Received_Percentage': 28, 'Adjuvant_Chemotherapy_Received_Percentage': 65, 'Postoperative_RT_Received_Percentage': 45, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'DA-EPOCH-R', 'Common_Adjuvant_Regimen_1': 'R-CVP', 'Common_Adjuvant_Regimen_2': 'R-Bendamustine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 35, 'Antiemetic_Agent_Percentage': 75, 'Painkiller_Antipyretic_Percentage': 60, 'Beds_Less_Than_200_Percentage': 10, 'Beds_200_To_499_Percentage': 50, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 70, 'Months_Between_Surgery_And_Index_Date': 3}, {'Drug_Name': 'Zynlonta (Loncastuximab Tesirine-lpyl)', 'STUDYID': 'ZynlontaStudy003', 'YEAR': 2023, 'Country': 'Japan', 'Dataset': 'MDV', 'Patient_Count': 280, 'Median_Age': 70, 'Female_Percentage': 48, 'Male_Percentage': 52, 'Median_BMI': 25.5, 'Smoking_History_Yes_Percentage': 45, 'Total_ADL_Independence_Percentage': 82, 'LHRH_Use_Percentage': 3, 'Tumor_Stage_T1_Percentage': 18, 'Tumor_Stage_T2_Percentage': 32, 'Tumor_Stage_T3_Percentage': 35, 'Tumor_Stage_T4_Percentage': 15, 'Nodal_Stage_N0_Percentage': 45, 'Nodal_Stage_N1_Percentage': 28, 'Nodal_Stage_N2_Percentage': 17, 'Nodal_Stage_N3_Percentage': 10, 'Stage_I_Percentage': 22, 'Stage_II_Percentage': 38, 'Stage_III_Percentage': 40, 'Diabetes_Mellitus_Percentage': 15, 'Congestive_Heart_Failure_Percentage': 7, 'Stroke_Percentage': 3, 'Atrial_Fibrillation_Percentage': 9, 'Myocardial_Infarction_Percentage': 5, 'Neoadjuvant_Chemotherapy_Received_Percentage': 22, 'Adjuvant_Chemotherapy_Received_Percentage': 55, 'Postoperative_RT_Received_Percentage': 35, 'Common_Neoadjuvant_Regimen_1': 'R-CHOP', 'Common_Neoadjuvant_Regimen_2': 'DA-EPOCH-R', 'Common_Adjuvant_Regimen_1': 'R-CVP', 'Common_Adjuvant_Regimen_2': 'R-Bendamustine', 'Tamoxifen_Percentage': 0, 'Letrozole_Percentage': 0, 'Anastrozole_Percentage': 0, 'Antidiarrheal_Agent_Probiotics_Percentage': 25, 'Antiemetic_Agent_Percentage': 65, 'Painkiller_Antipyretic_Percentage': 50, 'Beds_Less_Than_200_Percentage': 20, 'Beds_200_To_499_Percentage': 40, 'Beds_Greater_Or_Equal_To_500_Percentage': 40, 'Designated_Cancer_Hospital_Percentage': 60, 'Months_Between_Surgery_And_Index_Date': 2.5}]\n",
      "File created: Zynlonta (Loncastuximab Tesirine-lpyl)_postmarket_data.csv\n",
      "Successfully generated and saved postmarket data for Zynlonta (Loncastuximab Tesirine-lpyl)\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import csv\n",
    "import json\n",
    "import google.generativeai as genai\n",
    "from dotenv import load_dotenv\n",
    "import random\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "api_key = \"AIzaSyBSpjhnYk97Un4eTDcxs9I2oDosw7YNr6g\"  # Replace with your actual API key\n",
    "genai.configure(api_key=api_key)\n",
    "\n",
    "generation_config = {\n",
    "    \"temperature\": 0,\n",
    "    \"top_p\": 0.95,\n",
    "    \"top_k\": 40,\n",
    "    \"max_output_tokens\": 16384,\n",
    "    \"response_mime_type\": \"application/json\",\n",
    "}\n",
    "\n",
    "model = genai.GenerativeModel(\n",
    "    model_name=\"gemini-2.0-flash\",\n",
    "    generation_config=generation_config,\n",
    ")\n",
    "\n",
    "def save_postmarket_csv(filename, data):\n",
    "    csv_file = f\"{filename}.csv\"\n",
    "    headers = [\n",
    "        \"Drug_Name\",\n",
    "        \"STUDYID\",\n",
    "        \"YEAR\",\n",
    "        \"Country\",\n",
    "        \"Dataset\",\n",
    "        \"Patient_Count\",\n",
    "        \"Median_Age\",\n",
    "        \"Female_Percentage\",\n",
    "        \"Male_Percentage\",\n",
    "        \"Median_BMI\",\n",
    "        \"Smoking_History_Yes_Percentage\",\n",
    "        \"Total_ADL_Independence_Percentage\",\n",
    "        \"LHRH_Use_Percentage\",\n",
    "        \"Tumor_Stage_T1_Percentage\",\n",
    "        \"Tumor_Stage_T2_Percentage\",\n",
    "        \"Tumor_Stage_T3_Percentage\",\n",
    "        \"Tumor_Stage_T4_Percentage\",\n",
    "        \"Nodal_Stage_N0_Percentage\",\n",
    "        \"Nodal_Stage_N1_Percentage\",\n",
    "        \"Nodal_Stage_N2_Percentage\",\n",
    "        \"Nodal_Stage_N3_Percentage\",\n",
    "        \"Stage_I_Percentage\",\n",
    "        \"Stage_II_Percentage\",\n",
    "        \"Stage_III_Percentage\",\n",
    "        \"Diabetes_Mellitus_Percentage\",\n",
    "        \"Congestive_Heart_Failure_Percentage\",\n",
    "        \"Stroke_Percentage\",\n",
    "        \"Atrial_Fibrillation_Percentage\",\n",
    "        \"Myocardial_Infarction_Percentage\",\n",
    "        \"Neoadjuvant_Chemotherapy_Received_Percentage\",\n",
    "        \"Adjuvant_Chemotherapy_Received_Percentage\",\n",
    "        \"Postoperative_RT_Received_Percentage\",\n",
    "        \"Common_Neoadjuvant_Regimen_1\",\n",
    "        \"Common_Neoadjuvant_Regimen_2\",\n",
    "        \"Common_Adjuvant_Regimen_1\",\n",
    "        \"Common_Adjuvant_Regimen_2\",\n",
    "        \"Tamoxifen_Percentage\",\n",
    "        \"Letrozole_Percentage\",\n",
    "        \"Anastrozole_Percentage\",\n",
    "        \"Antidiarrheal_Agent_Probiotics_Percentage\",\n",
    "        \"Antiemetic_Agent_Percentage\",\n",
    "        \"Painkiller_Antipyretic_Percentage\",\n",
    "        \"Beds_Less_Than_200_Percentage\",\n",
    "        \"Beds_200_To_499_Percentage\",\n",
    "        \"Beds_Greater_Or_Equal_To_500_Percentage\",\n",
    "        \"Designated_Cancer_Hospital_Percentage\",\n",
    "        \"Months_Between_Surgery_And_Index_Date\"\n",
    "    ]\n",
    "    with open(csv_file, mode='w', newline='', encoding='utf-8') as file:\n",
    "        writer = csv.DictWriter(file, fieldnames=headers)\n",
    "        writer.writeheader()\n",
    "        for row in data:\n",
    "            writer.writerow(row)\n",
    "    print(\"File created:\", csv_file)\n",
    "\n",
    "def prompt_postmarket_data_generation(drug_name):\n",
    "    PROMPT = f'''\n",
    "    You are an expert in creating realistic, but entirely fictitious post-market data for oncology drugs. You have the following data.\n",
    "\n",
    "    Generate the realistic data for the drug = {drug_name}.\n",
    "\n",
    "    For EACH of the following columns, and where applicable, provide realistic and entirely fictitious data in a JSON with each patient being an element in the array:\n",
    "\n",
    "    \"Drug_Name\": drugname,\n",
    "    \"STUDYID\": A unique study identifier (e.g., \"Study123\").\n",
    "    \"YEAR\": The year the data was collected\n",
    "    \"Country\": The country where the study was conducted\n",
    "    \"Dataset\": What kind of database it was taken, such as MDV, claim database\n",
    "    \"Patient_Count\": The number of patients involved, use a realistic data, make most of them come from the range of 200 to 500\n",
    "\n",
    "    \"Median_Age\": Median age of the patient population, should be oncology patients (e.g., between 30 and 85).\n",
    "    \"Female_Percentage\": Percentage of female patients.\n",
    "    \"Male_Percentage\": Percentage of male patients, these 2 must add upto 100.\n",
    "    \"Median_BMI\": Median body mass index.\n",
    "    \"Smoking_History_Yes_Percentage\": Percentage of patients with a smoking history.\n",
    "    \"Total_ADL_Independence_Percentage\": Percentage of patients with total ADL independence.\n",
    "    \"LHRH_Use_Percentage\": Percentage of patients who were prescribed LHRH agonists\n",
    "\n",
    "    \"Tumor_Stage_T1_Percentage\": Percentage of patients with tumor stage T1.\n",
    "    \"Tumor_Stage_T2_Percentage\": Percentage of patients with tumor stage T2.\n",
    "    \"Tumor_Stage_T3_Percentage\": Percentage of patients with tumor stage T3.\n",
    "    \"Tumor_Stage_T4_Percentage\": Percentage of patients with tumor stage T4.\n",
    "    \"Nodal_Stage_N0_Percentage\": Percentage of patients with nodal stage N0.\n",
    "    \"Nodal_Stage_N1_Percentage\": Percentage of patients with nodal stage N1.\n",
    "    \"Nodal_Stage_N2_Percentage\": Percentage of patients with nodal stage N2.\n",
    "    \"Nodal_Stage_N3_Percentage\": Percentage of patients with nodal stage N3.\n",
    "    \"Stage_I_Percentage\": Percentage of patients in Stage I (defined by TNM classification).\n",
    "    \"Stage_II_Percentage\": Percentage of patients in Stage II (defined by TNM classification).\n",
    "    \"Stage_III_Percentage\": Percentage of patients in Stage III (defined by TNM classification).\n",
    "\n",
    "    \"Diabetes_Mellitus_Percentage\": Percentage of patients with diabetes mellitus.\n",
    "    \"Congestive_Heart_Failure_Percentage\": Percentage of patients with congestive heart failure.\n",
    "    \"Stroke_Percentage\": Percentage of patients with stroke (ischemic and hemorrhagic).\n",
    "    \"Atrial_Fibrillation_Percentage\": Percentage of patients with atrial fibrillation.\n",
    "    \"Myocardial_Infarction_Percentage\": Percentage of patients with myocardial infarction.\n",
    "\n",
    "    \"Neoadjuvant_Chemotherapy_Received_Percentage\": Percentage of patients who received neoadjuvant chemotherapy.\n",
    "    \"Adjuvant_Chemotherapy_Received_Percentage\": Percentage of patients who received adjuvant chemotherapy.\n",
    "    \"Postoperative_RT_Received_Percentage\": Percentage of patients who received postoperative radiotherapy.\n",
    "    \"Common_Neoadjuvant_Regimen_1\": 1st most common neoadjuvant chemotherapy regimen.\n",
    "    \"Common_Neoadjuvant_Regimen_2\": 2nd most common neoadjuvant chemotherapy regimen.\n",
    "    \"Common_Adjuvant_Regimen_1\": 1st most common adjuvant chemotherapy regimen.\n",
    "    \"Common_Adjuvant_Regimen_2\": 2nd most common adjuvant chemotherapy regimen.\n",
    "    \"Tamoxifen_Percentage\": Percentage of patients who received Tamoxifen as concomitant ET.\n",
    "    \"Letrozole_Percentage\": Percentage of patients who received Letrozole as concomitant ET.\n",
    "    \"Anastrozole_Percentage\": Percentage of patients who received Anastrozole as concomitant ET.\n",
    "    \"Antidiarrheal_Agent_Probiotics_Percentage\": Percentage of patients who used Antidiarrheal agents or Probiotics.\n",
    "    \"Antiemetic_Agent_Percentage\": Percentage of patients who used Antiemetic agents.\n",
    "    \"Painkiller_Antipyretic_Percentage\": Percentage of patients who used Pain killer/Antipyretic\n",
    "\n",
    "    \"Beds_Less_Than_200_Percentage\": Hospitals that had less than 200 beds\n",
    "    \"Beds_200_To_499_Percentage\": Hospitals that had beds between 200 and 499\n",
    "    \"Beds_Greater_Or_Equal_To_500_Percentage\": Hospitals that had beds greater than 500\n",
    "    \"Designated_Cancer_Hospital_Percentage\": hospitals that had designated cancer designations\n",
    "    \"Months_Between_Surgery_And_Index_Date\": median months\n",
    "   '''\n",
    "    return PROMPT\n",
    "\n",
    "def get_extracted_postmarket_data(drug_name):\n",
    "    chat_session = model.start_chat(\n",
    "        history=[\n",
    "            {\n",
    "                \"role\": \"user\",\n",
    "                \"parts\": [prompt_postmarket_data_generation(drug_name)],\n",
    "            },\n",
    "        ],\n",
    "    )\n",
    "    response = chat_session.send_message(prompt_postmarket_data_generation(drug_name))\n",
    "\n",
    "    # Print the raw response text for debugging\n",
    "    print(\"Raw patient data response text:\", response.text)\n",
    "\n",
    "    try:\n",
    "        extracted_data = json.loads(response.text)\n",
    "        if isinstance(extracted_data, list) and extracted_data:\n",
    "            print(\"Extracted patient data:\", extracted_data)\n",
    "            return extracted_data\n",
    "        else:\n",
    "            print(\"Extracted data is not in the expected format or is empty.\")\n",
    "            return None\n",
    "    except json.JSONDecodeError as e:\n",
    "        print(f\"Error parsing JSON: {e}. Response text may be incomplete.\")\n",
    "        try:\n",
    "            # Attempt to fix common JSON errors (e.g., missing closing bracket)\n",
    "            if not response.text.strip().endswith(']'):\n",
    "                repaired_text = response.text.strip() + ']'\n",
    "            else:\n",
    "                repaired_text = response.text.strip()\n",
    "\n",
    "            extracted_data = json.loads(repaired_text) # Attempt to parse fixed JSON\n",
    "            print(\"Successfully parsed recovered JSON\")\n",
    "            return extracted_data\n",
    "\n",
    "        except json.JSONDecodeError as recovery_exception:\n",
    "            print(f\"Failed to recover JSON: {recovery_exception}\")\n",
    "        return None\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    drugs = [\n",
    "       \"Abemaciclib\", \"Abiraterone Acetate\", \"Abraxane\", \"Adriamycin\", \"Afinitor\",\n",
    "        \"Alectinib\", \"Axitinib\", \"Balversa\", \"Brigatinib\", \"Cabozantinib\",\n",
    "        \"Capecitabine\", \"Carboplatin\", \"Ceritinib\", \"Crizotinib\", \"Cyclophosphamide\",\n",
    "        \"Cytarabine\", \"Dabrafenib\", \"Dasatinib\", \"Decitabine\", \"Docetaxel\",\n",
    "        \"Doxorubicin\", \"Enzalutamide\", \"Erlotinib\", \"Everolimus\", \"Fluorouracil\",\n",
    "        \"Gemcitabine\", \"Ibrutinib\", \"Imatinib\", \"Ixazomib\", \"Lapatinib\",\n",
    "        \"Lenalidomide\", \"Letrozole\", \"Lenvatinib\", \"Lorlatinib\", \"Methotrexate\",\n",
    "        \"Neratinib\", \"Olaparib\", \"Osimertinib\", \"Paclitaxel\", \"Palbociclib\",\n",
    "        \"Pemetrexed\", \"Ribociclib\", \"Sorafenib\", \"Sunitinib\", \"Tamoxifen\",\n",
    "        \"Temozolomide\", \"Thalidomide\", \"Venetoclax\", \"Vismodegib\", \"Vorinostat\",\n",
    "        \"Welireg (Belzutifan)\", \"Xalkori (Crizotinib)\", \"Xatmep (Methotrexate Sodium)\",\n",
    "        \"Xeloda (Capecitabine)\", \"Xgeva (Denosumab)\", \"Xofigo (Radium 223 Dichloride)\",\n",
    "        \"Xospata (Gilteritinib Fumarate)\", \"Xpovio (Selinexor)\", \"Xtandi (Enzalutamide)\",\n",
    "        \"Zaltrap (Ziv-Aflibercept)\", \"Zanubrutinib\", \"Zarxio (Filgrastim)\",\n",
    "        \"Zejula (Niraparib Tosylate Monohydrate)\", \"Zelboraf (Vemurafenib)\",\n",
    "        \"Zepzelca (Lurbinectedin)\", \"Zevalin (Ibritumomab Tiuxetan)\",\n",
    "        \"Zinecard (Dexrazoxane Hydrochloride)\", \"Zirabev (Bevcizumab)\",\n",
    "        \"Ziv-Aflibercept\", \"Zofran (Ondansetron Hydrochloride)\", \"Zoledronic Acid\",\n",
    "        \"Zolinza (Vorinostat)\", \"Zometa (Zoledronic Acid)\", \"Zyclara (Imiquimod)\",\n",
    "        \"Zydelig (Idelalisib)\", \"Zykadia (Ceritinib)\", \"Zynlonta (Loncastuximab Tesirine-lpyl)\"\n",
    "    ]\n",
    "\n",
    "    for drug_name in drugs:\n",
    "\n",
    "        report_name = f\"{drug_name}_postmarket_data\"\n",
    "        postmarket_data = get_extracted_postmarket_data(drug_name)\n",
    "\n",
    "        if postmarket_data:\n",
    "            save_postmarket_csv(filename=report_name, data=postmarket_data)\n",
    "            print(f\"Successfully generated and saved postmarket data for {drug_name}\")\n",
    "        else:\n",
    "            print(f\"No postmarket data to save for {drug_name}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9ec311bd-91a2-4ba8-9d90-8e36ef5e6a98",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "3102949a-7e31-420c-a602-8d94917bd4b7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting rdkit\n",
      "  Downloading rdkit-2024.9.5-cp39-cp39-win_amd64.whl (22.5 MB)\n",
      "     ---------------------------------------- 22.5/22.5 MB 4.7 MB/s eta 0:00:00\n",
      "Requirement already satisfied: Pillow in c:\\users\\mandv\\onedrive\\desktop\\new_ems\\ems_venv\\lib\\site-packages (from rdkit) (10.4.0)\n",
      "Requirement already satisfied: numpy in c:\\users\\mandv\\onedrive\\desktop\\new_ems\\ems_venv\\lib\\site-packages (from rdkit) (1.26.4)\n",
      "Installing collected packages: rdkit\n",
      "Successfully installed rdkit-2024.9.5\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING: You are using pip version 22.0.4; however, version 25.0.1 is available.\n",
      "You should consider upgrading via the 'C:\\Users\\mandv\\OneDrive\\Desktop\\NEW_EMS\\ems_venv\\Scripts\\python.exe -m pip install --upgrade pip' command.\n"
     ]
    }
   ],
   "source": [
    "pip install rdkit"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "19925d1d-c59a-4a1b-ae58-1ca11894c27e",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdin",
     "output_type": "stream",
     "text": [
      "Enter the chemical name of Drug A:  PF-07104091\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug A: Oncology, Drug B: Anthracycline Antibiotics; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Androgen Receptor Antagonists; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Epidermal Growth Factor Receptor Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: mTOR Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Bruton's Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Proteasome Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Receptor Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: HIF-2α Inhibitor, Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antiviral Agents, Immunomodulators, Similarity: 0\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antibody-Drug Conjugate, Antineoplastic Agent, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Anthracycline Antibiotics; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Androgen Receptor Antagonists; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Epidermal Growth Factor Receptor Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: mTOR Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Drug A: Oncology, Drug B: Bruton's Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Proteasome Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Receptor Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: HIF-2α Inhibitor, Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Drug A: Oncology, Drug B: Antiviral Agents, Immunomodulators, Similarity: 0\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antibody-Drug Conjugate, Antineoplastic Agent, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Anthracycline Antibiotics; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Androgen Receptor Antagonists; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Epidermal Growth Factor Receptor Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: mTOR Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Bruton's Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Proteasome Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Receptor Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: HIF-2α Inhibitor, Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antiviral Agents, Immunomodulators, Similarity: 0\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antibody-Drug Conjugate, Antineoplastic Agent, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Anthracycline Antibiotics; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Androgen Receptor Antagonists; Antineoplastic Agents, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Epidermal Growth Factor Receptor Inhibitors; Antineoplastic Agents, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Drug A: Oncology, Drug B: mTOR Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Bruton's Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Proteasome Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Receptor Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: HIF-2α Inhibitor, Antineoplastic Agents, Similarity: None\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antiviral Agents, Immunomodulators, Similarity: 0\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antibody-Drug Conjugate, Antineoplastic Agent, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Anthracycline Antibiotics; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Androgen Receptor Antagonists; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Epidermal Growth Factor Receptor Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: mTOR Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Bruton's Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Proteasome Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Receptor Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: HIF-2α Inhibitor, Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antiviral Agents, Immunomodulators, Similarity: 0\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antibody-Drug Conjugate, Antineoplastic Agent, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Anthracycline Antibiotics; Antineoplastic Agents, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Drug A: Oncology, Drug B: Androgen Receptor Antagonists; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Epidermal Growth Factor Receptor Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: mTOR Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Bruton's Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Proteasome Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Receptor Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: None\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: HIF-2α Inhibitor, Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antiviral Agents, Immunomodulators, Similarity: 0\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antibody-Drug Conjugate, Antineoplastic Agent, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Anthracycline Antibiotics; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Androgen Receptor Antagonists; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Epidermal Growth Factor Receptor Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: mTOR Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antimetabolites; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Bruton's Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Proteasome Inhibitors; Antineoplastic Agents, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Drug A: Oncology, Drug B: Receptor Tyrosine Kinase Inhibitors; Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: HIF-2α Inhibitor, Antineoplastic Agents, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Oncology, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Drug A: Oncology, Drug B: Antiviral Agents, Immunomodulators, Similarity: 0\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: 1\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Rate limit hit! Retrying in 8 seconds...\n",
      "Rate limit hit! Retrying in 16 seconds...\n",
      "Max retries reached. Skipping request.\n",
      "Drug A: Oncology, Drug B: Antineoplastic Agents, Enzyme Inhibitors, Similarity: None\n",
      "Rate limit hit! Retrying in 1 seconds...\n",
      "Rate limit hit! Retrying in 2 seconds...\n",
      "Rate limit hit! Retrying in 4 seconds...\n",
      "Drug A: Oncology, Drug B: Antibody-Drug Conjugate, Antineoplastic Agent, Similarity: 1\n"
     ]
    }
   ],
   "source": [
    "import time\n",
    "import json\n",
    "import pandas as pd\n",
    "from rdkit import Chem\n",
    "from rdkit.Chem import AllChem\n",
    "from rdkit import DataStructs\n",
    "import google.generativeai as genai\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "# Configure Gemini AI API\n",
    "api_key = \"AIzaSyBSpjhnYk97Un4eTDcxs9I2oDosw7YNr6g\"  # Replace with actual API key\n",
    "genai.configure(api_key=api_key)\n",
    "\n",
    "generation_config = {\n",
    "    \"temperature\": 0,\n",
    "    \"top_p\": 0.95,\n",
    "    \"top_k\": 40,\n",
    "    \"max_output_tokens\": 4096,\n",
    "    \"response_mime_type\": \"application/json\",\n",
    "}\n",
    "\n",
    "model_gemini = genai.GenerativeModel(\n",
    "    model_name=\"gemini-2.0-flash\", generation_config=generation_config\n",
    ")\n",
    "\n",
    "def load_drug_data(csv_file):\n",
    "    \"\"\"Loads drug data from a CSV file, ensuring valid entries.\"\"\"\n",
    "    try:\n",
    "        df = pd.read_csv(csv_file).dropna(subset=['Drug_Category'])\n",
    "        return df\n",
    "    except FileNotFoundError:\n",
    "        print(f\"Error: File not found - {csv_file}\")\n",
    "    except Exception as e:\n",
    "        print(f\"Error loading drug data: {e}\")\n",
    "    return pd.DataFrame()\n",
    "\n",
    "def calculate_tanimoto_similarity(smiles1, smiles2):\n",
    "    \"\"\"Calculates Tanimoto similarity between two SMILES representations.\"\"\"\n",
    "    mol1 = Chem.MolFromSmiles(smiles1)\n",
    "    mol2 = Chem.MolFromSmiles(smiles2)\n",
    "    \n",
    "    if mol1 is None or mol2 is None:\n",
    "        print(\"Invalid SMILES structure provided.\")\n",
    "        return None\n",
    "    \n",
    "    fp1 = AllChem.GetMorganFingerprintAsBitVect(mol1, 2, nBits=2048)\n",
    "    fp2 = AllChem.GetMorganFingerprintAsBitVect(mol2, 2, nBits=2048)\n",
    "    \n",
    "    return DataStructs.TanimotoSimilarity(fp1, fp2)\n",
    "\n",
    "def get_ai_similarity(drug_a, drug_b, max_retries=5):\n",
    "    \"\"\"Uses AI to determine drug similarity with proper JSON parsing.\"\"\"\n",
    "    prompt = (\n",
    "        f\"You are a medical expert in pharmacology. \"\n",
    "        f\"Determine if the drugs with categories '{drug_a['Drug_Category']}' \"\n",
    "        f\"and '{drug_b['Drug_Category']}' are similar based on their mechanism of action, \"\n",
    "        f\"therapeutic use, and chemical structure.\\n\"\n",
    "        f\"\\nRules:\\n\"\n",
    "        f\"- If the drugs have a similar mechanism of action or treat the same condition, output {{'similarity': 1}}.\\n\"\n",
    "        f\"- If the drugs have different uses, targets, or mechanisms, output {{'similarity': 0}}.\\n\"\n",
    "        f\"- Be strict: only mark them as similar if they are truly related.\\n\"\n",
    "        f\"- Output ONLY the JSON object, no extra text.\"\n",
    "    )\n",
    "\n",
    "    retries = 0\n",
    "    while retries < max_retries:\n",
    "        try:\n",
    "            chat_session = model_gemini.start_chat(history=[{\"role\": \"user\", \"parts\": [prompt]}])\n",
    "            response = chat_session.send_message(prompt)\n",
    "\n",
    "            response_text = response.text.strip()\n",
    "\n",
    "            # Try parsing response as JSON\n",
    "            try:\n",
    "                response_json = json.loads(response_text)\n",
    "\n",
    "                # Handle both { \"similarity\": 1 } and [ { \"similarity\": 1 } ]\n",
    "                if isinstance(response_json, list):\n",
    "                    response_json = response_json[0]  # Extract first object if it's a list\n",
    "                \n",
    "                if \"similarity\" in response_json and isinstance(response_json[\"similarity\"], int):\n",
    "                    return response_json[\"similarity\"]\n",
    "                else:\n",
    "                    print(f\"Invalid response format: {response_json}\")\n",
    "                    return None\n",
    "\n",
    "            except json.JSONDecodeError:\n",
    "                print(f\"Failed to parse JSON response: {response_text}\")\n",
    "                return None\n",
    "\n",
    "        except Exception as e:\n",
    "            if \"429\" in str(e):\n",
    "                wait_time = 2 ** retries  # Exponential backoff: 2, 4, 8, 16, etc.\n",
    "                print(f\"Rate limit hit! Retrying in {wait_time} seconds...\")\n",
    "                time.sleep(wait_time)\n",
    "                retries += 1\n",
    "            else:\n",
    "                print(f\"AI similarity prediction failed: {e}\")\n",
    "                return None\n",
    "\n",
    "    print(\"Max retries reached. Skipping request.\")\n",
    "    return None\n",
    "\n",
    "def main():\n",
    "    \"\"\"Main function to determine drug similarity.\"\"\"\n",
    "    drug_a_name = input(\"Enter the chemical name of Drug A: \")\n",
    "    \n",
    "    drug_a_list = load_drug_data(\"MAJORPROJECT/new_drugs.csv\")\n",
    "    drug_b_list = load_drug_data(\"MAJORPROJECT/drug_data_report.csv\")\n",
    "    \n",
    "    if drug_a_list.empty or drug_b_list.empty:\n",
    "        print(\"Error: One or both drug datasets could not be loaded.\")\n",
    "        return\n",
    "\n",
    "    results = []\n",
    "\n",
    "    for _, drug_a in drug_a_list.iterrows():\n",
    "        for _, drug_b in drug_b_list.iterrows():\n",
    "            similarity_score = get_ai_similarity(drug_a, drug_b)\n",
    "\n",
    "            # Append results for later use\n",
    "            results.append({\n",
    "                \"Drug_A\": drug_a[\"Drug_Category\"],\n",
    "                \"Drug_B\": drug_b[\"Drug_Category\"],\n",
    "                \"Similarity\": similarity_score\n",
    "            })\n",
    "\n",
    "            print(f\"Drug A: {drug_a['Drug_Category']}, Drug B: {drug_b['Drug_Category']}, Similarity: {similarity_score}\")\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    main()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "f5baee5b-1e03-4014-8689-f7f210b7096a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['models/chat-bison-001', 'models/text-bison-001', 'models/embedding-gecko-001', 'models/gemini-1.0-pro-vision-latest', 'models/gemini-pro-vision', 'models/gemini-1.5-pro-latest', 'models/gemini-1.5-pro-001', 'models/gemini-1.5-pro-002', 'models/gemini-1.5-pro', 'models/gemini-1.5-flash-latest', 'models/gemini-1.5-flash-001', 'models/gemini-1.5-flash-001-tuning', 'models/gemini-1.5-flash', 'models/gemini-1.5-flash-002', 'models/gemini-1.5-flash-8b', 'models/gemini-1.5-flash-8b-001', 'models/gemini-1.5-flash-8b-latest', 'models/gemini-1.5-flash-8b-exp-0827', 'models/gemini-1.5-flash-8b-exp-0924', 'models/gemini-2.0-flash-exp', 'models/gemini-2.0-flash', 'models/gemini-2.0-flash-001', 'models/gemini-2.0-flash-lite-001', 'models/gemini-2.0-flash-lite', 'models/gemini-2.0-flash-lite-preview-02-05', 'models/gemini-2.0-flash-lite-preview', 'models/gemini-2.0-pro-exp', 'models/gemini-2.0-pro-exp-02-05', 'models/gemini-exp-1206', 'models/gemini-2.0-flash-thinking-exp-01-21', 'models/gemini-2.0-flash-thinking-exp', 'models/gemini-2.0-flash-thinking-exp-1219', 'models/learnlm-1.5-pro-experimental', 'models/embedding-001', 'models/text-embedding-004', 'models/aqa', 'models/imagen-3.0-generate-002']\n"
     ]
    }
   ],
   "source": [
    "print([m.name for m in genai.list_models()])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0ab52064-45b5-409f-a534-7c5cc3cb0153",
   "metadata": {},
   "outputs": [],
   "source": [
    "PF-07104091"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "47568d66-8fa2-40c5-81ce-e0c435950c9e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('drug_name_similarity.csv', 'smiles_similarity.csv')"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "# Load datasets\n",
    "drug_data_path = \"MAJORPROJECT/drug_data_report.csv\"\n",
    "new_drug_data_path = \"MAJORPROJECT/new_drugs.csv\"\n",
    "\n",
    "drug_data = pd.read_csv(drug_data_path)\n",
    "new_drugs = pd.read_csv(new_drug_data_path)\n",
    "\n",
    "\n",
    "# Select relevant columns\n",
    "text_columns = [\"Drug_Name\", \"SMILES\"]\n",
    "\n",
    "# Ensure columns exist in both datasets\n",
    "for col in text_columns:\n",
    "    if col not in drug_data.columns or col not in new_drugs.columns:\n",
    "        raise ValueError(f\"Missing column '{col}' in one of the datasets.\")\n",
    "\n",
    "# Fill NaN values with empty strings\n",
    "drug_data[text_columns] = drug_data[text_columns].fillna(\"\")\n",
    "new_drugs[text_columns] = new_drugs[text_columns].fillna(\"\")\n",
    "\n",
    "# Function to compute TF-IDF similarity\n",
    "def compute_similarity(df1, df2, column):\n",
    "    vectorizer = TfidfVectorizer()\n",
    "    \n",
    "    # Combine data for consistent vectorization\n",
    "    combined_texts = pd.concat([df1[column], df2[column]], ignore_index=True)\n",
    "    tfidf_matrix = vectorizer.fit_transform(combined_texts)\n",
    "    \n",
    "    # Compute cosine similarity between new drugs and existing drugs\n",
    "    similarity_matrix = cosine_similarity(tfidf_matrix[len(df1):], tfidf_matrix[:len(df1)])\n",
    "    \n",
    "    return similarity_matrix\n",
    "\n",
    "# Compute similarity for both \"Drug_Name\" and \"SMILES\"\n",
    "similarity_results = {}\n",
    "for col in text_columns:\n",
    "    similarity_results[col] = compute_similarity(drug_data, new_drugs, col)\n",
    "\n",
    "# Convert results to DataFrame\n",
    "similarity_df_name = pd.DataFrame(similarity_results[\"Drug_Name\"], \n",
    "                                  index=new_drugs[\"Drug_Name\"], \n",
    "                                  columns=drug_data[\"Drug_Name\"])\n",
    "\n",
    "similarity_df_smiles = pd.DataFrame(similarity_results[\"SMILES\"], \n",
    "                                    index=new_drugs[\"Drug_Name\"], \n",
    "                                    columns=drug_data[\"Drug_Name\"])\n",
    "\n",
    "# Save results\n",
    "name_similarity_path = \"drug_name_similarity.csv\"\n",
    "smiles_similarity_path = \"smiles_similarity.csv\"\n",
    "\n",
    "similarity_df_name.to_csv(name_similarity_path)\n",
    "similarity_df_smiles.to_csv(smiles_similarity_path)\n",
    "\n",
    "name_similarity_path, smiles_similarity_path\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "0121f449-8b75-46ef-921a-d233ad8ab969",
   "metadata": {},
   "outputs": [
    {
     "name": "stdin",
     "output_type": "stream",
     "text": [
      "Enter the drug name under clinical trial:  PF-07248144\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "The drug most similar to PF-07248144 is Enzalutamide\n",
      "\n",
      "\n",
      "=== Enzalutamide_patient_data.csv ===\n",
      "        STUDYID     USUBJID  AESEQ    AETERM    AEDECOD AESER     AEOUT AESDISAB AESDTH AESHOSP AESLIFE AESMIE  AESTDY  AEENDY        MHCAT               MHSCAT MHTERM  Age   Sex   Race  Smoking_Status Alcohol_Consumption  Dosage Treatment_Duration\n",
      "0  StudyEnza001  Patient001    1.0   Fatigue    Fatigue    No  Resolved       No     No      No      No     No     5.0    12.0      Cardiac         Hypertension    I10   72  Male  White   Former Smoker               Light  100 mg            28 days\n",
      "1  StudyEnza001  Patient002    NaN       NaN        NaN   NaN       NaN      NaN    NaN     NaN     NaN    NaN     NaN     NaN    Endocrine    Diabetes Mellitus  E11.9   68  Male  Black    Never Smoker                 NaN  150 mg            42 days\n",
      "2  StudyEnza001  Patient003    1.0    Nausea     Nausea    No  Resolved       No     No      No      No     No     3.0     7.0  Respiratory                 COPD    J44   75  Male  White  Current Smoker            Moderate  100 mg            28 days\n",
      "3  StudyEnza001  Patient004    1.0  Diarrhea  Diarrhoea    No  Resolved       No     No      No      No     No    10.0    14.0          NaN                  NaN    NaN   62  Male  Asian    Never Smoker               Light   50 mg            21 days\n",
      "4  StudyEnza001  Patient005    NaN       NaN        NaN   NaN       NaN      NaN    NaN     NaN     NaN    NaN     NaN     NaN      Cardiac  Atrial Fibrillation    I48   78  Male  White   Former Smoker                 NaN  100 mg            28 days\n",
      "\n",
      "=== Enzalutamide_postmarket_data.csv ===\n",
      "      Drug_Name       STUDYID  YEAR Country         Dataset  Patient_Count  Median_Age  Female_Percentage  Male_Percentage  Median_BMI  Smoking_History_Yes_Percentage  Total_ADL_Independence_Percentage  LHRH_Use_Percentage  Tumor_Stage_T1_Percentage  Tumor_Stage_T2_Percentage  Tumor_Stage_T3_Percentage  Tumor_Stage_T4_Percentage  Nodal_Stage_N0_Percentage  Nodal_Stage_N1_Percentage  Nodal_Stage_N2_Percentage  Nodal_Stage_N3_Percentage  Stage_I_Percentage  Stage_II_Percentage  Stage_III_Percentage  Diabetes_Mellitus_Percentage  Congestive_Heart_Failure_Percentage  Stroke_Percentage  Atrial_Fibrillation_Percentage  Myocardial_Infarction_Percentage  Neoadjuvant_Chemotherapy_Received_Percentage  Adjuvant_Chemotherapy_Received_Percentage  Postoperative_RT_Received_Percentage Common_Neoadjuvant_Regimen_1 Common_Neoadjuvant_Regimen_2  Common_Adjuvant_Regimen_1  Common_Adjuvant_Regimen_2  Tamoxifen_Percentage  Letrozole_Percentage  Anastrozole_Percentage  \\\n",
      "0  Enzalutamide  EnzaStudy001  2021     USA             MDV            350          72                0.5             99.5        27.5                              35                                 85                   70                         10                         25                         35                         30                         60                         25                         10                          5                  15                   30                    35                            20                                    8                  5                              12                                 7                                             5                                         10                                    15                    Docetaxel                  Carboplatin                        NaN                        NaN                     0                     0                       0   \n",
      "1  Enzalutamide  EnzaStudy002  2022  Canada  Claim Database            420          75                0.3             99.7        28.1                              38                                 82                   72                          8                         22                         38                         32                         58                         27                          9                          6                  13                   28                    37                            22                                    9                  6                              13                                 8                                             6                                         11                                    16                    Docetaxel                  Carboplatin                        NaN                        NaN                     0                     0                       0   \n",
      "2  Enzalutamide  EnzaStudy003  2023      UK             MDV            280          70                0.7             99.3        26.8                              32                                 88                   68                         12                         28                         32                         28                         62                         23                         11                          4                  17                   32                    33                            18                                    7                  4                              11                                 6                                             4                                          9                                    14                    Docetaxel                  Carboplatin                        NaN                        NaN                     0                     0                       0   \n",
      "\n",
      "   Antidiarrheal_Agent_Probiotics_Percentage  Antiemetic_Agent_Percentage  Painkiller_Antipyretic_Percentage  Beds_Less_Than_200_Percentage  Beds_200_To_499_Percentage  Beds_Greater_Or_Equal_To_500_Percentage  Designated_Cancer_Hospital_Percentage  Months_Between_Surgery_And_Index_Date  \n",
      "0                                         10                           15                                 25                             15                          45                                       40                                     60                                      3  \n",
      "1                                         11                           16                                 26                             16                          46                                       38                                     62                                      4  \n",
      "2                                          9                           14                                 23                             14                          44                                       42                                     58                                      2  \n",
      "\n",
      "=== PF-07248144_patient_data.csv ===\n",
      "    STUDYID     USUBJID  AESEQ       AETERM      AEDECOD AESER       AEOUT  AESTDY  AEENDY AESDISAB AESDTH AESHOSP AESLIFE AESMIE        MHCAT               MHSCAT MHTERM  Age     Sex      Race  Smoking_Status Alcohol_Consumption  Dosage Treatment_Duration\n",
      "0  Study789  Patient001    1.0       Nausea       Nausea    No    Resolved     5.0     7.0       No     No      No      No     No      Cardiac         Hypertension    I10   62    Male     White   Former Smoker               Light  100 mg            28 days\n",
      "1  Study789  Patient002    NaN          NaN          NaN   NaN         NaN     NaN     NaN      NaN    NaN     NaN     NaN    NaN  Respiratory               Asthma    J45   58  Female     Black    Never Smoker                 NaN  150 mg            42 days\n",
      "2  Study789  Patient003    1.0      Fatigue      Fatigue    No  Recovering    10.0    14.0       No     No      No      No     No    Endocrine    Diabetes Mellitus    E11   70    Male     Asian  Current Smoker            Moderate   50 mg            21 days\n",
      "3  Study789  Patient004    1.0     Vomiting     Vomiting    No    Resolved     3.0     5.0       No     No      No      No     No          NaN                  NaN    NaN   65  Female  Hispanic   Former Smoker               Light  100 mg            28 days\n",
      "4  Study789  Patient005    1.0  Neutropenia  Neutropenia   Yes  Recovering    15.0    25.0       No     No     Yes      No    Yes      Cardiac  Atrial Fibrillation    I48   78    Male     White    Never Smoker                 NaN  150 mg            42 days\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Ensure all columns are displayed when printing DataFrames\n",
    "pd.set_option('display.max_columns', None)  \n",
    "pd.set_option('display.width', 1000)  \n",
    "\n",
    "# Load similarity data\n",
    "df_similarity = pd.read_csv(\"smiles_similarity.csv\")\n",
    "df_similarity.columns = df_similarity.columns.str.strip()  # Remove extra spaces\n",
    "\n",
    "# Get user input and clean it\n",
    "drug_name = input(\"Enter the drug name under clinical trial: \").strip()\n",
    "\n",
    "# Check if the drug exists in the dataset\n",
    "if drug_name in df_similarity[\"Drug_Name\"].str.strip().values:\n",
    "    row = df_similarity[df_similarity[\"Drug_Name\"].str.strip() == drug_name].iloc[:, 1:]  # Exclude Drug_Name column\n",
    "\n",
    "    # Find the most similar drug\n",
    "    most_similar_drug = row.idxmax(axis=1).values[0]\n",
    "    print(f\"\\nThe drug most similar to {drug_name} is {most_similar_drug}\\n\")\n",
    "\n",
    "    # **Load corresponding patient and post-market data files**\n",
    "    output_patient_file = f\"{most_similar_drug}_patient_data.csv\"\n",
    "    output_postmarket_file = f\"{most_similar_drug}_postmarket_data.csv\"\n",
    "    input_patient_file = f\"{drug_name}_patient_data.csv\"\n",
    "\n",
    "    # Load and print data safely\n",
    "    try:\n",
    "        df_output_patient = pd.read_csv(output_patient_file)\n",
    "        print(f\"\\n=== {output_patient_file} ===\")\n",
    "        print(df_output_patient.head())  # Print first few rows\n",
    "    except FileNotFoundError:\n",
    "        print(f\"File {output_patient_file} not found.\")\n",
    "\n",
    "    try:\n",
    "        df_output_postmarket = pd.read_csv(output_postmarket_file)\n",
    "        print(f\"\\n=== {output_postmarket_file} ===\")\n",
    "        print(df_output_postmarket.head())\n",
    "    except FileNotFoundError:\n",
    "        print(f\"File {output_postmarket_file} not found.\")\n",
    "\n",
    "    try:\n",
    "        df_input_patient = pd.read_csv(input_patient_file)\n",
    "        print(f\"\\n=== {input_patient_file} ===\")\n",
    "        print(df_input_patient.head())\n",
    "    except FileNotFoundError:\n",
    "        print(f\"File {input_patient_file} not found.\")\n",
    "\n",
    "else:\n",
    "    print(\"\\nDrug not found in similarity data. Please check the name and try again.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d69e0e16-028a-4863-bd5b-19711392aed3",
   "metadata": {},
   "outputs": [],
   "source": [
    "PF-07248144"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "id": "460cae5b-6ba8-4c42-aa31-cc8bf7b2963b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdin",
     "output_type": "stream",
     "text": [
      "Enter the drug name under clinical trial:  PF-07284892\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "The drug most similar to PF-07284892 is Doxorubicin\n",
      "\n",
      "Error loading patient data: [Errno 2] No such file or directory: 'Doxorubicin_patient_data.csv'\n",
      "\n",
      "Severe Outcome Rates (Percentage)\n",
      "Outcome     PF-07284892      Doxorubicin    \n",
      "AESDTH      3.33             0.00           \n",
      "AESHOSP     44.17            0.00           \n",
      "AESLIFE     15.00            0.00           \n",
      "AESMIE      9.17             0.00           \n",
      "AESDISAB    17.50            0.00           \n",
      "\n",
      "Postmarket Risk Factors (Average Percentage from similar drug):\n",
      "Stroke_Percentage: 3.12%\n",
      "Congestive_Heart_Failure_Percentage: 7.12%\n",
      "Myocardial_Infarction_Percentage: 4.12%\n",
      "Diabetes_Mellitus_Percentage: 17.50%\n",
      "Atrial_Fibrillation_Percentage: 9.12%\n",
      "\n",
      "🔍 **Final Prediction:**\n",
      "⚠️ PF-07284892 has a significantly higher rate of serious adverse events (26.67%) than Doxorubicin (0.00%). It may require caution.\n",
      "⚠️ PF-07284892 has an elevated AESDTH rate (3.33%) compared to Doxorubicin (0.00%).\n",
      "⚠️ PF-07284892 has an elevated AESHOSP rate (44.17%) compared to Doxorubicin (0.00%).\n",
      "⚠️ PF-07284892 has an elevated AESLIFE rate (15.00%) compared to Doxorubicin (0.00%).\n",
      "⚠️ PF-07284892 has an elevated AESMIE rate (9.17%) compared to Doxorubicin (0.00%).\n",
      "⚠️ PF-07284892 has an elevated AESDISAB rate (17.50%) compared to Doxorubicin (0.00%).\n",
      "⚠️ Postmarket data for Doxorubicin shows notable risks. PF-07284892 might require monitoring.\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Load similarity data\n",
    "df_similarity = pd.read_csv(\"smiles_similarity.csv\")\n",
    "df_similarity.columns = df_similarity.columns.str.strip()\n",
    "\n",
    "# Get user input\n",
    "drug_name = input(\"Enter the drug name under clinical trial: \").strip()\n",
    "\n",
    "if drug_name in df_similarity[\"Drug_Name\"].str.strip().values:\n",
    "    row = df_similarity[df_similarity[\"Drug_Name\"].str.strip() == drug_name].iloc[:, 1:]\n",
    "    most_similar_drug = row.idxmax(axis=1).values[0]\n",
    "    print(f\"\\nThe drug most similar to {drug_name} is {most_similar_drug}\\n\")\n",
    "\n",
    "    # Load patient data\n",
    "    try:\n",
    "        df_input_patient = pd.read_csv(f\"{drug_name}_patient_data.csv\")\n",
    "        df_output_patient = pd.read_csv(f\"{most_similar_drug}_patient_data.csv\")\n",
    "    except FileNotFoundError as e:\n",
    "        print(f\"Error loading patient data: {e}\")\n",
    "        exit()\n",
    "\n",
    "    # Load postmarket data\n",
    "    try:\n",
    "        df_output_postmarket = pd.read_csv(f\"{most_similar_drug}_postmarket_data.csv\")\n",
    "    except FileNotFoundError as e:\n",
    "        print(f\"Error loading postmarket data: {e}\")\n",
    "        exit()\n",
    "\n",
    "    # --- Step 1: Compare Serious Adverse Events ---\n",
    "    serious_events_new = df_input_patient[df_input_patient[\"AESER\"] == \"Y\"].shape[0]\n",
    "    serious_events_old = df_output_patient[df_output_patient[\"AESER\"] == \"Y\"].shape[0]\n",
    "\n",
    "    percent_serious_new = serious_events_new / len(df_input_patient) * 100\n",
    "    percent_serious_old = serious_events_old / len(df_output_patient) * 100\n",
    "\n",
    "    # --- Step 2: Compare Severe Outcomes ---\n",
    "    def calculate_severe_rate(df, column):\n",
    "        return df[df[column] == \"Y\"].shape[0] / len(df) * 100 if column in df.columns else 0\n",
    "\n",
    "    severe_outcomes = [\"AESDTH\", \"AESHOSP\", \"AESLIFE\", \"AESMIE\", \"AESDISAB\"]\n",
    "    new_drug_severity = {col: calculate_severe_rate(df_input_patient, col) for col in severe_outcomes}\n",
    "    old_drug_severity = {col: calculate_severe_rate(df_output_patient, col) for col in severe_outcomes}\n",
    "\n",
    "    print(\"\\nSevere Outcome Rates (Percentage)\")\n",
    "    print(f\"{'Outcome':<10}  {drug_name:<15}  {most_similar_drug:<15}\")\n",
    "    for col in severe_outcomes:\n",
    "        print(f\"{col:<10}  {new_drug_severity[col]:<15.2f}  {old_drug_severity[col]:<15.2f}\")\n",
    "\n",
    "    # --- Step 3: Compare Postmarket Trends ---\n",
    "    postmarket_risk_factors = [\n",
    "        \"Stroke_Percentage\", \"Congestive_Heart_Failure_Percentage\", \"Myocardial_Infarction_Percentage\",\n",
    "        \"Diabetes_Mellitus_Percentage\", \"Atrial_Fibrillation_Percentage\"\n",
    "    ]\n",
    "\n",
    "    postmarket_risks = {col: df_output_postmarket[col].mean() for col in postmarket_risk_factors}\n",
    "\n",
    "    print(\"\\nPostmarket Risk Factors (Average Percentage from similar drug):\")\n",
    "    for factor, value in postmarket_risks.items():\n",
    "        print(f\"{factor}: {value:.2f}%\")\n",
    "\n",
    "    # --- Step 4: Prediction ---\n",
    "    risk_threshold = 20  # Percentage increase threshold for concern\n",
    "\n",
    "    print(\"\\n🔍 **Final Prediction:**\")\n",
    "    \n",
    "    if percent_serious_new > percent_serious_old * 1.2:  # More than 20% increase\n",
    "        print(f\"⚠️ {drug_name} has a significantly higher rate of serious adverse events ({percent_serious_new:.2f}%) than {most_similar_drug} ({percent_serious_old:.2f}%). It may require caution.\")\n",
    "\n",
    "    for col in severe_outcomes:\n",
    "        if new_drug_severity[col] > old_drug_severity[col] * 1.2:\n",
    "            print(f\"⚠️ {drug_name} has an elevated {col} rate ({new_drug_severity[col]:.2f}%) compared to {most_similar_drug} ({old_drug_severity[col]:.2f}%).\")\n",
    "\n",
    "    if any(value > 10 for value in postmarket_risks.values()):\n",
    "        print(f\"⚠️ Postmarket data for {most_similar_drug} shows notable risks. {drug_name} might require monitoring.\")\n",
    "\n",
    "    if all(new_drug_severity[col] <= old_drug_severity[col] * 1.2 for col in severe_outcomes) and percent_serious_new <= percent_serious_old * 1.2:\n",
    "        print(f\"✅ {drug_name} does not show major safety concerns compared to {most_similar_drug}.\")\n",
    "else:\n",
    "    print(\"\\nDrug not found in similarity data. Please check the name and try again.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "e4896a03-8c49-44c4-af34-456485eb4fd6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 600x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\mandv\\AppData\\Local\\Temp\\ipykernel_17856\\1720213768.py:51: FutureWarning: \n",
      "\n",
      "Passing `palette` without assigning `hue` is deprecated and will be removed in v0.14.0. Assign the `x` variable to `hue` and set `legend=False` for the same effect.\n",
      "\n",
      "  sns.barplot(x=postmarket_risk_factors, y=risk_values, palette=\"Reds\")\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "\n",
    "# Load patient data for new and similar drug\n",
    "df_input_patient = pd.read_csv(\"PF-07248144_patient_data.csv\")\n",
    "df_output_patient = pd.read_csv(\"Enzalutamide_patient_data.csv\")\n",
    "\n",
    "# --- 1. Age Distribution ---\n",
    "plt.figure(figsize=(8, 5))\n",
    "sns.histplot(df_input_patient[\"Age\"], bins=10, kde=True, color=\"blue\", label=\"PF-07248144\", alpha=0.5)\n",
    "sns.histplot(df_output_patient[\"Age\"], bins=10, kde=True, color=\"red\", label=\"Enzalutamide\", alpha=0.5)\n",
    "plt.title(\"Age Distribution of Patients\")\n",
    "plt.xlabel(\"Age\")\n",
    "plt.ylabel(\"Count\")\n",
    "plt.legend()\n",
    "plt.show()\n",
    "\n",
    "# --- 2. Race Distribution ---\n",
    "plt.figure(figsize=(6, 6))\n",
    "df_input_patient[\"Race\"].value_counts().plot(kind=\"pie\", autopct=\"%1.1f%%\", cmap=\"coolwarm\", title=\"Race Distribution (New Drug)\")\n",
    "plt.ylabel(\"\")\n",
    "plt.show()\n",
    "\n",
    "# --- 3. Adverse Event Outcomes ---\n",
    "adverse_event_cols = [\"AESDTH\", \"AESHOSP\", \"AESLIFE\", \"AESMIE\", \"AESDISAB\"]\n",
    "new_drug_counts = [df_input_patient[col].eq(\"Y\").sum() for col in adverse_event_cols]\n",
    "old_drug_counts = [df_output_patient[col].eq(\"Y\").sum() for col in adverse_event_cols]\n",
    "\n",
    "plt.figure(figsize=(10, 5))\n",
    "x = range(len(adverse_event_cols))\n",
    "plt.bar(x, new_drug_counts, width=0.4, label=\"PF-07248144\", color=\"blue\", alpha=0.6)\n",
    "plt.bar([p + 0.4 for p in x], old_drug_counts, width=0.4, label=\"Enzalutamide\", color=\"red\", alpha=0.6)\n",
    "plt.xticks([p + 0.2 for p in x], adverse_event_cols)\n",
    "plt.ylabel(\"Number of Cases\")\n",
    "plt.title(\"Adverse Event Outcomes\")\n",
    "plt.legend()\n",
    "plt.show()\n",
    "\n",
    "# --- 4. Postmarket Data Risks ---\n",
    "df_postmarket = pd.read_csv(\"Enzalutamide_postmarket_data.csv\")\n",
    "postmarket_risk_factors = [\n",
    "    \"Stroke_Percentage\", \"Congestive_Heart_Failure_Percentage\",\n",
    "    \"Myocardial_Infarction_Percentage\", \"Diabetes_Mellitus_Percentage\",\n",
    "    \"Atrial_Fibrillation_Percentage\"\n",
    "]\n",
    "\n",
    "risk_values = [df_postmarket[col].mean() for col in postmarket_risk_factors]\n",
    "\n",
    "plt.figure(figsize=(8, 5))\n",
    "sns.barplot(x=postmarket_risk_factors, y=risk_values, palette=\"Reds\")\n",
    "plt.xticks(rotation=45)\n",
    "plt.ylabel(\"Percentage of Patients Affected\")\n",
    "plt.title(\"Postmarket Risk Factors (Enzalutamide)\")\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "84a926e8-cbb9-4221-b9c8-0008e8891b53",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generated and saved patient data for PF-07284892 and Tucatinib.\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import random\n",
    "\n",
    "# Generate dummy patient data for two drugs\n",
    "def generate_patient_data(drug_name, num_patients=100):\n",
    "    data = {\n",
    "        \"STUDYID\": [f\"STUDY_{i+1}\" for i in range(num_patients)],\n",
    "        \"USUBJID\": [f\"{drug_name}_P{i+1}\" for i in range(num_patients)],\n",
    "        \"AESEQ\": list(range(1, num_patients+1)),\n",
    "        \"AETERM\": random.choices([\"Headache\", \"Nausea\", \"Fatigue\", \"Seizure\", \"Cardiac Arrest\"], k=num_patients),\n",
    "        \"AEDECOD\": random.choices([\"Mild\", \"Moderate\", \"Severe\"], k=num_patients),\n",
    "        \"AESER\": random.choices([\"Y\", \"N\"], weights=[0.3, 0.7], k=num_patients),\n",
    "        \"AEOUT\": random.choices([\"Recovered\", \"Not Recovered\", \"Fatal\"], weights=[0.7, 0.2, 0.1], k=num_patients),\n",
    "        \"AESDISAB\": random.choices([\"Y\", \"N\"], weights=[0.2, 0.8], k=num_patients),\n",
    "        \"AESDTH\": random.choices([\"Y\", \"N\"], weights=[0.05, 0.95], k=num_patients),\n",
    "        \"AESHOSP\": random.choices([\"Y\", \"N\"], weights=[0.4, 0.6], k=num_patients),\n",
    "        \"AESLIFE\": random.choices([\"Y\", \"N\"], weights=[0.15, 0.85], k=num_patients),\n",
    "        \"AESMIE\": random.choices([\"Y\", \"N\"], weights=[0.1, 0.9], k=num_patients),\n",
    "        \"AESTDY\": random.choices(range(1, 100), k=num_patients),\n",
    "        \"AEENDY\": random.choices(range(1, 120), k=num_patients),\n",
    "        \"MHCAT\": random.choices([\"Cardiac\", \"Neurological\", \"Gastrointestinal\", \"Respiratory\"], k=num_patients),\n",
    "        \"MHSCAT\": random.choices([\"Hypertension\", \"Diabetes\", \"Asthma\", \"Epilepsy\"], k=num_patients),\n",
    "        \"MHTERM\": random.choices([\"Controlled\", \"Uncontrolled\"], k=num_patients),\n",
    "        \"Age\": random.choices(range(18, 90), k=num_patients),\n",
    "        \"Sex\": random.choices([\"Male\", \"Female\"], k=num_patients),\n",
    "        \"Race\": random.choices([\"White\", \"Black\", \"Asian\", \"Hispanic\"], weights=[0.5, 0.2, 0.2, 0.1], k=num_patients),\n",
    "        \"Smoking_Status\": random.choices([\"Smoker\", \"Non-Smoker\"], weights=[0.3, 0.7], k=num_patients),\n",
    "        \"Alcohol_Consumption\": random.choices([\"Yes\", \"No\"], weights=[0.4, 0.6], k=num_patients),\n",
    "        \"Dosage\": random.choices([100, 200, 300, 400, 500], k=num_patients),\n",
    "        \"Treatment_Duration\": random.choices(range(1, 365), k=num_patients)\n",
    "    }\n",
    "    return pd.DataFrame(data)\n",
    "\n",
    "# Generate datasets\n",
    "df_pf_07284892 = generate_patient_data(\"PF-07284892\", 120)\n",
    "df_tucatinib = generate_patient_data(\"Tucatinib\", 150)\n",
    "\n",
    "# Save to CSV\n",
    "df_pf_07284892.to_csv(\"PF-07284892_patient_data.csv\", index=False)\n",
    "df_tucatinib.to_csv(\"Tucatinib_patient_data.csv\", index=False)\n",
    "\n",
    "print(\"Generated and saved patient data for PF-07284892 and Tucatinib.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9d3e60c3-7828-4fc0-ba43-925e88dbf017",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
